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ABSTRACT
Abstract
GABAa receptors mediate the majority of fast synaptic inhibition in the adult 
mammalian brain, and play a critical role in controlling neuronal excitability during 
development. The functional properties and stability of cell-surface GABAa 
receptors are key determinants of the efficacy of GABAergic neurotransmission. I 
therefore employed a broad spectrum of biochemical, and cell and molecular 
biological techniques to identify molecular interactions that may be involved in 
regulating the activity and number of GABAa receptors at the neuronal surface.
In this thesis, I identified a novel interaction between the GABAa receptor and the 
calcium/calmodulin-dependent protein kinase II (CaMKII). Affinity-purification 
assays revealed that CaMKII forms a native complex with the GABAa receptor in 
brain, and that the kinase binds non-selectively to the major intracellular domain 
(ICD) of various GABAa receptor subunits. The interaction between CaMKII and the 
receptor (3 subunits was found to be dependent upon phosphorylation of the kinase at 
T286, but appeared to be independent of subunit phosphorylation. Furthermore, a 
CaMKII binding site was identified in the ICD of the receptor (3 subunits, between 
residues 304 and 323.
Further work demonstrated that CaMKII selectively phosphorylates the ICDs of the 
receptor |3 and y subunits, and identified protein phosphatases that dephosphorylate 
the receptor |33 subunit at the CaMKII sites. Depolarisation of cultured immature 
cortical neurons was found to increase the level of enzymatically-active CaMKII that 
associates with the ICD of the receptor [33 subunit, and to trigger CaMKII-dependent 
phosphorylation of the receptor [33 subunit at both the S408 and S409 residues.
Work presented in this thesis also identified multivalent interactions between GABAa 
receptor y subunits and the AP2 adaptor complex, a major component of the 
endocytic machinery. The ICD of each receptor y subunit was found to interact with 
the native AP2 complex from brain, and to bind selectively and directly to the \i2- 
adaptin of AP2. Two distinct binding sites for p,2-adaptin were identified in the ICD
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of the y2S subunit. The N-terminal half of the ICD was found to interact with sub- 
domain B of p.2-adaptin via a putative basic-rich motif. In contrast, the C-terminal 
half of the ICD was found to bind sub-domain A of p2-adaptin, likely via a tyrosine- 
based motif. Both p2-adaptin binding motifs were found to be common to all the y 
subunit isoforms.
4
CONTENTS
Contents
Abstract................................................................................................................  3
Contents................................................................................................................  5
List of Figures......................................................................................................  13
List of Tables ......................................................................................................  15
Abbreviations ......................................................................................................  16
Acknowledgements..............................................................................................  22
CHAPTER 1: Introduction ...............................................................................  23
PART ONE............................................................................................................  24
1.1 The Identification and Synthesis of the Neurotransmitter GABA .................. 24
1.2GABA Activates GABA Receptors to Mediate Neuronal Inhibition or
Excitation ................................................................................................................ 24
1.3GABAa Receptor Structure and Assembly .........................................................  29
1.4Membrane Clustering and Targeting of GABAa Receptors ..............................  32
1.5 Stability and Dynamics of GABAa Receptors at the Cell Surface .................... 34
1.6Trafficking of GABAa Receptors to the Cell Surface .......................................... 34
1.7Phosphorylation-Dependent Functional Modulation of GABAa Receptors ......  39
1.7.1 Phosphorylation-Dependent Modification of Proteins is a Key 
Component of Intracellular Signalling Networks and Modulates Various 
Neuronal Processes ..................................................................................... 39
1.7.2 GABAa Receptors undergo Phosphorylation-Dependent Modification .. 42
1.7.2.1 The Role o f Protein Kinases .........................................................  42
1.7.2.1.1 PKC and the RACK-1 Anchoring Protein .................... 42
1.7.2.1.2 PKA and AKAP Scaffold Proteins.................................  47
1.7.2.1.3 Akt ................................................................................... 49
1.7.2.1.4 GAPDH ..........................................................................  49
1.7.2.1.5 CaMKII ..........................................................................  50
1.7.2.1.6 PKG ...............................................................................  50
1.7.2.1.7 Src ..................................................................................  51
1.7.2.2 The Role o f Protein Phosphatases ...............................................  51
5
CONTENTS
1.7.2.2.1 PP1 and the Adaptor Protein PR1P-1 .........................  52
1.7.2.2.2 P P 2A ...............................................................................  52
1.7.2.23 PP 2B ...............................................................................  53
1.7.3 Phosphorylation-Dependent Modulation of GABAa Receptor Function .. 55
1.7.4 Phosphorylation-Dependent GABAa Receptor Cross-Talk ...................  57
PART TWO ..........................................................................................................  58
1.8 Structure and Regulation of CaMKII ................................................................. 58
PART THREE .....................................................................................................  63
1.9Thesis A im s............................................................................................................. 63
CHAPTER 2: Materials and Methods ..............................................................  64
2.1 General Materials, Reagents and Equipment ....................................................  65
2.2Bacteria ...................................................................................................................  65
2.2.1 Escherichia coli S trains............................................................................... 65
2.2.2 Media, Growth and Storage ......................................................................  65
2.2.3 Transformation............................................................................................  66
2.2.3.1 Heat-Shock ..................................................................................... 66
2.2.3.2 Production o f Electro-Competent Cells ....................................... 66
2.2.3.3 Electroporation...............................................................................  67
2.2.4 Production and Purification of Glutathione S-Transferase-Fusion
Proteins .......................................................................................................  67
2.2.5 Purification of Plasmid DNA from E. c o l i .................................................. 69
2.2.5.1 Mini-Preparation o f Plasmid DNA ...............................................  69
22.5.2 Maxi-Preparation o f Plasmid DNA ...............................................  69
22.5.3 Large-Scale Preparation o f Plasmid DNA .................................. 70
2.3 Molecular Biology...............................................................................................  71
2.3.1 DNA Manipulations ....................................................................................  71
2.3.2 Vectors..........................................................................................................  71
2.3.3 Oligonucleotides .........................................................................................  73
2.3.4 Purification of Plasmid DNA ....................................................................  73
2.3.4.1 Ethanol Precipitation ....................................................................  73
2.3.42 Phenol/Chloroform Extraction ...................................................  74
6
CONTENTS
2.3.5 Measurement of DNA Concentration and Purity ....................................  74
2.3.6 Polymerase Chain Reaction ...................................................................... 75
2.3.7 Agarose Gel Electrophoresis...................................................................... 75
2.3.8 Site-Directed Mutagenesis .........................................................................  76
2.3.9 Restriction Digests....................................................................................... 76
2.3.10 Ligations.......................................................................................................  76
2.3.11 DNA Sequence Analysis ............................................................................  77
2.4Cell Biology............................................................................................................. 77
2.4.1 Manipulations using COS-7 Cell Lines ..................................................  77
2.4.1.1 COS-7 Cell Lines ..........................................................................  77
2.4.1.2 Propagation o f COS-7 Cell Lines .................................................  77
2.4.1.3 Transient Transfection o f COS-7 Cell Lines ..............................  78
2.4.2 Primary Neuronal Culture .........................................................................  78
2.4.2.1 Rat Species ..................................................................................... 78
2.4.2.2 Preparation o f D ishes.................................................................... 78
2.4.2.3 Preparation o f Primary Rat Cortical Neurons ...........................  79
2.4.3 Production of Phosphorylation State-Specific Antibodies ......................  79
2.4.3.1 Production o f Synthetic Peptides for Immunisation o f Rabbits 
and Characterisation o f Phosphorylation State-Specific
Antisera ..........................................................................................  79
2.4.3.2 Conjugation o f Peptide/Carrier Proteins with Sulfo-MBS ........  80
2.4.3.3 Production o f Antisera .................................................................. 81
2.5 Biochemistry ....................................................................................................... 82
2.5.1 Antibodies...................................................................................................  82
2.5.2 Affinity-Purification of Antibodies ............................................................ 82
2.5.2.1 Preparation o f Affinity Columns ................................................  82
2.5.2.1.1 Protein A Columns.........................................................  82
2.5.2.1.2 Phosphopeptide Columns...............................................  82
2.5.2.1.3 GST-f}3 (345-408)-Fusion Protein Column ................. 84
2.5.2.2 Affinity Purification o f Antisera ....................................................  84
2.5.3 Preparation of Tissue and Cell Extracts ...................................................  85
2.5.3.1 Preparation o f Whole Brain Extract ........................................... 85
7
CONTENTS
2.5.3.2 Preparation o f Neuronal Extracts .............................................. 86
2.5.3.2.1 Using 2% (w/v) Sodium Dodecyl Sulphate ................. 86
2.5.3.2.2 Using Pre-Labelling/IP B uffer ....................................... 86
2.5.3.2.3 Using Affinity-Purification Buffer .................................  86
2.5.3.3 Preparation o f COS-7 Cell Extracts ...........................................  87
2.5.4 Measurement of Protein Concentration ....................................................  87
2.5.4.1 Bicinchoninic Protein Assay .........................................................  87
2.5.4.2 Bradford Protein A ssay .................................................................. 87
2.5.5 SDS-Polyacrylamide Gel Electrophoresis .................................................  87
2.5.5.1 Using the Bio-Rad System ............................................................. 87
2.5.52 Using the Invitrogen System .........................................................  88
2.5.6 Visualising Proteins in SDS-PAGE Gels by Staining with Brilliant
Blue R .......................................................................................................... 88
2.5.7 Western Blot Analysis ...............................................................................  89
2.5.8 Phosphorimaging..........................................................................................  90
2.5.9 Dot-Blot Assays .......................................................................................... 90
2.5.10 Coimmunoprecipitation Assays .................................................................. 90
2.5.11 Affinity-Purification (‘Pull-Down’) Assays ...............................................  90
2.5.11.1 Using Tissue or Cell Extracts .......................................................  91
2.5.11.2 Using In Vitro Transcribed/Translated DNA ..............................  91
2.5.12 Pre-Labelling Assays ..................................................................................  91
2.5.13 In Vitro Kinase Assays ...............................................................................  92
2.5.14 Calculation of the Stoichiometry of Phosphorylation ..............................  95
2.5.15 In Vitro Affinity-Purification Kinase (‘Pull-Down’-Kinase) Assays ......  95
2.5.16 In Vitro Dephosphorylation A ssays............................................................ 96
2.5.16.1 Preparative Phosphorylation o f Substrates .............................  96
2.5.16.1.1 Preparative Phosphorylation o f GST- f$3 Fusion 
Proteins by CaM KII....................................................  96
2.5.16.1.2 Preparative Phosphorylation o f Phosphorylase b by 
Phosphorylase Kinase..................................................  97
2.5.16.1.3 Preparative Phosphorylation ofDARRP-32 by PKA 97
2.5.16.1.4 Preparative Phosphorylation o f Casein by PKA ......  97
8
CONTENTS
2.5.16.2 Determination o f Initial Rate Conditions .................................  98
2.5.16.3In Vitro Dephosphorylation Assays o f Unknown Substrates .....  99
2.6Bioinformatics .......................................................................................................  99
CHAPTER 3: GABAa Receptors Interact with CaMKII ..................................  100
3.1 Background ............................................................................................................ 101
3.2Results....................................................................................................................... 103
3.2.1 Native CaMKIIa Interacts with the Major Intracellular Domain of 
Various GABAa Receptor Subunits .........................................................  105
3.2.2 CaMKIIa Forms a Native Complex with GABAa Receptors in Brain ... 107
3.2.3 The Interaction of Recombinant CaMKIIa with the Major Intracellular 
Domains of GABAa Receptor |3 Subunits is Phospho-Dependent ........  107
3.2.3.1 The Major Intracellular Domains ofGABAA Receptor f  Subunits 
Bind Selectively to the Constitutively Active CaMKIIa-T286D 
M utant.............................................................................................  107
3.2.3.2 Binding o f CaMKIIa-T286D to the Major Intracellular Domain
of the f33 Subunit Requires EGTA ....................................................110
3.2.4 Consensus In Vivo Phosphorylation Sites in the Major Intracellular 
Domain of the |33 Subunit are not Critical for the Interaction with Native 
CaMKIIa .....................................................................................................  112
3.2.5 CaMKIIa-T286D Interacts Directly with the Major Intracellular
Domains of GABAa Receptor (3 Subunits .................................................... 113
3.2.6 The Predominant Binding-Site for CaMKIIa-T286D in the Major 
Intracellular Domain of the (33 Subunit Lies within Amino Acids 304 to
322 ................................................................................................................ 117
3.2.6.1 The Proximal Quarter o f the Major Intracellular Domain o f the 
f33 Subunit Contains the Predominant Binding Site for 
CaMKII a-T286D ............................................................................  117
32.6.2 N-Terminal Deletions o f the f33 Subunit Major Intracellular 
Domain Disrupt CaMKIIa-T286D-Binding ................................  118
3.2.7 Analysis of the Major CaMKIIa-Binding Site in the GABAa Receptor
|33 Subunit.....................................................................................................  121
9
CONTENTS
32.7.1 Comparison o f the CaMKlla-Binding Sequence in the GABAa 
Receptor (33 Subunit with the other (3 Subunit Sequences ............  121
3.2.7.2 Comparison o f the CaMKlla-Binding Sequence in the GABAa 
Receptor f33 Subunit with CaMKlla-Binding Sequences in other
Proteins .......................................................................................... 123
3.3 Discussion............................................................................................................  123
3.3.1 The Nature of CaMKIIa-GABAA Receptor Complexes ........................  124
3.3.2 Functional Implications of Native CaMKIIa-GABAA Receptor 
Complexes.....................................................................................................  130
3.3.3 Potential Dynamics of GABAa Receptor Scaffolds ................................  133
3.4Conclusions............................................................................................................  135
CHAPTER 4: CaMKII-Dependent Phosphorylation of GABAa Receptors ... 136
4.1 Background .........................................................................................................  137
4.2Results ..................................................................................................................... 138
4.2.1 CaMKII Phosphoiylates GABAa Receptor Subunits, In Vitro ................ 138
4.2.1.1 CaMKII Selectively Phosphorylates the Major Intracellular 
Domains o f GABAa Receptor j3 and y Subunits, In Vitro ...........  138
4.2.1.2 CaMKII Phosphorylates the Major Intracellular Domain o f the 
GABAa Receptor j33 Subunit at S383 and S409, In Vitro ...........  139
4.2.1.3 Time-Course o f CaMKII Phosphorylation o f the Major 
Intracellular domain o f the GABAa Receptor f33 Subunit, In
Vitro ...............................................................................................  141
4.2.2 PP1, PP2A and PP2C Dephosphorylate Phospho-S383 and 
Phospho-S409 of the Major Intracellular Domain of the GABAa 
Receptor (33 Subunit, In Vitro .....................................................................  143
4.2.3 KCl-Induced Depolarisation of Cultured Immature Cortical Neurons 
Enhances the Functional Interaction of CaMKII with GST-(33 ................ 146
4.2.4 Depolarisation-Induced Autophosphorylation of CaMKII at T286 in
Cultured Immature Cortical Neurons .........................................................  147
4.2.4.1 Basal Activity o f CaMKII in Cultured Immature Cortical
Neurons ..........................................................................................  149
10
CONTENTS
4.2.4.2 Muscimol-Induced Phosphorylation o f CaMKII at T286 in
Cultured Immature Cortical Neurons .......................................... 151
4.2.43 Muscimol-Induced Phosphorylation ofPKC in Cultured
Immature Cortical Neurons .........................................................  155
4.2.5 CaMKII-Dependent Phosphorylation of GABAa Receptor (33 Subunits
In Situ in Cultured Immature Cortical Neurons ............................................157
4.2.6 Production and Characterisation of Phosphorylation State-Specific 
Antibodies that recognise GABAa Receptor (33 Subunits Phosphorylated
at S383, and at S409 ..................................................................................... 159
4.2.6.1 Design and Production o f Peptide Immunogens, and Inoculation
of Rabbits ........................................................................................ 160
4.2.6.2 Antibody Screen I  ..........................................................................  160
4.2.6.3 Antibody Screen II ..........................................................................  165
4.2.7 Analysis of GABAa Receptor Phosphorylation in Cultured Immature 
Cortical Neurons using Phosphorylation State-Specific Antibodies ......  168
4.3 Discussion............................................................................................................  169
4.4Conclusions............................................................................................................  181
CHAPTER 5: Molecular Determinants of AP2 Binding to GABAa Receptors 182
5.1 Background .........................................................................................................  183
5.2Results..................................................................................................................... 189
5.2.1 The Major Intracellular Domain of Each GABAa Receptor y Subunit 
Interacts with the Native, Neuronal AP2 Adaptor Complex .................... 189
5.2.2 The Major Intracellular Domain of Each GABAa Receptor y Subunit 
Binds Directly and Selectively to the p2-adaptin of the AP2 Adaptor 
Complex.......................................................................................................  191
5.2.3 The Major Intracellular Domain of the GABAa Receptor y2S Subunit 
Contains Two Distinct Sites that each Bind Different Regions of the 
p2-Adaptin ..................................................................................................  193
5.2.4 p2-Adaptin Binds to a Putative Basic-Rich Region in the N-Terminus of
the Major Intracellular Domain of the GABAa Receptor y2S Subunit ... 196
5.2.5 Investigating how the Interaction between the Major Intracellular
11
CONTENTS
Domain of the y2S Subunit and p2-Adaptin is regulated .........................  198
5.2.6 Analysis of the Putative p2-Binding Domains identified in the Major
Intracellular Domain of the y2S Subunit ....................................................  200
5.2.6.1 Sequence Alignment o f the Major Intracellular Domains o f 
GABAa Receptor y Subunits comparing the Similarity o f the 
Putative p2-Adapt in Binding Regions identified in the y2S
Subunit.............................................................................................  200
5.2.6.2 Comparison o f the Basic-Rich p2-Binding Region in the GABAa 
Receptor y2 Subunit with similar p.2-Binding Regions in other 
Proteins .......................................................................................... 202
5.3Discussion................................................................................................................ 202
5.4Conclusions............................................................................................................. 207
CHAPTER 6: General Discussion ......................................................................  209
6.1 Biological and Clinical Implications of the Physical and Functional Interaction
between CaMKII and the GABAa Receptor .........................................................210
6.2Biological and Clinical Implications of the Interaction between the AP2
Adaptor Complex and the GABAa Receptor .....................................................  216
6.3 Future Directions..................................................................................................  218
APPENDIX: Publications and Conference Abstracts ....................................... 221
REFERENCES ....................................................................................................  223
12
LIST OF FIGURES
List of Figures
1.1 Schematic representation of the structure of GABAa receptors.
1.2 Structure and T286-autophosphorylation of CaMKII.
3.1 General overview of the methodologies employed to investigate GABAa 
receptor phosphorylation and receptor-protein interactions.
3.2 CaMKIIa physically interacts with GABAa receptors in vitro and in vivo.
3.3 The major intracellular domains of the GABAa receptor (3 subunits bind 
selectively to a constitutively active CaMKIIa-T286D mutant.
3.4 Binding of CaMKIIa-T286D to the major intracellular domain of the (33 
subunit in vitro requires EGTA.
3.5 Neuronal CaMKIIa binds to the major intracellular domain of the GABAa 
receptor (33 subunit containing serine-to-alanine point mutations of consensus 
phosphorylation sites.
3.6 Identification of a direct docking domain for CaMKIIa-T286D in the major 
intracellular domain of the GABAa receptor (33 subunit.
3.7 N-terminal deletions of the major intracellular domain of the (33 subunit 
disrupt the binding of CaMKIIa-T286D.
3.8 Sequence analysis of the proposed CaMKIIa-docking region in the GABAa 
receptor (33 subunit.
3.9 CaMKII is a novel GABAa receptor-associated kinase.
4.1 CaMKII phosphorylates various GABAa receptor subunits, in vitro.
4.2 Time-course showing the in vitro phosphorylation of GST-(33 by CaMKII.
4.3 Determination of initial rate conditions for phosphatase assays with PP1, 
PP2A, PP2B and PP2C.
4.4 PP1, PP2A and PP2C, but not PP2B, dephosphorylate phospho-S383 and 
phospho-S409 of GST-|33, in vitro.
4.5 Depolarisation of immature cortical neurons enhances the functional 
interaction of neuronal CaMKII with GST-(33.
4.6 CaMKIIa is basally phosphorylated at T286 in immature cortical neurons.
13
LIST OF FIGURES
4.7 Time-course of muscimol-induced phosphorylation of CaMKIIa-T286 in 
immature cortical neurons.
4.8 Muscimol-induced phosphorylation of CaMKIIa at T286 in immature 
cortical neurons is calcium sensitive.
4.9 Time-course of PKC phosphorylation following treatment of immature 
cortical neurons with muscimol.
4.10 CaMKII-dependent phosphorylation of GABAa receptor (33 subunits in situ 
in immature cortical neurons.
4.11 Immunoreactivity of UCL-103 and UCL-104 to the synthetic immunising and 
control peptides.
4.12 Immunoreactivity of UCL-105 and UCL-106 to the synthetic immunising and 
control peptides.
4.13 The anti-|33-pS409 antibody specifically recognises GST-(33 phosphorylated 
at S409.
4.14 Analysis of agonist-induced phosphorylation of the GABAa receptor (33 
subunit in immature cortical neurons.
5.1 Schematic representation of the domain structure of AP2 and the p2-adaptin.
5.2 The major intracellular domains of GABAa receptor y subunits bind to the 
p2-adaptin of AP2 in brain.
5.3 The major intracellular domains of GABAa receptor y subunits bind 
selectively and directly to the p2-adaptin of AP2.
5.4 The major intracellular domain of the GABAa receptor y2S subunit contains 
two distinct sites that each bind different domains of the p.2-adaptin.
5.5 N-terminal deletions of the major intracellular domain of the y2S subunit 
disrupt binding to p2-adaptin.
5.6 Investigating the role of phosphorylation in regulating binding of p2-adaptin 
to the GABAa receptor y2S subunit.
5.7 Sequence analysis of GABAa receptor y subunits showing the position of the 
putative AP2 binding sites.
6.1 Proposed model of CaMKII-dependent phosphorylation and functional
modulation of GABAa receptors in immature cortical neurons.
14
LIST OF TABLES
List of Tables
1.1 Sites of phosphorylation in GABAa receptor subunits.
2.1 Strains of E. coli used in this study.
2.2 Vectors used in this study.
2.3 Oligonucleotides used in this study.
2.4 Synthetic peptides used for the production and characterisation of
phosphorylation state-specific antibodies.
2.5 Timetable for the production of polyclonal phosphorylation state-specific 
antibodies in rabbits UCL-103, UCL-104, UCL-105 and UCL-106.
2.6 Antibodies used in this study.
15
ABBREVIATIONS
Abbreviations
A alanine
Ax absorbance at x nm
AKAP A-kinase anchoring protein
AKAP-79/150 AKAP protein of 79/150 kDa
AMPA a-amino-3-hydroxy-5-methyl-4-isoxazole propionate
Amp ampicillin
AP alkaline phosphatase
AP2 adaptor-binding protein 2
APS ammonium Persulphate
ARF ADP-ribosylation factor
AS Angelman syndrome
ATP adenosine triphosphate
BAPTA l,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid
BAPTA-AM as for ‘BAPTA’ but membrane permeant
BCA bicinchoninic protein assay
BCIP 5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt
BDNF brain-derived neurotrophic factor
BIG2 brefeldin A-inhibited guanine nucleotide-exchange protein
type 2
BSA bovine serum albumin
C cysteine
CACA c/s-4-aminocrotonic acid
CaM calmodulin
CaMKII calcium/calmodulin-dependent protein kinase type 2
CaMKIIa CaMKII alpha subunit
CaMKII(3 CaMKII beta subunit
CaMKII-TA autophosphorylation-deficient CaMKII (T286A point
mutant)
CaMKII-TD constitutively active CaMKII (T286D point mutant)
CaMKII-WT wild type CaMKII
16
ABBREVIATIONS
CAMP cA-2-aminomethyl-cyclopropane carboxylic acid
cAMP cyclic adenosine monophosphate
CCC cation-chloride co-transporter
cDNA complementary DNA
cGMP cyclic guanosine monophosphate
Chloroamp chloramphenicol
CNS central nervous system
COS-7 African green monkey kidney
cpm counts per min
cSrc cellular Src
D aspartate
DARRP-32 dopamine and cAMP-regulated phosphoprotein of 32-kDa
dATP 2’-deoxyadenosine 5’-triphosphate
dCTP 2 ’ -deoxy cy tidine 5 ’ -triphosphate
DG 1,2-dioleoyl-sn-glycerol
dGTP 2’ -deoxy guanosine 5 ’ -triphosphate
DIV days in vitro
DMEM Dulbecco’s modified eagle medium
DNA deoxyribonucleic acid
dNTP deoxynucleotide triphosphate
DOC deoxycholate
DTT dithiothreitol
dTTP 2 ’ -deoxythymidine 5 ’ -triphosphate
E glutamate
E17 embryonic day 17
Ea equilibrium potential of chloride
ECL enhanced chemiluminescence
E. Coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
Egaba equilibrium potential for GABA
EGFR epidermal growth factor receptor
EGTA ethylenebis(oxonitrilo)tetraacetate
17
ABBREVIATIONS
ER endoplasmic reticulum
F phenylalanine
FBS foetal bovine serum
y2S y2 short subunit
y2L y2 long subunit
GABA gamma-aminobutyric acid
GABAa receptor type-A GABA receptor
GABAb receptor type-B GABA receptor
GABAC receptor type-C GABA receptor
GABARAP GABAa receptor-associated protein
GAD glutamic acid decarboxylase
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GAT GABA transporter
GATE-16 Golgi-associated transport enhancer of 16 kDa
GEC-1 GABARAP-like protein type 1
GluR2 AMPA-type glutamate receptor subunit type 2
GODZ Golgi-specific DHHC zinc finger protein
GPCR G-protein coupled receptor
G-protein guanine nucleotide binding proteins
GRIF-1 GABAa receptor interacting factor type-1
GRIP1 glutamate receptor interacting protein type 1
GST glutathione-S-transferase
h hour
HAP-1 huntingtin-associated protein type-1
HC1 hydrochloric acid
HEK-293 human embryonic kidney
HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulphonic acid
HPLC high performance liquid chromatography
HRP horseradish peroxidase
5-HT-2 receptor 5-hydroxytryptamine type 2 receptor
5-HT-3 receptor 5-hydroxytryptamine type 3 receptor
5-HT-4 receptor 5-hydroxytryptamine type 4 receptor
18
ABBREVIATIONS
ICD major intracellular domain
lie isoleucine
IN input
IP3 inositol-1,4,5-triphosphate
IPSC inhibitory postsynaptic current
IPSP inhibitory postsynaptic potential
IPTG isopropylthio-b-D-galactoside
K lysine
KCC2 K+-C1' co-transporter 2
kDa kilodalton
KN93 N- [2- [ [ [3-(4-Chlorophenyl)-2-propenyl]methylamino]
methyl ]phenyl]-A-(2-hydroxyethyl)-4- 
methoxybenzenesulphonamide 
KO knockout
L leucine
LB Luria-Bertani
Leu leucine
LTD long-term depression
LTP long-term potentiation
M methionine
MAP IX microtubule-associated protein IX
Met methionine
mGluR metabotropic glutamate receptor
min minute
mIPSC miniature IPSC
mRNA messenger RNA
n number of experiments
N asparagine
NaCl sodium chloride
NaOH sodium hydroxide
NBT nitro-blue tetrazolium chloride
NKCC1 Na+-K+-2C1' co-transporter 1
19
ABBREVIATIONS
NMDA N-methyl D-aspartate receptors
NP40 nonidet P-40
NSF N-ethylmaleimide-sensitive factor
OD optical density
P proline
PBS phosphate buffered saline
PCR polymerase chain reaction
Phe phenylalanine
PIP2 phosphatidylinositol biphosphate
PIP3 phosphatidylinositol-3,4,5 -triphosphate
PKA cAMP-dependent protein kinase
PKB protein kinase B (also known as Akt)
PKC calcium/phospholipid-dependent protein kinase
PKG cGMP-dependent protein kinase
PLIC-1 protein that links integrin-associated protein with the
cytoskeleton type-1 
PMSF phenylmethylsulfonyl fluoride
PP1 protein phosphatase type 1
PP2A protein phosphatase type 2A
PP2Ac catalytic subunit of PP2A
PP2B calcium/CaM-dependent phosphatase 2B/protein
phosphatase type 2B (also known as calcineurin)
PP2C protein phosphatase type 2C
PRIP-1 phospholipase C-related catalytically inactive protein type 1
PSEL L-a-phosphatidylserine
PSD postsynaptic density
PSD-95 postsynaptic density protein of 95 kDa
PTM post-translational modification
PVDF polyvinylidene fluoride
Q glutamine
R arginine
RACK-1 receptor for activated C-kinase type 1
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ABBREVIATIONS
RNA ribonucleic acid
rpm revolutions per minute
S serine
s second
SDS sodium dodecyl sulphate
SDS-PAGE SDS-polyacrylamide gel electrophoresis
sem standard error of the mean
SNAP25 synaptosomal-associated protein of 25-kDa
sulfo-MBS m-maleimidobenzoyl-A-hydroxysulfosuccinimide ester
T threonine
TASK-1 TWIK-related acid-sensitive potassium channel type 1
TAE tris-acetate EDTA
TBS tris buffered saline
TCA trichloroacetic acid
TE Tris-EDTA
TEMED N, N, N \ N’-tetramethyl-ethylene diamine
temp temperature
THIP 4,5,6,7-tetrahydroisoxazolo-pyridin-3-ol
TM transmembrane
TMX transmembrane domain X
TPMPA (1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid
UT untransfected/mock-transfected
V valine
VDCCs voltage-dependent calcium channels
VIAAT vesicular inhibitory amino acid transporter
W tryptophan
WT wild type
Y tyrosine
21
ACKNOWLEDGEMENTS
Acknowledgements
I would like to begin by thanking my fiance, Jon, for all of his love and generous 
support, for making me smile each day, and for being the person who has made all the 
effort worthwhile. I would also like to thank all of my family, in particular my 
parents, for all of their encouragement and strength. For without all these people, this 
thesis would not have been possible.
I would also like to thank my supervisor, Steve Moss, for welcoming me into his 
research group, and for his continued support and guidance throughout the PhD years.
In addition, I would like to thank Paul Greengard for welcoming me into his 
laboratory in The Rockefeller University, New York, over the summer of 2004, and 
for providing me with the reagents and expertise to investigate GABAa receptor 
dephosphorylation. I am also grateful to UCL for awarding me with a Bogue 
Research Fellowship, which funded this endeavour.
I am also grateful to Howard Schulman, Angus Naim, Trevor Smart, Volker Haucke, 
Wemer Sieghart and J. Anderson for providing purified kinases, various constructs 
and antibodies.
I would also like to thank all members of the Moss laboratory, both past and present, 
for their help and friendship over the years. In particular, I would like to thank Josef 
Kittler for his guidance on the AP2 work in Chapter 5, and for proofreading my 
chapters. I would also like to thank Verena Tretter for her contribution towards the 
coimmunoprecipitation assays in Chapter 3, Mike Lumb, for his help with the 
molecular biology, and Jasmina Jovanovic for her guidance on the phosphorylation 
work in Chapter 4. Special thanks also go to Fiona Bedford, Benjamin Fairfax, 
Lorena Arancibia-Carcamo, Sophie Restituito and Richard Saliba for all the scientific 
discussions, hot chocolates, swift halves and, of course, the gossip...
This work was supported by The Wellcome Trust.
22
CHAPTER 1
Introduction
23
CHAPTER 1 Introduction
PART ONE 
1.1 The Identification and Synthesis of the Neurotransmitter GABA
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the 
adult mammalian brain. This neutral amino acid was originally identified in 
mammalian brain in 1950 (Awapara et al., 1950; Roberts and Frankel 1950), and by 
the 1970s, several lines of evidence had culminated in the recognition of GABA as an 
inhibitory neurotransmitter (reviewed in Owens and Kriegstein, 2002 and Bowery 
and Smart, 2006; see also Kmjevic and Schwartz, 1967; Elliot and Florey, 1956; 
Bazemore et al., 1956; Basemore et al., 1957; Kravitz et al., 1963; Kravitz and Potter, 
1965; Otsuka et al., 1966; Obata, 1972; Kuffler and Edwards 1958; Bloom and 
Iversen, 1971). GABA is synthesised in the terminals of inhibitory neurons from the 
amino acid glutamate in a reaction catalysed by glutamic acid decarboxylase (GAD), 
of which there are at least two forms, GAD65 and GAD67 (Roberts and Frankel 
1950; Martin and Rimvall, 1993; Erlander et al., 1991; Owens and Kriegstein, 2002). 
Once produced, GABA is transported into synaptic vesicles by a vesicular inhibitory 
amino acid transporter (VIAAT) ready for calcium-dependent exocytosis (Owens and 
Kriegstein, 2002). However, GABA is also subject to non-vesicular release by the 
reverse action of plasma membrane GABA transporters (GATs) (Richerson and Wu, 
2003; Cavelier et al., 2005; Owens and Kriegstein, 2002). GABA is predominantly 
released from intemeurons, and exerts its effects by binding to plasma membrane 
GABA receptors (see Sections 1.2 and 1.3). The uptake of GABA into nearby 
neurons and glia by GATs terminates GABAergic transmission, and GABA is 
subsequently metabolised in a reaction catalysed by GABA transaminase, which 
transfers the amino group from GABA to a-oxoglutarate to yield the GABA 
precursor, glutamate, and succinic semialdehyde (Iversen and Neal, 1968; Owens and 
Kriegstein, 2002; Cherubini and Conti, 2001).
1.2 GABA Activates GABA Receptors to Mediate Neuronal Inhibition or 
Excitation
GABA receptors are expressed in most neurons, and are divided into two main 
classes: the ionotropic GABAa and GABAC receptors, which mediate an early fast
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response to GABA, and the metabotropic GABAb receptors, which mediate a later 
slower response to GABA.
GABAa receptors are ligand-gated hetero-oligomeric anion channels. Activation of 
these receptors is most effective following binding of two agonist molecules 
(Baumann et al., 2003), and results in increased membrane permeability to chloride 
and bicarbonate ions (Kaila, 1994). In mature neurons, this usually results in a net 
inward flow of anions and hyperpolarisation, which reduces neuronal excitability. 
This GABAa receptor-mediated inhibition can be described as either ‘phasic’ or 
‘tonic’ (reviewed in Farrant and Nusser, 2005). Phasic (fast synaptic) inhibition 
results from the release of GABA from presynaptic vesicles and the subsequent 
transient activation of postsynaptic GABAa receptors, which are clustered opposite 
the release site (Farrant and Nusser, 2005). The resultant inhibitory postsynaptic 
current (IPSC) is characterised by the magnitude and duration of the GABA transient 
and the functional properties, number and location of the GABAa receptors, and their 
exposure to modulators (Mody and Pearce, 2004; Cherubini and Conti, 2001). In 
addition, a ‘slower’ type of phasic inhibition has been described, which involves 
spillover of GABA from the synaptic cleft and transient activation of spatially distinct 
GABAa receptors, such as those at perisynaptic or extrasynaptic locations (Wei et al., 
2003; Rossi and Hamann, 1998; Mody and Pearce, 2004; Kullmann et al., 2005; 
Nusser et al., 1998a). In contrast to phasic inhibition, tonic inhibition involves the 
persistent activation of high-affinity extrasynaptic GABAa receptors by ambient 
concentrations of GABA (Mody and Pearce, 2004). GABA-mediated tonic 
conductances have been identified in several types of neurons (Brickley et al., 1996, 
2001; Farrant and Nusser, 2005; Nusser and Mody, 2002). In cerebellar granule cells, 
the tonic conductance is dependent upon the expression of GABAa receptor a6  and 6 
subunits (see Section 1.3) (Brickley et al., 2001). The importance of this conductance 
has been revealed in studies of transgenic animals that lack these subunits, which 
have shown that it is compensated by up-regulation of a TASK-1-like potassium 
conductance (Brickley et al., 2001).
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Whilst GABA is most commonly recognised as an inhibitory neurotransmitter, 
GABAa receptor-mediated neuronal excitation has now been described both in 
immature neurons and some mature neurons (Owens et al., 1996, 1999; Ben-Ari et 
ah, 1989; Ben-Ari, 2002; Chen et al., 1996; Wang et al., 2001; Gao and van den Pol, 
2001; Stein and Nicoll, 2003). In developing neurons, the equilibrium potential for 
GABA (Egaba) is more positive than the resting membrane potential of the cell (Stein 
and Nicoll, 2003). This forms the basis of excitation as activation of GABAa 
receptors results in a net outward flow of anions and depolarisation. This 
phenomenon can cause the firing of an action potential (Wang et al., 2001; Gao and 
van den Pol, 2001; Chen et al., 1996), in addition to activation of voltage-dependent 
calcium channels (VDCCs) (Owens et al., 1996) and removal of the magnesium 
block of the NMDA receptor (Leinekugel et al., 1997). GABA therefore plays a role 
in controlling neuronal excitability during development, and GABA-mediated 
signalling has been implicated in a number of developmental processes, such as 
synapse formation, neurite outgrowth and neuronal migration (Ben-Ari, 2002; Owens 
and Kriegstein, 2002).
Egaba is largely influenced by the equilibrium potential of chloride (Eq), as GABAa 
receptors are most permeable to this anion (Kaila, 1994; Stein and Nicoll, 2003). 
Neuronal chloride homeostasis is therefore a critical determinant of EgAba> and hence 
the excitatory action of GABA in immature neurons. The transmembrane chloride 
gradient is predominantly controlled by a family of cation-chloride co-transporters 
(CCCs) (Payne et al., 2003; Mercado et al., 2004). Immature neurons have a high 
intracellular concentration of chloride, and hence a depolarising value of EC1. This 
has been attributed to expression of the inwardly directed Na+-K+-2C1' co-transporter 
1 (NKCC1), which mediates chloride uptake (Yamada et al., 2004; Delpire, 2000; 
Payne et al., 2003; Stein and Nicoll, 2003). During neuronal maturation, the 
intracellular concentration of chloride decreases. This is caused in part by 
progressive down-regulation of NKCC1 (Plotkin et al., 1997) and up-regulation of 
the outwardly directed K+-C1 co-transporter 2 (KCC2), which extrudes chloride from 
the cell (Rivera et al., 1999, 2005; Clayton et al., 1998; Lu et al., 1999; Payne et al., 
2003; Luhmann and Prince, 1991). These changes are believed to account for the
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hyperpolarising shift of EC1 and hence the developmental switch in the action of 
GABA from excitatory to inhibitory (Rivera et al., 1999; Stein and Nicoll, 2003).
GABAa receptors contain a number of distinct binding sites that are accessible to 
various types of extracellular ligands. The GABA-binding site interacts with various 
GABAa receptor agonists and antagonists, in addition to the endogenous 
neurotransmitter. Receptor agonists include the mushroom product, muscimol, and 
synthetic compounds, such as THIP and isoguvacine (Bormann, 2000; Macdonald 
and Olsen, 1994; Mehta and Ticku, 1999). Receptor antagonists include the plant 
alkaloid and convulsant, bicuculline, gabazine (SR95531) and (-t-)-p-hydrastine 
(Bormann, 2000; Mehta and Ticku, 1999; Huang and Johnston, 1990). The GABAa 
receptor ion channel is blocked by convulsants such as picrotoxinin, which exhibits 
non-competitive inhibition, and TBPS (Macdonald and Olsen, 1994). GABAa 
receptor function is also subject to regulation by zinc ions and changes in pH (Hosie 
et al., 2003; Krishek etal., 1996; Wilkins etal., 2005).
GABAa receptors contain distinct modulatory binding sites for a number of centrally 
active drugs, including benzodiazepines, barbiturates neurosteroids, some 
anaesthetics and ethanol (reviewed in Macdonald and Olsen, 1994). The binding of 
an agonist ligand to the benzodiazepine site allosterically enhances the action of 
GABA, by increasing the opening frequency of the GABAa receptor channel 
(Macdonald and Olsen, 1994). Benzodiazepines can mediate anxiolytic, anti­
convulsant, muscle relaxant, amnesic, sedative and hypnotic effects, and include 
agents such as diazepam and lorazepam (Mohler et al., 2002). Studies using knockin 
mice have begun to relate these therapeutic actions to particular GABAa receptor 
subtypes and amino acid residues (Mohler et al., 2002; Rudolph and Mohler, 2004). 
However, disadvantages of the clinical use of benzodiazepines include symptoms of 
withdrawal and the development of tolerance and dependence. Inverse 
benzodiazepine agonists have also been developed, and these have been shown to 
exert anxiogenic and convulsant effects. The binding of an agonist ligand to the 
barbiturate site can activate GABAa receptors directly, and allosterically enhance the 
action of GABA, apparently by enhancing the mean channel open duration
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(Macdonald and Olsen, 1994). Barbiturate drugs can mediate anxiolytic, sedative, 
hypnotic, anti-convulsant and anaesthetic effects, and include agents such as 
pentobarbitone, phenobarbitone and thiopentone. However, barbiturates induce 
tolerance and dependence, and can be lethal when overdosed. Neurosteroids can also 
activate GABAa receptors directly and potentiate the effect of GABA (Macdonald 
and Olsen, 1994). The neurosteroid site binds metabolites of endogenous steroid 
hormones, such as androsterone and pregnanolone, which have a sedative effect, and 
synthetic compounds such as the anaesthetic alphaxalone (Macdonald and Olsen, 
1994). Several gaseous and intravenous anaesthetics, such as enflurane, halothane 
and propofol are also believed to act at distinct sites on GABAa receptors (Mehta and 
Ticku, 1999; Rudolph and Mohler, 2004).
Like GABAa receptors, GABAc receptors are ligand-gated chloride-permeable 
hetero-pentameric ion channels. Although GABAC receptors display some structural 
similarity to the GABAa receptor (see Section 1.3), they are predominantly expressed 
in the vertebrate retina and are pharmacologically distinct (Polenzani et al., 1991; 
Feigenspan et al., 1993; Cutting et al., 1991; Koulen et al., 1997, 1998; Bormann and 
Feigenspan, 1995). For example, GABAC receptors exhibit greater sensitivity to 
GABA than GABAa receptors, and desensitise more slowly. Furthermore, unlike 
GABAa receptors, GABAC receptors are activated by the agonists CACA and CAMP, 
and bind the antagonist, TPMPA (Bormann, 2000; Bormann and Feigenspan, 1995). 
Conversely, the GABAC receptor is insensitive to the GABAa receptor antagonist, 
bicuculline, and GABAa receptor modulators such as benzodiazepines, barbiturates 
and neurosteroids (Bormann, 2000).
In contrast to the ionotropic GABAa and GABAC receptors, which mediate fast 
synaptic transmission, the metabotropic GABAb receptor mediates slow inhibitory 
neurotransmission. The GABAb receptor exists as a heterodimer and is expressed 
pre- and postsynaptically. The two constituent subunits, GABAB1 and GABAB2, were 
only recently cloned (Kaupmann et al., 1997, 1998; White et al., 1998; Jones et al., 
1998), although a number of splice variant isoforms have since been identified for 
each subunit (Kaupmann et al., 1997; Isomoto et al., 1998; Couve et al., 2000). Each
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GABAb receptor subunit comprises a large extracellular N-terminal region, seven 
transmembrane (TM) domains and an intracellular C-terminal tail, which contains a 
coiled-coil domain involved in subunit coupling (Kammerer et al., 1999). Functional 
GABAb receptors are trafficked to the plasma membrane in the heterodimeric form 
(White et al., 1998; Kuner et a l, 1999; Couve et al., 2000). The extracellular domain 
of the GABAbi subunit confers binding to GABA, and the extracellular domain of the 
GABAB2 subunit contains a binding site for an allosteric modulator (Bowery and 
Smart, 2006). GABAb receptors decrease neuronal excitability by activating 
postsynaptic potassium currents and inhibiting pre-synaptic calcium currents via G- 
protein coupling. Receptor-G-protein-coupling also leads to inhibition of adenylate 
cyclase. In addition to endogenous GABA, GABAb receptors also bind agonists such 
as baclofen and APPA, and antagonists such as 2-OH-saclofen, phaclofen and 
SCH50911 (Bonanno and Raiteri, 1993). GABAb receptor modulators have been 
used in the treatment of spasticity and neuralgia, and such agents may have 
therapeutic potential in the treatment of drug abuse, and as anti-depressants, anti­
convulsants and enhancers of cognition (Cousins et al., 2002; Bowery and Smart, 
2006; Couve et al., 2000).
1.3 GABAa Receptor Structure and Assembly
The ionotropic GABAa (and GABAC) receptors belong to the superfamily of ligand- 
gated ion channels, members of which include the nicotinic acetylcholine receptor, 
the glycine receptor and the 5-hydroxytryptamine type 3 (5-HT-3) receptor (Ortells 
and Lunt, 1995; Schofield et al., 1987; Unwin, N, 1993; Maricq et al., 1991; 
Grenningloh et al., 1987). All receptors within this superfamily are hetero- 
pentameric ion channels assembled with subunits that share a common topology 
(Ortells and Lunt, 1995; Unwin, N, 1998). Indeed, GABAa (and GABAC) receptor 
subunits each have extracellular N- and C-terminal domains, four putative 
hydrophobic transmembrane (TM) regions (TM1-TM4) and a major intracellular 
domain (ICD) between TM3 and TM4 (Fig. 1.1A) (Nayeem et al., 1994; Macdonald 
and Olsen, 1994). The large, extracellular N-terminal region contains a short 
conserved cysteine loop and putative sites for glycosylation, ligand binding and 
subunit oligomerisation (Taylor et al., 2000, 1999; Klausberger et al., 2000, 2001a,b;
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Adapted, from Moss and Smart, 2001
Figure 1.1. Schematic representation of the structure of GABAa receptors. A.
GABAa (and GABAC) receptor subunits contain extracellular N- and C-terminal 
regions and four hydrophobic transmembrane (TM) domains, numbered 1-4. TM2 
(coloured light green) is believed to line the pore of the putative pentameric ion 
channel complex. The major intracellular domain between TM3 and TM4 is the most 
divergent region of the subunit. It mediates numerous protein-protein interactions and 
is subject to post-translational modifications, such as phosphorylation. B. Most 
neuronal GABAa receptors are believed to comprise a, (3 and y subunits in the ratio 
2:2:1. In some complexes, the y subunit is exchanged for a 6, s or 0 subunit. GABAC 
receptors are homomeric or heteromeric pentameric assemblies of p i-3 subunits. 
Their subunit stoichiometry is unknown.
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Srinivasan et al., 1999; Macdonald and Olsen, 1994; Kittler et al., 2002). TM2 of 
each subunit is believed to line the channel (Fig. 1.1 A). The ICD is the least 
conserved region of the subunit protein. It mediates numerous protein-protein 
interactions and is subject to post-translational modifications, such as palmitoylation 
and phosphorylation (see Section 1.7.2) (Rathenberg et al., 2004; Keller et al., 2004; 
Moss and Smart, 2001).
There are currently 16 known mammalian GABAa receptor subunits, which can be 
arranged into seven classes according to amino acid sequence identity: a  1-6, (31-3, 
yl-3, 6 , e , j t  and 0 (Fig. 1.1B) (Rabow et al., 1995; Davies et al., 1997; Hedblom and 
Kirkness, 1997; Bonnert et al., 1999; Moss and Smart, 2001). An additional distinct 
class of subunits, the p l - 3  subunits, has also been described. These assemble as 
homo- or hetero-oligomers to form GABAC receptors (Fig. 1.1B; Section 1.2) 
(Bormann, 2000; Mehta and Ticku, 1999). Alternative mRNA splicing generates 
further GABAa receptor subunit diversity. For example, two splice variants of the y2 
subunit have been identified, namely y2 short (y2S) and y2 long (y2L), which differ 
on account of an eight amino acid insert (LLRMFSFK) in the ICD of the y2L subunit 
(Whiting et al., 1990; Kofuji et al., 1991). Splice variant forms of mammalian a6  
and {33 subunits have also been identified (Korpi et al., 1994; Kirkness and Fraser,
1993).
GABAa receptor subunits are differentially expressed throughout the brain in a 
spatially and temporally controlled manner (Wisden et al., 1992; Laurie et al., 
1992a,b; Fritschy and Mohler, 1995; Pirker et al., 2000). For example, cerebellar 
granule cells are enriched with mRNA of the a6  subunit but do not appear to contain 
mRNA of the a5 subunit (Laurie et al., 1992a). Furthermore, in the cortex, mRNA of 
the (33 subunit is markedly expressed prenatally, whereas mRNA of the {32 subunit is 
mainly expressed postnatally (Laurie et al., 1992b). Individual neurons express a 
variety of GABAa receptor subunits, which assemble into various receptor 
complexes. The large pool of GABAa receptor subunits provides potential for 
extensive receptor heterogeneity. However, although the precise subunit composition 
of native receptors remains unknown, the majority of neuronal receptors are believed
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to be composed of a , (3 and y subunits in a ratio of 2 to 2 to 1, respectively (Fig. 1.1B) 
(Tretter et al., 1997; Farrar et al., 1999; Chang et al., 1996). Indeed, the most 
prevalent receptor complex has been suggested to contain a l ,  ^2 and y l  subunits 
(Sieghart and Sperk, 2002; McKeman and Whiting, 1996). In addition, some 
receptor assemblies are thought to contain a 6, £ or 0 subunit in place of the y subunit 
(Fig. 1.1B), and form functional high-affinity GABAa receptors that are insensitive to 
benzodiazepines (Moss and Smart, 2001; McKeman and Whiting, 1996; Saxena and 
MacDonald, 1996). Indeed, evidence suggests that the binding site for GABA is 
located at the interface between the a  and (3 subunits, and the binding site for 
benzodiazepines at the interface between the a  and y subunits (Baumann et al., 2003; 
Sigel and Buhr, 1997).
In addition to determining pharmacological properties of GABAa receptors, subunit 
composition is also involved in determining channel properties and the clustering and 
sub-cellular targeting of the receptors, as discussed in the following section (Rudolph 
et al., 2001; Macdonald and Olsen, 1994; Kittler et al., 2002; Nusser et al., 1996, 
1998a; Fritschy etal., 1998; Koulen etal., 1996).
1.4 Membrane Clustering and Targeting of GABAa Receptors
Subunit composition is believed to be a major determinant of the sub-cellular 
localisation of GABAa receptors. For example, in hippocampal pyramidal neurons 
a2  subunit-containing GABAa receptors are predominantly localised to the axon 
initial segment, whereas a5 subunit-containing GABAa receptors are found at 
extrasynaptic sites (Nusser et al., 1996; Fritschy et al., 1998; Brunig et al., 2002; 
Caraiscos et al., 2004). Furthermore, in cerebellar granule cells, y l  subunit- 
containing GABAa receptors are localised mainly at synaptic sites, whereas 5 
subunit-containing GABAa receptors are located exclusively at extrasynaptic sites 
(Nusser et al., 1998a; Brickley et al., 1999; Moss and Smart, 2001).
The synaptic targeting and clustering of GABAa receptors is a critical determinant of 
the efficacy of inhibitory synaptic transmission and animal behaviour (Kneussel and 
Betz, 2000; Crestani et al., 1999; Essrich et al., 1998). However, the mechanisms
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involved in the accumulation and clustering of GABAa receptors remain elusive. The 
y l  subunit is believed to be a component of all postsynaptic GABAa receptors, and 
analyses of y2 (-/-) subunit knockout mice have revealed a critical role of this subunit 
in the postsynaptic localization and clustering of GABAa receptors containing yl, a l  
and a2  subunits, and the multifunctional tubulin-binding protein, gephyrin (Essrich et 
al., 1998). Whereas TM4 of the y2 subunit appears to be necessary and sufficient for 
the clustering of postsynaptic receptors, both TM4 and the major intracellular domain 
of this subunit appear to be involved in the accumulation of gephyrin (Alldred et al., 
2005).
Gephyrin is essential for the localization of glycine receptors at synaptic sites, and is 
believed to be involved in the accumulation and clustering of GABAa receptors at 
inhibitory synapses (Essrich et al., 1998; Kneussel et al., 1999; Levi et al., 2004; 
Kneussel and Betz, 2000). This 93-kDa protein has been shown to co-localise with 
GABAa receptors in various brain regions, though a direct interaction between 
gephyrin and GABAa receptors has not yet been described (Essrich et al., 1998; 
Kneussel and Betz, 2000). Analysis of gephyrin (-/-) knockout mice has revealed that 
gephyrin is involved in the clustering of most GABAa receptor y l  and a2  subunits in 
spinal cord and cultured hippocampal neurons (Kneussel et al., 1999; Levi et al., 
2004). Furthermore, antisense-mediated knockdown of gephyrin has revealed that 
this protein plays a major role in the clustering of GABAa receptor y l  and a l  
subunits in cultured cortical neurons (Essrich et al., 1998).
Interestingly, the presynaptic transmembrane protein, neurexin, has been shown to 
trigger postsynaptic clustering of GABAa receptors and gephyrin, an effect that is 
believed to be mediated via the postsynaptic transmembrane counterpart protein, 
neuroligin-2 (Graf et al., 2004). However, although neuroligin-2 has been localised 
to GABAergic synapses, it does not appear to interact directly with either GABAa 
receptors or gephyrin (Graf et al., 2004). This suggests that other GABAa receptor- 
associated proteins are involved in the aggregation of these receptors. Subunit- 
specific differences in the mechanism of GABAa receptor clustering have also been 
proposed and further support this view. For example, the clustering of GABAa
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receptor a l  and a5  subunits in the spinal cord is believed to be independent of 
gephyrin, and therefore involve other, possibly unidentified, proteins (Kneussel et al., 
2001). Interestingly, a recent study has demonstrated that the activated actin-binding 
protein, radixin, is a direct binding-partner of the GABAa receptor a5 subunit, and is 
involved in the clustering of these subunits in cultured hippocampal neurons 
(Loebrich et al., 2006). The protein rapsyn has also been implicated in the clustering 
of GABAa receptors containing a l ,  p i and y2 subunits in QT-6 cells (Yang et al.,
1997).
1.5 Stability and Dynamics of GABAa Receptors at the Cell Surface
The number of GABAa receptors localised at postsynaptic sites is a major 
determinant of inhibitory synaptic strength (Nusser et al., 1997, 1998b; Otis et al.,
1994) (see Section 5.1). The level of expression of postsynaptic GABAa receptors 
therefore has significant consequences for neuronal excitability. GABAa receptors 
are believed to cycle continuously between the plasma membrane and intracellular 
compartments (Kittler et al., 2000a, 2004a; Connolly et al., 1999a,b). The relative 
rates of receptor insertion and removal into or from the neuronal membrane are 
therefore thought to play a major role in determining the number of GABAa receptors 
at synaptic sites. The lateral diffusion of GABAa receptors in the plane of the 
membrane has also been suggested to control the movement of receptors into and out 
of synaptic sites (Thomas et al., 2005; Jacob et al., 2005).
GABAa receptors can be delivered to the plasma membrane as newly assembled 
complexes via a de novo secretory pathway, or reinserted into the neuronal membrane 
following internalisation (these processes are discussed in Sections 1.6 and 5.1). 
However, it is not yet known whether GABAa receptors are inserted directly into 
synaptic sites, or whether they first incorporate into extrasynaptic membrane regions 
and subsequently accumulate at postsynaptic specialisations.
1.6 Trafficking of GABAa Receptors to the Cell Surface
The oligomerisation of GABAa receptor subunits into channel complexes is believed 
to occur in the endoplasmic reticulum, and evidence suggests that this assembly
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process is involved in regulating the trafficking of channel complexes to the cell 
surface (reviewed in Kittler et al., 2002). In addition, a number of cytoplasmic 
proteins have been identified that appear to be involved in delivering GABAa 
receptors to the neuronal membrane.
The 17-kDa, GABAa receptor-associated protein, GABARAP, belongs to a family of 
proteins involved in membrane transport, members of which include the transport 
factor GATE-16 and light-chain 3 of MAPI A and MAP1B (Sagiv et al., 2000; 
Kabeya et al., 2000; Mann and Hammarback, 1994; Kittler et al., 2002). Several 
lines of evidence suggest that GABARAP is involved in the trafficking of GABAa 
receptors. Biochemical and immunofluorescence experiments have shown that 
GABARAP coimmunoprecipitates with GABAa receptors from brain, and co- 
localises with GABAa receptors in cultured cortical neurons (Wang et al., 1999; Leil 
et al., 2004). In vitro binding studies have further revealed that GABARAP 
selectively interacts with the major intracellular domain of the GABAa receptor y 
subunit (Nymann-Anderson et al., 2002; Wang et al., 1999). Interestingly, this 
interaction appears to be involved in, though is not essential for, the trafficking of 
GABAa receptors to the neuronal surface (Leil et al., 2004; O’Sullivan et al., 2005). 
Localisation studies have revealed that GABARAP is associated predominantly with 
intracellular structures, such as the Golgi apparatus and a sub-synaptic tubulo- 
vesicular compartment, which is consistent with a role of this protein in GABAa 
receptor transport (Kittler et al., 2001). Furthermore, GABARAP has been shown to 
interact with NSF (Kittler et al., 2001), a direct binding-partner of GABAa receptors 
(Goto et al., 2005) that is involved in membrane trafficking processes. GABARAP 
and NSF have also been shown to co-localise on intracellular membranes in cultured 
neurons (Kittler et al., 2001). The interaction between GABARAP and tubulin has 
been proposed to form a link between GABAa receptors and the cytoskeleton that 
may be involved in the trafficking and clustering of GABAa receptors (Wang and 
Olsen, 2000; Wang et al., 1999; Coyle et al., 2002; Chen et al., 2000). Indeed, 
GABARAP has been shown to promote the clustering of GABAa receptors that 
contain the y2 subunit in QT-6 quail fibroblasts (Chen et al., 2000). GABARAP has 
also been shown to interact with the synaptic proteins gephyrin (Kneussel et al.,
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2000) and GRIP1 (glutamate receptor interacting protein type 1) (Kittler et al., 
2004b). However, the association with gephyrin does not play a role in the anchoring 
of synaptic GABAa receptors (Kneussel et a l, 2000), and gephyrin and GABARAP 
do not co-localise significantly in cultured neurons (Kittler et al., 2001). Indeed, 
ultrastructural studies suggest that GABARAP is not a major component of inhibitory 
synapses (Kittler et al., 2001). GABARAP may therefore induce GABAa receptor 
clustering indirectly by enhancing the movement of these receptors to the neuronal 
surface. Notably, an in vitro interaction between the GABARAP-like protein, GEC1, 
and both GABAa receptors and tubulin has also been described (Mansuy et al., 2004). 
However, the role of this association in the trafficking of GABAa receptors remains 
to be determined.
The phospholipase C-related catalytically inactive protein type 1 (PRIP-1; also known 
as p i30) is believed to be involved in regulating the function of GABAa receptors. 
Indeed, it has been suggested that PRIP-1 may be involved in the phosphorylation- 
dependent regulation and trafficking of these receptors. PRIP-1 
coimmunoprecipitates with GABAa receptor p3 subunits from brain, and binds 
directly and selectively to the major intracellular domains of the receptor p subunits 
(Terunuma et al., 2004). PRIP-1 also binds the serine/threonine phosphatase P P la , 
and is believed to target this enzyme to the GABAa receptor (Terunuma et al., 2004; 
Yoshimura et al., 2001; Uji et al., 2002). This anchoring process has been proposed 
to play a role in regulating the phosphorylation state and activity of GABAa 
receptors, and is discussed further in Section 1.7.2.2.1 (Terunuma et al., 2004; 
Yoshimura et al., 2001). PRIP-1 (and its homologue PRIP-2) has also been shown to 
bind GABARAP (Kanematsu et al., 2002; Yoshimura et al., 2001; Terunuma et al., 
2004; Uji et al., 2002). This interaction may regulate the effect of GABARAP on the 
trafficking and clustering of y l  subunit-containing GABAa receptors, as PRIP-1 and 
the receptor y2 subunit have been shown to compete for the interaction with 
GABARAP (Kanematsu et al., 2002; Uji et al., 2002). Indeed, the behaviour and 
GABAa receptor pharmacology of PRIP-1 (-/-) knockout mice is consistent with an 
altered function of y l  subunit-containing GABAa receptors (Kanematsu et al., 2002).
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The ubiquitin-like protein Plic-1 (protein that links integrin-associated protein with 
the cytoskeleton type-1) has also been implicated in regulating GABAa receptor 
trafficking. Plic-1 is believed to be involved in stabilising proteins by interfering with 
ubiquitin-mediated proteolysis (Kleijnen et al., 2000; Mah et al., 2000). This 67-kDa 
protein has been shown to bind the major intracellular domains of GABAa receptor a  
and p subunits, and these interactions are believed to increase the half-life of 
intracellular GABAa receptors, and facilitate their delivery to the neuronal surface 
(Bedford et al., 2001). This putative role is consistent with localisation studies, 
which have detected Plic-1 at a number of intracellular compartments, including the 
Golgi apparatus and sub-synaptic cistemae, in addition to GABAergic synapses 
(Bedford et al., 2001). These findings further suggest that Plic-1 may facilitate the 
insertion of both internalised and newly synthesised receptors into the plasma 
membrane.
The huntingtin-associated protein type-1 (HAP-1) is also believed to play a role in 
regulating the function of GABAa receptors. HAP-1 has been shown to 
coimmunoprecipitate with P subunit-containing GABAa receptors from brain, and to 
bind selectively to the major intracellular domains of the receptor p subunits, in vitro 
(Kittler et al., 2004a). HAP-1 has also been shown to co-localise with y2 subunit- 
containing GABAa receptors in cultured hippocampal neurons (Kittler et al., 2004a). 
The interaction of HAP-1 with the GABAa receptor is believed to play a role in the 
post-endocytic sorting and trafficking of GABAa receptors, as overexpression of 
HAP-1 in cultured neurons has been shown to inhibit the degradation of internalised 
GABAa receptors, and promote receptor recycling to the plasma membrane (Kittler et 
al., 2004a). It has also been shown to increase the number of synaptic GABAa 
receptors, and to potentiate the mean amplitude of miniature inhibitory post-synaptic 
currents (mIPSCs) (Kittler et al., 2004a). Previous studies have implicated HAP-1 in 
membrane transport and post-endocytic protein sorting (Gutekunst et al., 1998; 
Martin et al., 1999; Li et al., 2002; Engelender et al., 1997). Indeed, this protein has 
been shown to bind a number of proteins involved in membrane transport, such as the 
pl508lued subunit of dynactin (Engelender et al., 1997) and the light-chain subunit of 
the microtubule-based kinesin motor complex (McGuire et al., 2006). Interestingly,
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GRIP1, which co-localises with GABAa receptors in cultured neurons (Kittler et al., 
2004b; Charych et al., 2004a), and GRIF-1 (GABAa receptor interacting factor type- 
1), which binds (32 subunit-containing GABAa receptors (Beck et al., 2002), have 
also been shown to interact with kinesins (Setou et al., 2002; Brickley et al., 2005; 
Pozo and Stephenson, 2006). A number of proteins may therefore be involved in 
GABAa receptor trafficking by linking receptor complexes to microtubule motors. 
However, it remains to be determined whether GABAa receptors bind directly to 
kinesins and GRIP1.
Another protein that is believed to play a role in regulating GABAa receptor function 
is BIG2 (brefeldin A-inhibited guanine nucleotide-exchange protein type 2), which 
has been shown to activate small GTPases of the ADP-ribosylation factor (ARF) 
family, and play an important role in vesicular trafficking (Morinaga et al., 1997; 
Welsh et al., 1994; Jones et al., 2005). The interaction of BIG2 with (3 subunit- 
containing GABAa receptors has been implicated in facilitating the trafficking of 
GABAa receptors to the cell surface, a role that is consistent with localisation studies, 
which have detected BIG2 in various intracellular compartments, including the trans- 
Golgi network, recycling endosomes and inhibitory synapses (Charych et al., 2004b; 
Shin et al., 2004).
It is now believed that GABAa receptors are subject to regulation by palmitoylation 
(or thioacylation) (Keller et al., 2004; Rathenberg et al., 2004), a reversible post- 
translational modification that is known to regulate the localisation of numerous 
proteins, and which involves the addition of the 16-carbon fatty acid, palmitate, to 
cysteine residues (Huang and El-Husseini, 2005). Recent studies have identified an 
association between GABAa receptors and the palmitoyl acyl transferase, GODZ 
(Golgi-specific DHHC zinc finger protein) (Keller et al., 2004; Uemura et al., 2002). 
GODZ binds selectively to a region of the receptor y subunit that contains a number 
of conserved cysteine residues (Keller et al., 2004), and is believed to be involved in 
palmitoylation of these sites (Keller et al., 2004; Rathenberg et al., 2004). 
Palmitoylation of GABAa receptors has been shown to enhance both receptor 
clustering and cell-surface expression (Rathenberg et al., 2004). These effects may
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result from an enhancement in the trafficking of receptors to the neuronal surface, 
which would be consistent with the enrichment of GODZ in the Golgi apparatus 
(Uemura et al., 2002), and a reduction in the internalisation of receptors from the cell 
surface. Indeed, this would be consistent with GODZ-mediated palmitoylation of 
AMPA receptors, which regulates receptor levels in the Golgi apparatus and receptor 
internalisation (Hayashi etal., 2005).
Protein kinases have also been implicated in the cell-surface trafficking of GABAa 
receptors. For example, activation of PKC has been shown to reduce the level of 
expression of recombinant y2 subunit-containing GABAa receptors on the cell surface 
of HEK-293 cells (Connolly et al., 1999a). This effect is believed to result from 
inhibition of receptor recycling to the plasma membrane following internalisation, 
and has been shown to be independent of the PKC phosphorylation sites (Connolly et 
al., 1999a). Similar results have also been seen in Xenopus oocytes (Chapell et al.,
1998). The role of direct receptor phosphorylation in the trafficking of GABAa 
receptors is discussed in Section 1.7.3 and in Chapter 5.
1.7 Phosphorylation-Dependent Functional Modulation of GABAa Receptors
1.7.1 Phosphorylation-Dependent Modification of Proteins is a Key Component 
of Intracellular Signalling Networks and Modulates Various Neuronal Processes
Phosphorylation and dephosphorylation by protein kinases and phosphatases is 
fundamental to the activity of cellular signalling networks. Phosphorylation is one of 
the most well-studied and ubiquitous post-translational modifications (PTMs) of 
protein structure. Like other PTMs, such as palmitoylation and ubiquitination, 
phosphorylation regulates protein activity.
Protein phosphorylation involves the transfer of the terminal (y) phosphoryl group of 
a magnesium-ATP complex to an intracellular protein at a serine, threonine or 
tyrosine residue. This occurs in a reaction catalysed by either a serine/threonine- or 
tyrosine-specific protein kinase. Phosphorylation is a covalent modification and can 
be reversed by hydrolysis of the phosphoryl group in a reaction catalysed by a protein
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phosphatase. Phosphorylation reactions are characterised by distinct kinetics, and can 
trigger transient or long-lasting downstream events. The addition of a phosphoryl 
moiety to a protein induces conformational change due to alterations in properties 
such as charge and hydrogen-bonding capacity. This structural modification can alter 
protein interactions and the catalytic activity of enzymes, as well as ion channel and 
receptor function.
The human genome encodes for 518 protein kinases and an estimated 150 protein 
phosphatases (Manning et al., 2002; Papin et al., 2005). This diversity is increased 
further by alternative splicing of the phosphoregulator genes, which produces mRNA 
transcripts for ~1,295 kinase and ~375 phosphatase isoforms (Papin et al., 2005). 
The complexity of phosphorylation-dependent signalling networks is believed to 
underlie the remarkable specificity of phosphorylation-dependent signalling 
responses to various extracellular stimuli, and is increased further by the 
combinatorial assembly of kinases, phosphatases and other protein complexes (Papin 
et al., 2005). Protein kinases and phosphatases often recognise specific binding and 
phosphorylation motifs, which are present in a number of different proteins. 
Consequently, individual cells contain large repertoires of potential kinase binding- 
partners and substrates. As well as increasing the potential for combinatorial 
interactions, this forms a basis for signal amplification. Indeed, phosphorylation- 
dependent signalling pathways can be particularly extensive if any of the target 
substrates proceed to modulate a further set of proteins. However, tight spatio- 
temporal control of the expression, alternative-splicing, sub-cellular targeting and 
stability of signalling proteins plays a critical role in limiting combinatorial protein 
interactions and in restricting the potential complexity of phosphorylation-dependent 
signalling (Papin et al., 2005).
One-third of intracellular proteins are estimated to be phosphoproteins (Johnson and 
Hunter, 2005). Many of these substrates can be modulated by more than one protein 
kinase (or PTM or other signalling component). Although this can lead to 
convergence of signalling pathways, it can also increase the number of functional 
states of a protein, particularly if the upstream modulators have multiple and distinct
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sites of phosphorylation. This can enable a phosphoprotein to exert specific functions 
in a regulated manner in response to various external stimuli.
The profound importance of phosphorylation-dependent modulation and signal 
integration in the control of neuronal signalling and animal behaviour is exemplified 
in a series of experiments examining the dopamine and cyclic AMP-regulated 
phosphoprotein of 32-kDa (DARRP-32), which can be regarded as a type of neuronal 
intracellular signalling hub. DARRP-32 has multiple functional states determined by 
the phosphorylation state of four distinct sites (Greengard et al., 2001; Svenningsson 
et al., 2003). Phosphorylation of T34 by PKA converts DARRP-32 into a potent 
inhibitor of PP1 (Hemmings et al., 1984), and this effect can be enhanced by 
phosphorylation of S97 (Girault et al., 1989). In addition to this, in vitro 
phosphorylation of S I30 by casein kinase-1 has also been shown to prevent 
dephosphorylation of phospho-T34 by PP2B (Desdouits et al., 1995). 
Phosphorylation of T75 by cyclin-dependent kinase 5 (Cdk5) converts DARRP-32 
into an inhibitor of PKA, and causes activation of PP1 (Bibb et al., 1999). 
Collectively, these studies suggest that phosphorylation events are important 
determinants of downstream PP1 and PKA signalling (Greengard et al., 1999). 
Interestingly, a further study by Greengard and colleagues showed that treating mice 
with psychotomimetics, which disrupt glutamatergic, serotonergic or dopaminergic 
neurotransmission, alters the phosphorylation state of DARRP-32 at three of the 
above-mentioned sites in a manner predicted to cause synergistic blockade of PP1 
function (Svenningsson et al., 2003). The authors showed that some of the 
behavioural effects of these psychotomimetics are dependent upon DARRP-32 
phosphorylation by using DARRP-32 knockout mice and phosphomutant mice 
containing alanine point mutations at various DARRP-32 phosphorylation sites 
(Svenningsson et al., 2003).
The co-ordinated activity of protein kinases and phosphatases plays a pivotal role in 
controlling many neuronal processes, including neurotransmission and synaptic 
plasticity (Turner et al., 1999; Swope et al., 1999; Levitan, 1999, 1994). Indeed, the 
phosphorylation of ligand-gated ion channels can regulate several receptor properties,
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such as channel activity and receptor trafficking, and have a significant impact on the 
efficacy of synaptic transmission and neuronal excitability (Wang et al., 2005; 
Luscher and Keller, 2004; Turner et al., 1999; Levitan, 1999). It is therefore essential 
to elucidate the precise mechanisms by which protein kinases and phosphatases 
regulate the phosphorylation state and activity of ligand-gated ion channels.
1.7.2 GABAa Receptors undergo Phosphorylation-Dependent Modification
GABAa receptors are well-established phosphoproteins. Evidence suggests that the 
phosphorylation state of these receptors is determined by the activity of various 
serine/threonine and tyrosine protein kinases and phosphatases (Moss and Smart,
2001). A num ber of these enzym es have been shown to 
phosphorylate/dephosphorylate specific residues located within the major 
intracellular domain of particular receptor subunits in neurons, heterologous cell lines 
and in vitro (Moss and Smart, 2001; Kittler and Moss, 2003; Table 1.1). The 
targeting of individual protein kinases and phosphatases to GABAa receptors is 
believed to ensure stoichiometric phosphorylation of the receptor subunits. Indeed, 
emerging evidence suggests that GABAa receptors are components of dynamic 
protein scaffolds containing various phosphomodulators and other phosphorylation- 
dependent signalling components (see Fig. 3.9).
In this section, I will discuss the known roles of protein kinases and phosphatases in 
phosphorylation-dependent modification of GABAa receptors. I will discuss the 
known physical interactions between GABAa receptors and these signalling enzymes, 
the known sites of phosphorylation and the effects of this modification on GABAa 
receptor function. Finally, I shall discuss some known roles of phosphorylation- 
dependent signalling in GABAa receptor cross-talk in neurons.
1.7.2.1 The Role of Protein Kinases
1.72.1.1 PKC and the RACK-1 Anchoring Protein
PKC has been extensively investigated as a GABAa receptor kinase. In vitro 
biochemical studies using purified, bacterially expressed GST-fusion proteins of the
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GABAa Receptor Phosphorylation 
Subunit Site Protein Kinase
In Vitro HeterologousCell-Lines
Primary
Neurons
a l T337
S416
GAPDH
GAPDH
PI S384
S409
Y370
Y372
CaMKII 
PKC, PKA, 
CaMKII, PKG
PKC, PKA
vSRC
vSRC
(32 S410 PKC, PKA, Akt, 
CaMKII, PKG
PKC, Akt Akt
(33 S383
5408
5409
CaMKII
PKC
PKC, PKA, 
CaMKII, PKG
PKC, PKA 
PKC, PKA
PKC, PKA 
PKC, PKA
Y2 S327 
S343 (in y2L only) 
S348 
T350 
Y365 
Y367
PKC
PKC, CaMKII
CaMKII
CaMKII
cSrc
cSrc
vSRC
vSRC
(Adapted from Brandon et al., 2002)
Table 1.1. Sites of phosphorylation in GABAa receptor subunits. Phosphorylation 
sites were identified from in vitro studies using purified GST-fusion proteins of the 
major intracellular domains of GABAa  receptor subunits, and from studies of 
recombinant receptors expressed in heterologous cell lines, or native receptor 
complexes in primary neuronal cultures. Protein kinases involved in phosphorylation 
of individual sites in a particular system are indicated where known. See text for 
references.
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major intracellular domains of GABAa receptor subunits have revealed that this 
serine/threonine protein kinase selectively phosphorylates the (3 and y receptor 
subunits, but not the a l  subunit (Moss et al., 1992a; McDonald and Moss, 1997). 
Further analysis utilising site-directed mutagenesis showed that the (3 subunits are 
each phosphorylated by PKC at a conserved serine residue, namely S409 of the (31 
subunit (Moss et al., 1992a), S410 of the |32 subunit, and S409 of the |33 subunit 
(McDonald and Moss, 1997) (Table 1.1). An additional site of phosphorylation, 
S408, was also identified in the (33 subunit (McDonald and Moss, 1997) (Table 1.1). 
These studies also showed that the y2S and y2L subunits are phosphorylated by PKC 
at S327 (Moss et al., 1992a), and that the y2L subunit contains a second site at S343, 
within the alternatively spliced eight amino acid insertion (Moss et al., 1992a; Machu 
etal., 1993; Whiting etal., 1990) (Table 1.1).
PKC has been shown to phosphorylate the full-length (3 subunits of purified GABAa 
receptors in vitro (Browning et al., 1990, 1993). Pre-labelling experiments with [32P]- 
orthophosphate have subsequently been used to examine the phosphorylation of 
recombinant and neuronal GABAa receptors by PKC in situ. These have shown 
PKC-induced phosphorylation of each of the GABAa receptor |3 subunits, when 
expressed with an a l  subunit in HEK293 cells (Krishek et al., 1994; McDonald et al., 
1998; Brandon et al., 2000) (Table 1.1). The sites of phosphorylation in the p i and 
(32 subunits were identical to those identified in vitro, namely S409 and S410, 
respectively (Krishek et al., 1994; McDonald et al., 1998). Likewise, the (33 subunit 
is believed to be phosphorylated at S408 and S409 (Brandon et al., 2000). Additional 
studies utilising pre-labelling assays or a phosphorylation state-specific antibody that 
recognises the GABAa receptor (33 subunit phosphorylated at S408 and S409 (anti- 
|33-p408/409) (Jovanovic et al., 2004) were used to investigate PKC activity in a 
neuronal system. These analyses revealed PKC-dependent phosphorylation of the 
GABAa receptor (33 subunit at S408 and S409 in primary cultures of neurons under 
basal conditions (Brandon et al., 2000, 2002; Jovanovic et al., 2004). They also 
showed that the basal level of (33 subunit phosphorylation is increased following 
activation of PKC with a phorbol ester, muscarine or BDNF (Brandon et al., 2000,
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2002, 2003; Jovanovic et al., 2004), and decreased following inhibition of PKC with 
calphostin C (Brandon et al., 2000).
PKC interacts directly with GABAa receptor (3 subunits at a region that encompasses 
the site of PKC phosphorylation. Affinity-purification assays using GST-fusion 
proteins of the major intracellular domains of GABAa receptor subunits have 
demonstrated that PKC binds selectively to the GABAa receptor p i -3 subunits, but 
not the a  1 or y2 subunits, and that the associated kinase phosphorylates S409 of the 
p i subunit, and S408 and S409 of the P3 subunit (Brandon et al., 1999, 2002, 2003). 
Further analysis revealed that the intracellular domain of the p i subunit interacts 
directly with the a  and pil isoforms of PKC (PKC-a and PKC-PII) (Brandon et al.,
1999), that the intracellular domain of the p2 subunit interacts with PKC-a (Brandon 
et al., 2003), and that the intracellular domain of the p3 subunit associates with PKC- 
a  and PKC-piI (Brandon et al., 1999). Mapping studies also found that PKC-PII 
binds to a site located between residues 405 and 415 of the p i subunit major 
intracellular domain, a region which includes the sole site of phosphorylation, S409 
(Brandon et al., 2002). Both the binding and phosphorylation sites are conserved 
between the p subunit isoforms.
The level of PKC binding to GABAa receptors is enhanced following activation of 
the kinase. Coimmunoprecipitation assays have shown that an increase in the 
association of PKC with P 1/3 subunit-containing GABAa receptors is caused by 
treatment of cultured cortical neurons with phorbol esters (Brandon et al., 1999). A 
similar study has also shown that treatment of cultured cortical neurons with BDNF 
triggers activation of PKC, and induces temporary docking of the kinase to GABAa 
receptors that contain p3 subunits (Jovanovic et al., 2004). The transient nature of 
the interaction between GABAa receptors and PKC in primary neurons has been 
attributed in part to the kinase having differential binding-affinities for 
phosphorylated and dephosphorylated forms of the p3 subunit. This view is based on 
findings from in vitro binding studies and experiments using a phosphorylation-state 
specific anti-p3-p408/409 antibody. These studies demonstrated that although the 
interaction between PKC and the major intracellular domain of the p 1 subunit is not
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abolished by a serine-to-alanine point mutation of the S409 phosphorylation site, the 
extent of binding is reduced when this residue is phosphorylated by PKA (Brandon et 
al., 1999, 2002). Similarly, binding of PKC to the major intracellular domain of the 
(33 subunit is not dependent upon the PKC phosphorylation sites, S408 and S409, but 
is reduced by phosphorylation of the S409 residue by PKA (Brandon et al., 1999; 
Jovanovic et al., 2004). It is not yet known whether the phospho-dependent 
interaction between PKC and the GABAa receptor (3 subunits results from the kinase 
having a reduced binding-affinity or an increased rate of dissociation for the 
phosphorylated form of the (3 subunit, or whether there are additional contributing 
factors. Nevertheless, this regulation provides a potential mechanism for PKC to 
negatively modulate its own binding and phosphorylation, in vivo. Indeed, activity- 
and phosphorylation-dependent binding is believed to contribute to the transient 
increase in PKC-dependent phosphorylation of the GABAa receptor (33 subunit at 
S408 and S409 that is observed following treatment of cultured cortical neurons with 
muscarine, BDNF or phorbol esters (Brandon et al., 1999, 2000, 2002; Jovanovic et 
al., 2004).
The anchoring protein RACK-1 regulates GABAa receptors by facilitating PKC- 
dependent phosphorylation (Brandon et al., 1999, 2002; Feng et al., 2001). Like 
PKC-(3II, RACK-1 immunoprecipitates with GABAa receptors containing (31/(33 
subunits from HEK-293 cells, brain and cultured cortical neurons that have been 
treated with phorbol esters (Brandon et al., 1999, 2002). In cultured cortical neurons, 
activation of Trk B neurotrophin receptors with BDNF has been shown to induce 
transient recruitment of RACK-1, in addition to PKC, to GABAa receptors containing 
the (33 subunit (Jovanovic et al., 2004). Although RACK-1 binds directly to PKC-a 
and PKC-(3II (Brandon et al., 1999; Jaken and Parker, 2000) (and may therefore bind 
indirectly to GABAa receptors), a direct interaction between RACK-1 and the major 
intracellular domains of GABAa receptor a ,  p i  and (33 subunits has been 
demonstrated (Brandon et al., 1999, 2002). RACK-1 binds directly to the major 
intracellular domain of the p i subunit between residues 395 and 404 (Brandon et al.,
2002). This binding region lies immediately upstream of the binding site for PKC-piI 
and is conserved between the p subunit isoforms (Brandon et al., 2002). Although
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their binding sites are within close proximity of one another, PKC-piI and RACK-1 
can bind independently to GABAa receptor (3 subunits (Brandon et al., 1999, 2002). 
Indeed, RACK-1 has been shown to bind a fragment of the intracellular domain of the 
p i subunit that does not contain the PKC-piI-binding region (Brandon et al., 2002). 
Furthermore, binding of RACK-1 to the intracellular domain of the p i subunit does 
not require S409, and is not regulated by phosphorylation of this residue (Brandon et 
al., 2002). A peptide mimicking the RACK-1-binding sequence in the pi subunit has 
been shown to block the interaction of RACK-1, but not PKC, with the receptor pi 
subunit (Brandon et al., 2002). This peptide has also been shown to reduce PKC- 
dependent phosphorylation and functional modulation of GABAa receptors that 
contain a p i subunit in HEK-293 cells and superior cervical ganglion neurons 
(Brandon et al., 2002). RACK-1 is therefore believed to facilitate PKC-dependent 
phosphorylation and functional modulation of GABAa receptors by enhancing the 
activity of receptor-associated PKC, rather than by targeting activated PKC isoforms 
to the receptor (Brandon et al., 2002).
1.7.2.1.2 PKA and AKAP Scaffold Proteins
The serine/threonine kinase, PKA, has also been identified as a GABAa receptor 
kinase. In vitro studies using purified, bacterially expressed GST-fusion proteins of 
the major intracellular domains of GABAa receptor subunits have revealed that this 
kinase selectively phosphorylates the receptor p subunits, but not the a  1 or y2 
subunits (Moss et al., 1992a; McDonald and Moss, 1997) (Table 1.1). Further studies 
using site-directed mutagenesis demonstrated that PKA phosphorylates each of the p 
subunits at the same conserved serine residue as PKC, namely S409 of the p i and p3 
subunits (Moss et al., 1992a; McDonald and Moss, 1997) and S410 of the p2 subunit 
(McDonald and Moss, 1997) (Table 1.1).
Purified GABAa receptors are also phosphorylated by PKA, in vitro (Kirkness et al., 
1989; Browning et al., 1990,1993; Tehrani and Barnes, 1994). However, in situ 
analyses of recombinant GABAa receptors expressed in HEK-293 cells have revealed 
a number of differences between the phosphorylation of GABAa receptor subunits in 
vitro and in situ. For example, PKA has been shown to phosphorylate the receptor pi
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subunit at S409 (Moss et al., 1992b), which is in agreement with the in vitro findings 
(see above; Table 1.1). However, in contrast to the in vitro findings, PKA-dependent 
phosphorylation of the (33 subunit occurs at S408 and S409 (rather than S409 alone). 
In this system, phosphorylation also occurs at an unidentified serine residue; and 
activation of PKA does not lead to phosphorylation of the (32 subunit (McDonald et 
al., 1998; Table 1.1). In hippocampal slices, activation of PKA with forskolin has 
been shown to trigger phosphorylation of the GABAa receptor (32/3 subunits, and 
experiments using a phosphorylation-state specific anti-(33-pS408/S409 subunit 
antibody showed that phosphorylation of the (33 subunit occurs at S408/S409 
(Terunuma et al., 2004). Activation of PKA also leads to phosphorylation of the (33 
subunit at S408/4S09 in primary cultures of striatal neurons (Brandon et al., 2003), 
and in cultured cortical neurons when endogenous PKC activity is inhibited (Brandon 
et al., 2000; Table 1.1). These studies collectively suggest that a number of factors 
are involved in determining the sites of PKA-dependent phosphorylation of GABAa 
receptors in cells.
The A-kinase anchoring proteins (AKAPs), AKAP79/150 and Yotiao, are 
fundamental to PKA-mediated phosphorylation and functional modulation of GABAa 
receptors (Brandon et al., 2003; Wang et al., 2002; Cai et al., 2002). These 
scaffolding proteins interact directly with the regulatory RII subunit of PKA to target 
the kinase to its substrates (Colledge and Scott, 1999). Indeed, AKAPs are believed 
to facilitate PKA-dependent phosphorylation of the GABAa receptor p i and |33 
subunits in cells by targeting the kinase to the major intracellular domains of these 
subunits (Brandon et al., 2003; McDonald et al., 1998). Affinity-purification assays 
have demonstrated that native AKAP79/150 interacts selectively with the major 
intracellular domains of the GABAa receptor p i and P3 subunits, but not the p2, a l -  
3, y2 or 6 subunits, and that the interaction of recombinant AKAP79 with the receptor 
p i and p3 subunits is direct (Brandon et al., 2003). Additional studies have also 
shown that the association of the catalytic subunit of PKA with the receptor p 1 and 
P3 subunits is indirect (Brandon et al., 2003). Although the p i and P3 receptor 
subunits may associate with the catalytic subunit of PKA via a direct interaction with 
the regulatory RII subunit, the binding of PKA to AKAP79 has been shown to be
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critical for PKA-mediated phosphorylation of the GABAa receptor (33 subunit at 
S408/S409 in heterologous cells (Brandon et al., 2003).
AKAPs have also been shown to interact directly with PKC and PP2B, in addition to 
PKA (Klauck et al., 1996; Colledge and Scott, 1999). However, the targeting of PKC 
and PP2B to GABAa receptors by AKAPs remains to be investigated (see Section 
1.7.2.2.3).
1.72.1.3 Akt
In addition to PKA and PKC, GABAa receptors are also substrates of the 
serine/threonine kinase, Akt, or PKB. Akt selectively phosphorylates the major 
intracellular domain of the GABAa receptor (32 subunit, but not the a l  or y l  subunit, 
in vitro (Wang et al., 2003b) (Table 1.1). Phosphorylation of the (32 subunit occurs at 
the conserved serine residue, S410, which is also the in vitro phosphorylation site of 
PKA and PKC (Wang et al., 2003b; McDonald and Moss, 1997) (Table 1.1). 
Activation of Akt has been shown to trigger phosphorylation of the (32 subunit at 
S410 in HEK293 cells expressing recombinant GABAa receptors (Wang et al., 
2003b) (Table 1.1). Furthermore, endogenous Akt has been implicated in the insulin- 
induced phosphorylation of native GABAa receptor (32 subunits at S410 in primary 
cultures of neurons (Wang et al., 2003b) (Table 1.1). Immunofluorescence studies 
have shown that insulin induces co-localisation of activated Akt and GABAa 
receptors containing the (32 subunit in the distal dendrites of cultured hippocampal 
neurons (Wang et al., 2003b). However, a direct physical interaction between Akt 
and the neuronal GABAa receptor substrate remains to be determined.
1.7.2.1.4 GAPDH
A physical and functional interaction between GABAa receptors and the glycolytic 
enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), has now been 
reported. This serine/threonine protein kinase directly phosphorylates the major 
intracellular domain of the GABAa receptor a l  subunit at T337 and S416, in vitro 
(Laschet et al., 2004) (Table 1.1). Furthermore, GAPDH is believed to be the a l -  
subunit-specific kinase that is associated with purified preparations of GABAa
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receptors from bovine cerebral cortex (Sweetnam et al., 1988; Bureau and Laschet, 
1995; Laschet et al., 2004). Indeed, in addition to co-purifying with GABAa 
receptors from bovine cortex, GAPDH co-localises with GABAa receptor a l  
subunits at the neuronal surface of cultured hippocampal neurons (Laschet et al., 
2004).
1.7.2.1.5 CaMKII
In vitro studies using purified GST-fusion proteins of the major intracellular domains 
of GABAa receptor subunits have revealed that the serine/threonine kinase, CaMKII, 
phosphorylates the receptor p and y l  subunits (McDonald and Moss, 1994, 1997). 
Further investigations using site-directed mutagenesis revealed that the p i subunit is 
phosphorylated on S384 and S409 (McDonald and Moss, 1994), the (32 subunit on 
S410, and the p3 subunit on S383 and S409 (McDonald and Moss, 1997; Table 1.1). 
Interestingly, whereas the S409/410 residue is conserved in all the p subunit isoforms, 
the S383/384 residue is conserved only in the p i and P3 subunits. CaMKII has also 
been shown to phosphorylate the y2S and y2L subunits at S348 and T350, and S343 
in the y2L subunit only (McDonald and Moss, 1994; Machu et al., 1993; Table 1.1). 
Activation of CaMKII has also been shown to cause an increase in phosphorylation of 
the GABAa receptor a l  subunit in a synaptosomal membrane fraction (Chum et al., 
2002).
Further information regarding the physical and functional interaction of CaMKII with 
GABAa receptors can be found in Chapters 3 and 4 of this thesis, and an overview of 
the structure and regulation of CaMKII is provided in Section 1.8.
1.7.2.1.6 PKG
PKG is perhaps the least well characterised of the known GABAa receptor-associated 
serine-threonine kinases. PKG has been shown to phosphorylate the major 
intracellular domain of the receptor p subunits at the conserved serine residue that is 
also a phosphorylation site for kinases such as PKC, PKA and CaMKII, namely S410 
of the P2 subunit, and S409 of the p i and P3 subunits (McDonald and Moss, 1994, 
1997; Table 1.1).
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1.72.1.7 Sre
In addition to the serine/threonine kinases, GABAa receptor-associated kinases also 
include a member of the Src family of non-receptor tyrosine kinases. Indeed, v-src 
phosphorylates both purified GABAa receptors and the major intracellular domains of 
the receptor p i and y2L subunits, in vitro (Valenzuela et al., 1995). Additional 
studies have shown that c-Src phosphorylates the major intracellular domain of the y l  
subunit at Y365/367, in vitro (Brandon et al., 2001; Table 1.1). vSRC has also been 
shown to phosphorylate recombinant GABAa receptors expressed in HEK293 cells, 
and site-directed mutagenesis identified a number of phosphorylation sites, namely 
Y365 and Y367 of the y l  subunit and Y370 and Y372 of the |31 subunit (Moss et al., 
1995; Table 1.1). Studies using phosphorylation state-specific antibodies have shown 
that the P2/3 subunits of the GABAa receptor are phosphorylated on tyrosine residues 
in cultured dorsal hom neurons (Wan et al., 1997a), and that the receptor y l  subunit is 
phosphorylated on Y365 and Y367 in cultured cortical neurons upon inhibition of 
tyrosine phosphatases (Brandon et al., 2001).
An interaction between endogenous Src and the major intracellular domains of the 
GABAa receptor a l ,  p i, p2 and y2S subunits has now been demonstrated (Brandon 
et al., 2001; Wang et al., 2003a). Although it is not yet known whether Src binds 
directly or indirectly to these subunits, the association of this kinase with the major 
intracellular domain of the y2S> subunit has been shown to involve residues 317 to 332 
(Wang et al., 2003a). Furthermore, although Src has been reported to bind directly to 
RACK-1 (Chang et al., 1998), it is not yet known whether RACK-1 directs Src, as 
well as PKC, to GABAa receptors.
1.7.2.2 The Role o f Protein Phosphatases
The relative activity of protein kinases and phosphatases is pivotal to the overall 
phosphorylation state of a protein. The activity of protein phosphatases at GABAa 
receptors is therefore a key determinant of phosphorylation-dependent modulation. 
The role of protein phosphatases in controlling the phosphorylation state of GABAa 
receptors is not as well defined as that of protein kinases. However, evidence has
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emerged in recent years in support of an intimate association between GABAa 
receptors and various protein phosphatases.
1.7.2.2.1 PP1 and the Adaptor Protein PRIP-1
Several lines of evidence now suggest that GABAa receptors are a substrate of the 
serine/threonine phosphatase, PP1. Recombinant P P la  has been shown to 
dephosphorylate the major intracellular domain of the GABAa receptor (33 subunit 
that has been phosphorylated by PKA at S409, in vitro (Terunuma et al., 2004; 
McDonald and Moss, 1997). Furthermore, dephosphorylation of the |33 subunit 
intracellular domain by hippocampal extracts has been partly attributed to 
endogenous P P la  activity (Terunuma et al., 2004). Treatment of cultured cortical 
neurons with okadaic acid, at a concentration that inhibits both PP1 and PP2A, 
increases the basal phosphorylation of GABAa receptor (33 subunits at S408 and S409 
(Jovanovic et al., 2004). This indicates that one or both of these phosphatases are 
active at GABAa receptors under basal conditions. Furthermore, treatment of 
hippocampal slices with the PP1 and PP2A inhibitor, calyculin A, has been shown to 
cause an increase in forskolin-induced phosphorylation of the GABAa receptor (32/3 
subunits, in situ, again implicating these phosphatases in the dephosphorylation of 
GABAa receptors (Terunuma et al., 2004).
Coimmunoprecipitation studies have shown that P P la forms a complex with GABAa 
receptors containing the |33 subunit in brain (Terunuma et al., 2004). A direct 
interaction between PP1 and GABAa receptors has not yet been demonstrated, 
however it has been suggested that P P la  is targeted indirectly to these receptors in an 
inactive form via its interaction with the GABAa receptor-associated protein, PRIP-1 
(see Section 1.6; Terunuma et al., 2004; Yoshimura et al., 2001; Uji et al., 2002). 
Indeed, it has been proposed that phosphorylation of PRIP-1 by PKA induces the 
release of catalytically active P P la , and dephosphorylation of the GABAa receptor 
(33 subunit at phospho-S408 and phospho-S409 (Terunuma et al., 2004; Yoshimura et 
al., 2001).
1.7.2.2.2 PP2A
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PP2A has also been described as a GABAa receptor serine/threonine phosphatase. 
Purified PP2A has been shown to dephosphorylate the major intracellular domain of 
the GABAa receptor (33 subunit that has been phosphorylated at S409 by PKA, in 
vitro (Terunuma et al., 2004; McDonald and Moss, 1997). Dephosphorylation of the 
(33 subunit intracellular domain by hippocampal extracts has also been partly 
attributed to endogenous PP2A activity, in addition to P P la  activity (Section 
1.7.2.2.1), based on inhibition by okadaic acid (Terunuma et al., 2004). Furthermore, 
as described above, PP2A has been implicated in the dephosphorylation of the 
GABAa receptor (33 subunit in cultured cortical neurons (Section 1.7.2.2.1; Jovanovic 
et al., 2004).
The catalytic subunit of PP2A (PP2Ac) has been shown to form a complex with 
GABAa receptors containing (33 subunits in cultured cortical neurons (Jovanovic et 
al., 2004). Affinity-purification assays have further demonstrated that neuronal 
PP2Ac associates with the major intracellular domain of the receptor (33 subunit, and 
that this interaction is enhanced when S409 is in the phosphorylated state (Jovanovic 
et al., 2004). Treatment of cortical neurons with BDNF has also been shown to 
enhance binding of PP2Ac to GABAa receptors, an effect that correlates temporally 
with the transient BDNF-induced PKC-dependent phosphorylation of the receptor (33 
subunit at S408 and S409 (Jovanovic et al., 2004). The increased interaction of 
PP2Ac with the phosphorylated form of the (33 subunit is therefore thought to be 
involved in the ensuing dephosphorylation of the receptor (33 subunit (Jovanovic et 
al., 2004).
1.7.2.2.3 PP2B
The serine/threonine phosphatase PP2B (also known as calcineurin) has also been 
implicated in dephosphorylating GABAa receptors. Both a recombinant and 
endogenous form of PP2B have been shown to dephosphorylate the major 
intracellular domain of the GABAa receptor y2S subunit that has been phosphorylated 
at S327 by PKC, in vitro (Wang et al., 2003a; Moss et al., 1992a). PP2B has also 
been implicated in long-term depression (LTD)-dependent dephosphorylation of the 
GABAa receptor y l  subunit at S327 in hippocampal CA1 slices (Wang et al., 2003a).
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However, purified PP2B does not dephosphorylate the major intracellular domain of 
the GABAa receptor p3 subunit that has been phosphorylated at S409 by PKA, in 
vitro (Terunuma et al., 2004). Furthermore, PP2B activity is not involved in the basal 
dephosphorylation of GABAa receptor (33 subunits at S408/409 in cultured cortical 
neurons (Jovanovic et al., 2004).
PP2B is believed to interact with GABAa receptors in an activity-dependent manner. 
In hippocampal CA1 neurons, recruitment of PP2B catalytic subunits to GABAa 
receptor complexes is both necessary and sufficient for inducing LTD of inhibitory 
synapses (Wang et a l, 2003a; Lu et al., 2000). Coimmunoprecipitation assays from 
hippocampal slices have also demonstrated that PP2B and GABAa receptors do not 
form a native complex under basal conditions, but that the catalytic subunit of PP2B 
is associated with GABAa receptors containing a l ,  (32 and y l  subunits after the 
induction of LTD (Wang et al., 2003a). In vitro binding studies have further 
demonstrated that a recombinant catalytic fragment of PP2B (that exhibits calcium- 
independent phosphatase activity), but not the regulatory subunit of PP2B, binds 
directly and selectively to the major intracellular domain of the GABAa receptor y l  
subunit, but not the a l  or (32 subunits (Wang et al., 2003a). The interaction with the 
y l  subunit intracellular domain is dependent on amino acids 317 to 332 (Wang et a l,  
2003a). This region includes the S327 phosphorylation site, and is involved in 
binding the non-receptor tyrosine kinase Src (Wang et al., 2003a; Section 1.7.2.1.7). 
It is possible therefore, that PP2B and Src compete physically for binding to the y l  
subunit.
I previously documented that PP2B interacts with AKAP79/150 and that this 
anchoring protein interacts directly with the major intracellular domains of GABAa 
receptor p i and (33 subunits (Brandon et al., 2003; Section 1.7.2.1.2). It is perhaps 
surprising therefore, that affinity-purification assays from brain do not detect an 
(indirect) association between native PP2B and the intracellular domains of the 
receptor p i and P3 subunits (Brandon et al., 2003). However, it is possible that 
GABAa receptor p 1/3 subunits bind to the same region of AKAP79/150 as PP2B and 
that the binding of each protein to AKAP79/150 is mutually exclusive.
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1.7.3 Phosphorylation-Dependent Modulation of GABAa Receptor Function
Phosphorylation is believed to be a major means of regulating GABAa receptor 
function, and hence the efficacy of inhibitory neurotransmission and neuronal 
excitability (Moss and Smart, 1996, 2001; Sigel, 1995). Although phosphorylation- 
dependent functional modulation of GABAa receptors may arise from indirect 
phosphorylation of GABAa receptor-associated proteins (or other signalling 
components), evidence suggests that direct phosphorylation of receptor subunits plays 
a major role in this process. Indeed, direct receptor phosphorylation may alter 
channel activity and the cell-surface stability of GABAa receptors by altering 
biophysical, pharmacological and biochemical properties, such as channel open 
probability and open time, channel conductance, receptor desensitisation, ligand 
docking and receptor-protein interactions.
Phosphorylation-dependent functional modulation of GABAa receptors has been 
extensively investigated in heterologous cell-systems and neurons. These studies 
have revealed differential effects of phosphorylation that range from enhancement to 
inhibition of GABA-activated currents, and which are dependent upon the identity of 
the kinase, the site(s) of phosphorylation, the subunit composition of the receptor 
complex and the cell-type investigated (Moss and Smart, 1996, 2001). For example, 
studies of recombinant GABAa receptors expressed in heterologous cell-lines have 
demonstrated that activation of PKC leads to a reduction in GABA-mediated currents, 
and that this effect is mediated by the PKC phosphorylation sites, S409 of the (31 
subunit (Krishek et al., 1994; Brandon et al., 2002), S410 of the (32 subunit, and S327 
and S343 of the y l  subunit (Kellenberger et al., 1992; Krishek et al., 1994; Table 1.1; 
Section 1.7.2.1.1). However, these phosphorylation sites have also been implicated in 
a PKC-dependent enhancement of recombinant GABAa receptor-mediated currents in 
L929 fibroblasts (Lin et al., 1996). Similar investigations have revealed that in 
contrast to PKC, PKA-dependent functional modulation of GABAa receptors is not 
mediated by the receptor (32 subunit (McDonald et al., 1998). This subunit is an in 
vitro substrate for both of these kinases, and the difference in functional modulation is 
believed to result from the lack of targeting of PKA to the (32 subunit in cells 
(Brandon et al., 2003; McDonald et al., 1998; Sections 1.7.2.1.1 and 1.7.2.1.2).
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PKA-dependent functional modulation of GABAa receptors is therefore dependent 
upon the type of receptor (3 subunit present. Evidence suggests that the availability of 
either a single (S409) or dual (S408/S409) PKA phosphorylation site determines the 
type of modulation that occurs. Indeed, as demonstrated for PKC, PKA-induced 
phosphorylation of the p i subunit at the conserved S409 residue results in a reduced 
GABA-mediated response (Moss et al., 1992b; McDonald et al., 1998). Conversely, 
PKA-induced phosphorylation of the p3 subunit at both the conserved S409 residue 
and the neighbouring S408 residue leads to potentiation of the GABA-activated 
response (McDonald etal., 1998).
Subunit/site-specific differences in the functional modulation of GABAa receptors 
have also been demonstrated in studies investigating the effect of tyrosine 
phosphorylation on recombinant GABAa receptors expressed in HEK-293 cells. 
These have shown that whereas tyrosine kinase-dependent phosphorylation of the 
GABAa receptor p i subunit has no apparent functional effect, tyrosine kinase- 
dependent phosphorylation of the y2 subunit correlates with an enhancement of 
GABA-mediated currents (which is also in contrast to the negative modulation that 
follows PKC-dependent phosphorylation of the y l  subunit at serine residues) (Moss et 
al., 1995; Kellenberger et al., 1992; Krishek et al., 1994; see also Valenzuela et al., 
1995). The GABAa receptor P2 subunit also mediates tyrosine kinase-dependent 
positive functional modulation of recombinant GABAa receptors (Wan et al., 1997a).
Cell-type-specific differences in GABAa receptor functional modulation have been 
observed with various protein kinases in distinct neuronal preparations. For example, 
PKA activity has been shown to cause a reduction of GABA-mediated currents in 
sympathetic ganglion neurons (Moss et al., 1992b), spinal neurons (Porter et al., 
1990) and cerebellar granule cells (Robello et al., 1993), and a decrease in the 
amplitude of miniature inhibitory postsynaptic currents (mIPSCs) in hippocampal 
pyramidal cells (Poisbeau et al., 1999). Conversely, PKA has been shown to cause an 
enhancement of GABA-mediated currents and mIPSCs in cerebellar Purkinje cells 
(Kano and Konnerth, 1992), of mIPSCs in olfactory bulb granule cells (Nusser et al., 
1999), and of GABAa receptor-mediated currents in hippocampal dentate granule
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cells (Kapur and MacDonald, 1996). Such neuron-specific differences are also 
exemplified with PKC. For example, activation of PKC leads to a decrease of 
GABA-mediated currents in sympathetic ganglion neurons (Krishek et al., 1994; 
Brandon et al., 2002) and cortical pyramidal neurons (Brandon et al., 2000), but an 
increase in the peak amplitude of GABAa receptor-mediated mIPSCs in hippocampal 
dentate gyrus granule cells (Poisbeau et al., 1999).
Evidence is beginning to emerge for a role of direct receptor phosphorylation in 
regulating the number of GABAa receptors at the cell surface. Insulin has been 
shown to increase the level of expression of GABAa receptors on the plasma 
membrane by enhancing the insertion of receptors (Wan et al., 1997b). Subsequent 
studies have suggested that this effect involves direct Akt-dependent phosphorylation 
of the GABAa receptor (32 subunit at S410 (Wang et al., 2003b). In addition, direct 
phosphorylation of the GABAa receptor (33 subunit has been suggested to regulate the 
internalisation of GABAa receptors from the cell surface by inhibiting the binding of 
the clathrin adaptor protein 2 (AP2) complex to this receptor subunit (this is discussed 
further in Section 5.1) (Kittler et al., 2005).
1.7.4 Phosphorylation-Dependent GABAa Receptor Cross-Talk
GABAa receptors are functionally modulated following activation of various 
neuronal membrane receptors, and a number of distinct protein kinases and 
phosphatases have been implicated in such receptor cross-talk. For example, several 
lines of evidence suggest that PKA is involved in the modulation of GABAa receptor 
function by dopamine. Activation of D1 dopamine receptors in neostriatal medium 
spiny neurons has been shown to cause phosphorylation of GABAa receptor (31/3 
subunits, and a reduction of GABAa receptor-mediated currents via a PKA/DARPP- 
32/PP1 signalling cascade (Flores-Hemandez et al., 2000). Stimulation of these G- 
protein coupled receptors also leads to a PKA-mediated decrease of GABA-activated 
currents in olfactory bulb intemeurons (Brunig et al., 1999). Activation of D3 
dopamine receptors in acutely dissociated neurons of the nucleus accumbens causes a 
reduction of GABA-mediated currents that has been attributed to inhibition of PKA 
(Chen et al., 2006). Furthermore, stimulation of D4 dopamine receptors in globus
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pallidus neurons has been shown to decrease mIPSCs via inhibition of PKA (Shin et 
al., 2003). PKA has also been implicated in the D4 dopamine receptor-mediated 
inhibition of GABAa receptor-mediated currents in prefrontal cortex pyramidal 
neurons (Wang et al., 2002), and the D5 dopamine receptor-mediated enhancement of 
GABA-mediated currents in cholinergic intemeurons (Yan and Surmeier, 1997). In 
addition to PKA, dopamine-mediated modulation of GABAa receptor function has 
also been shown to involve PKC. Indeed, activation of D2 dopamine receptors in 
olfactory bulb mitral/tufted cells causes an enhancement of GABA-mediated currents 
via a PKC-dependent signalling cascade (Brunig et al., 1999).
Serotonin-dependent modulation of GABAa receptor function also involves PKA and 
PKC. For example, activation of 5HT-2 receptors in prefrontal cortex pyramidal 
neurons produces a decrease in GABAa receptor-mediated currents that is dependent 
upon PKC (Feng et al., 2001). Stimulation of 5-HT-4 receptors also leads to a PKA- 
dependent bi-directional modulation of GABAergic currents (Cai et al., 2002).
PKC has been implicated in the regulation of GABAa receptor function following 
activation of the muscarinic acetylcholine receptor (Brandon et al., 2002), in addition 
to the Trk B tyrosine kinase receptor (Brunig et al., 2001; Jovanovic et al., 2004; 
Boxall, 2000; Cheng and Yeh, 2003). Other kinases have also been implicated in 
GABAa receptor cross talk. Examples include Akt, which has been implicated in the 
insulin-induced positive modulation of GABAa receptor function (Wang et al., 
2003b; Wan et al., 1997b), and CaMKII. A discussion of CaMKII-mediated 
regulation of GABAa receptors can be found in Section 3.1.
PART TWO
1.8 Structure and Regulation of CaMKII
The calcium/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a 
ubiquitously expressed serine/threonine protein kinase, which plays a major role in 
transducing calcium signals in cells. This multifunctional kinase is enriched in brain, 
where it accounts for up to 2% of the total protein in some regions, such as the
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hippocampus (Erondu and Kennedy, 1985). CaMKII is targeted to most neuronal 
compartments, including the postsynaptic density (PSD), dendritic shafts, the nucleus 
and pre-synaptic terminals (Kennedy et al, 1983; Hudmon and Schulman, 2002). Its 
activity was first described in the late 1970s (Schulman and Greengard, 1978), and 
subsequent work has revealed a role for this kinase in many neuronal processes, such 
as neurotransmission, synaptic plasticity, signal transduction, cytoskeletal 
organisation and gene expression (Colbran, 2004; Hudmon and Schulman, 2002). 
Indeed, CaMKII is believed to play a major role in the long-term regulation of 
excitatory glutamatergic synapses, where it has been shown to mediate the insertion 
of AMPA-type glutamate receptors into the plasma membrane, and to directly 
phosphorylate AMPA receptor subunits to potentiate channel function (Lisman et al., 
2002; Colbran, 2004; Hayashi et al., 2000; Derkach et a l,  1999; Barria et al., 1997). 
These processes are believed to be involved in animal learning and behaviour (Barria 
etal., 1997; Lisman etal., 2002; Derkach etal., 1999; Colbran, 2004).
CaMKII is a large multimeric holoenzyme assembled with structurally related 
subunits that are encoded by four genes (a, (3, y and 5). Each subunit contains an N- 
terminal catalytic domain, a central regulatory domain, a C-terminal association 
domain and a linker region, which is located between the regulatory and association 
domains (Fig. 1.2A; Hudmon and Schulman, 2002). The catalytic domain is highly 
conserved between the subunit isoforms and the catalytic domains of other kinases, 
and contains the substrate- and ATP-binding sites (Colbran, 2004). The shorter 
regulatory domain is also highly homologous (~90% sequence identity) between the 
CaMKII isoforms. This region contains CaM-binding and autoinhibitory sub- 
domains, and several sites of autophosphorylation, including T286, T305 and T306 
(Fig. 1.2A; Colbran, 2004). The association domain mediates multimerisation of the 
subunits into the holoenzyme complex (Shen and Meyer, 1998; Kolb et al., 1998; 
Gaertner et al., 2004; Morris and Torok, 2001; Woodgett et al., 1983). Alternative 
mRNA splicing generates additional subunit diversity by inserting a variable cassette 
at up to four locations in the subunit protein (Fig. 1.2A; Hudmon and Schulman, 
2002). In addition, the CaMKII isoform, aKAP, which is derived from the a  gene, 
has been shown to contain a short hydrophobic N-terminal domain that binds the
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Figure 1.2. Structure and T286-autophosphorylation of CaMKII. A. Schematic 
representation of the primary structure of CaMKII highlighting the different functional 
domains. Each of the four isoforms (a, (3, y and 8) contain an N-terminal catalytic 
domain (dark grey), a central regulatory domain (light grey) and a C-terminal 
association domain (blue). A linker region is positioned between the regulatory and 
association domains. Most of the diversity between the CaMKII isoforms is generated 
by the introduction of up to four variable inserts (green) by alternative splicing. The 
regulatory domain contains two overlapping sub-domains, which contain 
(auto)inhibitory and CaM (purple)-binding sequences, and several sites of 
autophosphorylation, such as T286, T305 and T306. B. Schematic representation of the 
holoenzyme structure of CaMKII highlighting the mechanism of T286- 
autophosphorylation. CaMKII subunits are believed to assemble via their association 
domains to form two hexameric planar discs that stack together to form a dodecameric 
structure (diagram depicts a single ring). Whilst the association domains form the core 
region of the holoenzyme, the kinase domains radiate outwards towards their substrate. 
Binding of calcium/CaM to any two adjacent subunits is required for trans- 
autophosphorylation at T286 and maximal activation.
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association domain in place of the catalytic and regulatory domains (Bayer et al., 
1998; Colbran, 2004).
CaMKII is believed to be a dodecameric holoenzyme, formed by oligomerisation of 
individual subunits into two stacked hexameric planar disc structures (Fig. 1.2B; 
Gaertner et al., 2004; Morris and Torok, 2001; Woodgett et al., 1983; Kolodziej et 
al., 2000; Rosenberg et al., 2005). The subunits assemble as either homomers or 
heteromers via a C-terminal region of their association domain (Shen and Meyer, 
1998; Kolodziej et al., 2000; Kolb et al., 1998). The association domains of each 
subunit thereby form the core of the holoenzyme, and the catalytic domains radiate 
outwards towards their substrate (Fig. 1.2B; Kolodziej et al., 2000; Morris and Torok, 
2001; Gaertner et al., 2004; Hoelz et al., 2003). The a  and p subunits of CaMKII are 
the predominant subunits in brain, and the subunit heterogeneity of the holoenzyme is 
believed to influence several properties, such as the ability to bind other cellular 
proteins and sensitivity to calcium (De Koninck and Schulman, 1998; Hudmon and 
Schulman, 2002; Colbran and Brown, 2004; Gaertner et al., 2004; Shen et al., 1998; 
Colbran, 2004; Fink et al., 2003; Bayer et al., 2002; Thiagarajan et al., 2002; Section 
3.3.1).
The activity of CaMKII is subject to intricate regulation. Under basal conditions, 
CaMKII is maintained in an inactive conformational state by a number of intrasubunit 
interactions that occur between the autoinhibitory sub-domain (an N-terminal region 
of the regulatory domain) and the catalytic domain (Fig. 1.2A). These are believed to 
interfere with the binding of substrate molecules and ATP (Hudmon and Schulman, 
2002; Colbran, 2004).
CaMKII is activated by an extracellular stimulus that leads to a rise in the 
intracellular calcium concentration and the level of calcium-bound CaM 
(calcium/CaM). Calcium/CaM binds to a C-terminal region of the regulatory domain 
(the CaM-binding sub-domain) that overlaps with the autoinhibitory sub-domain (Fig. 
1.2; Meador et al., 1993). This association is believed to disrupt the autoinhibitory 
interactions and therefore disinhibit the kinase (Smith et al., 1992; Yang and
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Schulman, 1999; Meador et al., 1993; Colbran, 2004). The binding of calcium/CaM 
to adjacent subunits in the CaMKII holoenzyme also triggers t rans-  
autophosphorylation of the kinase at a conserved residue, T286 (numbering used is of 
the a  isoform) (Fig. 1.2; Hanson et al., 1994; Bradshaw et al., 2002). 
Autophosphorylation at T286 increases the affinity of the kinase for calcium/CaM by 
more than a 1000-fold, a phenomenon known as CaM trapping (Meyer et al., 1992; 
Waxham et al., 1998; Singla et al., 2001). This enables calcium/CaM to remain 
associated with the kinase as cytosolic calcium levels return towards basal values. 
When calcium/CaM eventually dissociates, the kinase retains autonomous activity, an 
effect that is believed to be due to the continued disruption of some of the 
autoinhibitory interactions by the phosphorylated T286 residue, and which persists 
until this site is dephosphorylated by a protein phosphatase (Yang and Schulman, 
1999; Colbran, 2004; Lai et al., 1986; Miller and Kennedy, 1986; Miller et al., 1988; 
Schworer et al., 1986; Schworer et al., 1988; Thiel et al., 1988; Lou and Schulman, 
1989). The stability of CaMKII’s active state has contributed to this kinase being 
described as a ‘memory molecule’ (Lisman et al., 2002). T286 of CaMKII can be 
dephosphorylated by PP1, PP2A and PP2C (Bradshaw et al., 2003; Shields et al., 
1985; Strack et al., 1997a; Fukunaga et al., 1993). Whereas PP2A predominantly 
dephosphorylates soluble forms of CaMKII, PP1 dephosphorylates the majority of 
CaMKII associated with the postsynaptic density (PSD) (Shields et al., 1985; Strack 
et al., 1997a; Lisman et al., 2002).
Dissociation of calcium/CaM triggers autophosphorylation of T305 or T306, and 
S314, which are located in the CaM-binding sub-domain, and blocks the re-binding of 
calcium/CaM (Hanson and Schulman, 1992; Patton et al., 1990; Colbran, 1993; 
Colbran, 2004). Autophosphorylation of T306 is also believed to occur under basal 
conditions, and prevent binding of calcium/CaM. This is believed to contribute to the 
basal inactivity of the kinase (Colbran, 1993; Hanson and Schulman, 1992).
In addition to controlling the enzymatic activity of CaMKII, subunit 
autophosphorylation has also been shown to regulate the spatial localisation of the 
holoenzyme and interactions of the kinase with various cellular proteins (see Sections
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3.1 and 3.3). Traw^-autophosphorylation of CaMKII subunits at T286 is also believed 
to contribute to the function of the kinase as a decoder of calcium oscillations (De 
Koninck and Schulman, 1998).
PART THREE
1.9 Thesis Aims
The work presented in this thesis aims to describe molecular interactions that may be 
involved in regulating the functional properties and stability of GABAa receptors at 
the neuronal surface, and hence the efficacy of inhibitory neurotransmission and 
neuronal excitability. The phosphorylation state of GABAa receptors is a major 
determinant of receptor function, and the internalisation of GABAa receptors from 
the neuronal membrane to intracellular compartments plays a major role in 
controlling the number of receptors at the cell surface. I therefore aim to employ a 
broad spectrum of biochemical, and cell and molecular biological techniques to 
examine both physical and functional interactions between GABAa receptors and 
protein kinases and phosphatases, and receptor-protein interactions that are involved 
in the endocytosis of GABAa receptors.
I propose the following:
In Chapter 3, I aim to determine whether the protein kinase, CaMKII, binds to 
GABAa receptors in brain, and to examine the nature of any such interaction.
In Chapter 4 , 1 aim to examine the reversible phosphorylation of GABAa receptors by 
CaMKII, in vitro, and to determine whether GABAa receptors are subject to CaMKII- 
dependent phosphorylation in neurons.
In Chapter 5 , 1 aim to examine the interaction between the GABAa receptor and the 
AP2 adaptor complex, a key component of the endocytic machinery. I aim to 
determine whether AP2 binds to the family of GABAa receptor y subunits, and to 
identify the molecular determinants of any such interactions.
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2.1 General Materials, Reagents and Equipment
All chemicals, unless otherwise stated, were purchased from Sigma-Aldrich (Dorset, 
UK), BDH (Dorset, UK), Calbiochem (Nottingham, UK) or Tocris (Bristol, UK). 
Redivue™ [y-32P]-ATP (~3000 Ci/mmol; 10 mCi/ml), [33P]-orthophosphate (>2500 
Ci/mmol; 10 mCi/ml), Redivue™ PRO-MIX™ L-[35S] in vitro Cell Labelling Mix 
(>1000 Ci/mmol; 14.3 mCi/ml) and [125I]-labelled anti-rabbit whole antibody from 
donkey (12.7 mCi/mg; 100 pCi/ml) were obtained from Amersham Biosciences 
(Buckinghamshire, UK). All tissue culture reagents were purchased from 
Invitrogen/Gibco (Paisley, UK). All enzymes for the manipulation of DNA were 
bought from Promega (Madison, WI, USA) or New England Biolabs (Beverly, MA, 
USA). All oligonucleotides were purchased from MWG Biotech (Milton Keynes, 
UK). All centrifugations, unless otherwise stated, were carried out in an Eppendorf 
5415-D bench-top centrifuge or a 5415-R refrigerated centrifuge at 4 °C. All 
absorbance readings were measured using a Bio-Rad SmartSpec 3000 
spectrophotometer.
2.2 Bacteria
Standard bacterial manipulations were performed as described in Sambrook et al., 
1989.
2.2.1 Escherichia coli Strains
Table 2.1 lists the genotypes and sources of the E. coli strains used in this study.
2.2.2 Media, Growth and Storage
Bacteria cultures were grown at 37 °C in sterile Luria-Bertani (LB) medium (tryptone 
(10 g/1), yeast extract (5 g/1), NaCl (10 g/1) and pH to 7.5 with NaOH) with shaking at 
225-250 rpm, or on LB-agar plates (LB with agar (12 g/1)). Plasmid selection was 
maintained by adding chloramphenicol (Chloramp) to a final concentration of 25 
pg/ml (for BL21 (DE3) pLysS) and/or ampicillin (Amp) (for BL21 (DE3) pLysS, 
DH5a, DH10B, MC1061 and XLl-Blue) to a final concentration of 50 pg/ml. For 
short-term storage, bacterial cultures were kept on LB-agar plates at 4 °C, and for 
long-term storage they were kept in LB medium with 20% (v/v) glycerol, at -80 °C.
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Table 2.1. Strains of E. coli used in this study.
Strain Genotype Source
BL21 (DE3) pLysS F  ompT hsdSB (rB" mB ) dcm gal A,(DE3) pLysS Cmr Promega
F  <J>80/acZAM15 A(JacZYA-argF)U169 recAl endAl 
hsdRll(rk mk+) phoA supE44 thi-1 gyrA96 relAl X  nV1 °^eD 
F  mcrA A(mrr-hsdRMS-mcrBC) <j>80/acZAM15 
AlacX14 recAl endAl araD 139 A {ora leu)1691 galU Invitrogen 
galK X rpsL nupG 
F  hsdR (rk‘ mk+) araD 139 A(araABC-leu)1679 galU .  .
galK AlacXlA rpsh thi mcrB nV1 °^en
recAl endAl gyrA96 thi- 1 hsdRllsupE44 relA l „
lac [¥’proAB lacPZAMl5 TnlO (Tef)] btratagene
2.2.3 Transformation
22.3.1 Heat-Shock
BL21 (DE3) pLysS, DH5a, MC1061 or XLl-Blue competent cells were thawed on 
ice (Table 2.1). A 100-pl aliquot of cells was mixed with between 1 and 50 ng of 
DNA in a chilled Falcon polypropylene tube and incubated on ice for 30 min. The 
cells were heat-shocked for 45 s in a 42 °C water bath and then immediately 
incubated for 2 min on ice. 0.9 ml of warm (37 °C) LB media was then added and the 
tube was incubated for 1 h at 37 °C. Dilutions of the transformation mixture were 
plated on LB-agar plates containing the appropriate antibiotic. Plates were incubated 
overnight at 37 °C.
22.3.2 Production of Electro-Competent Cells
10 ml of LB medium was inoculated with a single colony of DH10B cells and 
incubated overnight at 37 °C. The overnight culture was transferred to 1 1 of LB 
medium (1/100 dilution) and grown at 37 °C until the absorbance at 600 nm reached 
0.6 (A ^  = 0.6). The bacteria were harvested in chilled tubes by centrifugation at
3,000 rpm for 30 min at 4 °C. The cells were washed twice in 500 ml of chilled 
water, and once in 20 ml of chilled 10% (v/v) glycerol. The final pellet was re­
suspended in 2.5 ml of chilled 10% (v/v) glycerol. 100-^il aliquots were ‘snap- 
frozen’ in liquid nitrogen, and stored at -80 °C until required.
DH5a
DH10B
MC1061
XLl-Blue
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22.3.3 Electroporation
Electro-competent DH10B cells were thawed on ice (Table 2.1). A 50-pl aliquot was 
mixed with 0.1 ng of vector DNA (or 1 pi of pUC18 control DNA (0.1 ng/pl)) (Table 
2.2) and transferred to a 0.2-cm electroporation cuvette (Equibio; Middlesex, UK). 
The bacteria were electroporated using a Bio-Rad Gene Pulser II (single pulse; 2.5 
kV, 200 Q and 25 pF), and were immediately re-suspended in 950 pi of warm (37 
°C) LB medium and incubated for 1 h at 37 °C. Dilutions of the transformation 
mixture (or 2.5 pi of the control mixture) were plated onto LB-agar plates containing 
the appropriate antibiotic (LB-Amp-agar plates were used for the control) and 
incubated overnight at 37 °C. The number of colonies obtained from the test 
transformation was compared to that from the control transformation, which was 
expected to produce 250 colonies (for the maximal transformation efficiency of 
aTxlO9 colony forming units per pg of pUC18 DNA).
2.2.4 Production and Purification of Glutathione S-Transferase-Fusion Proteins
10 ml of sterile LB-Amp/Chloramp medium was inoculated with a single colony of 
BL21 (DE3) pLysS bacteria transformed with the appropriate pGEX vector (Tables
2.1 and 2.2; Section 2.2.3), and incubated at 37 °C overnight.
The following day, the culture was added to 1 1 of LB-Amp/Chloramp medium and 
grown at 37 °C, until A^  = 0.4-0.6 (approx 2.5 h). Isopropylthio-b-D-galactoside 
(IPTG) was then added to a final concentration of 0.5 mM, to induce protein 
expression, for a further 3 h at room temp. The cells were harvested by centrifugation 
at 4,000 rpm for 15 min at 4 °C, re-suspended in 10 ml of chilled Buffer A (50 mM 
Tris pH 8, 25% (w/v) sucrose and 10 mM EDTA) and re-centrifuged. The final pellet 
was drained and stored overnight at -20 °C.
The next day, the pellet was re-suspended in 10 ml of chilled Buffer B (10 mM Tris 
pH 7.4, 1 mM EDTA, 1% (v/v) triton-X-100, 1 mM dithiothreitol (DTT), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 0.4% (v/v) aprotinin, and 1 pg/ml each of 
antipain, leupeptin and pepstatin) and the suspension was sonicated, on ice, for 30 s, 
five times, to lyse cells and shear the DNA. Following addition of 25 ml of chilled
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Buffer C (20 mM HEPES, pH 7.6, 100 mM KC1, 0.2 mM EDTA, 20% (v/v) glycerol, 
1 mM DTT, 1 mM PMSF, 0.4% (v/v) aprotinin and 1 p.g/ml each of antipain, 
leupeptin and pepstatin), the lysate was centrifuged in a Beckman L-70 
ultracentrifuge (45 Ti rotor), at 35,000 rpm for 30 min at 4 °C. The supernatant was 
then mixed with 2 ml of glutathione-agarose beads (hydrated in water, and washed 
and retained as a 50% (v/v) slurry in Buffer C) and rotated for 1 to 2 h at 4 °C. The 
beads were then centrifuged at 2,000 rpm for 2 min at 4 °C, and washed 3 times in 5 
ml of chilled Buffer C. In the final wash step, the beads were re-suspended in 1 ml of 
chilled Buffer C, and transferred to a microfuge tube.
To elute the glutathione S-transferase (GST)-fusion proteins from the beads, samples 
were centrifuged at 6,500 rpm for 2 min at 4 °C, and the supernatant was discarded. 
After addition of 1 ml of chilled Buffer D (Buffer C with 70 mM reduced glutathione, 
and pH to 7.5 with NaOH), the solution was re-centrifuged and the supernatant was 
retained. The beads were then mixed with a further 1 ml of chilled Buffer D for 15 
min at 4 °C. After centrifuging again, the supernatant was pooled with that previously 
obtained. The eluted protein was transferred to a 0.5-3-ml dialysis cassette (Pierce; 
Rockford, IL, USA), and dialysed against 2 1 of phosphate buffered saline (PBS) 
(NaCl (8 g/1), KC1 (0.2 g/1), disodium hydrogen orthophosphate (1.15 g/1), potassium 
dihydrogen orthophosphate (0.2 g/1), and pH to 7.2 with HC1) overnight at 4 °C to 
remove impurities and to enable an accurate determination of concentration. The 
following morning, the buffer was replaced, and dialysis was continued for a further 2 
h. The proteins were transferred to a microfuge tube and glycerol was added to a 
final concentration of 25% (v/v).
The protein concentration of the GST-fusion protein preparation was measured using 
the Bradford protein assay (Section 2.5.4.2). The GST-fusion proteins, and any 
protein contaminants, were visualised and assessed for degradation following Sodium 
Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and staining 
with Brilliant Blue R (Sections 2.5.5 and 2.5.6). 100-p,l aliquots of the GST-fusion 
proteins were ‘snap-frozen’ in liquid nitrogen and stored at -80 °C until required.
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2.2.5 Purification of Plasmid DNA from E. coli
22.5.1 Mini-Preparation of Plasmid DNA
A  Strataprep® Plasmid Miniprep Kit (Stratagene; CA, USA) was used to extract and 
purify approx 20 p,g of plasmid DNA from a bacterial culture for use in restriction 
digestions, ligations and automated sequencing reactions. Briefly, 5 ml of LB 
medium containing the appropriate antibiotic was inoculated with a single bacterial 
colony, and incubated overnight at 37 °C. To harvest the bacteria, 1.5 ml of the cell 
culture was transferred into a microfuge tube and centrifuged at 13,000 rpm for 1 
min. Plasmid DNA was recovered in accordance with the manufacturer’s guidelines. 
The DNA yield and purity was determined by optical density measurement using a 
Bio-Rad SmartSpec 3000 spectrophotometer (Section 2.3.5). Where appropriate, 
plasmid DNA was further purified using ethanol and phenol/chloroform extractions 
(Sections 2.3.4.1 and 2.3.4.2). Aliquots of plasmid DNA were stored at 4 °C, in the 
short-term, and at -20 °C, in the long-term.
22.5.2 Maxi-Preparation of Plasmid DNA
A HiSpeed™ Plasmid Maxi Kit (QIAGEN; West Sussex, UK) was used to isolate 
and purify approx 750 p,g of plasmid DNA from a bacterial culture for use in 
transfections, enzymatic modifications and automated sequencing reactions. Briefly, 
2 ml of LB medium containing the appropriate antibiotic was inoculated with a single 
bacterial colony and incubated for approx 8 h at 37 °C. 0.3 ml of the starter culture 
was diluted into 150 ml of selective LB medium and grown for 12-16 h at 37 °C, with 
vigorous shaking. The bacterial cells were harvested by centrifugation in a Beckman 
J6-MC centrifuge (rotor JS 4.2) at 4,000 rpm for 15 min at 4 °C. Plasmid DNA was 
then recovered in accordance with the manufacturer’s guidelines.
The DNA yield and purity was determined by optical density measurement using a 
Bio-Rad SmartSpec 3000 spectrophotometer (Section 2.3.5). Where appropriate, the 
plasmid DNA was further purified using ethanol and phenol/chloroform extractions 
(Sections 2.3.4.1 and 2.3.4.2). Aliquots of plasmid DNA were stored at 4 °C, in the 
short-term, and at -20 °C, in the long-term.
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22.5.3 Large-Scale Preparation of Plasmid DNA
Caesium chloride/ethidium bromide fractionation was used to purify a large quantity 
(typically mg) of high-quality plasmid DNA from a cleared bacterial lysate for use in 
transfections, enzymatic modifications and automated sequencing reactions. 10 ml of 
LB medium containing the appropriate antibiotic was inoculated with a single 
bacterial colony and incubated for 12-16 h at 37 °C. The starter culture was then 
transferred to 1 1 of selective LB medium and grown overnight at 37 °C. The bacteria 
were harvested by centrifugation at 4,000 rpm in a J6-MC centrifuge (rotor JS 4.2) for 
15 min at 4 °C, and re-suspended in 40 ml of solution I (50 mM glucose, 25 mM Tris, 
pH 8, and 10 mM EDTA). 20 ml of solution II (1% (w/v) SDS and 200 mM NaOH) 
was then added, and the lysate was mixed gently and left on ice for 5 min. 15 ml of 
solution III (5 M potassium acetate) was then added, and the suspension was 
incubated on ice for a further 5 min. A cleared lysate was obtained following 
centrifugation at 3,000 rpm in a J6-MC centrifuge for 20 min at room temp. DNA 
was precipitated upon addition of an equal volume of isopropanol, and pelleted by 
centrifugation at 3,000 rpm for 10 min at room temp.
To further purify the plasmid DNA, the pellet was re-suspended in 10 ml of 10X Tris- 
EDTA (TE) (10 mM Tris-Cl, pH 7.6, and 1 mM EDTA, pH 8) and mixed with 1 ml 
of 5 M ammonium acetate and 2 volumes of approx 100% (v/v) ethanol. Following 
centrifugation at 3,000 rpm for 10 min at room temp, the pellet was re-suspended in 6 
ml of 10X TE, and exactly 1.1 g of caesium chloride was added per ml of 
supernatant. 100 pi of ethidium bromide (10 mg/ml) was added, and the mixture was 
transferred to two Beckman Quick-Seal™ tubes, and centrifuged in a Beckman 
optima™ ultracentrifuge (TLN 100 rotor) at 100,000 rpm overnight at room temp. 
The lower band of covalently closed, circular, plasmid DNA was extracted from each 
sample using a syringe and hypodermic needle, and pooled. To remove the ethidium 
bromide, 1 volume of water-saturated butanol was added, mixed well, and left to 
stand to allow the two phases to separate. The upper phase, containing the ethidium 
bromide, was discarded and the process was repeated until all the ethidium bromide 
was removed.
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The plasmid DNA was then subjected to two ethanol precipitations (Section 2.3.4.1), 
followed by a phenol/chloroform extraction (Section 2.3.4.2) and a further ethanol 
precipitation. The DNA pellet was re-suspended in 1 ml of sterile water, and the 
yield and purity of the DNA was determined (Section 2.3.5). Aliquots of plasmid 
DNA were stored at 4 °C, in the short-term, or at -20 °C, in the long-term.
2.3 Molecular Biology
2.3.1 DNA Manipulations
All DNA manipulations were performed as described in Sambrook et al., 1989.
2.3.2 Vectors
The DNA vectors that were used in this study are described in Table 2.2.
Table 2.2. Vectors used in this study.
Vector
pUC18
pcDNA3
pcDNA3-CaMKII-WT
pcDNA3-CaMKII-TD
pcDNA3-CaMKII-TA
pRK5
pRK5-03-S383A
pRK5-|33-S383A/
S409A
pGEX-2T
Description
Small, high copy number E. coli cloning 
vector
Mammalian expression vector containing a 
cytomegalovirus promoter and designed for 
high-level expression of cloned genes
CaMKIIa subunit cloned into pcDNA3
CaMKIIa-T286D subunit cloned into 
pcDNA3
CaMKIIa-T286A subunit cloned into 
pcDNA3
Mammalian expression vector containing a 
cytomegalovirus promoter and designed for 
high-level expression of cloned genes 
GABAa receptor (33-S383A 
subunit cloned into pRK5 
GABAa receptor |33-S383A/S409A 
subunit cloned into pRK5 
GST gene fusion vector containing a tac 
promoter for chemically inducible, high-level 
expression in any E. coli host
Source
Stratagene
Invitrogen
H. Schulman
H. Schulman
H. Schulman
BD
Pharmingen
T. Smart
K. McAinsh
Amersham
Biosciences
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Vector
pGEX-4Tl/
pGEX-4T2/
pGEX-4T3
pGEX-4T-al
pGEX-4T-(31
pGEX-4T3-|32
pGEX-4T3-p3
pGEX-4T2-|33-N
pGEX-4T2-|33-C
PGEX-4T2-P3-Q1
pGEX-4T2-|33-Q2
pGEX-4T2-|33-Q3
pGEX-4T2-p3-Q4
pGEX^T3-p3-Tl
pGEX-4T3-|33-T2
pGEX-4T3-03-T3
pGEX-4T-03
(345-408)
pGEX-4T3-|33-S383A 
pGEX-4T-(33-S408A
PGEX-4T-P3-S409A
pGEX-4T3-p3-
S408A/S409A
pGEX-4T3-(33-
S383A/S409A
pGEX-4T3-|33-
S383A/S408A/S409A
pGEX-4Tl-yl
Description
GST gene fusion vectors derived from pGEX- 
2T with an expanded multiple cloning site
GABAa receptor a l  subunit ICD 
cloned into pGEX-4T3 
GABAa receptor p i subunit ICD 
cloned into pGEX-4T3 
GABAa receptor (32 subunit ICD 
cloned into pGEX-4T3 
GABAa receptor (33 subunit ICD (304-426) 
cloned into pGEX-4T3 
GABAa receptor (33 subunit ICD (residues 
304-365) cloned into pGEX-4T2 
GABAa receptor (33 subunit ICD (residues 
366-426) cloned into pGEX-4T2 
GABAa receptor (33 subunit ICD (residues 
304-333) cloned into pGEX-4T2 
GABAa receptor (33 subunit ICD (residues 
334-365) cloned into pGEX-4T2 
GABAa receptor (33 subunit ICD (residues 
366-395) cloned into pGEX-4T2 
GABAa receptor (33 subunit ICD (residues 
396-426) cloned into pGEX-4T2 
GABAa receptor (33 subunit ICD (residues 
313-420) cloned into pGEX-4T3 
GABAa receptor (33 subunit ICD (residues 
323-420) cloned into pGEX^tT3 
GABAa receptor (33 subunit ICD (residues 
332-420) cloned into pGEX-4T3 
GABAa receptor (33 subunit ICD (residues 
345-408) cloned into pGEX-4T 
GABAa receptor (33-S383A (residues 304- 
420) subunit ICD cloned into pGEX-4T3 
GABAa receptor (33-S408A subunit ICD 
cloned into pGEX-4T3 
GABAa receptor (33-S409A subunit ICD 
cloned into pGEX-4T3 
GABAa receptor (33-S408A/S409A subunit 
ICD cloned into pGEX-4T3 
GABAa receptor |33-S383A/S409A (residues 
304-420) subunit ICD cloned into pGEX-4T3 
GABAa receptor (33-S383A/S408A/S409A 
subunit ICD cloned into pGEX-4T3 
GABAa receptor yl subunit ICD 
cloned into pGEX-4Tl
Source
Amersham
Biosciences
S J . Moss
S.J. Moss
S J . Moss
S J . Moss
S .J. Moss
S .J. Moss
S .J. Moss
S .J. Moss
SJ. Moss
S.J. Moss
K. McAinsh
K. McAinsh
K. McAinsh
S .J. Moss
K. McAinsh
S.J. Moss
S.J. Moss
S .J. Moss
K. McAinsh
S J . Moss
J. Anderson
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Vector
pGEX-2T-y2S
pGEX-2T-y2S-N
pGEX-2T-y2S-C
pGEX-4T3-y2S
(327-404)
pGEX-4T3-y2S
(338-404)
pGEX-4T3-y2S
(347-404)
pGEX-2T-y2L 
pGEX-4Tl-y3 
pGEX-4T2-8 
pGEX-4T-EGER 
pcDNA3-a adaptin
Description
GABAa receptor y2S subunit ICD (full-length, 
residues 318-404) cloned into pGEX-2T 
The N-half of the GABAa receptor y2S 
subunit ICD (318-362) cloned into pGEX-2T 
The C-half of the GABAa receptor y2S subunit 
ICD (363-404) cloned into pGEX-2T 
GABAa receptor y2S subunit ICD (327-404) 
cloned into pGEX-4T3 
GABAa receptor y2S subunit ICD (338-404) 
cloned into pGEX-4T3 
GABAa receptor y2S subunit ICD (347-404) 
cloned into pGEX-4T3 
GABAa receptor y2L subunit ICD 
cloned into pGEX-2T 
GABAa receptor y3 subunit ICD 
cloned into pGEX-4Tl 
GABAa receptor 8 subunit ICD 
cloned into pGEX-4T2 
EGF receptor intracellular domain cloned into 
pGEX-4T
-100 kDa a  adaptin of the AP2 complex
pcDNA3-02 adaptin -100 kDa 02 adaptin of the AP2 complex
DNA3 2 d ti ^  adaptin (residues 1-435) of the AP2
complex
pcDNA3-p2 (158-435), 
pcDNA3-p2 (158-407) 
pcDNA3-p2 (283-394) 
pcDNA3-o2 adaptin
p2-adaptin, residues 158-435 
p2-adaptin, residues 158-407 
p2-adaptin, residues 283-394 
17 kDa o2 adaptin of the AP2 complex
Source
S J . Moss 
S.J. Moss 
SJ. Moss 
K. McAinsh 
K. McAinsh 
K. McAinsh 
S J .  Moss 
J. Anderson 
S .J. Moss 
V. Haucke 
V. Haucke 
V. Haucke 
V. Haucke 
V. Haucke 
V. Haucke 
V. Haucke 
V. Haucke
ICD = major intracellular domain
2.3.3 Oligonucleotides
The oligonucleotides that were used in this study are listed in Table 2.3.
2.3.4 Purification of Plasmid DNA
2.3.4.1 Ethanol Precipitation
DNA was precipitated from an aqueous solution by first adding 0.1 volume of 3 M
73
CHAPTER 2 Materials and Methods
Table 2.3. Oligonucleotides used in this study.
Oligonucleotide Sequence (5' to 3')
(33-S409A-Mutagenesis 1 CACCTACGGAGGAGGTCTGCCCAGCTCAAAATC
03-S4O9A-Mutagenesis2 GA1TTTGAGCTGGGCAGACCTCCTCCGTAGGTG
|33-ICD(304-)-Forward CGCCGCGGATCCAACTACATTTTCTTTGGAAG
|33-ICD(-420)-Reverse CATCATCTCGAGAGTCATCGGTTAGATCAGGG
{33-ICD-Tl(313-)-Forward CGCCGCGGATCCCAAAGGCAGAAGAAGCTTGC
03-ICD-T2(323-)-Forward CGCCGCGGATCCGCCAAGGCCAAGAATGATCG
p3-ICD-T3(332-)-Forward CGCCGCGGATCCGAAATAAACCGGGTGGATGC
Y2S-ICD(327-)-Forward CGCGGATCCAAGGATAAAGACAAAAAG
y2S-ICD(338-)-Forward CGCGGATCCGCCCCTACCATTGATATTC
y2S-ICD(347-)-Forward CGCGGATCCGCAACCATTCAAATGAAC
y2S-ICD(-404)-Reverse CGGAATTCGGAGTCCA1TTT GGCAATG
ICD=major intracellular domain
NaOAc, pH 5.2, and then two volumes of approx 100% (v/v) ethanol. The solution 
was incubated for 10 min at -20 °C and centrifuged at 13,000 rpm for 15 min. The 
pellet was washed in 500 pi of 70% (v/v) ethanol and air-dried at room temp.
23.4.2 Phenol!Chloroform Extraction
DNA was purified from protein by adding 1 volume of phenol/chloroform/isoamyl 
alcohol (25:24:1; ICN Biomedicals; Aurora, OH, USA) to the DNA solution and 
vortexing. Following centrifugation at 13,000 rpm for 5 min at room temp, the 
aqueous phase was transferred to a new microfuge tube. The process was then 
repeated with an equal volume of chloroform/isoamyl alcohol (24:1), and followed by 
an ethanol precipitation (Section 2.3.4.1).
2.3.5 Measurement of DNA Concentration and Purity
The absorbance of a diluted DNA sample was measured at 260 nm and 280 nm. The
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formula for calculating the concentration of DNA, where A260 is the absorbance at 260 
nm, and/is the dilution factor, is given by
[DNA |ig / ml] = 50A260/  (2.1)
The purity of the DNA solution was measured by calculating the ratio A1(J A m). 
Samples with a value greater than 1.8 were used in further DNA manipulations.
2.3.6 Polymerase Chain Reaction
Each polymerase chain reaction (PCR) reaction was assembled in a 0.2-ml thin- 
walled tube on ice in a total volume of 50 pi, as follows: 5 pi of Pfu DNA 
Polymerase 10X buffer with MgS04, 250 pM of each deoxynucleotide triphosphate 
(dNTP; dATP, dCTP, dGTP, dTTP), 50 pmol of the upstream primer, 50 pmol of the 
downstream primer, 40 ng of template DNA, and 2 u of Pfu DNA polymerase. The 
amplification reaction was performed in a PTC-200 Peltier Thermal Cycler with a 
heated lid, in accordance with the following programme: initial denaturation at 94 °C 
for 1 min (1 cycle); further denaturation at 94 °C for 30 s, annealing at 45-65 °C for 
30 s and extension at 72 °C for 1 min (30 cycles); a final extension at 72 °C for 5 min 
(1 cycle). The annealing temp depended upon primer melting temp. The extension 
time depended upon the extension rate of Pfu DNA polymerase (approx 2 min per kb 
of DNA).
DNA fragments were purified from the PCR reaction using a QIAquick® PCR 
purification kit (QIAGEN), in accordance with the manufacturer’s guidelines. PCR 
products were stored at 4 °C following analysis by agarose gel electrophoresis 
(Section 2.3.7).
2.3.7 Agarose Gel Electrophoresis
DNA samples were mixed with 0.2 volumes of 6X Loading Buffer (0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol FF and 30% (v/v) glycerol), and 
loaded into gels comprising 1% (w/v) agarose in IX TAE (Tris-Acetate EDTA; 40 
mM Tris-acetate and 1 mM EDTA, pH 8) and ethidium bromide at a concentration of
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0.15 pg/ml. A 1-kb DNA ladder (0.1 pg/pl in IX Loading Buffer) was loaded as a 
standard. DNA was resolved at 120 V in IX TAE, and visualised using a UV 
transilluminator.
2.3.8 Site-Directed Mutagenesis
In vitro site-directed mutagenesis was performed using the Stratagene QuikChange® 
mutagenesis kit, in accordance with the manufacturer’s guidelines. The 
oligonucleotide primers used were designed individually according to the desired 
mutation and are listed in Table 2.3.
2.3.9 Restriction Digests
A double restriction enzyme digest was set up in a 0.2-ml thin-walled tube on ice, in a 
total volume of 20 pi, as follows: 2 pi of the appropriate 10X buffer (provides 
conditions amenable to both restriction enzymes to be used), 2 pg of acetylated 
bovine serum albumin (BSA), 1 pg of DNA (or 5 pi of PCR product DNA), and 5 u 
each of restriction endonucleases 1 and 2 (5-fold excess of enzyme over DNA). The 
reaction was incubated at 37 °C for 1 to 2 h. The digested samples were resolved 
using agarose gel electrophoresis (Section 2.3.7). A QIAquick gel extraction kit 
(QLAGEN) was used in accordance with the manufacturer’s guidelines to extract and 
purify the DNA from the agarose gel for further DNA manipulations. If desired, the 
digested DNA was stored at -20 °C until required.
2.3.10 Ligations
Ligation reactions were set up in a 0.2-ml thin-walled tube on ice in a total volume of 
20 pi. The concentration of both vector and insert DNA was approximated on the 
basis of their band intensity on an agarose gel. A vector/insert molar ratio of 1:3 or 
1:5 was typically used. Ligation reactions were assembled as follows: 2 pi of 10X T4 
DNA Ligase Buffer, digested vector DNA (approx 100 ng), digested insert DNA 
(amount as appropriate) (or 3 pi of water as a control), 1 pi of 10 mM ATP, pH 7.5, 
and between 0.1 and 1 u of T4 DNA ligase. The reaction was incubated overnight at 
4 °C. 1 pi of the ligation reaction was then used to transform XLl-Blue cells (Section 
2.2.3; Table 2.1). Mini-preps (Section 2.2.5.1) were performed if a two-fold
76
CHAPTER 2 Materials and Methods
enhancement in the number of colonies was detected with respect to the control 
reaction. Restriction digests (Section 2.3.9) were performed at the cloning sites using 
the mini-prep DNA to verify the presence of the insert before DNA sequence analysis 
(Section 2.3.11).
2.3.11 DNA Sequence Analysis
All constructs were checked by DNA sequence analysis at the Automated DNA 
Sequencing Service at Cytomyx (Cambridge, UK) or the MRC Gene Service 
(Cambridge, UK). Sequencing data was analysed using DNA Strider 1.2 (by 
Christian Marck; Gif-sur-Yvette, France) and TraceViewer (CodonCode; Dedham, 
MA, USA) software.
2.4 Cell Biology
2.4.1 Manipulations using COS-7 Cell Lines
2.4.1.1 COS-7 Cell Lines
The African green monkey (Cercopithecus aethiops) kidney (COS-7) cell line 
(ATCC; Manassas, VA, USA) was used as a transfection host. It is derived from the 
CV-1 cell line by transformation with an origin-defective mutant of SV40 (Gluzman, 
1981). COS-7 cells have a fibroblast-like morphology, are adherent and grow as 
monolayers.
2.4.1.2 Propagation of COS-7 Cell Lines
A vial of COS-7 cells was removed from the liquid nitrogen store and placed in a 37 
°C water bath to defrost. An aliquot of cells was transferred to Dulbecco’s Modified 
Eagle Medium (DMEM) with high glucose, which was supplemented with 2 mM L- 
glutamine, penicillin (100 u/ml)/ streptomycin (100 pg/ml) and 10% (v/v) foetal 
bovine serum (FBS), and was incubated at 37 °C, 5% C 02 and 100% humidity. Cells 
were grown as monolayers in 100-mm dishes (Nunc; Rochester, NY, USA), and 
passaged at approx 80% confluence.
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COS-7 cells were subcultured two to three times per week: the medium was aspirated, 
and the cells were rinsed twice in 2 ml of trypsin/EDTA (NaCl (8 g/1), KC1 (0.2 g/1), 
disodium hydrogen orthophosphate (1.15 g/1), potassium dihydrogen orthophosphate 
(0.2 g/1), trypsin (2.5 g/1), EDTA (0.2 g/1) and phenol red (0.0015 g/1)). A further 2 
ml of trypsin was added and cells were incubated for 5 min at 37 °C. COS-7 cells 
were re-suspended in 8 ml of supplemented DMEM, and an appropriate aliquot of the 
cell suspension was transferred to fresh supplemented DMEM (the cell suspension 
was usually diluted 1/10). If desired, aliquots of the cell suspension were ‘snap- 
frozen’ in supplemented DMEM and kept in a liquid nitrogen store until required.
2.4.1.3 Transient Transfection of COS-7 Cell Lines
Two 100-mm dishes of COS-7 cells were used per transfection, when the cells were 
approx 80 % confluent. Cells were trypsinised (Section 2.4.1.2) and re-suspended in 
5 ml of supplemented DMEM. Following centrifugation at 2000 rpm for 2 min at 
room temp, cells were re-suspended in 10 ml of optimem, centrifuged again and re­
suspended in another 0.5 ml of optimem. Cells were transferred to a sterile 0.4-cm 
electroporation cuvette (Equibio) and mixed with 10 pg of the plasmid DNA of 
interest (Table 2.2). Cells were then electroporated using a Bio-Rad Gene Pulser II (2 
pulses; 400 V, o° Q and 125 pF; time constant between 5 and 6), and transferred to 6 
ml of supplemented DMEM in a 60-mm dish (Nunc). Transfected cells were 
maintained for 24 h before use.
2.4.2 Primary Neuronal Culture
2.4.2.1 Rat Species
Sprague-Dawley female rats (UCL breeding colony) were obtained from the UCL 
animal facility. Dissections were performed in compliance with UK Home Office 
regulations and UCL guidelines.
2.42.2 Preparation of Dishes
100-mm dishes (Nunc) were treated with poly-D-lysine (0.1 mg/ml) for a minimum 
of 45 min at 37 °C, washed twice in sterile water, and incubated for at least 1 h in
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DMEM supplemented with 10% (v/v) FBS and penicillin (100 u/ml)/ streptomycin 
(100 pg/ml). The medium was aspirated immediately before plating the neurons.
2.4.2.3 Preparation of Primary Rat Cortical Neurons
Dissociated cortical neurons were prepared following a protocol modified from 
Banker and Goslin, 1998, and by using a Nikon C-DS dissecting microscope and 
appropriate surgical instruments (FST; Heidelberg, Germany). Briefly, brains were 
removed from embryonic day 17 (E17) rat embryos and placed in chilled, sterile PBS. 
Following removal of the meninges, cortices were isolated from the rest of the brain, 
and placed in 1 ml of supplemented neurobasal medium (neurobasal medium with 2% 
(v/v) (IX) B27 supplement, 2 mM L-glutamine, penicillin (100 u/ml)/ streptomycin 
(100 pg/ml) and 0.6% (w/v) D-+-glucose). Neurons were dissociated by trituration 
with a flame-polished glass Pasteur pipette, and the number of viable cells were 
estimated using 0.4% (w/v) Trypan Blue Solution and an Improved Neubauer 
haemocytometer. Neurons were plated at high density (approx 12 million cells per 
100-mm dish) in an appropriate volume of supplemented neurobasal medium, and 
were maintained at 37 °C, 5% C 02 and 100% humidity until required (6-8 DIV).
2.4.3 Production of Phosphorylation State-Specific Antibodies
2.4.3.1 Production of Synthetic Peptides for Immunisation of Rabbits and 
Characterisation of Phosphorylation State-Specific Antisera
All peptides used in this study (Table 2.4) were synthesised and HPLC purified at 
The Rockefeller University Protein/DNA Technology Centre, NY, USA, 
(www.pdtc.rockefeller.eduf  Each peptide was designed in accordance with the 
Centre’s guidelines, and comprised a sequence of the GABAa receptor (33 subunit 
that surrounded either S383 or S408/S409 (Table 2.4). The peptides were modified, 
where appropriate, with a chemically phosphorylated serine residue, and an N- 
terminal cysteine residue for conjugation to the Limulus hemocyanin carrier-protein, 
via the cross-linker, sulfo-MBS (m-Maleimidobenzoyl-A-hydroxysulfosuccinimide 
ester) (Table 2.4; Section 2.4.3.2). The (33-S383 and (33-S383-P peptides were 
designed and synthesised in this study. Steve Moss provided the other peptides.
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2.4.3.2 Conjugation of Peptide! Carrier Proteins with Sulfo-MBS
The cysteine-containing (33-S383-P and |33-S409-P phospho-peptides were 
conjugated to the carrier protein, Limulus hemocyanin, using the hetero-bifunctional 
cross-linker sulfo-MBS. The carrier protein was dissolved to 2 mg/ml in Coupling 
Buffer (75 mM Na phosphate, pH 7.2, and 250 mM NaCl) and the solution was 
passed through an Acrodisc 0.45-pm-syringe filter (Pall; MI, USA). The cross-linker, 
sulfo-MBS, was dissolved to 2.5 mg/ml in Coupling Buffer immediately prior to use. 
125 pi of the sulfo-MBS solution was added to 1.25 ml of the carrier protein solution 
and incubated for 60 min at room temp to first couple the NHS moiety of the cross­
linker to free amino groups (NH2-terminal and/or E-amino groups of lysine residues) 
in the carrier protein. During the carrier/sulfo-MBS incubation, a 10-ml PD-10 
desalting column (Pharmacia Biotech) was equilibrated with 50 ml of Coupling 
Buffer. To remove excess sulfo-MBS, the carrier/sulfo-MBS solution was loaded 
onto the column and eluted with 0.5-ml aliquots of Coupling Buffer. The Bradford 
protein assay (Section 2.5.4.2) was used to identify the peak fractions, which were 
then pooled. 2 mg of peptide was then dissolved in 100 pi of coupling buffer and the 
pH was adjusted to 7.5 with 2 M NaOH. The peptide solution was added to the 
pooled column fraction and incubated for 2 h at room temp to covalently couple the
Table 2.4. Synthetic peptides used for the production and characterisation of 
phosphorylation state-specific antibodies.
Synthetic Peptide Sequence (N to C terminus) Use
03-S383 CSGIQYRKQSMPK Characterisation
P3-S383-P CSGIQYRKQSpMPK Immunogen and characterisation
03-S4O8/S4O9 CKTHLRRRSSQLK Characterisation
P3-S408-P CKTHLRRRSPSQLK Characterisation
P3-S409-P CKTHLRRRSSPQLK Immunogen and characterisation
P3-S408/S409-P CKTHLRRRSPSPQLK Characterisation
Sp indicates a phosphorylated serine residue
C highlights the introduction of an N-terminal cysteine residue
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cysteine-containing peptide to the cross-linker via a reaction with its maleimide 
group. The solution was then diluted to a final volume of 1.8 ml with sterile water 
and five aliquots were prepared as follows: one aliquot of 0.6 ml (for immunisation) 
and four aliquots of 0.3 ml (for four boosts). Each aliquot was shared between two 
rabbits. Each rabbit therefore received 300 pg of peptide at the immunisation step 
and 150 pg of peptide at each boost. The aliquots were stored at -20 °C until 
required.
2.43.3 Production of Antisera
Each peptide antigen was used to raise polyclonal antibodies in two rabbits. This part 
of the project was contracted out to Cocalico Biologicals Inc, PA, USA. The rabbits 
were immunised using the standard company protocol, in Freund’s Complete 
Adjuvant. Table 2.5 shows the schedule that was followed for production of the 
antibodies in rabbits UCL-103 and UCL-104 (for anti-phospho-S383), and rabbits 
UCL-105 and UCL-106 (for anti-phospho-S409). The methodology used to affinity - 
purify antibodies in this study is described in Section 2.5.2.
Table 2.5. Timetable for the production of polyclonal phosphorylation state- 
specific antibodies in rabbits UCL-103, UCL-104, UCL-105 and UCL-106.
Day Procedure
0
0
Pre-bleed
Initial
inoculation
14 Boost
21 Boost
35 Test-bleed 1
49 Boost
56 Test bleed 2
93 Exsanguination
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2.5 Biochemistry
2.5.1 Antibodies
A list of all antibodies used in this study is given in Table 2.6.
2.5.2 Affinity-Purification of Antibodies
2.5.2.1 Preparation of Affinity Columns
2.52.1.1 Protein A Columns
0.5 g of protein A Sepharose CL-4B (Amersham Biosciences) was re-suspended in 10 
ml of deionised water and incubated with rotation for 30 min at 4 °C. The beads were 
washed twice in Tris Buffered Saline (TBS) (50 mM Tris-HCl and 150 mM NaCl, pH
7.5), with centrifugation at 2000 rpm for 2 min at room temp between washes. After 
the final wash the beads were re-suspended in 10 ml of TBS and packed into a glass 
Econo-Column chromatography column (Bio-Rad) to give a 4 to 5 ml bed volume. 
Once packed, the column was washed with 40 ml of TBS-T (TBS with 0.1% (v/v) 
Tween-20) and stored at 4 °C until required.
2 5 2 .1 2  Phosphopeptide Columns
1 g of activated CH Sepharose 4B (Amersham Biosciences) was re-suspended in 10 
ml of 1 mM HC1 and incubated with rotation for 10 min at 4 °C. The Sepharose 
beads were washed twice in 1 mM HC1, with centrifugation, at 2000 rpm for 2 min at 
4 °C, between washes. After the final wash, the beads were re-suspended in 10 ml of 
Coupling Buffer II (0.1 M NaHC03 and 0.5 M NaCl, pH 8.3) and incubated, with 
rotation, for 10 min at 4 °C. Following centrifugation at 2000 rpm for 2 min at 4 °C, 
the beads were re-suspended in 16 ml Coupling Buffer II. 10 to 15 mg of peptide was 
then dissolved in 1 ml of water and the pH was adjusted to 7.5 with 2M NaOH. The 
peptide solution was mixed with 8 ml of Coupling Buffer II and 4 ml of Sepharose 
beads, and rotated overnight, with rotation, at 4 °C. The following day, the beads 
were washed twice in Coupling Buffer II, and blocked in 1 M ethanolamine, pH 8, for 
1 h. The beads were first washed in Wash Buffer (0.1 M NaOAc and 0.5 M NaCl, pH
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Table 2.6. Antibodies used in this study.
Antibody
Mouse anti- 
CaMKIIa
Rabbit anti-CaMKII- 
pT286
Rabbit anti-pPKC 
(pan)
Anti-p2
UCL-95 and 
UCL-98
UCL-39
(anti-03-pS4O8/S4O9)
UCL-103 
(anti-03-pS383)
UCL-104
(anti-03-pS383)
UCL-105 
(anti-03-pS4O9)
UCL-106 
(anti-03-pS4O9)
Rabbit anti-y2 
subunit
Description
Monoclonal antibody to recombinant and 
native phosphorylated and non-phosphoiylated 
CaMKIIa; clone 6G9; 1:1500 dilution 
Polyclonal antibody to CaMKII 
phosphorylated on T286; 1:2000 dilution 
Polyclonal antibody to PKC isoforms 
(a/|3I/piI/6/e/T]/T) phosphorylated at a C- 
terminal residue homologous to S660 of PKC- 
011; 1:1000 dilution 
Monoclonal anti-p,2 adaptin antibody; 1:250 
dilution
Polyclonal antibodies to residues 345-408 of 
the GABAa receptor 03 subunit intracellular 
domain; used at 0.5 or 1 pg/ml 
Polyclonal antibody to the GABAa receptor 03 
subunit phosphorylated on S408 and S409; 
used at 1 pg/ml 
Polyclonal antibody to the GABAa receptor 03 
subunit phosphorylated on S383; serum was 
diluted 1:100; affinity-purified used at 1 pg/ml 
Polyclonal antibody to the GABAa receptor (33 
subunit phosphorylated on S383; serum was 
diluted 1:100 
Polyclonal antibody to the GABAa receptor (33 
subunit phosphorylated on S409; serum was 
diluted 1:100 
Polyclonal antibody to the GABAa receptor 03 
subunit phosphorylated on S409; serum was 
diluted 1:100; affinity-purified used at 1 pg/ml 
Polyclonal antibody to the N-terminus of the 
GABAa receptor y2 subunit
Source
Oncogene
Research
Products
Promega
Cell Signalling
BD Biosciences 
S.J. Moss
S .J. Moss
This Study
This Study
This Study
This Study 
W. Sieghart
Control rabbit IgG ChromPure rabbit IgG, whole molecule Jackson Labs
Rabbit anti-mouse 
IgG
Anti-mouse-HRP
Anti-mouse-HRP 
(min X)
Anti-rabbit-AP
Polyclonal antibody to heavy chains on mouse 
IgG and light chains common to most mouse 
immunoglobulins; used at 5 pg/ml 
Polyclonal antibody to mouse IgG conjugated 
to horseradish peroxidase; 1:7000 dilution 
Peroxidase conjugated affinity purified goat 
anti-mouse IgG (H&L) (min cross-reactivity);
1:5000 dilution 
Polyclonal antibody to rabbit IgG conjugated 
to alkaline phosphatase; 1:1000 dilution
Jackson Labs
Jackson Labs
Rockland
Immunochem.
Promega
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Antibody Description Source
And-mouse-AP
[125I]-anti-rabbit
antibody
Polyclonal antibody to mouse IgG conjugated 
to alkaline phosphatase; 1:1000 dilution 
Polyclonal anti-rabbit whole antibody raised in 
donkey, [I25I]-coupled; 1:1000 dilution
Promega
Amersham
Biosciences
4), and then Coupling Buffer II, pH 8.3. This was repeated three times. The beads 
were then re-suspended in 10 ml of TBS and packed into a glass Econo-Column 
chromatography column to give a 4 to 5 ml bed volume. Once packed, the column 
was washed with 40 ml of TBS-T (Section 2.5.2.1.1) and stored at 4 °C until 
required.
2.52.1.3 GST-{$3 (345-408)-Fusion Protein Column
GST-p3 (345-408) fusion proteins were expressed in 2 1 of bacterial culture and 
purified as described in Section 2.2.4. The GST-fusion proteins were dialysed against 
2 1 of Coupling Buffer II. A CNBr-activated Sepharose 4B column was prepared and 
stored essentially as described in Section 2.5.2.1.2, except that the Sepharose beads 
were incubated with GST-^3 (345-408)-fusion proteins instead of peptides.
2.5.22 Affinity Purification o f Antisera
5 ml of each serum sample (UCL-103, UCL-106, UCL-39, UCL-95 and UCL-98; 
Table 2.6) was thawed on ice and passed through a 0.45-pm filter. EDTA was added 
to 5 mM and EGTA to 1 mM. Pepstatin, antipain and leupeptin were each added to 
20 pg/ml, and PMSF to 100 pM. The column was washed with 25 ml of TBS-T 
(Section 2.5.2.1.1), and the serum was passed through the column three times. The 
column was washed with 30 ml of TBS-T, 30 ml of BBS-T (25 mM Na borate, 3.1 g/1 
boric acid, 1 M NaCl, pH to 8.3 and 0.1% (v/v) Tween-20), 30 ml of ABS-T (50 mM 
NaOAc, 1 M NaCl, pH to 5.5 with HC1 and 0.1% (v/v) Tween-20) and, finally, 40 ml 
of TBS. Antibodies were eluted with 0.1 M glycine, pH 2 or 2.5, and immediately 
neutralised with 1 M Tris base. The peak fractions were pooled and dialysed 
overnight at 4 °C against 4 1 of PBS. Following dialysis, the absorbance at 280 nm 
was measured using a Bio-Rad SmartSpec 3000 spectrophotometer. The formula for 
calculating the concentration of antibody, where is the absorbance at 280 nm, is
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given by
1 mg/ml IgG = A2so 1-4 (2.2)
The antibody solution was frozen in aliquots and stored at 4 °C or -20 °C. The 
column was recycled by several washes, in the following order: 10 ml of TBS, 10 ml 
of 0.1 M glycine, pH 2 or 2.5, 10 ml of TBS, 10 ml of 4.3 M MgCl2 and finally 10 ml 
of TBS-T. The column was stored at 4 °C until required.
2.5.3 Preparation of Tissue and Cell Extracts
2.5.3.1 Preparation of Whole Brain Extract
An adult Sprague-Dawley rat (Section 2.4.2.1) brain was homogenised in a 50-cm3 
homogeniser containing 10 ml of Affinity-Purification Buffer (50 mM HEPES, pH 
7.6, 1% (v/v) nonidet P-40 (NP-40), 0.5% (w/v) deoxycholate (DOC), 5 mM EGTA, 
5 mM EDTA, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 10 mM sodium 
pyrophosphate, pepstatin, antipain and leupeptin (each to 10 pg/ml), 1 mM PMSF and 
150 mM NaCl). The homogenate was rotated for 1 h at 4 °C, and transferred to four 
Beckman polycarbonate centrifuge tubes. Insoluble material was removed by 
centrifugation in a Beckman optima ultracentrifuge (TLA 110 rotor) at 60,000 rpm 
for 30 min at 4 °C. The supernatant was retained and kept at 4 °C for the rest of the 
day. Protein concentration of the extract was determined using the Bradford protein 
assay (Section 2.5.4.2).
For coimmunoprecipitation (co-IP) studies, a mouse brain was homogenised in a 50- 
cm3 homogeniser containing 3 ml of Co-IP Buffer (0.5% (w/v) DOC, 1% (v/v) NP- 
40, 20 mM HP04, pH 8.0, one protease inhibitor cocktail tablet (Roche; Penzberg, 
Germany) and one phosphatase inhibitor cocktail tablet (Calbiochem) and extracted 
overnight at 4 °C. Insoluble material was removed by centrifugation in a Beckman 
optima ultracentrifuge (TLA 110 rotor) at 35,000 rpm for 30 min at 4 °C. The 
supernatant was retained and kept at 4 °C for the rest of the day. The protein 
concentration was determined using the Bradford protein assay (Section 2.5.4.2).
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2.5.32 Preparation o f Neuronal Extracts
2.5.3.2.1 Using 2% (w/v) Sodium Dodecyl Sulphate
Dishes were placed on ice and neurons were washed twice with chilled PBS. Cells 
were lysed in 166 pi of 2% (w/v) Sodium Dodecyl Sulphate (SDS), and the extract 
was collected using a cell scraper (Coming; NY, USA), and transferred to a 
microfuge tube. Samples were sonicated for 10 s and boiled for 5 min at 95 °C. The 
protein concentration of the cell extract was determined using the BCA protein assay 
(Section 2.5.4.1). Samples were stored at -20 °C until required.
25.3.22 Using Pre-LabellingllP Buffer
Dishes were placed on ice and neurons were washed twice with chilled PBS. Cells 
were lysed in 166 pi PB/SDS Buffer (PBS containing 5 mM EGTA, 5 mM EDTA, 50 
mM sodium fluoride, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 
pepstatin, antipain and leupeptin (each to 10 pg/ml), 1 mM PMSF and 1% (w/v) 
SDS). The extract was collected using a cell scraper and transferred to a 15-ml falcon 
tube. 1 ml of PB/NP-40 Buffer (PBS containing 5 mM EGTA, 5 mM EDTA, 50 mM 
sodium fluoride, 1 mM sodium ortho vanadate, 10 mM sodium pyrophosphate, 
pepstatin, antipain and leupeptin (each to 10 pg/ml), 1 mM PMSF and 1% (v/v) NP- 
40) was added and samples were solubilised for 1 h at 4 °C. Samples were either 
sonicated for 10 s, or passed through a 21-gauge hypodermic needle. Samples were 
centrifuged at 13,000 rpm for 15 min at 4 °C and the supernatant was retained and 
kept on ice.
2.5.32.3 Using Affinity-Purification Buffer
Dishes were placed on ice and neurons were washed twice with chilled PBS. Cells 
were then lysed in 500 pi of Affinity-Purification Buffer (Section 2.5.3.1). The 
extract was collected using a cell scraper and transferred to a 15-ml Falcon tube. 
Samples were solubilised for 1 h at 4 °C and centrifuged at 13,000 rpm for 15 min at 
4 °C. The supernatant was transferred to a new tube and kept on ice until required, 
and the protein concentration was determined using the Bradford protein assay 
(Section 2.5.4.2).
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2.53.3 Preparation of COS-7 Cell Extracts
COS-7 cells were lysed according to the method described in Section 2.5.3.2.3.
2.5.4 Measurement of Protein Concentration
23.4.1 Bicinchoninic Protein Assay
Protein concentration was determined using the Bicinchoninic Protein Assay (BCA) 
reagents (Pierce). The assay reagent was prepared by mixing 50 parts of Reagent A 
with 1 part of Reagent B. A standard curve was generated by diluting BSA (1 mg/ml; 
Pierce) in 2 ml of assay reagent to a final concentration of 0.5, 1, 1.5, 2, 2.5, 5, 7.5 
and 10 pg/ml, and by adding 15 pi of 2% (w/v) SDS to each tube. 5 pi of unknown 
sample (containing 2% (w/v) SDS) and 10 pi of 2% (w/v) SDS were added to 2 ml of 
assay reagent mix. All standards and samples were transferred to a 37 °C water bath 
for 30 min. The absorbance was measured at 562 nm using a spectrophotometer, and 
the sample concentration was extrapolated from the standard curve.
2.5.4.2 Bradford Protein Assay
Protein concentration was determined using the Bradford protein assay reagent. A 
standard curve was generated by diluting BSA (1 mg/ml) in 1 ml of assay reagent 
(diluted 1:5) to a final concentration of 1, 2, 5 and 10 pg/ml, and measuring the 
absorbance at 595 nm (A595) with a spectrophotometer. 1 pi of unknown sample was 
added to 1 ml of the diluted assay reagent, and the A595 was measured. Protein 
concentration was determined by extrapolation from the standard curve.
2.5.5 SDS-Polyacrylamide Gel Electrophoresis
Proteins were resolved by SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
using Bio-Rad or Invitrogen equipment.
2.5.5.1 Using the Bio-Rad System
Polyacrylamide gels were cast and run using Bio-Rad Mini-PROTEAN®3 or large- 
format PROTEAN II xi gel apparatus, in accordance with the manufacturer’s 
guidelines. Briefly, the Laemmli resolving gel, which consisted of 10% (w/v)
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acrylamide/0.27% (w/v) bisacrylamide (National Diagnostics; Hull, UK), or 12% 
(w/v) acrylamide/0.32% (w/v) bisacrylamide, and 375 mM Tris-HCl, pH 8.8, 0.1% 
(w/v) SDS, 0.1% (w/v) ammonium persulphate (APS) and 0.04% (v/v) N, N, N’, N’- 
tetramethyl-ethylene diamine (TEMED), was cast between two glass plates and 
overlaid with water-saturated butanol until gel polymerisation was complete. The 
Laemmli stacking gel, which consisted of 5.1% (w/v) acrylamide/0.14% (w/v) 
bisacrylamide, 125 mM Tris-HCl, pH 6.8, 0.1% (w/v) SDS, 0.1% (w/v) APS and 
0.1% (v/v) TEMED, was then poured above the resolving gel and left to polymerise 
after insertion of a comb.
Samples were loaded onto the gel in SDS Loading Buffer (62.5 mM Tris-HCl, pH 
6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol and 0.0005% 
bromophenol blue), after being boiled for 5 min at 95 °C. Molecular weight 
standards (Bio-Rad or Amersham) were also loaded onto each gel. Gels were run in 
Tris-Glycine Electrophoresis Buffer (25 mM Tris base, 250 mM glycine and 0.1% 
(w/v) SDS) at approx 70 V (large gels) or 150 V (small gels) until the bromophenol 
blue dye-front reached the desired position on the gel.
25 .5 2  Using the Invitrogen System
Novex NuPAGE® 4-12% Bis-Tris pre-cast gels and buffers were used with the XCell 
SureLock™ Mini-Cell, in accordance with the manufacturer’s guidelines. Samples 
were prepared and loaded onto the gel, which was run as described in Section 2.5.5.1.
2.5.6 Visualising Proteins in SDS-PAGE Gels by Staining with Brilliant Blue R
To visualise molecular weight markers and other proteins in an SDS-PAGE gel (and 
to check the loading and degradation of the GST-fusion proteins) the resolving gel 
was immersed in approx 5 volumes of 0.25% (w/v) Brilliant Blue R in destain 
solution (30% (v/v) methanol, 10% (v/v) glacial acetic acid) for 15 min. The gel was 
then rinsed and immersed in destain solution, which was replaced every 15 min until 
proteins bands became visible. If desired, the gel was also rinsed in 1% (v/v) glycerol 
for 5 min before drying with a Bio-Rad 583 gel dryer for 1 to 2 h at 80 °C.
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2.5.7 Western Blot Analysis
Following separation by SDS-PAGE, protein bands were transferred from the 
polyacrylamide gel onto a Hybond-C nitrocellulose membrane (Amersham) using 
Bio-Rad Protean Trans-Blot apparatus, in accordance with the manufacturer’s 
guidelines. Proteins were transferred in Transfer Buffer (48 mM Tris base, 39 mM 
glycine, 0.037% (w/v) SDS and 20% (v/v) methanol) at 300 mA for 3 h.
The nitrocellulose membrane was rinsed in a solution of 0.1% (w/v) Ponceau-S in 5% 
(v/v) glacial acetic acid for 2 min at room temp to visualise molecular weight markers 
and other proteins (and to check the loading and degradation of the GST-fusion 
proteins). After rinsing with deionised water, the nitrocellulose membrane was 
incubated with Milk Blocking Buffer (PBS containing 4% (w/v) Marvel milk and 
0.1% (v/v) Tween-20) or TBS-T Blocking Buffer (TBS-T (Section 2.5.2.1.1) 
containing 2 mg/ml BSA), for 1 h at room temp or overnight at 4 °C. The membrane 
was then incubated with the primary antibody, which was diluted to the appropriate 
concentration in the blocking buffer, for 1 h at room temp or overnight at 4 °C, with 
agitation. After three 10 min washes in the blocking buffer, the membrane was 
incubated with secondary antibody, which was diluted to the appropriate 
concentration in the blocking buffer, for 1 or 2 h at room temp. The membrane was 
then washed for 10 min with the blocking buffer followed by two 10-min washes with 
PBS containing 0.1% (v/v) Tween-20, or TBS-T, as appropriate.
Secondary antibodies were conjugated to horseradish peroxidase (HRP), alkaline 
phosphatase (AP) or the [125I]-radiolabel (Table 2.6). Those antibodies conjugated to 
HRP were detected using the Pierce enhanced chemiluminescence (ECL™) system. 
The membrane was exposed to Kodak X-ray film, and was processed in an RG II Fuji 
X-ray film processor. Secondary antibodies conjugated to AP were detected by first 
rinsing the membrane in AP Buffer (100 mM Tris-HCl, 100 mM NaCl and 10 mM 
MgCl2, pH 9.5), and then in AP Buffer containing 0.35% (v/v) NBT and 0.7% (v/v) 
BCIP (Promega) until the protein bands were visible. The membrane was rinsed in 
deionised water to stop the reaction. The [125I]-conjugated secondary antibody was 
detected by phosphorimaging (Section 2.5.8).
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2.5.8 Phosphorimaging
Radioactive protein bands were detected by exposing the membrane to a Bio-Rad 
phosphorimager screen, which was processed in a Bio-Rad phosphorimager 
(molecular imager FX). Bio-Rad Quantity One software was used for data capture 
and quantitation of band intensities.
2.5.9 Dot-Blot Assays
Synthetic peptides (Table 2.4) were dissolved in 50 mM HEPES, pH 7.4, or sterile 
water to 1 mg/ml and the pH was adjusted to 7.5 with 2 M NaOH, where necessary. 
The peptides were then serially diluted to give the following concentration range: 100 
ng/pl, 50 ng/pl, 25 ng/pl and 5 ng/pl. 1 pi of each peptide solution was spotted onto 
a PVDF membrane (Immobilon P; Millipore), which had been marked into a grid 
using a pencil, soaked in methanol and partially dried at room temp. After the 
spotting, the membrane was soaked in methanol, and washed in water. Western 
blotting was then performed as previously described in Section 2.5.7, using TBS-T 
Blocking Buffer, and crude rabbit serum (UCL-103, UCL-104, UCL-105 and UCL- 
106) diluted 1:100 in TBS-T, and an anti-rabbit-AP secondary antibody (Table 2.6).
2.5.10 Coimmunoprecipitation Assays
A mouse brain extract was prepared as described in Section 2.5.3.1. 10 pg of control 
rabbit IgG or anti-|33 subunit antibody (Table 2.6), and 50 pi of a 50%-slurry of 
protein-A beads were added to 0.5 ml of extract, and immunoprecipitations were 
incubated overnight, with agitation, at 4 °C. The beads were then washed five times 
in 500 pi of Co-IP Buffer (Section 2.5.3.1), with centrifugation at 4,000 rpm for 2 
min at 4 °C in a 5415-R centrifuge, between washes. After the final wash, samples 
were boiled for 5 min at 95 °C in SDS Loading Buffer, and subjected to SDS-PAGE 
(Section 2.5.5). Western blotting was then performed (Section 2.5.7) using a primary 
anti-CaMKIIa antibody and a Rockland secondary anti-mouse-HRP antibody (Table 
2.6).
2.5.11 Affinity-Purification (‘Pull-Down’) Assays
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2.5.11.1 Using Tissue or Cell Extracts
A tissue or cell extract was prepared in Affinity-Purification Buffer as described in 
Sections 2.5.3.2.3 and 2.5.3.3, and the protein concentration was determined as 
described in Section 2.5.4.2. 0.5 mg or 1 mg of extract was incubated with 25 pg of 
the appropriate GST-fusion protein (Table 2.2 and Section 2.2.4) and 50 pi of a 50%- 
slurry of glutathione-agarose beads, for 1 h at 4 °C, with rotation. Samples were then 
centrifuged at 6,500 rpm for 2 min at 4 °C in a 5415-R centrifuge and washed with 1 
ml of Affinity-Purification Buffer. Following two more washes, including one wash 
in 1 ml of Affinity-Purification Buffer containing 500 mM NaCl, samples were boiled 
for 5 min at 95 °C in SDS Loading Buffer. Samples were subjected to SDS-PAGE 
and proteins of interest were detected by Western blotting (Sections 2.5.5 and 2.5.7).
23.11.2 Using In Vitro Transcribed!Translated DNA
The plasmid DNA (Table 2.2) of interest was transcribed and translated in vitro using 
the SP6 or T7 Promega TNT® quick-coupled transcription/translation system and 
easy-tag express [35S]-methionine, in accordance with the manufacturer’s guidelines. 
5 pi of the in vitro transcription/translation reaction was then mixed with 25 pg of the 
appropriate GST-fusion protein (Table 2.2 and Section 2.2.4) and 50 pi of a 50%- 
slurry of glutathione-agarose beads, and the total volume was made up to 0.5 ml with 
In Vitro Affinity-Purification Buffer (0.5% (v/v) triton-X-100, 20 mM HEPES, pH
7.4, 5 mM EDTA, 150 mM NaCl, 1 mM PMSF and pepstatin, leupeptin and antipain 
(each at 10 pg/ml). Following incubation for 1 h at 4 °C, with rotation, beads were 
washed three times with 1 ml of In Vitro Affinity-Purification Buffer, with 
centrifugation at 6,500 rpm for 2 min at 4 °C, between washes. Following the final 
wash, samples were boiled for 5 min at 95 °C in SDS Loading Buffer, and subjected 
to SDS-PAGE (Section 2.5.5). GST-fusion proteins and molecular weight markers 
were visualised (and checked for equal loading where appropriate) by staining with 
Brilliant Blue R (Section 2.5.6), and [35S]-labelled proteins were detected and 
quantitated, by phosphorimaging (Section 2.5.8).
2.5.12 Pre-Labelling Assays
Cultured cortical neurons (E17; 6DIV) (Section 2.4.2) were washed twice in 4 ml of
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minimum essential medium eagle without phosphate (MEME), supplemented with 
2% (v/v) (IX) B27 and 2 mM L-glutamine, and incubated in a further 4 ml of 
supplemented MEME for 1 h at 37 °C, 5% C 02 and 100% humidity. 0.5 mCi of 
[33P]-orthophosphate was then added to the neurons for a further 4 h, and KN93 (4 
pM), was also added, where appropriate, during the last 20 min of the 4 h. incubation 
to enable it to enter neurons and inhibit CaMKII. The neurons were then rinsed twice 
in 3 ml of HEPES-buffered saline (HBS; 150 mM NaCl, 3 mM KC1, 3 mM calcium 
chloride, 2 mM magnesium chloride, 5 mM D-glucose, 10 mM HEPES, pH 7.4), and 
incubated for a further 5 min in HBS, or HBS containing the appropriate treatment: 
50 pM muscimol with or without 4 pM KN93.
Following the pre-labelling and neuronal treatments, neurons were lysed in 166 pi of 
PB/SDS Buffer (Section 2.5.3.2.2) and transferred to a 15-ml falcon. Following 
addition of 2 ml of PB/NP-40 Buffer (Section 2.5.3.2.2), the cell lysate was rotated 
for 1 h at 4 °C. The DNA was sheared through a 21-gauge hypodermic needle and 
samples were centrifuged at 13,000 rpm for 15 min at 4 °C. The supernatant was pre­
cleared by incubation with 2 pg of control rabbit IgG and 50 pi of a 50%-slurry of 
BSA-coated protein-A beads (Amersham) for 30 min at 4 °C, with rotation. Samples 
were centrifuged at 4,000 rpm for 10 min at 4 °C, and the cleared supernatant was 
incubated with 2 pg of the appropriate antibody (control rabbit IgG or rabbit anti-(33 
subunit) and 50 pi of a 50%-slurry of BSA-coated protein-A beads for 2 h at 4 °C. 
Following centrifugation at 4,000 rpm for 2 min at 4 °C, the beads were washed in 1 
ml of PB/NP-40 Buffer and rotated at 4 °C for 10 min. Following two more washes, 
samples were boiled for 5 min at 95 °C in SDS Loading Buffer, and subjected to 
SDS-PAGE (Section 2.5.5). Molecular weight markers were visualised by staining 
with Brilliant Blue R, and [33P]-labelled proteins were detected by phosphorimaging 
(Sections 2.5.6 and 2.5.8).
2.5.13 In Vitro Kinase Assays
In vitro kinase reactions were set up, on ice, in CaMKII Buffer (50 mM HEPES, pH
7.4, 10 mM MgCl2, 1 mM EGTA and 1.5 mM CaCl2) (Grossman et a i, 2004) as 
follows: GST-fusion proteins were mixed with calmodulin (CaM; 10 pg/ml), the PKC
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inhibitor, 19-36 (1 pM), the PKA inhibitor, 5-24 (0.1 pM) and CaMKII, which had 
been purified from brain (1/20 dilution; a generous gift from Howard Schulman 
Stanford University, CA and Paul Greengard, Rockefeller University, NY (~0.5 
mg/ml)). Reactions were incubated at 30 °C for 1 min prior to addition of the ATP 
mix, which contained ATP (usually at 2 mM) and [y-32P]-ATP) (usually between 10 
and 25% (v/v)). The ATP was added to give a final concentration of 0.2 mM in the 
kinase assay (except for the phosphatase assays in which it was added to 0.5 mM). 
Reactions were incubated for the appropriate time at 30 °C and stopped by addition of 
SDS Loading Buffer. Samples were boiled for 5 min at 95 °C, and proteins were 
resolved by SDS-PAGE (Section 2.5.5). GST-fusion proteins and molecular weight 
markers were visualised by staining with Brilliant Blue R (Section 2.5.6), and r e ­
labelled proteins were detected and quantitated by phosphorimaging. The 
stoichiometry of phosphorylation (mol phosphate mol protein1) was also calculated, 
where appropriate (Section 2.5.14).
One variation of this method involved performing kinase assays in the presence of 
ATP only (‘cold’ assays) in parallel to assays in the presence of [y-32P]-ATP and ATP 
(‘hot’ assays). The method was essentially as described above, except that before 
pre-incubation and addition of ATP, 10% (v/v) of each kinase reaction was 
transferred to a new tube (e.g. 4.5 pi from a total volume of 45 pi) to form a duplicate 
second set of assays. The first set of reactions was started by addition of ATP (to 200 
pM) in a volume that restored the total volume (e.g. 4.5 pi of ATP; the volume 
previously transferred) and the second set by addition of [y-32P]-ATP/ATP mix (ATP 
also to 200 pM, and in a volume that comprised 10% (v/v) of the total volume; e.g. 
0.5 pi to give a total volume of 5 pi). Both sets of reactions were incubated in 
parallel at 30 °C for 15 min. The first set was then immediately transferred to dry ice 
and stored at -80 °C until required (e.g. for Western blotting with phosphorylation- 
state specific antibodies). The second set of reactions was stopped upon addition of 
SDS Loading Buffer and the proteins were resolved by SDS-PAGE. [32P]-labelled 
proteins were then detected by phosphorimaging after staining all proteins with 
Brilliant Blue R.
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Another variation of this protocol was used in the In Vitro Affinity-Purification 
Kinase Assays (Section 2.5.15). In these, the kinase reactions were performed in the 
presence of immobilised GST-fusion proteins, which had previously been mixed with 
a neuronal extract, and were therefore associated with various cellular proteins. The 
reactions were performed in CaMKII buffer and started upon addition of [y-32P]- 
ATP/ATP mix (ATP to 0.2 mM) (calmodulin was not added). The reaction was 
incubated at 30 °C for 30 min and stopped upon addition of SDS Loading Buffer. 
Proteins were resolved by SDS-PAGE and then stained with Brilliant Blue R. [32P]- 
labelled proteins were detected by phosphorimaging.
For in vitro kinase assays using purified PKC, two sets of reactions (one ‘hot’ (25 pi 
total volume) and one ‘cold’ (200 pi total volume)) were set up. Each set comprised 
a phosphorylation reaction and a mock-phosphorylation reaction. Each reaction was 
set up on ice, in PKC Buffer (20 mM HEPES, pH 7.4, 10 mM MgOAc, 1 mM EGTA 
and 1.5 mM CaCl2), as follows: GST-y2S fusion proteins (10 pg: for ‘hot’ assays; 100 
pg: for ‘cold’ assays), 4 pg/ml DG/50 pg/ml PSEL, and either purified PKC (1/25 
dilution; a generous gift from Angus Naim, Rockefeller University, New York) 
(‘phospho’ reaction) or the equivalent volume of sterile water (mock ‘phospho’) 
(Picciotto et al., 1992). Reactions were incubated at 30 °C for 1 min before addition 
of the ATP mix. For one set of GST-y2S fusion proteins this contained ATP (usually 
at 2 mM) and [y-32P]-ATP) (usually between 10 and 25% (v/v)). The ATP was added 
to give a final concentration of 0.2 mM in the kinase assay. For the other set ‘cold’ 
ATP was added to a final assay concentration of 0.2 mM. Reactions were incubated 
for 60 min at 30 °C. ‘Hot’ reactions were then stopped by addition of SDS Loading 
Buffer, and ‘cold’ reactions by transferring tubes immediately to dry ice, and then to 
-80 °C. Hot samples were boiled for 5 min at 95 °C, and proteins were resolved by 
SDS-PAGE (Section 2.5.5). GST-fusion proteins and molecular weight markers were 
visualised by staining with Brilliant Blue R (Section 2.5.6), and [32P]-labelled proteins 
were detected and quantitated by phosphorimaging. The stoichiometry of 
phosphorylation (mol phosphate mol protein'1) was also calculated, where appropriate 
(Section 2.5.14). The ‘cold’ samples were then used in affinity-purification assays 
(see 2.5.11.2).
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2.5.14 Calculation of the Stoichiometry of Phosphorylation
The stoichiometry of phosphorylation (mol. phosphate mol. protein'1) was assessed 
following SDS-PAGE and phosphorimaging by measuring the incorporation of [32P], 
and normalising to the amount of protein used. To do this, the specific activity of 
ATP (mol counts'1) was first determined. The ATP mix was diluted 1/10, and two 1- 
pl spots and two 2-pil spots were pipetted onto a piece of Whatman filter paper 
(Middlesex, UK). The mean number of counts per pil of ATP mix was then 
calculated following quantitation of the signals by phosphorimaging (Section 2.5.8), 
and used to calculate moles of phosphate per count. The number of counts obtained 
for the GST-fusion protein was then determined by phosphorimaging, and used with 
the value of the specific activity to calculate the moles of phosphate incorporated into 
all of the GST-fusion protein present. Secondly, I calculated the total moles of GST- 
fusion protein present. Finally, I calculated the stoichiometry of phosphorylation 
(mol phosphate mol protein'1; the moles of phosphate incorporated per mole of 
protein) by dividing the moles of phosphate incorporated by the total moles of GST- 
fusion protein present.
2.5.15 In Vitro Affinity-Purification Kinase (‘Pull-Down’-Kinase) Assays 
Cultured cortical neurons (E17; 6DIV) were rinsed twice in HBS (Section 2.5.12), 
and incubated in 3 ml of HBS, or HBS containing KC1 (50 mM), with or without 
KN93 (4 pM) or EGTA (4 mM) for the appropriate time, at 37 °C. KN93 was added 
to the neurons, where appropriate, 20 min before treatment to enable it to enter 
neurons and inhibit CaMKII; EGTA was added 5 min before treatment. Following 
the treatments, dishes were placed on ice, and neurons were lysed in 500 pi of 
Affinity-Purification Buffer (Section 2.5.3.1). Following incubation for 1 h at 4 °C, 
with rotation, the extract was centrifuged at 13,000 rpm for 15 min at 4 °C, and the 
supernatant was transferred to a new tube. The protein concentration was determined 
by the Bradford assay (Section 2.5.4.2). 3.5 mg of neuronal extract was mixed with 
25 pg of the appropriate GST-fusion protein (Table 2.2 and Section 2.2.4) and 50 pi 
of a 50%-slurry of glutathione-agarose beads for 1 h at 4 °C, with rotation. Samples 
were washed three times with 1 ml of Affinity-Purification Buffer, and a further three 
times in CaMKII Buffer (Section 2.5.13), with centrifugation at 6,500 rpm for 2 min
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at 4 °C between washes. Kinase reactions were set up as follows: the beads 
containing the bound GST-fusion proteins were re-suspended in CaMKII Buffer, on 
ice. A CaMKII substrate peptide (autocamtide; 100 piM) was added to a fraction of 
the assay as a further control, but this did not yield reliable data. Reactions were 
incubated at 30 °C for 1 min before addition of the ATP mix, which contained ATP 
(usually at 2 mM) and [y-32P]-ATP (usually between 10 and 25% (v/v)). ATP was 
added to give a final concentration of 0.2 mM in the kinase assay. Reactions were 
incubated for 30 min at 30 °C and were stopped by addition of an equal volume of 
150 mM phosphoric acid. Samples were centrifuged at 6,500 rpm for 3 min at 4 °C. 
The excess phosphoric acid was removed and spotted onto P81 Whatmann filter 
paper, which was then washed 3 times 10 min in phosphoric acid. The [32P]-emission 
was counted using a scintillation counter. The beads were washed twice in CaMKII 
Buffer, with centrifugation between washes, as above. Samples were boiled in SDS- 
PAGE Loading Buffer for 5 min at 95 °C, and subjected to SDS-PAGE (Section
2.5.5). GST-fusion proteins and molecular weight markers were visualised with 
Brilliant Blue R, and [32P]-labelled proteins were detected by phosphorimaging 
(Sections 2.5.6 and 2.5.8).
2.5.16 In Vitro Dephosphorylation Assays
23.16.1 Preparative Phosphorylation of Substrates
2.5.16.1.1 Preparative Phosphorylation of GST- Fus i on  Proteins by CaMKII
The GST-fusion proteins, GST-03, GST-03-S383A and GST-03-S4O9A were 
expressed and purified as described in Table 2.2 and Section 2.2.4. Following 
dialysis against 4 1 of PBS, the GST-fusion proteins were concentrated using Amicon 
Ultra-15 PLGC centrifugal filter units (Millipore; Billerica, MA, USA). 330 pig of 
each GST-fusion protein was then phosphorylated in vitro by purified CaMKII (1/20 
dilution) in the presence of [y-32P]-ATP, as described in Section 2.5.13. The reaction 
was stopped after 30 min at 30 °C, by using a Sephadex G-50 NICK column 
(Amersham Biosciences) to separate phosphorylated GST-fusion proteins from ATP 
and [y-32P]-ATP. [32P]-labelled phospho-GST-fusion proteins were stored in 50%
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(v/v) glycerol at -20 °C until required.
2.5.16.1.2 Preparative Phosphorylation of Phosphorylase b by Phosphorylase 
Kinase
Phosphorylase b (Calzyme, CA, USA) was phosphorylated in vitro in a total reaction 
volume of 2 ml. The reaction was set up as follows: 32 mg of phosphorylase b, 2 mg 
of phosphorylase kinase, 200 pM ATP and 100 pil of [y-32P]-ATP in IX Reaction 
Buffer (100 mM Tris, pH 8.2, 100 mM Na-Glycerol-l-P, 0.1 mM CaCl2 and 10 mM 
magnesium acetate). The reaction was incubated for 1 h at 30 °C, and was stopped by 
desalting on a PD-10 column. An equal volume of 90% (w/v) saturated ammonium 
sulphate was added to the reaction mix. The solution was centrifuged at 13,000 rpm 
for 10 min at room temp, and the pellet was washed with 45% (w/v) ammonium 
sulphate. After re-centrifuging, the pellet was re-suspended in 100 pi of Buffer I (50 
mM Tris-HCl, pH 7, 0.1 mM EGTA, 1 mM DTT and 10% (v/v) glycerol) and 
desalted into the same buffer using a Sephadex G-50 NICK column. The solution 
was incubated overnight at 4 °C to allow for re-crystallisation. The crystals were 
centrifuged at 13,000 rpm for 15 min and re-suspended in Buffer I. The supernatant 
was concentrated by dialysing overnight in 10 mM Tris-HCl, pH 7, and 0.1% (v/v) 2- 
mercaptoethanol, at 4 °C. The contents of the dialysis cassette were transferred to a 
new tube and incubated on ice for 30 min. The crystals were centrifuged and re­
suspended as before, and the solution was pooled with that previously obtained. 
[32P]-labelled phosphorylase a was stored at 4 °C until required.
2.5.16.1.3 Preparative Phosphorylation ofDARRP-32 by PKA
Tom McAvoy performed the preparative phosphorylation of DARRP-32. Briefly, 
DARRP-32 was phosphorylated at T34 in vitro by the catalytic subunit of PKA in the 
presence of [y-32P]-ATP (Hemmings et al., 1984). [32P]-labelled DARRP-32-T34 was 
separated from ATP and [y-32P]-ATP by using a Sephadex G-50 NICK column. [32P]- 
labelled phospho-DARRP-32-T34 was stored in 50% (v/v) glycerol at -20 °C until 
required.
2.5.16.1.4 Preparative Phosphorylation of Casein by PKA
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Hydrolysed casein was phosphorylated in vitro in a total reaction volume of 100 pi. 
The reaction was set up on ice, as follows: 5 pi of 5% (w/v) casein, 500 pM ATP, 10 
pi of purified PKA catalytic subunit and 20 pi of [y-32PJ-ATP in IX PKA Buffer (50 
mM HEPES, pH 7.4, 10 mM magnesium acetate and 1 mM EGTA). The reaction 
was stopped after 1 h at 30 °C, by using a Sephadex G-50 NICK column to separate 
phosphorylated casein from ATP and [y-32P]-ATP. [32P]-labelled phospho-casein was 
stored in 50% (v/v) glycerol at -20 °C until required.
2.5.162 Determination of Initial Rate Conditions
All protein phosphatases used in this study were generous gifts from Paul Greengard. 
Protein phosphatases 1 (PP1) and 2A (PP2A) were purified from rabbit skeletal 
muscle and human red blood cells, respectively, and were purchased from Upstate 
(Lake Placid, NY, USA). Protein phosphatase 2B (PP2B; calcineurin) was purified 
from rat brain (Sihra et al., 1995). I also used a recombinant a  isoform of protein 
phosphatase 2C (PP2Ca) that was cloned from brain (Flajolet et al., 2003).
PP1, PP2A, PP2B and PP2C phosphatase activities were assayed using the reference 
substrates, [32P]-phosphorylase a (PP1 and PP2A), [32P]-DARRP-32 and [32P]-casein, 
respectively, in the appropriate assay buffer. The PP1 and PP2A Reaction Buffer 
consisted of 0.01% (v/v) Brij-35, 0.1 mM EGTA, 5 mM caffeine, 50 mM Tris, pH
7.5, 0.1% (v/v) 2-mercaptoethanol and BSA (1 mg/ml). The PP2B Reaction Buffer 
consisted of 1 mM CaCl2, 1 pM CaM, 6 mM MgCl2, 100 mM KC1, 20 mM Tris, pH
7.5, 1 mM ATP, 0.1% (v/v) 2-mercaptoethanol and BSA (1 mg/ml). The PP2C 
Reaction Buffer consisted of 50 mM Tris, pH 8, 40 mM MgCl2, 150 mM NaCl, 5 mM 
DTT and BSA (10 mg/ml).
Dephosphorylation assays were performed in duplicate in at least three individual 
experiments (see Jovanovic et al., 2001). Each protein phosphatase was diluted as 
desired in the appropriate reaction buffer, on ice. 10 pi of diluted protein phosphatase 
(or of the reaction buffer as a blank) was transferred to a tube containing 10 pi of the 
appropriate reaction buffer, on ice. Each tube was placed in a water bath at 30 °C for 
5 min, before the reactions were initiated by addition of 10 pi of [32P]-labelled
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reference substrate (phosphorylase a, DARRP-32 and casein; ~1.5 pM; to give a final 
concentration of ~0.5 pM). The reactions proceeded for the desired time at 30 °C, 
and were stopped by addition of 200 pi of 20% (w/v) trichloroacetic acid (TCA). The 
tubes were vortexed briefly and centrifuged at 13,000 rpm for 3 min at room temp. 
100 pi of each supernatant was transferred to a new tube, and the [32P]-emission was 
measured for 1 min using a liquid scintillation counter and Cerenkov programme to 
determine the number of sample counts per min (cpm). 10 pi of the [32P]-reference 
substrate (~1.5 pM) was added to 20 pi of reaction buffer and counted with the 
supernatants to determine total cpm. The formula for calculating percent phosphate 
removed, which should be 15% to 25% of the total counts, is given by
„  , , sample cpm - blank cpm
% phosphate removed = -----  — ----------------- —  x 100 (2.3)
total cpm
2.5.16.3 In Vitro Dephosphorylation Assays of Unknown Substrates 
Dephosphorylation assays were performed in duplicate in at least three separate 
experiments, essentially as described in Section 2.5.16.2. The [32P]-labelled reference 
substrate (~0.5 pM) and the [32P]-labelled GST-fusion protein unknown substrate 
(~0.5 pM) were assayed under initial rate conditions (the release of phosphate is 
linear with respect to enzyme concentration and time, and was 15-25% of the [32P]- 
phosphate incorporated into the substrate (Jovanovic et al., 2001)) (Section 2.5.16.2). 
Analysis of dephosphorylation was performed using the formula in Section 2.5.16.2.
2.6 Bioinformatics
Searches were performed using the NCBI database (www.ncbi.nlm.nih.gov). 
Multiple sequence alignments were constructed using ClustalW (Higgins, 1994) and 
manual editing with The Jalview Java Alignment Editor (Clamp et al., 2004).
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3.1 Background
In Chapter 1, I discussed the known cellular mechanisms that are involved in the 
trafficking, sub-cellular localisation and functional modulation of GABAa receptors.
I highlighted the importance of these processes in regulating the efficacy of inhibitory 
neurotransmission and neuronal excitability, and drew particular attention to the 
crucial role of phosphorylation-dependent modification. Moreover, I described the 
known associations between protein kinases and GABAa receptors, and related these 
interactions, where possible, to modifications of the phosphorylation state and 
function of these receptors. This suggested that the differential targeting of protein 
kinases to neuronal GABAa receptors is a key step during phosphorylation-dependent 
functional modulation. It is therefore fundamental to our understanding of 
GABAergic neurotransmission to understand how kinases are targeted to GABAa 
receptor scaffolds.
The results of electrophysiological studies based on the modulation of postsynaptic 
calcium/CaM signalling cascades and intracellular application of CaMKII suggest 
that CaMKII is involved in modulating GABAergic neurotransmission (Kano et al., 
1996; Kawaguchi and Hirano, 2002; Wei et al., 2004; Wang et al., 1995; Aguayo et 
al., 1998; see Section 1.8 for an overview of the structure and regulation of CaMKII). 
In cortical neurons, an increase in intracellular calcium concentration has been shown 
to cause transient augmentation of the GABA current, and inhibitors of both CaM and 
CaMKII have been shown to block this effect (Aguayo et al., 1998). In hippocampal 
pyramidal neurons, postsynaptic activation of IP3 receptors and induction of calcium 
release results in an enhancement of GABAa receptor-mediated inhibitory 
postsynaptic currents (IPSCs) (Wei et al., 2004). The calcium chelator, BAPTA, and 
a CaM-binding peptide have each been shown to block this effect (Wei et al., 2004). 
Similarly, the postsynaptic application of calcium/CaM leads to an enhancement of 
both evoked and spontaneous GABAa receptor-mediated IPSCs (Wei et al., 2004). 
This is attenuated by the autoinhibitory peptide of CaM-dependent protein kinases, 
CaM-KII (281-301) (Wei et al., 2004). Intracellular application of the alpha subunit 
of CaMKII has been shown to potentiate GABA-induced currents in spinal dorsal 
horn neurons, and evoked IPSPs in hippocampal CA1 neurons (Wang et al., 1995).
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Moreover, in cerebellar Purkinje neurons, intracellular application of purified, active 
CaMKII has been shown to enhance the amplitude of both GABA-mediated currents 
and spontaneous IPSCs (Kano et al., 1996). In cerebellar Purkinje neurons, GABA- 
mediated inhibitory synaptic currents undergo a long lasting “rebound potentiation” 
following activation of an excitatory synaptic input and elevation of the intracellular 
calcium concentration (Kano et al., 1992). Interestingly, a CaMKII inhibitor, KN62, 
has been shown to block the induction of “rebound potentiation” (Kano et al., 1996). 
Furthermore, CaMKII may be directly involved in the induction of this potentiation, 
as a regulatory calcineurin/PKA/DARRP-32/PPl signalling cascade has been located 
upstream of CaMKII activity (Kawaguchi and Hirano, 2002).
The above evidence suggests that CaMKII potentiates the activity of GABAa 
receptors in neurons. However, the molecular mechanism of such regulation remains 
to be elucidated. It is possible that CaMKII lies upstream of other cellular proteins 
that modify GABAa receptor function, or that CaMKII modifies receptor activity 
directly. The latter process seems to be a likely candidate since CaMKII is one of a 
number of protein kinases so far identified, which are capable of phosphorylating 
GABAa receptors directly (McDonald and Moss, 1994, 1997; Moss and Smart, 2001; 
Kittler and Moss, 2003; Section 1.7.2.1; Table 1.1). In vitro kinase assays have 
shown that CaMKII directly phosphorylates specific residues within the major 
intracellular domains of GABAa receptor (3 and y2 subunits (McDonald and Moss, 
1994, 1997; Table 1.1). These include S384 and S409 in the (31 subunit (McDonald 
and Moss, 1994), S410 in the |32 subunit, and S383 and S409 in the (33 subunit 
(McDonald and Moss, 1997). The y2 subunit sites include S348 and T350, as well as 
S343 in y2L only (McDonald and Moss, 1994; Machu et al., 1993).
Although GABAa receptors are in vitro substrates of CaMKII, a physical relationship 
between CaMKII and GABAa receptors remains to be determined. Several processes 
could regulate such an interaction, including kinase activation, sub-cellular targeting 
by anchoring proteins and the phosphorylation state of receptor subunits. 
Interestingly, autophosphorylation of CaMKII is known to play a critical role in 
modulating the sub-cellular localisation of this kinase. For example, phosphorylation
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of T286 is implicated in promoting the association of CaMKII with the PSD (McNeill 
and Colbran, 1995; Shen and Meyer, 1999; Shen et al., 2000), while phosphorylation 
of T305/306 is thought to destabilise this interaction (Shen et al., 2000; Elgersma et 
al., 2002; Weeber et al., 2003). The phosphorylation state of CaMKII has also been 
shown to influence its binding to a number of postsynaptic proteins (McNeill and 
Colbran, 1995; Merrill et a l, 2005). For example, autophosphorylation of T286 is 
necessary for the association of CaMKII with the NR1 subunit of the NMDA receptor 
(Leonard et al., 1999, 2002), and potentiates binding to the NR2A (Gardoni et al., 
1999, 2001) and NR2B receptor subunits (Bayer et al., 2001). The spatial 
distribution of CaMKII in neurons can also be governed by the activity of PKC (Fong 
et al., 2002).
CaMKII may stably bind and remain associated with the GABAa receptor to ensure 
that the desired stoichiometry of phosphorylation is achieved. However, CaMKII 
may also form a transient, unstable association with the receptor complex. In this 
chapter, I have taken a biochemical-based approach using coimmunoprecipitation and 
affinity-purification ‘GST-pull-down’ assays, to investigate how CaMKII is recruited 
to the GABAa receptor to mediate phosphorylation. I set the following aims: (i) to 
determine whether the GABAa receptor forms a native complex with CaMKII in 
brain, and if so, (ii) to determine whether the interaction between the GABAa 
receptor and CaMKII is direct, (iii) to identify specific regions in both GABAa 
receptor subunits and CaMKII isozymes, which are involved in binding, and (iv) to 
investigate how the interaction between the GABAa receptor and CaMKII is 
regulated. This approach has led to the discovery that CaMKII forms a stable 
phosphorylation-dependent interaction with the GABAa receptor, and that CaMKII 
docks to a site in the N-terminus of the major intracellular domain of the receptor (33 
subunit. I propose that this interaction underlies the ability to differentially target 
CaMKII to GABAa receptors, and that this is a key step in the regulation of GABAa 
receptor function in neurons.
3.2 Results
An overview of the methodology used in this chapter can be seen in Figure 3.1.
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In vitro transcription and 
translation of [35S]-labelled 
proteins
Protein expression 
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Purification of 
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with protein-A beads
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Figure 3.1. General overview o f the m ethodologies em ployed to investigate  
GABAa  receptor phosphorylation and receptor-protein interactions. Boxes 
shaded in grey describe the preparation of tissue and cell extracts, and in vitro 
transcribed and translated radiolabelled proteins. Green boxes describe the production 
and purification of GST-fusion proteins. Pink boxes describe immunoprecipitation 
assays and blue boxes describe affinity-purification ('GST-pull-down') assays. The 
yellow box represents in vitro kinase assays and the taupe boxes describe the 
techniques used to visualise proteins.
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3.2.1 Native CaMKIIa Interacts with the Major Intracellular Domain of Various 
GABAa Receptor Subunits
Previous studies have identified numerous proteins that interact with GABAa 
receptors (see Sections 1.4, 1.5, 1.6 and 1.7.2). Affinity-purification assays (‘pull­
down’ assays) using GST-fusion proteins of the major intracellular domains of 
receptor subunits have been a useful tool for the experimental investigation of these 
interactions. This technique allows for a study of protein-protein interactions that 
occur directly or indirectly between precise regions of receptor subunits and both 
native and recombinant proteins. I drew on the versatility of this assay by using GST- 
fusion proteins of the major intracellular domains of distinct receptor subunits to 
examine whether this intracellularly located subunit region is sufficient to mediate an 
association with native CaMKII, and if so, to determine any selectivity in binding 
between the subunit isoforms (Section 2.5.11).
To test for binding of native CaMKII to different GABAa receptor subunits, I used 
purified, bacterially expressed GST-fusion proteins of the major intracellular domains 
of the GABAa receptor a l ,  p i, p2, |33, y l, y2S, y2L, y3 and 6 subunits (G ST-al, 
GST-01, GST-|32, GST-|33, GST-yl, GST-y2S, GST-y2L, GST-y3 and GST-6), as 
well as recombinant GST (Section 2.2.4; Smith and Johnson, 1988; Kittler et al., 
2000a, 2005). The GST-fusion proteins were each exposed to a detergent-solubilised 
brain extract, and purified, together with any bound proteins, using glutathione- 
agarose beads. After resolving the protein complexes by SDS-PAGE, I probed for 
co-purified CaMKIIa by Western blotting with a monoclonal anti-CaMKIIa antibody 
(Sections 2.5.5 and 2.5.7; Table 2.6). A single 50-kDa immunoreactive band 
corresponding to CaMKIIa was obtained in the affinity-purification input lane, and 
from affinity-purifications using GST-al, GST-|31, GST-|32, GST-|33, GST-yl, GST- 
y2S, GST-y2L, GST-y3 and GST-5, but not GST alone (Fig. 3.2A). These results 
demonstrated that the major intracellular domains of various GABAa receptor 
subunits (a l ,  pl-3, y 1-3 and 5) mediated either direct or indirect binding to native 
CaMKIIa. This suggested that the major intracellular domain is sufficient for the 
interaction of CaMKII with GABAa receptor subunits, and that neuronal CaMKIIa 
binds non-selectively to the major intracellular domains of various GABAa receptor
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Figure 3.2. CaMKIIa physically interacts with GABAa receptors in vitro and in 
vivo. A. Neuronal CaMKIIa binds to the major intracellular domain of various 
GABAa  receptor subunits. Upper panel: affinity-purification assays were performed 
using 20 pg of GST-fusion proteins of the major intracellular domain of receptor a l ,  
p i, p2, p3, y l, y2S, y2L, y3 and 8 subunits, as well as GST alone. The GST-fusion 
proteins were exposed to a detergent-solubilised brain extract, and precipitated using 
glutathione-agarose beads. The protein complexes were then resolved by SDS-PAGE 
and probed for CaMKIIa by immunoblotting with a monoclonal anti-CaMKIIa 
antibody (CaMKIIa), and a Jackson (in 'A.') or Rockland (in 'B.') anti-mouse-HRP 
antibody for detection. 'IN' represents 1% (v/v) of the extract used in each affinity- 
purification assay. Lower panel: ponceau-S stain of the GST-fusion proteins in 'A.'. B. 
CaMKIIa co-immunoprecipitates with GABAa  receptors containing the P3 subunit 
from brain. Immunoprecipitations were performed from a detergent-solubilised mouse 
brain extract using control rabbit non-immune IgG or a rabbit polyclonal anti-P3 
subunit antibody, and protein-A beads. Precipitated proteins were resolved by SDS- 
PAGE and probed for CaMKIIa as in 'A.'.
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subunits, in vitro.
3.2.2 CaMKIIa Forms a Native Complex with GABAa Receptors in Brain
To determine whether GABAa receptors form native complexes with CaMKII, I 
carried out coimmunoprecipitation experiments from detergent-solubilised brain 
extracts (Section 2.5.10). The immunoprecipitations were performed using a 
polyclonal antibody that recognises the GABAa receptor (33 subunit (Brandon et a l, 
2003), or non-specific rabbit IgG as a control, and protein-A beads (Table 2.6). The 
cell-lysis and immunoprecipitations were performed under non-denaturing conditions 
that allowed sufficient (33 subunit antigens to be solubilised without disrupting the 
binding sites for the anti-(33 subunit antibody or other protein-protein interactions, 
and with minimal release of background proteins. After resolving the immune- 
complexes by SDS-PAGE, I probed for CaMKIIa by immunoblotting with a 
monoclonal anti-CaMKIIa antibody, and a secondary Rockland anti-mouse-HRP 
antibody (that exhibits minimum cross-reactivity to serum proteins of rabbit (and 
other species)) for detection (Table 2.6). As shown in Figure 3.2B, I obtained an 
immunoreactive band of 50 kDa, the predicted molecular weight of the CaMKIIa 
isozyme, from immunoprecipitations performed with the anti-(33 subunit antibody, 
but not control IgG. These data demonstrated that CaM KIIa was 
coimmunoprecipitated with the anti-(33 subunit antibody via a direct or indirect 
association with the |33 subunit. This suggested that CaMKIIa-containing 
holoenzymes and |33-subunit-containing GABAa receptors are both present in a 
protein complex in brain.
3.2.3 The Interaction of Recombinant CaMKIIa with the Major Intracellular 
Domains of GABAa Receptor (3 Subunits is Phospho-Dependent
3.2.3.1 The Major Intracellular Domains o f GABAa Receptor f3 Subunits Bind 
Selectively to the Constitutively Active CaMKIIa-T286D Mutant
I was next interested in examining the effect of phosphorylation of CaMKIIa at T286 
on the binding of the kinase to GABAa receptors, because of its critical role in the 
targeting of CaMKII to specific sub-cellular locations (Section 3.1). To address this
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issue, I performed affinity-purification assays from extracts of COS-7 cells transiently 
transfected with wild type CaMKIIa (CaMKIIa-WT) or mutant CaMKIIa isozymes 
(Section 2.4.1 and Table 2.2). I utilised a CaMKIIa-T286D mutant, which mimics 
autophosphorylation at T286 thus rendering the kinase constitutively active, and an 
autophosphorylation-deficient CaMKIIa-T286A mutant, which is predominantly in 
the inactive conformational state (Section 1.8). By using expression of recombinant 
CaMKIIa in COS-7 cells, I was able to investigate CaMKII proteins that were 
permanently modified in a cellular environment. The T286D mutation also enabled 
me to investigate the activated form of the kinase without having to trigger 
intracellular changes in the concentration of calcium.
To test the binding of the different CaMKIIa constructs to GABAa receptor subunits, 
I used purified, bacterially expressed GST-fusion proteins of the major intracellular 
domains of the GABAa receptor |3 subunits, and recombinant GST. The (3 subunits 
were chosen for further investigation because they are essential components of all 
functional GABA-gated receptors (Connolly et al., 1996a,b; Gorrie et al., 1997; 
Perez-Velazquez and Angelides, 1993), and because they are currently the most 
extensively characterised receptor subunit with regard to protein-protein interactions 
and phosphorylation (Moss and Smart, 2001; Kittler and Moss, 2003). To perform 
the assays, the GST-fusion proteins were each exposed to each of the COS-7 cell 
extracts, and purified, together with any bound proteins, with glutathione-agarose 
beads. After resolving the protein complexes by SDS-PAGE, I probed for co-purified 
CaMKIIa by Western blotting with a monoclonal anti-CaMKIIa antibody.
I obtained a single ~50-kDa immunoreactive band corresponding to recombinant 
CaMKIIa in the input lanes of affinity-purification assays from CaMKIIa-WT-, 
CaMKIIa-T286D- and CaMKIIa-T286A-transfected cells, but not untransfected cells 
(Fig. 3.3, left hand side panels). Whereas CaMKIIa-WT and CaMKIIa-T286A both 
migrated during SDS-PAGE to give 50-kDa bands, I observed a small upward band- 
shift with CaMKIIa-T286D to ~51 kDa (Fig. 3.3). Nevertheless, these data showed 
that CaMKIIa was not endogenously expressed at a detectable level in COS-7 cells, 
and that the wild type and mutant CaMKIIa isozymes were expressed following
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GST-p2: — - < CaMKIIa
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Figure 3.3. The major intracellular domains of the GABAa receptor (3 subunits 
bind selectively to a constitutively active CaMKIIa-T286D mutant. COS-7 cells 
were mock-transfected (UT) or transiently transfected with wild type CaMKIIa (WT), 
autophosphorylation-deficient CaMKIIa-T286A (TA) or constitutively active 
CaMKIIa-T286D (TD), and lysed 24 h later under non-denaturing conditions. 
Affinity-purification assays were performed using 20 pg each of GST-(31, GST-(32 and 
GST-(33, as well as GST alone. Each of the GST-fusion proteins was exposed to each 
of the COS-7 cell extracts, and precipitated using glutathione-agarose beads. Proteins 
were then resolved by SDS-PAGE and probed for CaMKIIa by immunoblotting with a 
monoclonal anti-CaMKIIa antibody (CaMKIIa) and an anti-mouse-HRP antibody for 
detection. 'Inputs' represent 10% (v/v) of the COS-7 cell extract used in each respective 
affinity-purification assay.
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transfection. Furthermore, it showed that all the expressed proteins remained stable 
throughout the assay. I also obtained ~51-kDa bands from affinity-purification assays 
using GST-pl, GST-|32 and GST-f33 from extracts of COS-7 cells transiently 
transfected with CaMKIIa-T286D, but not CaMKIIa-T286A, CaMKIIa-WT or 
untransfected cells (Fig. 3.3 right hand side panels). I did not obtain bands with 
control GST from any affinity-purification assays (Fig. 3.3 right hand side panels). 
These results demonstrated that constitutively active CaMKIIa, but not wild type or 
autophosphorylation-deficient CaMKIIa interacted with the major intracellular 
domains of the GABAa receptor p i, p2 and p3 subunits. This suggested that 
CaMKIIa binds directly or indirectly to the major intracellular domains of the 
GABAa receptor P subunits only when phosphorylated at T286, and that formation of 
CaMKII-GABAA receptor complexes in vivo may be dependent upon neuronal 
activity and kinase autophosphorylation.
3.2.3.2 Binding of CaMKIIa-T286D to the Major Intracellular Domain of the f$3 
Subunit Requires EGTA
I next investigated whether EGTA affected the physical relationship between the wild 
type and mutant CaMKIIa isozymes and the intracellular domain of the GABAa 
receptor p3 subunit. I performed affinity-purification assays from extracts of COS-7 
cells transiently transfected with CaMKIIa-WT, CaMKIIa-T286A or CaMKIIa- 
T286D, using GST-P3. The protocol was identical to that described in Section
3.2.3.1, except that the assays were performed in duplicate, with EGTA either absent 
from or present in the extraction/assay buffer. After resolving the protein complexes 
by SDS-PAGE, I probed for co-purified CaMKIIa by Western blotting with a 
monoclonal anti-CaMKIIa antibody.
I obtained a single ~50-kDa band corresponding to recombinant CaMKIIa in all of 
the input lanes of affinity-purification assays from CaMKIIa-WT-, CaMKIIa- 
T286A- and CaMKIIa-T286D-transfected cells, but not untransfected cells (Fig. 
3.4A). Once again, I observed immunoreactive bands for CaMKIIa-WT and 
CaMKIIa-T286A at 50-kDa, and at ~51 kDa for CaMKIIa-T286D (Fig. 3.4). These 
data again showed that CaMKIIa was not endogenously expressed to a detectable
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Figure 3.4. Binding of CaMKIIa-T286D to the major intracellular domain of the 
(33 subunit in vitro requires EGTA. COS-7 cells were mock-transfected (UT) or 
transiently transfected with wild type CaMKIIa (WT), CaMKIIa-T286A (TA) or 
CaMKIIa-T286D (TD), and lysed 24 h later under non-denaturing conditions in a 
buffer either with (+) or without (-) 2 mM EGTA. Affinity-purification assays were 
performed using 20 pg of GST-|33. Each of the GST-fusion proteins was exposed to 
each of the COS-7 cell extracts, and precipitated using glutathione-agarose beads. 
Proteins were then resolved by SDS-PAGE and probed for CaMKIIa by 
immunoblotting with a monoclonal anti-CaMKIIa antibody (CaMKIIa) and an anti- 
mouse-HRP antibody for detection. A. Analysis of assay inputs, which represent 10% 
(v/v) of the COS-7 cell extract used in each respective affinity-purification assay. B. 
Analysis of the affinity-purification assays.
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level in COS-7 cells, and that the wild type and mutant CaMKIIa isozymes were 
expressed following transfection. Furthermore, it showed that all the expressed 
proteins remained stable throughout the assay. I also obtained an ~51-kDa 
immunoreactive band from affinity-purification assays from extracts of COS-7 cells 
transiently transfected with CaMKIIa-T286D, in which EGTA was present in the 
extraction/assay buffer (Fig. 3.4B). A band was not obtained in the assays from 
extracts of COS-7 cells transiently transfected with CaMKIIa-T286D, in which 
EGTA was absent from the buffer, or from cells transfected with CaMKIIa-T286A or 
CaMKIIa-WT, or untransfected cells, in the absence or presence of EGTA (Fig. 
3.4B). These assays demonstrated that the association of the constitutively active 
form of CaMKIIa, CaMKIIa-T286D, with the major intracellular domain of the 
GABAa receptor |33 subunit was dependent upon EGTA, but that the binding status 
of wild type and autophosphorylation-deficient CaMKIIa (CaMKIIa-WT and 
CaMKIIa-T286A, respectively) was unchanged by EGTA. This suggested that, in 
vitro, EGTA either disinhibits or promotes the interaction of CaMKIIa-T286D with 
the major intracellular domain of the GABAa receptor (33 subunit.
3.2.4 Consensus In Vivo Phosphorylation Sites in the Major Intracellular 
Domain of the p3 Subunit are not Critical for the Interaction with Native 
CaMKIIa
My previous findings suggested that kinase phosphorylation at T286 mediated 
binding of CaMKIIa to the major intracellular domain of the GABAa receptor (3 
subunits (Figs. 3.3 and 3.4). I was therefore interested in examining whether 
phosphorylation of GABAa receptor (3 subunits might also be involved in mediating 
this interaction.
To investigate the role of GABAa receptor phosphorylation in CaMKIIa binding, I 
employed affinity-purification assays, and used purified, bacterially expressed wild 
type and mutant GST-fusion proteins of the major intracellular domain of the (33 
subunit, and recombinant GST. The mutant GST-fusion proteins contained serine-to- 
alanine point mutations of consensus, in vivo CaMKII phosphorylation sites (S383, 
S408 and S409) in various combinations. These included GST-(33-S408A, GST-133-
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S409A, GST-|33-S408A-S409A and GST-|33-S383A-S408A-S409A (McDonald and 
Moss, 1997). The wild type and mutant GST-fusion proteins were exposed to 
detergent-solubilised brain extracts, and purified using glutathione-agarose beads. 
After resolving the protein complexes by SDS-PAGE, I probed for co-purified 
CaMKIIa by Western blotting with a monoclonal anti-CaMKIIa antibody. A 50-kDa 
band was obtained in the affinity-purification input lane, and from affinity- 
purifications using GST-|33, GST-|33-S408A, GST-|33-S409A, GST-|33-S408A- 
S409A and GST-|33-S383A-S408A-S409A, but not GST alone (Fig. 3.5). These 
assays demonstrated that neuronal CaMKIIa was co-purified with wild type GST-(33, 
and that this interaction was not abolished by any of the GST-|33 serine-to-alanine 
mutants (GST-|33-S408A, GST-|33-S409A, GST-|33-S408A-S409A and GST-p3- 
S383A-S408A-S409A). This suggested that phosphorylated/dephosphorylated S383, 
S408 and S409 are not critical components of the interaction between native 
CaMKIIa-containing holoenzymes and the major intracellular domain of the GABAa 
receptor |33 subunit.
3.2.5 CaMKIIa-T286D Interacts Directly with the Major Intracellular Domains 
of GABAa Receptor j3 Subunits
I was next interested in identifying the site (or sites) within the |33 subunit major 
intracellular domain that mediates the interaction with neuronal CaMKIIa. As 
GABAa receptors can interact with protein kinases by direct and indirect means 
(Sections 1.7.2.1), and as there is currently no evidence for a specific neuronal 
CaMKII anchoring protein (Sections 1.8 and 3.3.1), I began by determining whether 
CaMKIIa binds directly to the major intracellular domain of the receptor |3 subunits. 
An important consideration in the experimental design was the previous finding that 
the major intracellular domains of the receptor (3 subunits bound selectively to the 
CaMKIIa mutant, CaMKIIa-T286D, which mimics T286-autophosphorylation, and 
not to the wild type or autophosphorylation-deficient mutant (Fig. 3.3). It was 
therefore essential that the kinase be phosphorylated at T286 in any further 
investigations of the association of CaMKIIa with the major intracellular domains of 
the p subunits. I therefore utilised an in vitro protein expression system to transcribe 
and translate CaMKIIa-T286D (Section 2.5.11.2) for use in an in vitro affinity-
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Figure 3.5. Neuronal CaMKIIa binds to the major intracellular domain of the 
GABAa receptor 03 subunit containing serine-to-alanine point mutations of 
consensus phosphorylation sites. A. Affinity-purification assays were performed 
using 20 pg of wild type GST-03 (WT) and the following mutant GST-03 fusion 
proteins containing serine-to-alanine point mutations: GST-03-S4O8A, GST-03- 
S409A, GST-03-S4O8,4O9A and GST-03-S4O8,4O9,383A, as well as GST alone. The 
GST-fusion proteins were each exposed to a detergent-solubilised brain extract, and 
precipitated using glutathione-agarose beads. The protein complexes were resolved by 
SDS-PAGE and probed for CaMKIIa by immunoblotting with a monoclonal anti- 
CaMKIIa antibody (CaMKIIa), and an anti-mouse alkaline phosphatase-conjugated 
antibody for detection. 'Input' represents 0.5% (v/v) of the brain extract used in each 
affinity-purification assay. B. Ponceau-S stain of the GST-fusion proteins in the gel in 
'A.'.
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purification assay. In vitro expression of CaMKIIa-T286D was the preferred source 
of kinase for several reasons. Firstly, the mutant kinase could be rapidly synthesised 
in a relatively inexpensive manner. Secondly, the kinase could be radiolabelled, and 
therefore tagged, by incorporation of [35S]-labelled methionine residues during 
protein expression. Thirdly, direct binding assays could be performed in the absence 
of other ‘contaminating’ proteins, and finally, all of the tagged kinase proteins would 
be permanently modified at T286.
I first transcribed and translated CaMKIIa-T286D cDNA, in vitro, in the presence of 
[35S]-labelled methionine under the control of the T7 promoter, or the SP6 promoter 
as a control. Following expression of the CaMKIIa-T286D cDNA, different volumes 
of reaction mix were resolved by SDS-PAGE, and [35S]-CaMKIIa-T286D was 
visualised by phosphorimaging (Section 2.5.8). I detected a single band at ~51 kDa, 
the predicted molecular weight of [35S]-CaMKIIa-T286D, when the cDNA was 
expressed under the T7 promoter, but not the SP6 promoter (Fig. 3.6A; Section
3.2.3.1). The band intensity increased in proportion to the volume of reaction mix 
loaded (Fig. 3.6A). These data demonstrated exclusive expression of CaMKIIa- 
T286D cDNA under the T7 promoter, and linear signal detection.
To test for direct binding of CaMKIIa to the major intracellular domains of the 
GABAa receptor |3 subunits, I used purified, bacterially expressed GST-fusion 
proteins of the major intracellular domain of each (3 subunit, and recombinant GST. 
The GST-fusion proteins were each exposed to [35S]-CaMKIIa-T286D, and purified 
with glutathione-agarose beads. After the protein complexes were resolved by SDS- 
PAGE, [35S]-CaMKIIa-T286D was visualised by phosphorimaging. I detected a 
single band of ~51 kDa corresponding to [35S]-CaMKIIa-T286D from affinity- 
purification assays using GST-|31, GST-|32 and GST-|33, but not GST alone (Fig. 
3.6B). This demonstrated that [35S]-CaMKIIa-T286D was co-purified with GST-|31, 
GST-|32 and GST-|33, in vitro, and suggested that [35S]-CaMKIIa-T286D binds 
directly to the major intracellular domains of the GABAa receptor (3 subunits, in 
vitro.
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Figure 3.6. Identification of a direct docking domain for CaMKIIa-T286D in the 
major intracellular domain of the GABAa receptor (33 subunit A. CaMKIIa- 
T286D was in vitro transcribed and translated in the presence of [35S]-labelled  
methionine under the T7 promoter, or the SP6 promoter as a control. Increasing 
amounts of reaction mix were separated by SDS-PAGE and [35S]-CaMKIIa-T286D  
was visualised by phosphorimaging. B. Affinity-purification assays were performed 
using GST-fusion proteins (20 pg) of the major intracellular domain (ICD) o f the 
GABAa  receptor (31, (32 and (33 subunit, or GST alone. The GST-fusion proteins were 
each exposed to 5 pi of reaction mix, and purified using glutathione-agarose beads. 
Proteins were resolved by SDS-PAGE, and [35S]-CaMKIIa-T286D was visualised by 
phosphorimaging. 'Input' represents the given percentage (v/v) of the [35S]-CaMKII- 
T286D mix used in each assay. C. Binding assays were performed as described in 'B.', 
using GST-fusion protein deletion constructs of the major intracellular domain of the 
|33 subunit (see 'D.'), or GST alone. D. Schematic diagram of the GST-(33 deletion 
constructs used in the binding assays. Those that bound strongly to CaMKIIa-T286D 
are coloured dark blue.
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3.2.6 The Predominant Binding-Site for CaMKIIa-T286D in the Major 
Intracellular Domain of the (33 Subunit Lies within Amino Acids 304 to 322
3.2.6.1 The Proximal Quarter of the Major Intracellular Domain of the 03 Subunit 
Contains the Predominant Binding Site for CaMKIIa-T286D
To locate the precise region (or regions) of the major intracellular domain of the (33 
subunit that mediates the interaction with CaMKIIa, I performed affinity-purification 
assays using in vitro transcribed and translated CaMKIIa-T286D (Section 3.2.5), and 
purified, bacterially expressed GST-fusion proteins of various fragments of the major 
intracellular domain of the (33 subunit, and recombinant GST. I used wild type GST- 
133 (residues 304-426) (McDonald and Moss, 1997) and the following GST-|33 
fragments: GST-N (residues 304-365), GST-C (residues 366-426), GST-Q1 (residues 
304-333), GST-Q2 (residues 334-365), GST-Q3 (residues 366-395) and GST-Q4 
(residues 396-426) (Fig. 3.6C and D) (Kittler et al., 2005).
To perform the assays, the GST-fusion proteins were exposed to [35S]-CaMKIIa- 
T286D, and purified using glutathione-agarose beads. After resolving the protein 
complexes by SDS-PAGE, [35S]-CaMKIIa-T286D was visualised by 
phosphorimaging. I detected a strong band of ~51-kDa in the input lane, which 
showed that the full-length [35S]-CaMKIIa-T286D subunit had been transcribed and 
translated, and in the lanes from affinity-purification assays using GST-N and GST- 
Q1 (Fig. 3.6C). I also obtained a weak ~51-kDa band from the affinity-purification 
assays using GST-C and GST-Q4 (although in some assays GST-C gave a stronger 
band), and a very weak ~51-kDa band, only just visible above background, from 
assays using GST-Q2 and GST-Q3 (Fig. 3.6C). I did not detect bands from binding 
assays using GST alone (Fig. 3.6C). These data demonstrated strong and direct 
binding of [35S]-CaMKIIa-T286D to the N-terminal half (residues 304-365) and the 
first quarter (residues 304-333) of the major intracellular domain of the |33 subunit, 
and weak binding to the C-terminal half (residues 366-426) and the C-terminal 
quarters (residues 366-395; residues 396-426) of the intracellular domain (Fig. 3.6D). 
This suggested that [35S]-CaMKIIa-T286D binds predominantly to a region within 
the first 30 amino acids of the major intracellular domain of the (33 subunit, and that
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an additional weak CaMKII-binding site may be present in the C-terminal half of the 
loop.
3.2.6.2 N-Terminal Deletions of the f$3 Subunit Major Intracellular Domain 
Disrupt CaMKIIa-T286D-Binding
To map more precisely the predominant CaMKIIa-T286D-binding site in the first 
quarter of the major intracellular domain of the (33 subunit, I employed in vitro 
protein expression and affinity-purification assays as described in Sections 3.2.5 and
3.2.6.1. I synthesised a second generation of GST-|33-fusion protein constructs, 
which contained N-terminal deletions of the major intracellular domain at intervals of 
~10 amino acids (as well as a 6 amino acid C-terminal deletion) (Fig. 3.7A). This 
mapping strategy was used in order to preserve as much of the loop sequence and 
secondary-structure as possible, whilst reducing the size of the N-terminal region 
known to contain the [35S]-CaMKIIa-T286D-binding site. The wild type and 
truncated GST-(33-fusion proteins were expressed in E. coli, and purified using 
glutathione-agarose beads. They included full-length GST-(33 (residues 304 to 426), 
and the N-terminal deletions GST-T1 (residues 313 to 420), GST-T2 (residues 323 to 
420) and GST-T3 (residues 332 to 420), as well as GST alone. To perform the 
assays, the GST-fusion proteins were each exposed to [35S]-CaMKIIa-T286D and 
purified using glutathione-agarose beads. Protein complexes were then resolved by 
SDS-PAGE, and [35S]-CaMKIIa-T286D was visualised by phosphorimaging. I 
obtained a strong band of ~51-kDa in the input lane, and from affinity-purification 
assays using GST-p3 (Fig. 3.7B). A weaker band of ~51-kDa was detected from 
binding assays using GST-T1, GST-T2 and GST-T3 (Fig. 3.7B). I did not detect any 
bands with GST alone (Fig. 3.7B).
One advantage of this experimental approach was that the magnitude of [35S]- 
CaMKIIa-T286D-binding to each GST-fusion protein could be determined by 
measuring the intensity of each [35S]-CaMKIIa-T286D band using Bio-Rad Quantity 
One software. This type of analysis enabled us to quantitatively examine the extent 
to which each successive N-terminal deletion was able to perturb binding to the 
kinase. To perform the analysis, I first ensured that the GST-fusion proteins were
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Figure 3.7. N-terminal deletions of the major intracellular domain of the [33 
subunit disrupt the binding of CaMKIIa-T286D. A. Schematic diagram of the 
GST-|33 deletion constructs used in this binding study. ICD: major intracellular 
domain. B. Upper panel: affinity-purification assays were performed using 20 pig of 
the GST-fusion proteins described in 'A.', as well as GST alone. The GST-fusion 
proteins were each exposed to [35S]-CaM KIIa-T286D, and precipitated using 
glutathione-agarose beads. Proteins were then resolved by SDS-PAGE, and [35S]- 
CaMKIIa-T286D was visualised by phosphorimaging. 'Input' represents 10% (v/v) of 
the assay mix used in each of the binding assays. Lower panel: brilliant-blue R stain 
of the gel in the upper panel showing equal loading of the GST-fusion proteins. C. 
Quantitation of 'B.'. The band intensity of each truncated GST-fusion protein was 
normalised to full-length GST-(33 and expressed as a percentage. The results of several 
individual experiments were then compared using the Student's paired t test. * denotes 
p<0.01 (mean ± sem; n = 4).
119
CHAPTER 3 GABAa Receptors Interact with CaMKII
equally loaded (Fig. 3.7B). I then measured the intensity of the [35S]-CaMKIIa- 
T286D band obtained from the affinity-purification assays using the full-length GST- 
(33-fusion protein, and each of the truncated GST-(33-fusion proteins, as well as GST 
alone. Each band intensity measurement was normalised to the value of the wild type 
GST-|33-fusion protein, and expressed as a percentage (Fig. 3.7C). The results of a 
number of individual experiments were then used to calculate the mean and standard 
error (sem), and to perform a statistical analysis (Student’s paired t test) (Fig. 3.7C).
Quantitative analysis revealed a 61.9% reduction in the level of [35S]-CaMKIIa- 
T286D-binding in affinity-purification assays using GST-T1 (38.1±1.2%) compared 
to GST-|33 (100%), and statistical analysis showed this difference to be highly 
significant (p<0.01; n=4) (Fig. 3.7C). A further 16.4% of [35S]-CaMKIIa-T286D- 
binding was lost in assays using GST-T2 (21.8±1.3%) compared to GST-T1, and this 
decrease was found to be highly statistically significant (p<0.01; n=4) (Fig. 3.7C). I 
did not detect a further statistically significant reduction in the level of [35S]- 
CaMKIIa-T286D-binding in assays using GST-T3 (14.3±3.1%) compared to GST- 
T2 (p>0.05; n=4) (Fig. 3.7C). However, there was a statistically significant level of 
residual [35S]-CaMKIIa-T286D-binding to GST-T3 compared to background 
(p<0.05; n=4) (Fig. 3.7C). I did not detect a statistically significant reduction in the 
level of [35S]-CaMKIIa-T286D-binding in assays using GST alone (4.9±2.3%) 
compared to GST-T3 (p>0.05; n=4) (Fig. 3.7C). Furthermore, I did not detect a 
significant level of [35S]-CaMKIIa-T286D-binding using GST alone compared to 
background (p>0.05; n=4) (Fig. 3.7C).
These data collectively demonstrated that the first nine residues (304 to 312), and 
possibly the last six residues (421 to 426), of the major intracellular loop of the (33 
subunit played a major role in binding [35S]-CaMKIIa-T286D. The results also 
showed that residues 313 to 322 mediated some binding to [35S]-CaMKIIa-T286D. 
Residues 323 to 331 did not appear to be involved in binding [35S]-CaMKIIa-T286D, 
at least in the absence of the N-terminal loop region (residues 304-322). Given that 
[35S]-CaMKIIa-T286D binds GST-Q1 (304-333) (Fig. 3.6C and D), these results 
suggested that the first 19 amino acids of the major intracellular domain of the (33
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subunit are sufficient to mediate an interaction with [3jS]-CaMKIIa-T286D, in vitro. 
They also suggest that this association mediates the majority (~80%) of the total 
binding of the kinase to GST-(33. Together with the results from Section 3.2.6.1, 
these data further suggested that a secondary binding site is present between residues 
332 and 420, and that this region binds a much smaller proportion (~20%) of [35S]- 
CaMKIIa-T286D than the N-terminal site, in vitro.
3.2.7 Analysis of the Major CaMKIIa-Binding Site in the GABAa Receptor {33 
Subunit
I have shown that native CaMKII binds non-selectively to various GABAa receptor 
subunits (Section 3.2.1), and that recombinant CaMKIIa-T286D binds to some or all 
of the first 19 N-terminal amino acids of the major intracellular domain of the 
receptor (33 subunit (Section 3.2.6). I was therefore interested in examining whether 
this CaMKIIa-T286D-binding region is conserved between the (3 subunit isoforms, 
and in comparing the docking sequence to other known CaMKII-binding domains to 
try to identify a common binding motif.
32.7.1 Comparison of the CaMKIIa-Binding Sequence in the GABAa Receptor f33 
Subunit with the other f$ Subunit Sequences
I first analysed the sequence similarity of the major CaMKII-docking region 
identified in the (33 subunit with that of the homologous regions in the (31 and (32 
subunits because recombinant CaMKIIa has been shown to bind directly to all the 
GABAa receptor (3 subunits (Section 3.2.5; Fig. 3.6B). I annotated murine sequences 
of the major intracellular domains of GABAa receptor (3 subunits (Fig. 3.8A), as this 
is the species of (3 subunit used in all binding assays in this study. Multiple sequence 
alignments were constructed using ClustalW (Higgins, 1994), and manual editing 
using the Jalview Java Alignment Editor (Clamp et al., 2004).
I detected a high degree of amino acid identity within the major CaMKII-docking 
region comprising residues 304 to 322 (Fig. 3.8A). Interestingly, the following nine 
residues, residues 323-331, which did not appear to mediate any binding to CaMKII, 
displayed little sequence identity (Fig. 3.8A). It is likely therefore that the major
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Figure 3.8. Sequence analysis of the proposed CaMKIIa-docking region in the 
GABAa receptor (33 subunit. A. Sequence alignment of the murine p subunit major 
intracellular domains. Black letters on pink boxes indicate 100% amino acid identity 
between proteins. Numerals indicate amino acid position of the given alignment, 
beginning with respect to the P3 subunit. The P3 subunit truncations, T l (313-420), T2 
(323-420) and T3 (332-420) are indicated with arrows. The open bar indicates the 
GST-Q 1 binding-partner. The black bar indicates the proposed CaMKII docking 
domain in the P3 subunit, the dark grey bar indicates the PKC binding region in the P3 
subunit and the light-grey bar indicates the RACK-1 binding region in the p3 subunit. 
* indicates the position of the conserved in vitro CaMKII phosphorylation sites, and 
major known sites of phosphorylation are underlined. B. Sequence comparison of 
some known CaMKII-docking regions less than 30 amino acids in length. The regions 
underlined indicate the only sequence similarity to be found, which occurs between a 
region of NR2B (residues 1290 to 1309) and the CaMKII autoinhibitory subdomain 
(residues 281 to 302). A single consensus binding motif is not apparant.
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CaMKII-docking region is conserved between the p subunit isoforms. This binding 
site is located at least 60 amino acids upstream of the conserved in vitro CaMKII 
phosphorylation sites (S383/S384 and S409), and is also distal from conserved sites 
of binding and phosphorylation (S408/S409/S410 and surrounding region) for a 
number of other kinases and kinase-auxiliary proteins (Fig. 3.8A; Section 1.7.2). 
This suggests that phosphorylation of the GABAa receptor P subunits at these sites, 
and the binding of other proteins to these sites, is unlikely to directly interfere with 
the docking of CaMKIIa to this major N-tenninal binding site.
32 .72  Comparison o f the CaMKIIa-Binding Sequence in the GABAa Receptor fi3 
Subunit with CaMKIIa-Binding Sequences in other Proteins 
I was also interested in comparing the CaMKII-binding region identified in the 
GABAa receptor p3 subunit with CaMKII-docking sites that have been described for 
other proteins to determine whether there is any sequence homology. Figure 3.8B 
shows the amino acid sequences of some known CaMKII-binding regions in other 
proteins that are less than 30 amino acids in length. Apart from a small degree of 
homology between a region of NR2B (residues 1290-1309) and the autoinhibitory 
domain of CaMKII (residues 281-302), I did not detect any significant sequence 
homology between the protein regions (Fig. 3.8B). This suggested that CaMKII does 
not interact with its binding-partners via a single consensus motif.
3.3 Discussion
The differential targeting of protein kinases to GABAa receptor scaffolds has been 
shown to facilitate phosphorylation and to regulate receptor activity (Section 1.7; 
Moss and Smart, 2001; Kittler and Moss, 2003). It is therefore fundamental to our 
understanding of inhibitory neurotransmission, to understand the mechanisms by 
which protein kinases are recruited to GABAa receptors. CaMKII has been 
implicated in regulating the activity of neuronal GABAa receptors, and has been 
shown to phosphorylate some receptor subunits, in vitro (Section 3.1; McDonald and 
Moss, 1994, 1997). However, CaMKII remains to be identified as a GABAa 
receptor-associated kinase.
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In this chapter, I investigated the physical relationship between the GABAa receptor 
and CaMKII, with the aim of understanding how CaMKII is targeted to receptor 
complexes to mediate phosphorylation. This study has led to the identification of a 
stable, phosphorylation-dependent physical interaction between CaMKII and the 
GABAa receptor. I demonstrated that this association occurs in brain, and that the 
native kinase binds to the major intracellular domain of various receptor subunits 
without any apparent selectivity. In addition, I found that the major intracellular 
domains of the receptor p subunits bound selectively to a recombinant form of 
CaMKIIa that contains a threonine-to-aspartate point mutation at T286, which 
mimics T286-autophosphorylation and induces constitutive activity. Although the 
interaction between CaMKIIa and the major intracellular domain of the p3 subunit 
was shown to require kinase phosphorylation, it appeared to be independent of 
GABAa receptor subunit phosphorylation. This finding was supported by subsequent 
mapping studies, which identified a direct CaMKIIa-docking site at the N-terminal 
end of the major intracellular domain of the |33 subunit. These studies further 
revealed that this binding site is located within the first 19 amino acids of the major 
intracellular domain, at least 60 residues upstream of the consensus CaMKII in vivo 
phosphorylation motifs. I also demonstrated that this binding region displays a large 
degree of sequence homology across all the j3 subunit isoforms. I propose that this 
phosphorylation-dependent interaction underlies the differential targeting of 
CaMKIIa to GABAa receptors, and that this may facilitate the regulation of GABAa 
receptor functionality in brain.
3.3.1 The Nature of CaMKIIa-GABAA Receptor Complexes
My studies demonstrated that CaMKIIa-containing holoenzymes are able to form 
native complexes with GABAa receptors in brain. I also showed that native 
CaMKIIa binds directly and/or indirectly to the major intracellular domain of various 
GABAa receptor subunits, including a l ,  p 1-3, yl-3 and 5. Most neuronal GABAa 
receptors are thought to comprise a , (3 and y subunits (Section 1.3; Fig. 1.1). A 5 
subunit is also believed to replace the y subunit in some receptor assemblies (Section 
1.3; Fig. 1.1). It is therefore possible that CaMKIIa-containing holoenzymes form 
native complexes with most GABAa receptor populations in brain. As CaMKII
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holoenzymes can be assembled as subunit heteromers as well as homomers, it is also 
possible that other neuronal CaMKII isozymes are also part of the native CaMKIIa- 
GABAa receptor complex (Section 1.8; Fig. 1.2). Furthermore, as the ratio of 
substituent isozymes in a given holoenzyme influences properties of CaMKII such as 
calmodulin sensitivity and protein-protein interactions (Section 1.8; see below), then 
the presence of other isozymes could have a significant impact on any CaMKII- 
dependent modulation of GABAa receptors, which may itself be characterised by 
receptor subtype.
The large macromolecular structure of CaMKII provides numerous spatially 
dispersed points of contact for the binding of GABAa receptor subunits. Since the 
majority of neuronal GABAa receptor assemblies are thought to comprise 2a, 2(3 and 
ly or 15 subunits (Section 1.3; Fig. 1.1), then it is likely that most receptor complexes 
contain at least three subunit binding-partners for CaMKIIa. This complexity may be 
further increased by the presence of multiple CaMKII binding sites in the major 
intracellular domains of the receptor subunits (discussed below). Furthermore, 
although my findings demonstrated that this region is sufficient to mediate an 
interaction with native CaMKIIa, additional points of contact may also exist between 
CaMKII and other subunit domains, such as the minor intracellular loop between 
TM1 and TM2, and the TM regions (Fig. 1.1). Notably, direct binding-partners have 
yet to be identified for these regions. However, TM4 has been shown to facilitate the 
recruitment of gephyrin to clusters of postsynaptic GABAa receptors (Alldred et al., 
2005).
In this study, I found that the interaction between recombinant CaMKIIa and each of 
the GABAa receptor (3 subunits is dependent upon T286 phosphorylation. This is 
similar to the enhanced binding of PKC to GABAa receptor (3 subunits following its 
activation and phosphorylation by phorbol esters or BDNF (Brandon et al., 1999; 
Jovanovic et al., 2004). A key question, however, is how phosphorylation of CaMKII 
regulates binding. One possibility is that the phosphorylated T286 residue and a 
flanking region comprise the binding site for the receptor subunits. The 
autoregulatory domain (which contains this region) (Fig. 1.2) has been shown to
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mediate binding to the neuronal protein Camguk in Drosophila, although this has not 
yet been shown with the mammalian homologue, CASK (Lu et al., 2003). 
Alternatively, the conformational change in isozyme structure induced by 
phosphorylation of T286 (Section 1.8) may expose a receptor-binding site elsewhere 
in the protein. Other CaMKII subunit domains have been shown to mediate binding 
of the kinase to postsynaptic proteins. For example, the catalytic domain has been 
shown to mediate binding to a-actinin (Walikonis et al., 2001; Dhavan et al., 2002), 
the NR2B (Bayer et al., 2001; Strack et al., 2000) and NR2A (Gardoni et al., 1999, 
2001) subunits of NMDA-type glutamate receptors, the cyclin-dependent kinase 5 
activators, p35 and p39, (Dhavan et al., 2002) and the Eag K+ channel (Sun et al., 
2004). Furthermore, the association domain has been shown to mediate binding to 
densin-180 (Strack et al., 2000; Walikonis et al., 2001) and MUPP-1 (Krapivinsky et 
al., 2004). Interestingly, intracellular application of pre-activated CaMKII subunits 
containing the catalytic and autoregulatory domains, but not the association domain, 
to cerebellar granule cells has been shown to increase the amplitude of both GABA- 
mediated currents and spontaneous IPSCs (C.M. Houston, unpublished data). 
Addition of pre-activated CaMKII (catalytic and autoregulatory domains only) to 
NG108-15 cells expressing GABAa receptor subunits also induces potentiation of 
GABA-mediated currents (C.M. Houston, unpublished data). This suggests that any 
interaction between the association domain of CaMKII and the receptor subunits is 
not necessary for functional modulation of GABAa receptors. It is perhaps important 
to note that a binding sequence for the GABAa receptor (3 subunits may also lie 
within an isozyme-specific domain of CaMKII (Section 1.8; Fig. 1.2). If this is the 
case, then the interaction between CaMKII and the GABAa receptor may also be 
regulated in an isozyme-specific manner. Indeed, such a binding mechanism has 
been shown to determine the interaction between CaMKII(3 and F-actin (Shen et al., 
1998), and CaMKIIa and densin-180 (Walikonis et al., 2001). Additional 
experiments that determine the region(s) of CaMKII involved in binding GABAa 
receptor subunits will therefore be of interest.
Although my findings indicate that phosphorylation of CaMKII at T286 induces 
binding of the kinase to the GABAa receptor |3 subunits, my data does not necessarily
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suggest that this modification alone is sufficient for binding. My studies utilised a 
recombinant form of CaMKIIa containing a permanent T286D point mutation to 
mimic autophosphorylation and induce constitutive activity. However, 
autophosphorylation at T305, T306 and S314 (and possibly other sites that have yet to 
be characterised) is known to follow autophosphorylation at T286 and the subsequent 
removal of calcium/CaM (Hanson and Schulman, 1992; Hashimoto et al., 1987; 
Patton et al., 1990; LeVine et al., 1985; Miller et al., 1988; Lengyel et al., 2000). 
Furthermore, the phosphorylation state of T305/T306 is known to be involved in 
regulating the localisation of CaMKII at the PSD of excitatory synapses (Shen et al., 
2000; Elgersma et al., 2002; Weeber et al., 2003). It is therefore possible that 
autophosphorylation of one or all of these residues (T305, T306 and S314) also plays 
a role in regulating the association of CaMKII with GABAa receptor complexes. 
Indeed, additional phosphorylation of CaMKIIa-T286D may contribute to the altered 
migration of this kinase mutant during SDS-PAGE (to ~51 kDa) compared to 
CaMKIIa-WT and CaMKIIa-T286A, which both migrate to 50 kDa (Section 3.2.3). 
It is also possible that the upward band shift is caused by the substitution of the 
neutral threonine residue for an aspartate residue.
My studies further revealed that EGTA is required for the binding of constitutively 
active CaMKIIa to the GABAa receptor (33 subunit, in vitro. In the binding studies, 
kinase autophosphorylation at T286 was independent of calcium/CaM (due to the use 
of a T286D point mutation to mimic autophosphorylation) and, hence, EGTA- 
mediated chelation of calcium. However, the chelation of free calcium and zinc ions 
by EGTA might promote (or disinhibit) the interaction between CaMKIIa-T286D 
and the receptor (33 subunit by stabilising/destabilising the conformation of the kinase 
and/or receptor proteins, or by regulating the phosphorylation state of other CaMKII 
sites. For example, the chelation of calcium by EGTA may be necessary to ensure 
phosphorylation of T305, T306 and S314 (see above). Furthermore, phosphorylation 
of CaMKII may be altered by the chelation of zinc, as this ion has been shown to 
have an effect on the phosphorylation state and activity of this kinase (Lengyel et al., 
2000).
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My studies revealed that recombinant CaMKIIa interacts directly with the major 
intracellular domain of each GABAa receptor (3 subunit. A major binding site for 
recombinant CaMKIIa was also found to include some or all of the first 19 amino 
acids of the major intracellular domain of |33 subunit. The high sequence homology 
between the |3 subunit isoforms in this region further suggested that the CaMKII 
binding site is conserved within the p subunit family. However, in the absence of a 
known consensus binding-motif for CaMKII, the precise CaMKII-binding sequence 
in this region of the GABAa receptor p subunits remains to be delineated. The lack 
of sequence homology between known CaMKII-docking sites of various neuronal 
proteins implies that CaMKII does not interact with all its binding-partners via a 
single mechanism. It is possible that some CaMKII-binding motifs consist of general 
‘basic-rich’ or ‘charged’ regions. CaMKII binding may also be determined by three- 
dimensional motifs in the protein structure.
My findings suggested that CaMKII interacts with at least two distinct sites within the 
major intracellular domain of the GABAa receptor P3 subunit. A major CaMKIIa- 
docking site was located at the N-terminal end of the major intracellular domain, and 
a secondary weak binding site appeared to be present in the C-terminal half of the 
loop. Multiple CaMKII-binding sites have been identified in the NMDA receptor 
NR2B subunit (Leonard et al., 1999; Strack and Colbran, 1998; Strack et al., 2000; 
Bayer et al., 2001), although not all CaMKII-binding partners are thought to form 
multivalent interactions with the kinase (Merrill et al., 2005). Indeed, the weak 
binding observed in the C-half of the loop may be due to a non-specific low-affinity 
association of the kinase around the in vitro substrate sites, S383 and S409. 
Biochemical and electrophysiological experiments using a synthetic peptide of the N- 
terminal CaMKII-binding sequence may help determine the importance of this site in 
mediating binding of CaMKII to GABAa receptor complexes, and the role of 
CaMKII-binding in CaMKII-dependent phosphorylation and functional modulation 
of GABAa receptors.
The major CaMKII binding site in the receptor (33 subunit is located at least 60 amino 
acids upstream of the in vitro CaMKII phosphorylation sites, S383 and S409. This
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apparently distinct location may enhance the specificity of (3 subunit phosphorylation 
by CaMKII (Johnson and Hunter, 2005), and is consistent with my finding that S383, 
S408 and S409 were not critical components of the interaction between CaMKIIa 
and the (33 subunit. It is possible that S383, S408 and S409 are components of the 
secondary binding site, and that phosphorylation of these residues regulates (inhibits 
or enhances) the binding of CaMKII. This could be explored by performing binding 
assays with receptor |33 subunits that have been phosphorylated or mock 
phosphorylated by purified CaMKII, or that contain serine-to-aspartate point 
mutations that mimic phosphorylation. Notably, binding of PKC to the receptor (3 
subunits is negatively regulated by phosphorylation at the PKC sites (Brandon et al., 
1999,2002; Jovanovic etal., 2004) (Section 1.7.2.1.1).
Although the interactions between protein kinases and GABAa receptors can be 
direct, previous binding studies have shown that they often involve auxiliary proteins 
(Section 1.7.2.1). Both PKC and PKA engage in co-operative binding; PKA is 
localised to receptors by the AKAP-79/150 anchoring protein, and the RACK-1 
auxiliary protein enhances the activity of receptor-associated PKC (Sections 1.7.2.1.1 
and 1.7.2.1.2). Whilst my findings suggest that CaMKIIa-containing holoenzymes 
bind directly to GABAa receptors, I cannot exclude the possibility that CaMKIIa 
forms an indirect association with receptor complexes via an adaptor protein. As 
CaMKIIa interacts with various receptor subunits, it is possible that such a linker 
protein is a common subunit binding-partner. Alternatively, there may be several 
distinct adaptor proteins. Although adaptor proteins are not necessary for formation 
of CaMKII-GABAA receptor complexes in vitro, they may be required to localise the 
kinase to the receptor in intact cells. These proteins might be bound to receptor 
subunits, or be detached from receptor scaffolds but in close enough molecular 
proximity to promote the formation of kinase-receptor complexes. Furthermore, such 
auxiliary proteins may be static elements of receptor scaffolds or the immediate 
surroundings, or be subject to dynamic localisation.
Although inhibitory synaptic scaffolds comprise a diverse collection of signalling and 
scaffolding proteins (Sections 1.4, 1.5, 1.6 and 1.7), there are currently few candidate
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CaMKII-anchoring proteins present. Both PP1 and PP2A are involved in 
dephosphorylating CaMKII, and have been localised to GABAa receptors (Section
1.7.2.2), but it is not yet known whether these phosphatases are involved in recruiting 
CaMKII to inhibitory synapses. It is possible that non-kinase components of the 
CaMKII holoenzyme function to target kinase activity to GABAa receptors. In 
skeletal muscle, the incorporation of an aKAP protein (a CaMKIIa subunit in which 
the kinase domain is substituted with a hydrophobic region) into a CaMKII 
holoenzyme has been shown to induce membrane targeting and altered regulation of 
ryanodine receptor activity (Bayer et al., 1998; Section 1.8). However, the presence 
of aKAP proteins in neurons as integral CaMKII anchoring units has not yet been 
investigated, and so any function aKAPs may have in directing CaMKII to cell- 
surface GABAa receptors remains highly speculative.
3.3.2 Functional Implications of Native CaMKIIa-GABAA Receptor Complexes
In this study, I have provided the first biochemical evidence that CaMKII forms a 
native complex with GABAa receptors in brain. This is consistent with a previous 
ultrastructural study of CaMKII localisation in the basolateral amygdala 
demonstrating CaMKII immunoreactivity at the PSD of some GABAergic synapses 
(McDonald et al., 2002). However, similar electron microscopy studies of the sub- 
cellular localisation of CaMKII in the thalamus, neocortex (Liu and Jones, 1996) and 
CA1 region of the hippocampus (Liu and Jones, 1997) do not detect CaMKIIa in the 
PSD of symmetrical synapses. Furthermore, double-labelling immunofluorescence 
studies do not detect colocalisation of CaMKII and GABA in the majority of 
forebrain regions (Benson et al, 1992; McDonald et al, 2002).
My finding that the interaction of CaMKIIa with GABAa receptor subunits is 
dependent upon phosphorylation at T286 supports the idea that CaMKIIa is 
translocated to, and binds GABAa receptors at inhibitory synaptic sites following 
autophosphorylation. Indeed, CaMKII has been shown to undergo activity-dependent 
translocation to the PSD of excitatory synapses (Strack et al., 1997b; Shen and 
Meyer, 1999; Shen et al., 2000; Gleason et al., 2003; Otmakhov et al., 2004; 
Dosemeci et al., 2001). Although phosphorylation of T286 is not believed to be
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essential for such translocation (Shen and Meyer, 1999; Shen et al., 2000), it is 
thought to be involved in the retention of the kinase at these postsynaptic sites (Shen 
et al., 2000). Furthermore, phosphorylation of T286 has been shown to either 
enhance or be required for the interaction of CaMKII with a number of postsynaptic 
proteins, including the NR1-, NR2A- and NR2B-type NMDA receptor subunits 
(Bayer et al., 2001; Strack and Colbran, 1998; Gardoni et al., 1999) and densin-180 
(Strack et al., 2000, Walikonis et al., 2001). Some of these molecular partnerships 
exist to recruit CaMKII to specific sub-cellular locations (Bayer et al., 2001; Shen et 
al., 1998; Strack et al., 2000), whereas others are involved in ‘trapping’ 
active/inactive forms of CaMKII at, or close to, substrate sites (Bayer et al., 2001; 
Sun et al., 2004; Lu et al., 2003). It is possible that the interaction between CaMKII 
and GABAa receptors fulfils either or both of these roles.
Activity-dependent translocation of CaMKII may explain some of the inconsistencies 
in the published literature regarding the sub-cellular distribution of CaMKII in 
neurons. For example, the localisation studies described above were performed using 
neurons that were fixed under basal conditions. The variation in CaMKII localisation 
observed in these studies may therefore be due to neuron-specific differences in the 
activity and autophosphoiylation of CaMKII in the basal state.
The putative translocation of CaMKIIa to inhibitory synaptic scaffolds might occur 
over small or large distances and be either transient or long lasting. It is possible that 
in the inactivated state, CaMKIIa is associated with synaptic scaffolds near to, but 
physically distinct from GABAa receptors, and that autophosphorylation at T286 
induces binding to receptor subunits. However, the apparent low occupancy of 
CaMKII at the PSDs of symmetrical synapses under basal conditions (McDonald et 
al., 2002) suggests that soluble CaMKII is shuttled to GABAa receptors following 
activation and autophosphorylation from a location beyond the active zone of the 
synapse. If this is the case, then the activity-dependent targeting of CaMKII to 
GABAa receptors would be expected to increase the proportion of GABAergic 
synapses containing CaMKII, and hence detection of the kinase. There are several 
potential advantages of activity-dependent targeting of CaMKII to inhibitory
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synapses. For example, such translocation would provide an additional level of 
regulation in the neuronal signalling network, which would enhance the specificity of 
intracellular signalling events. Furthermore, this mechanism of spatial regulation 
could enable fine control of the concentration of activated CaMKII at the synapse, 
which could be important if the kinase is susceptible to rapid and prolonged kinase 
deactivation by the local action of protein phosphatases or degradative mechanisms.
My finding that CaMKIIa interacts with GABAa receptors is consistent with 
previous reports showing phosphorylation of the major intracellular domains of the 
GABAa receptor subunits by purified CaMKII in vitro (McDonald and Moss, 1994, 
1997), and functional modulation of GABAa receptors following intracellular 
application of CaMKII to heterologous cells and neurons (Section 3.1). Nevertheless, 
the binding of CaMKIIa to GABAa receptors does not necessarily indicate that 
phosphorylation will occur, as protein kinases have been shown to interact with non­
substrate proteins (Johnson and Hunter, 2005). Indeed, given the large size of the 
multimeric CaMKII holoenzyme and evidence suggesting that CaMKII can self­
associate in neurons to form large clusters (Hudmon et al., 2005), it is possible that 
CaMKII functions as a structural hub of inhibitory synapses, acting as a scaffold for 
various synapse-associated proteins. However, as my results suggested that 
phosphorylation of CaMKIIa at T286 is required for the association with GABAa 
receptor subunits, it is likely that the bound kinase is enzymatically active. 
Furthermore, as GABAa receptor subunits are substrates of CaMKII in vitro 
(McDonald and Moss, 1994, 1997), then it is likely that subunit phosphorylation is a 
consequence of binding. Modification of the phosphorylation state of GABAa 
receptors is believed to play a pivotal role in regulating channel activity and the 
efficacy of inhibitory neurotransmission (Section 1.7). Phosphorylation of GABAa 
receptors by CaMKII may therefore play a key role in modulating the strength of 
GABAergic synapses. A more detailed discussion of the functional implications of 
CaMKII-dependent regulation of GABAa receptors can be found in Chapters 4 and 6.
In addition to being a component of post-synaptic GABAa receptor scaffolds, 
CaMKII may also bind presynaptic and extrasynaptic GABAa receptors. For
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example, CaMKII may interact with presynaptic GABAa receptors localised in 
glutamatergic axon terminals (Engelman and MacDermott, 2004), where CaMKII- 
mediated phosphorylation of synapsin I is involved in neurotransmitter release (Lin et 
al., 1990; Benfenati et al, 1992; Waxham et al, 1993). As well as being associated 
with GABAa receptors on the cell-surface of neurons, CaMKII may also bind sub- 
membranous and intracellular GABAa receptors, such as those in endocytic or 
recycling pathways. These interactions might take place in axonal, somatic or 
dendritic compartments, and have a significant effect on the trafficking of GABAa 
receptors to and from inhibitory synapses. Further investigations of the sub-cellular 
location of GABAa receptor-CaMKIIa complexes will be critical in unravelling the 
potentially diverse functional effects of such interactions in neurons.
3.3.3 Potential Dynamics of GABAa Receptor Scaffolds
I have identified CaMKII as a novel GABAa receptor-associated kinase. CaMKII 
therefore joins a growing family of signalling proteins that interact with GABAa 
receptors. Several members of this family include enzymes that modify the 
phosphorylation state of GABAa receptors, and auxiliary proteins that support protein 
kinase or phosphatase activity (Fig. 3.9; Section 1.7). Although having multiple 
protein kinase and phosphatase effectors may enhance the specificity of signal 
transduction to GABAa receptors, the dynamic interplay of these signalling proteins 
at individual receptor subunits and complexes remains poorly understood. Whereas 
PKC is recruited to a distinct region of the (3 subunit major intracellular domain 
(Section 1.7.2.1.1) to CaMKII, the binding domains of other protein kinases and 
phosphatases remain unknown. Binding of CaMKII may therefore compete with or 
be facilitated by these enzymes or other GABAa receptor-associated proteins.
Interestingly, CaMKII may compete with the ubiquitin-like protein Plic-1 for binding 
to GABAa receptor a  and (3 subunits. Plic-1 has been shown to bind the first ten 
amino acids (NYFTKRGYAW) of the major intracellular domain of the receptor a l  
subunit (Bedford et al., 2001). Sequence analysis has further revealed that the first 
half of this sequence (NYFTK) is conserved in the receptor a  1-3, a6  and (3 subunits 
(Bedford et al., 2001). I have demonstrated that CaMKII binds to the receptor (3
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Figure 3.9. CaMKII is a novel GABAa receptor-associated kinase. Schematic 
diagram of protein kinase and phosphatase signalling complexes at the major 
intracellular domain (ICD) of the GABAa  receptor (33 subunit. Known interactions are 
shown. The schematic does not illustrate exact points of contact.
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subunits at a site located within the first 19 amino acids of the major intracellular 
domain. It is therefore possible that CaMKII and Plic-1 bind to a common region in 
these subunits. If so, then this would suggest that the interaction identified in this 
study between CaMKII and the a l  subunit is direct. Furthermore, it would suggest 
that CaMKII and Plic-1 compete for the a l  and (3 binding regions. Plic-1 has been 
localised to GABAergic synapses as well as various intracellular compartments 
(Bedford et al., 2001). However, the predominant effect of Plic-1 on GABAa 
receptor function appears to involve the stabilisation of intracellular pools of GABAa 
receptors to facilitate the insertion of receptors into the plasma membrane (Bedford et 
al., 2001). It will be interesting to perform further experiments to determine whether 
CaMKII and Plic-1 compete for a common GABAa receptor binding site, and to 
determine the functional significance of any such competition.
3.4 Conclusions
Overall, I conclude that CaMKIIa physically interacts with GABAa receptors in 
brain. CaMKII binds non-selectively to the major intracellular domains of various 
receptor subunits. The interaction with the receptor (3 subunits is dependent upon 
phosphorylation of the kinase at T286, but does not appear to require GABAa 
receptor subunit phosphorylation. Indeed, a major binding site for CaMKII has been 
identified within the proximal region of the major intracellular domain of the (3 
subunits, at least 60 amino acids upstream of the in vitro CaMKII phosphorylation 
sites. The stable, phosphorylation-dependent interaction of CaMKIIa with GABAa 
receptors may underlie the ability to differentially target CaMKII to GABAa receptor 
complexes. This may facilitate the regulation of receptor activity in brain, and 
therefore have significant consequences for the efficacy of inhibitory 
neurotransmission and plasticity at GABAergic synapses.
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4.1 Background
In Chapter 3, I demonstrated that CaMKIIa interacted with GABAa receptors in 
brain, and that the kinase bound non-selectively to the major intracellular domains of 
various GABAa receptor subunits. This interaction did not appear to require GABAa 
receptor subunit phosphorylation, but was dependent upon phosphorylation of 
CaMKII at T286. Although I established a physical interaction between neuronal 
CaMKII and GABAa receptors, such an association will not necessarily coincide with 
phosphorylation (Johnson and Hunter, 2005). I was therefore interested in 
determining whether GABAa receptors are substrates of CaMKII in neurons.
Several lines of evidence suggest that CaMKII may be involved in phosphorylating 
GABAa receptors in neurons. Firstly, the results of electrophysiological studies 
based on the intracellular application of CaMKII and modulation of postsynaptic 
calcium/CaM signalling cascades suggest that CaMKII is involved in modulating 
GABAergic neurotransmission (see Section 3.1 for a detailed discussion; Kano et al., 
1996; Kawaguchi and Hirano, 2002; Wei et al., 2004; Wang et al., 1995; Aguayo et 
al., 1998). Secondly, biochemical studies have shown that CaMKII phosphorylates 
GST-fusion proteins of the major intracellular domains of GABAa receptor (3 and y2 
subunits, in vitro (McDonald and Moss, 1994, 1997). Further investigations using 
site-directed mutagenesis revealed a number of phosphorylation sites. These include 
S384 and S409 in the p i subunit (McDonald and Moss, 1994), S410 in the (32 
subunit, and S383 and S409 in the [33 subunit (McDonald and Moss, 1997). They 
also include S348 and T350, in the y2S and y2L subunits, as well as S343 in the y2L 
subunit only (McDonald and Moss, 1994; Machu et al., 1993). CaMKII has also 
been shown to phosphorylate the GABAC receptor subunit, p i ,  at T431, in vitro 
(Sedelnikova and Weiss, 2002). Finally, activation of CaMKII in a synaptosomal 
membrane fraction has been shown to cause an increase in phosphorylation of the 
GABAa receptor a l  subunit (Chum et al., 2002), and to enhance agonist and 
allosteric modulator binding (Chum and DeLorenzo, 1998; Chum et al., 2002).
Although GABAa receptors are binding-partners and in vitro substrates of CaMKII, it 
remains largely unknown whether GABAa receptors are substrates of CaMKII in
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neurons. In this chapter, I have taken a biochemical-based approach using in vitro 
kinase and phosphatase assays, pre-labelling assays, affinity-purification assays and 
quantitative Western blotting to address this issue. I set the following aims: (1) to 
confirm and extend previous findings demonstrating that GABAa receptor (3 and y2 
subunits are in vitro substrates of CaMKII; (2) to identify protein phosphatases that 
dephosphorylate GABAa receptor subunits that have been phosphorylated b y 
CaMKII, in vitro; (3) to determine whether phosphorylation-dependent targeting of 
CaMKII to receptor (33 subunits is accompanied by enhanced kinase activity, and (4) 
to examine the phosphorylation of GABAa receptors in situ, in cultured cortical 
neurons. This approach has led to the discovery that CaMKII selectively 
phosphorylates the GABAa receptor {3 and y subunits, but not the a  or 6 subunits, in 
vitro. It has also shown that the yl and y3 subunits are novel in vitro substrates of 
CaMKII, and that the (33 subunit is dephosphorylated at the CaMKII sites by PP1, 
PP2A and PP2C, in vitro. Depolarisation of cultured immature cortical neurons has 
also been found to enhance the level of enzymatically active CaMKII that associates 
with the major intracellular domain of the GABAa receptor (33 subunit, and to trigger 
CaMKII-dependent phosphorylation of the (33 subunit, but not the y2 subunit, in situ. 
Since protein phosphorylation plays an important role in regulating GABAa receptor 
function and hence inhibitory synaptic transmission (Moss and Smart, 2001; Poisbeau 
et al., 1999; Section 1.7.2), I propose that CaMKII-dependent phosphorylation of 
GABAa receptors is a major mechanism for modulating GABAergic synaptic 
transmission and neuronal excitability.
4.2 Results
An overview of the methods used in this chapter can be found in Figure 3.1.
4.2.1 CaMKII Phosphorylates GABAa Receptor Subunits, In Vitro
4.2.1.1 CaMKII Selectively Phosphorylates the Major Intracellular Domains of 
GABAa Receptor p  and y Subunits, In Vitro
To confirm that the major intracellular domains of GABAa receptor (3 and y2 subunits 
are in vitro substrates of CaMKII (McDonald and Moss, 1994, 1997), I performed in
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vitro kinase assays using purified CaMKII and purified, bacterially expressed GST- 
fusion proteins of the major intracellular domain of GABAa receptor (31, (32, (33, y2S 
and y2L subunits (GST-(31, GST-(32 GST-(33 GST-y2S GST-y2L) as well as 
recombinant GST (Section 2.2.4; Kittler et a l,  2005). GST-fusion proteins of the 
major intracellular domain of the yl, y3 and 6 subunits (GST-yl, GST-y3 GST-8) 
were also included in the assays to determine whether these subunits are in vitro 
substrates of CaMKII. The GST-fusion proteins were each incubated with CaMKII, 
which had been purified from brain (a generous gift from Howard Schulman) 
(Schulman, 1984), calmodulin, PKA and PKC inhibitors, and a [y-32P]-ATP/ATP 
mix, in CaMKII Buffer at 30 °C for 15 min (Section 2.5.13). After resolving the 
proteins by SDS-PAGE, phosphorylated proteins were detected by phosphorimaging. 
I obtained [32P]-protein bands at the predicted molecular weight of the GST-fusion 
proteins tested, in assays using GST-(31 (-43 kDa), GST-(32 (-42 kDa), GST-J33 (-46 
kDa), GST-yl (-34 kDa), GST-y2S (-36 kDa), GST-y2L (-38 kDa) and GST-y3 (-42 
kDa) (Fig. 4.1 A) (McDonald and Moss, 1994, 1997). I did not detect any [32P]- 
protein bands in assays using GST-al, GST-8 or GST alone (-29 kDa) (Fig. 4.1 A). 
The strongest [32P]-protein band was obtained with GST-(33 (Fig. 4.1 A). [32P]-protein 
bands detected at lower molecular weights represented degradation products of the 
GST-fusion proteins (Fig. 4.1 A). These results suggested that purified CaMKII 
selectively and directly phosphorylates the major intracellular domains of GABAa 
receptor (3 and y subunits, but not a l  or 8 subunits, in vitro, and that GST-|33 is the 
preferred in vitro substrate.
4.2.1.2 CaMKII Phosphorylates the Major Intracellular Domain of the GABAa 
Receptor 03 Subunit at S383 and S409, In Vitro
To confirm that S383 and S409 are the sites of CaMKII phosphorylation in GST-(33 
(McDonald and Moss, 1997) (the preferred in vitro substrate of CaMKII), I 
performed in vitro kinase assays using purified CaMKII and purified, bacterially 
expressed GST-fusion proteins. These included wild type GST-(33, and mutant GST- 
13 3-fusion proteins in which various serine residues were replaced with alanine 
residues (GST-(33-S408A, GST-|33-S409A, GST-|33-S408A-S409A, GST-(33-S383A- 
S408A-S409A) (McDonald and Moss, 1997). The wild type and mutant GST-fusion
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Figure 4.1. CaMKII phosphorylates various GABAa receptor subunits, in vitro. 
A. CaMKII selectively phosphorylates the major intracellular domains of GABAa  
receptor (3 and y subunits. In vitro kinase assays were performed with purified 
CaMKII and GST-fusion proteins of the major intracellular domain of GABAa  
receptor a l  (3 pg), p i (5 pg), p2 (5 pg), p3 (5 pg), yl (3 pg), y2S (3 pg), y2L (3 pg), 
y3 (3 pg) and 6 (3 pg) subunits, as well as GST alone (5 pg), at 30 °C for 15 min. 
Proteins were then resolved by SDS-PAGE, and phosphorylated proteins were 
detected by phosphorimaging. B. CaMKII phosphorylates the major intracellular 
domain of the GABAa  receptor P3 subunit at S383 and S409. In vitro kinase assays 
were performed as in 'A.' but with 4  pg each of wild-type GST-p3, and the mutants 
GST-P3-S408A, G ST-P3-S409A , G ST-P3-S408A /S409A  and GST-(33-
S383A /S408A /S409A . Proteins were then resolved by SDS-PAGE, and 
phosphorylated proteins were detected by phosphorimaging.
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proteins were each incubated with purified CaMKII, calmodulin, PKA and PKC 
inhibitors and a [y-32P]-ATP/ATP mix, in CaMKII Buffer at 30 °C for 15 min. All 
proteins were then resolved by SDS-PAGE, and phosphorylated proteins were 
detected by phosphorimaging. I detected [32P]-protein bands at the predicted 
molecular weight of GST-(33 (~46 kDa) for wild type GST-(33, and the GST-J33 
mutants, GST-|33-S408A, GST-|33-S409A and GST-(33-S408A/S409A, but not with 
the triple mutant GST-(33-S383A/S408A/S409A (Fig. 4 .IB). The [32P]-protein band 
was stronger for wild type GST-J33 and GST-(33-S408A, which contain both sites of 
phosphorylation, than for GST-(33-S409A and GST-(33-S408A/S409A, which contain 
only one of the phosphorylation sites, S383 (Fig. 4. IB). These data demonstrated that 
wild type GST-(33, and the GST-(33 mutants, GST-(33-S408A, GST-(33-S409A and 
GST-|33-S408A/S409A, but not GST-|33-S383A/S408A/S409A, were in vitro 
substrates of purified CaMKII, and that GST-|33-S409A and GST-|33-S408A/S409A 
were the weakest substrates. These results suggested that purified CaMKII 
phosphorylates the major intracellular domain of the (33 subunit at S383 and S409.
4.2.1.3 Time-Course of CaMKII Phosphorylation of the Major Intracellular 
domain of the GABAa Receptor f33 Subunit, In Vitro
I next analysed the in vitro phosphorylation of wild type GST-J33 by CaMKII with 
respect to time. GST-(33 (5 p,g) was incubated with CaMKII, which had been purified 
from brain (a generous gift from Paul Greengard) (Naim and Greengard, 1987), 
calmodulin, and a [y-32P]-ATP/ATP mix, in CaMKII Buffer at 30 °C for 1, 2, 5, 10, 
20, 30 and 60 min (Section 2.5.13). After resolving the proteins by SDS-PAGE, 
phosphorylated proteins were detected and quantitated by phosphorimaging. I 
obtained a [32P]-protein band at the predicted molecular weight of GST-(33 (~46 kDa) 
and the autophosphorylated 50- and 60-kDa subunits of CaMKII in each kinase assay 
(Fig. 4.2A and B). The intensity of the [32P]-GST-(33 band increased with time (Fig. 
4.2A and B), and the maximum stoichiometry of phosphorylation (~0.22 mol. 
phosphate mol. protein'1) was attained within 20 min (Fig. 4.2C). The rapid and 
robust phosphorylation of GST-(33 by CaMKII suggested that the major intracellular 
domain of the GABAa receptor (33 subunit is a good in vitro substrate of purified
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Figure 4.2. Time-course showing the in vitro phosphorylation of GST-(33 by 
CaMKII. A. GST-|33 (5 pig) fusion proteins were phosphorylated in vitro using 
purified CaMKII and [y-32P]-ATP for the indicated times at 30 °C. Proteins were then 
resolved by SDS-PAGE, and [32P]-GST-fusion proteins were detected by 
phosphorimaging. B. Brilliant Blue-R stain of the gel in A.'. C. The stoichiometry of 
phosphorylation was assessed after SDS-PAGE and phosphorimaging.
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CaMKII. This analysis also provided a control of the reaction conditions to be used 
in the phosphatase assays in Section 4.2.2.
4.2.2 PP1, PP2A and PP2C Dephosphorylate Phospho-S383 and Phospho-S409 
of the Major Intracellular Domain of the GABAa Receptor (33 Subunit, In Vitro 
I was also interested in identifying protein phosphatases that dephosphorylate GST- 
133 at the in vitro CaMKII phosphorylation sites, S383 and S409 (Fig. 4.1). To 
investigate this, I performed in vitro phosphatase assays (Section 2.5.16) using the 
purified protein phosphatases, PP1, PP2A, PP2B and the a  isoform of PP2C 
(PP2Ca), all of which are major eukaryotic serine/threonine-protein phosphatases 
(Cohen, 1989). I also used purified, bacterially expressed GST-(3 3 fusion proteins 
phosphorylated at S383 and/or S409. These included [32P]-GST-p3 (phospho- 
S383/S409), [32P]-GST-|33-S383A (phospho-409) and [32P]-GST-|33-S409A 
(phospho-S383) (Table 2.2; Section 2.5.13). Each phosphatase assay was performed 
with a reference control substrate: [32P]-phosphorylase a (for PP1 and PP2A), [32P]- 
DARRP-32 (for PP2B) and [32P]-casein (for PP2C) (Section 2.5.16). The activity of 
each phosphatase was measured under initial rate conditions. These were determined 
by performing phosphatase assays with a fixed concentration of the [32P]-reference 
substrate, and variable incubation times and enzyme concentrations (Section 2.5.16.2; 
Fig. 4.3). The conditions chosen ensured that the release of phosphate was 15-25% of 
the total [32P]-phosphate incorporated into the substrate, and approximately linear: 
PP1 (1:300; 10 min), PP2A (1:600; 10 min), PP2B (1:15; 10 min) and PP2C (1:150; 
20 min) (Section 2.5.16.2; Fig. 4.3). The wild type and mutant GST-fusion proteins 
were then phosphorylated in vitro with purified CaMKII in the presence of 
calmodulin and a [y-32P]-ATP/ATP mix, in CaMKII Buffer at 30 °C for 30 min 
(Section 2.5.13). A sample of each kinase assay was resolved by SDS-PAGE, and 
phosphorylated proteins were detected by phosphorimaging. I detected [32P]-protein 
bands at the predicted molecular weight of each of the GST-|33 fusion proteins (~46 
kDa) (Fig. 4.4A). Although [32P]-protein bands were also detected at the predicted 
molecular weight of the autophosphorylated 50- and 60-kDa subunits of CaMKII, 
these contributed only a small proportion of the total [32P]-signals (Fig. 4.4A).
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Figure 4.3. Determination of initial rate conditions for phosphatase assays with 
PP1, PP2A, PP2B and PP2C. The activities of the indicated dilutions of PP1, PP2A, 
PP2B and PP2C were measured at 30 °C for the indicated time (min) using a [32P]- 
labelled control substrate (~0.5 pM). The [32P]-substrates were also incubated in the 
absence of phosphatase as a control. The amount of [32P] released (cpm) in the 
presence of phosphatase in the indicated time was expressed as a percentage of the 
total [32P] input (cpm). The data represents the rate o f dephosphorylation (% 
phosphate removed) from at least 3 independent experiments (mean ± sem), which 
were each done in duplicate. A. PP1 and B. PP2A activity was assayed using [32P]- 
phosphorylase a as a standard. C. PP2B activity was assayed using [32P]-DARRP-32- 
T34 as a standard. D. PP2Ca activity was assayed using [32P]-casein as a standard, 
cpm: counts min-T
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Figure 4.4. PP1, PP2A and PP2C, but not PP2B, dephosphorylate phospho-S383 
and phospho-S409 of GST-(33, in vitro. A. Phosphorylation of the GST-|33 fusion 
proteins to be used in the phosphatase assays. [32P]-GST-(33 (WT), [32P]-GST-(33- 
S383A (S383A) and [32P]-GST-(33-S409A (S409A) were each phosphorylated in vitro 
by purified CaMKII at 30 °C for 15 min. A sample of each reaction was separated by 
SDS-PAGE and [32P]-proteins were visualised by phosphorimaging. B-E. The 
activities of purified protein phosphatases were measured under initial rate conditions 
using each [32P]-GST-(33 fusion protein (~0.5 pM; dark grey bars), and a [32P]- 
reference substrate (-0.5 pM; light grey bars). The amount of [32P] released (cpm) in 
the absence of phosphatase was subtracted from that released in the presence of 
phosphatase, and the resultant value was expressed as a percentage of the total [32P] 
incorporated (cpm). The rates of dephosphorylation (% phosphate removed) were 
determined from at least 3 independent experiments, each done in duplicate, and 
plotted as shown (mean ± sem). Dephosphorylation of each test and reference 
substrate was compared to baseline (0%) using the Student's paired t test. * denotes 
/?<0.05. B. PP1 C. PP2A and D. PP2B activities were assayed for 10 min, and E. 
PP2C, for 20 min. cpm: counts min"1, Ph a: [32P]-phosphorylase a; D-32: [32P]- 
DARRP-32-T34, Cas: [32P]-casein.
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As shown in Figure 4.4 (B, C and E), [32P]-GST-|33, [32P]-GST-|33-S383A and [32P]- 
GST-(33-S409A, as well as the respective [32P]-reference substrates, were substrates 
of PP1 ([32P]-GST-|33: 2.7%±0.4; [32P]-GST-|33-S383A: 4.7%±0.5; [32P]-GST-|33- 
S409A: 3.7%±0.7; [32P]-phosphorylase a: 16.3%±1.3; n=3; /?<0.05, Student’s paired t 
test), PP2A ([32P]-GST-[33: 8.5%±1.2; [32P]-GST-|33-S383A: 8.8%±0.5; [32P]-GST- 
(33-S409A: 8.5%±1.5; [32P]-phosphorylase a: 9.9%±0.8; n=at least 3; p<0.05, 
Student’s paired t test) and PP2C ([32P]-GST-|33: 14.2%±1.7; [32P]-GST-|33-S383A: 
17.3%±0.6; [32P]-GST-|33-S409A: 15.7%±1.7; [32P]-casein: 20.8%±1.9; n=at least 3; 
/?<0.05, Student’s paired t test). In contrast, PP2B did not dephosphorylate any of the 
GST-(33 fusion proteins ([32P]-GST-|33: 1.1%±1.1; [32P]-GST-|33-S383A: 1.6%±0.6; 
[32P]-GST-p3-S409A: 0.9%±0.5; n=3; /?>0.05, Student’s paired t test), despite being 
able to dephosphorylate the reference substrate, [32P]-DARRP-32-T34 (28.2%±1.3; 
n=3; /?<0.05, Student’s paired t test) (Fig. 4.4D). These results suggested that 
phospho-S383 and phospho-S409 of GST-|33 are each dephosphorylated by PP1, 
PP2A and PP2C, but not PP2B, in these in vitro phosphatase assays.
4.2.3 KCl-Induced Depolarisation of Cultured Immature Cortical Neurons 
Enhances the Functional Interaction of CaMKII with GST-|33
I have previously shown that CaMKII phosphorylates GST-(33 fusion proteins in vitro 
(Figs. 4.1 and 4.2), and that recombinant CaMKIIa binds to the major intracellular 
domain of the GABAa receptor (3 subunits only when in the constitutively active form 
(CaMKIIa-T286D) (Fig. 3.3). I was therefore interested in examining whether 
depolarisation of neurons and physiological activation of endogenous CaMKII 
increases the binding of enzymatically active CaMKII to GST-J33. To investigate 
this, I used a combination of neuronal treatments, affinity-purification assays and in 
vitro kinase assays (Section 2.5.15; Fig. 3.1), which will be collectively referred to as 
‘pull-down’-kinase assays from hereon, and purified, bacterially expressed GST-|33 
and recombinant GST fusion proteins. To perform the ‘pull-down’-kinase assays, 
primary cultures of cortical neurons (E17; 6-8DIV) were incubated in the absence or 
presence of KC1 (50 mM) with or without the CaMKII inhibitor KN93 (4 pM) for 5 
min at 37 °C (in HEPES-buffered saline (HBS); Section 2.5.12). KN93 competes 
with calmodulin to inhibit autophosphorylation of CaMKII (Sumi et al., 1991), and
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was added 20 min before the KC1 incubation to enable it to enter the neurons and 
exert its effect. Following the treatments, the neurons were lysed under non­
denaturing conditions, and the neuronal extracts were used in affinity-purification 
assays with GST-J33 or GST alone. Following extensive washing, the precipitates 
were re-suspended in CaMKII Buffer (which does not contain calmodulin) and in 
vitro kinase assays were performed in the presence of [y-32P]-ATP at 30 °C for 30 
min. After resolving the proteins by SDS-PAGE, [32PJ-GST-(33 bands were detected 
and quantitated by phosphorimaging, and normalised to the untreated control.
As shown in Figure 4.5A, I detected [32P]-protein bands at the predicted molecular 
weight of GST-(33 (~46 kDa) from all ‘pull-down’-kinase assays using GST-(33. I did 
not detect any [32P]-protein bands in the assays performed using GST alone (Fig. 
4.5A). I obtained a stronger [32P]-GST-(33 band in assays that were performed using 
extracts of KCl-treated neurons (146.9±13.2%; p<0.05; Student’s paired t test; n=4) 
compared to control neurons (100%) (Fig. 4.5). However, a significant enhancement 
in phosphorylation of GST-(3 3 was not observed when the neurons were pre-treated 
with KN93 (113.6±18.2%; p>0.05; Student’s paired t test; n=3) (Fig. 4.5). These data 
demonstrated that depolarisation of cultured immature cortical neurons by KC1 
increased the level of KN93-sensitive kinase activity that bound to GST-(33. This 
suggested that depolarisation of cultured immature cortical neurons enhances the 
level of enzymatically active CaMKII that binds and phosphorylates GST-(33.
4.2.4 Depolarisation-Induced Autophosphorylation of CaMKII at T286 in 
Cultured Immature Cortical Neurons
I was next interested in investigating CaMKII activity in neurons with a view to 
examining CaMKII-dependent phosphorylation of GABAa receptors, in situ. 
GABAa receptors mediate depolarising responses during neuronal development 
(Section 1.2), and previous studies have shown that activation of GABAa receptors 
triggers depolarisation and calcium influx in primary cultures of immature cortical 
neurons (E17; 6DIV; Section 2.4.2) (J.N. Jovanovic, unpublished data). I was 
therefore interested in determining whether stimulation of GABAa receptors triggers 
autophosphorylation and activation of CaMKII in this neuronal preparation.
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Figure 4.5. Depolarisation of immature cortical neurons enhances the functional 
interaction of neuronal CaMKII with GST-(33. Primary cultures of cortical neurons 
(E17; 6-8DIV) were incubated in the absence (-) or presence (+) of KC1 (50 mM) with 
(+) or without (-) KN93 (4 pM; added 20 min prior to treatment) for 5 min at 37 °C. 
Neurons were then lysed under non-denaturing conditions, and the extracts were used 
in an affinity-purification assay with GST-j33 or GST. A kinase assay was then 
performed in CaMKII buffer in the presence of [y-32P]-ATP at 30 °C for 30 min and 
proteins were resolved by SDS-PAGE. A. Visualisation of [32P]-GST-fusion proteins 
by phosphorimaging. B. Quantitation of [32P]-GST-(33 protein bands from A.' (mean ± 
sem; n = 3 or above; Student's paired t test; * denotes p<0.05).
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4.2.4.1 Basal Activity o f CaMKII in Cultured Immature Cortical Neurons 
I began by examining the level of basal CaMKII activity in primary cultures of 
immature cortical neurons (E17; 6DIV). To do this, neurons were incubated for 5 
min at 37 °C in the absence or presence of the CaMKII inhibitor, KN93 (4 pM), and 
the calcium (intracellular and extracellular) chelator, BAPTA-AM (25 pM) (in HBS). 
KN93 and BAPTA-AM were added 20 min and 5 min, respectively, before the 5 min 
incubation to enable them to enter the neurons and exert their effect. Following the 
incubations, the neurons were lysed under denaturing conditions, and equal amounts 
of protein were resolved by SDS-PAGE and analysed by quantitative Western 
blotting and phosphorimaging. Phosphorylation of endogenous CaMKIIa at T286 
was detected using a polyclonal anti-CaMKII-pT286 phosphorylation state-specific 
antibody (Table 2.6). Total CaMKIIa protein levels were also examined using a 
monoclonal anti-CaMKIIa antibody.
As shown in Figure 4.6, I detected an immunoreactive band at the predicted 
molecular weight (50 kDa) of CaMKIIa-pT286 (Fig. 4.6A) and CaMKIIa (Fig. 4.6C) 
from the control and treated neurons. I performed a quantitative analysis of these 
findings by measuring the intensity of the band from each set of treated neurons, and 
normalising it to the value obtained from the untreated control neurons. The results 
from several experiments (mean ± sem; n=3-7) were compared with the untreated 
control using the Student's paired t test (Fig. 4.6B and D). This analysis revealed a 
statistically significant decrease in the basal level of CaMKIIa-T286 phosphorylation 
in neurons that were treated with KN93 (63.3±13.2; p<0.05; Student’s paired t test; 
n=7) or BAPTA-AM (64.7±4.0; p<0.05; Student’s paired t test; n=4) (Fig. 4.6B). I 
did not detect a statistically significant change in the total level of CaMKIIa protein 
in neurons treated with KN93 (91.7±11.1; p>0.05; Student’s paired t test; n=5) (Fig. 
4.6D). However, a statistically significant decrease in the total level of CaMKIIa 
protein was detected in neurons that were treated with BAPTA-AM (75.6±5.2; 
p<0.05; Student’s paired t test; n=3) (Fig. 4.6D). These data demonstrated that 
CaMKIIa is basally phosphorylated at T286 in cultured immature cortical neurons, 
and that the basal level of T286-phosphorylation is sensitive to the CaMKII inhibitor, 
KN93, and the calcium chelator, BAPTA-AM. The results also demonstrated that
149
A B.
con KN93 BAP
CaM KIIa-► 
pT286
con KN93 BAP
c. D.
con KN93 BAP
CaMKIIa ►
con KN93 BAP
Figure 4.6. CaMKIIa is basally phosphorylated at T286 in immature cortical 
neurons. Primary cultures of cortical neurons (E17; 6DIV) were incubated at 37 °C  
for 5 min in the absence (con) or presence of the CaMKII inhibitor, KN93 (4 pM; 20 
min pre-incubation), or the calcium chelator, BAPTA-AM (BAP; 25 pM; 5 min pre­
incubation). Neurons were lysed under denaturing conditions and equal amounts of 
protein were separated by SDS-PAGE and analysed by quantitative Western blotting. 
A. Autophosphorylation of CaMKIIa at T286 (CaMKIIa-pT286) was analysed by 
probing cortical extracts (300 pg of protein) with a polyclonal anti-pT286 antibody 
and an [125I]-anti-rabbit antibody. B. Quantitation of 'A.'. The data from each set of 
drug-treated neurons was normalised to that of the untreated control neurons. The 
results for a number of experiments (mean ± sem; n = 3-7) were then compared to the 
control group using the Student's paired t test (* denotes p<0.05). C. Total CaMKIIa 
protein levels were examined by immunoblotting cortical extracts (100 pg of protein) 
with a monoclonal anti-CaMKIIa antibody (CaMKIIa), a rabbit anti-mouse bridge 
antibody and an [125I]-anti-rabbit antibody. D. Quantitation of 'C.', as for 'B.'.
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total CaMKIIa protein levels were reduced by BAPTA-AM but not KN93. These 
data collectively suggested that CaMKIIa undergoes basal T286-autophosphorylation 
in cultured cortical neurons and that there is therefore some level of basal CaMKII 
activity. They also suggested that the stability of the CaMKIIa protein is calcium- 
sensitive.
4.2.4.2 Muscimol-Induced Phosphorylation o f CaMKII at T286 in Cultured 
Immature Cortical Neurons
I next examined whether muscimol-induced depolarisation of cultured immature 
cortical neurons (J.N. Jovanovic, unpublished data) induces autophosphorylation of 
CaMKIIa at T286. To investigate this, primary cultures of cortical neurons (E17; 
6DIV) were incubated in the absence or presence of muscimol (50 pM) for 5, 15, 30 
or 60 min at 37 °C (in HBS). Neurons were then lysed under denaturing conditions, 
and equal amounts of protein (300 pg) were resolved by SDS-PAGE. 
Autophosphorylation of CaMKIIa at T286 and total CaMKIIa protein levels were 
analysed by quantitative Western blotting and phosphorimaging, as previously 
(Section 4.2.4.1).
As shown in Figure 4.7, I detected a 50-kDa immunoreactive band corresponding to 
CaMKIIa-pT286 (Fig. 4.7A) and CaMKIIa (Fig. 4.7C) with control and muscimol- 
treated neurons. Quantitative analysis revealed a statistically significant increase in 
phosphorylation of CaMKIIa-T286 above control levels following incubation with 
muscimol for 5 min (135.1±8.1; /?<0.05; Student’s paired t test; n=9) and 15 min 
(128.0±6.0; /?<0.05; Student’s paired t test; n=5), but not 30 min (118.4±9.1; /?>0.05; 
Student’s paired t test; n=5) or 60 min (99.6±12.4; p>0.05; Student’s paired t test; 
n=6) (Fig. 4.7B). I did not detect a statistically significant change in the total level of 
CaMKIIa protein after treatment with muscimol for 5 min (105.9±8.2; /?>0.05; 
Student’s paired t test; n=7), 15 min (109.0±10.4; p>0.05; Student’s paired t test; 
n=4), 30 min (106.7±8.7; p>0.05; Student’s t test; n=5) or 60 min (100.4±14.9; 
p>0.05; Student’s paired t test; n=6) (Fig. 4.7D). These data demonstrated a 
statistically significant increase in phosphorylation of CaMKIIa at T286 above 
control levels in cultured immature cortical neurons following incubation with
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Figure 4.7. Time-course of muscimol-induced phosphorylation of CaMKIIa- 
T286 in immature cortical neurons. Primary cultures of cortical neurons (E17; 
6DIV) were incubated at 37 °C  for the indicated time (min) in the absence (control) 
or presence of muscimol (50 pM). Neurons were lysed under denaturing conditions, 
and equal amounts o f protein were resolved by SDS-PAGE and analysed by 
quantitative Western blotting. A. Phosphorylation of CaMKIIa at T286 (CaMKIIa- 
pT286) was analysed by probing cortical extracts (300 p,g o f protein) with a 
polyclonal anti-CaMKII-pT286 antibody and an [125I]-anti-rabbit antibody. B. 
Quantitation o f 'A.'. The band intensity measured from each muscimol-treated group 
was normalised to the untreated control value. The results o f several experiments 
(mean ± sem; n = 4-9) were compared with the untreated control using the Student's 
paired t test (* denotes p<0.05). C. Total CaMKIIa protein levels (CaMKIIa) were 
examined by immunoblotting extracts (100 p,g o f protein) with a monoclonal anti- 
CaMKIIa antibody, a rabbit anti-mouse bridging antibody and an [125I]-anti-rabbit 
antibody. D. Quantitation of 'C.', as for 'B.'.
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muscimol for 5 and 15 min, but not 30 or 60 min. They also showed that muscimol 
treatment had no effect on total CaMKIIa protein levels for up to 1 h. These data 
suggested that short-term stimulation of GABAa receptors (up to 15 min) triggers an 
increase in CaMKIIa autophosphorylation and activity.
I next examined whether the muscimol-induced phosphorylation of CaMKIIa at 
T286 was calcium-dependent. To investigate this, primary cultures of immature 
cortical neurons (E17; 6DIV) were incubated at 37 °C in the absence or presence of 
muscimol (50 pM; 5 min), with or without KN93 (4 pM; added 20 min prior to 
treatment) or BAPTA-AM (25 pM; added 5 min prior to treatment) (in HBS). 
Neurons were lysed under denaturing conditions, and equal amounts of protein were 
resolved by SDS-PAGE and analysed by quantitative Western blotting and 
phosphorimaging. Phosphorylation of endogenous CaMKIIa-T286 and total 
CaMKIIa protein levels were detected as above.
As shown in Figure 4 .8 ,1 detected a 50-kDa immunoreactive band corresponding to 
CaMKIIa-pT286 (Fig. 4.8A) or CaMKIIa (Fig. 4.8C) from control and muscimol- 
treated neurons. Quantitative analysis revealed a statistically significant increase in 
phosphorylation of CaMKIIa at T286 above control levels following incubation with 
muscimol for 5 min (135.1±8.1; p<0.05; Student’s paired t test; n=9) (Fig. 4.8B). 
This was not detected when neurons were also treated with KN93 (103.6±4.2; 
p>0.05; Student’s paired t test; n=5), or BAPTA-AM, which caused a statistically 
significant decrease in autophosphorylation of CaMKIIa-T286 from control levels 
(69.3±10.9; p<0.05; Student’s paired t test; n=5) (Fig. 4.8B). The analysis also 
revealed a statistically significant difference in the level of phosphorylation between 
neurons treated with muscimol, and neurons treated with muscimol and KN93 
(p<0.05; Student’s paired t test; n=5), or muscimol and BAPTA-AM (p<0.05; 
Student’s paired t test; n=5) (Fig. 4.8B). I did not detect any statistically significant 
change from control in the level of total CaMKIIa protein following treatment with 
muscimol (105.9±8.2; p>0.05; Student’s paired t test; n=7), muscimol with KN93 
(116.5±8.3; /?>0.05; Student’s paired t test; n=5) or muscimol with BAPTA-AM 
(91.2±10.8; p>0.05; Student’s paired t test; n=5) (Fig. 4.8D). These data
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Figure 4.8. Muscimol-induced phosphorylation of CaM KIIa at T286 in 
immature cortical neurons is calcium sensitive. Primary cultures of cortical neurons 
(E17; 6DIV) were incubated at 37 °C  for 5 min with (+; lanes 2-4) or without (-; lane 
1) muscimol (50 pM) in the absence or presence o f KN93 (4 uM; added 20 min prior 
to treatment; lane 3), or BAPTA-AM (BAP; 25 pM; added 5 min prior to treatment; 
lane 4). Neurons were lysed under denaturing conditions and equal amounts of protein 
were separated by SDS-PAGE and analysed by quantitative Western blotting. A. 
Phosphorylation of CaMKIIa at T286 (CaMKIIa-pT286) was analysed by probing 
cortical extracts (300 pg of protein) with a polyclonal anti-CaMKII-pT286 antibody 
and an [125I]-anti-rabbit antibody. B. Quantitation of 'A.'. Data from each drug-treated 
group was normalised to the untreated control. The results from each drug-treated 
group from several experiments (mean ± sem; n = 5-9) were then compared to the 
control group using the Student's paired t test (* denotes /?<0.05). C. Total CaMKIIa 
(CaMKIIa) protein levels were examined by immunoblotting extracts (100 pg of 
protein) with a monoclonal anti-CaMKIIa antibody, a rabbit anti-mouse bridging 
antibody and an [125I]-anti-rabbit antibody. D. Quantitation of 'C.', as with 'B.'.
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demonstrated that muscimol-induced phosphorylation of CaMKIIa at T286 in 
cultured immature cortical neurons is blocked by KN93 and BAPTA-AM. 
Furthermore, it demonstrates that muscimol has no effect on the level of total 
CaMKIIa protein. These data suggested that stimulation of GABAa receptors in 
developing cultured cortical neurons triggers a calcium-sensitive increase in 
CaMKIIa autophosphorylation at T286 and, hence, CaMKII activity.
4.2.4.3 Muscimol-Induced Phosphorylation o f PKC in Cultured Immature Cortical 
Neurons
I next examined whether muscimol-induced depolarisation of immature cortical 
neurons triggered phosphorylation of the GABAa receptor kinase, PKC, at a site 
involved in controlling PKC activity, S660 (Tanaka and Nishizuka, 1994; Keranen et 
al., 1995). To investigate this, primary cultures of cortical neurons (E17; 6DIV) were 
incubated in the absence or presence of muscimol (50 pM) for 5, 15, 30 or 60 min at 
37 °C (in HBS). Neurons were then lysed under denaturing conditions, and equal 
amounts of protein (100 pg) were resolved by SDS-PAGE and analysed by 
quantitative Western blotting and phosphorimaging. Phosphorylation of endogenous 
PKC at S660 was detected using a pan PKC phosphorylation state-specific antibody 
(Table 2.6).
As shown in Figure 4.9, I detected two immunoreactive bands from control and 
muscimol-treated neurons: an upper band at 97 kDa and a lower band between 97 and 
66 kDa, both of which are within the molecular weight range of the different PKC 
isoforms. I performed a quantitative analysis of these findings by measuring the 
intensity of the bands in each muscimol-treated group, and normalising each one to 
the value obtained from the respective untreated control. The results of several 
experiments (mean ± sem; n=5-8) were compared with the untreated control in the 
Student's paired t test (Fig. 4.9B). I detected a small but significant increase in 
phosphorylation of PKC at S660 following incubation with muscimol for 15 min 
(upper band: 114.9±4.9; p<0.05; n=6) (lower band: 111.0±2.8; p<0.05; n=6) (Fig. 
4.9B). I did not detect a significant change in the level of phospho-PKC-S660 after 
treatment with muscimol for 5 min (upper band: 115.3±8.9; /?>0.05; n=7) (lower
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Figure 4.9. Time-course of PKC phosphorylation following treatment of 
immature cortical neurons with muscimol. Primary cultures of cortical neurons 
(E17; 6 DIV) were incubated at 37 °C  for the indicated time (min) in the absence 
(control) or presence of muscimol (50 pM). Neurons were lysed under denaturing 
conditions, and equal amounts of protein (100 pg) were resolved by SDS-PAGE and 
analysed by quantitative Western blotting. Phosphorylation of PKC at S660 (pPKC- 
S660) was detected with a polyclonal anti-pan PKC phosphorylation state-specific 
antibody and an [125I]-anti-rabbit antibody. A. Time-course of PKC-S660 
phosphorylation. B. Quantitation of the upper (left panel) and lower (right panel) 
pPKC-S660 bands in 'A.'. The data from each muscimol-treated group were 
normalised to the respective untreated control. The results of several experiments 
(mean ± sem; n = 5-8) were compared with the untreated control using the Student's 
paired t test (* denotes p<0.05).
156
CHAPTER 4 CaMKlI-Dependent Phosphorylation o f GAB A A Receptors
band: 109.7±6.5; p>0.05; n=7), 30 min (upper band: 107.2±8.6; p>0.05; n=5) (lower 
band: 108.1±3.8; /?>0.05; n=6) or 60 min (upper band: 104.4±8.7; /?>0.05; n=8) 
(lower band: 114.8±7.3; p>0.05; n=8) (Fig. 4.9B). These data demonstrated a small 
increase in phosphorylation of PKC at S660 in cultured cortical neurons following 
incubation with muscimol for 15 min, but not 5, 30 or 60 min. This suggested that 
short-term activation of GABAa receptors might trigger a small increase in PKC 
activity in cultured immature cortical neurons.
4.2.5 CaMKII-Dependent Phosphorylation of GABAa Receptor (33 Subunits In 
Situ in Cultured Immature Cortical Neurons
I next performed pre-labelling experiments with [33P]-orthophosphate (Section
2.5.12), to determine whether muscimol-induced activation of CaMKIIa in cultured 
immature cortical neurons correlated with a change in the phosphorylation state of 
GABAa receptors. Primary cultures of cortical neurons (E17; 6DIV) were incubated 
at 37 °C in phosphate-free medium for 2 h, and then for a further 4 h in the presence 
of [33P]-orthophosphate. The neurons were then incubated for a further 5 min in the 
absence or presence of muscimol (50 pM), with or without KN93 (4 pM; added 20 
min prior to treatment) (in HBS). Following the treatments, the neurons were lysed 
under denaturing conditions for optimal preservation of the phosphorylation state of 
the receptor subunits. The proteins were then partially renatured and 
immunoprecipitations were performed using polyclonal anti-(3 3 or anti-y2 subunit 
antibodies, or non-specific rabbit IgG as a control, (Table 2.6) and protein-A beads. 
Notably, the expression of the y2 and (33 subunits in cultured immature cortical 
neurons has previously been confirmed by metabolic labelling with [35S]-methionine 
and immunoprecipitation using the same antibodies and conditions as in this study 
(Jovanovic et al., 2004; see also Macdonald and Olsen, 1994). Following the 
immunoprecipitations, proteins were resolved by SDS-PAGE and [33P]-labelled 
subunits were visualised by phosphorimaging.
As shown in Figure 4.10, I detected a [33P]-protein band at the predicted molecular 
weight of the GABAa receptor (33 subunit, 58 kDa, from immunoprecipitations 
performed with the anti-(33 subunit antibody. The [33P]-protein band from neurons
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Figure 4.10. CaMKII-dependent phosphorylation of GABAa receptor (33 
subunits in situ in immature cortical neurons. Primary cultures of cortical neurons 
(E17; 6DIV) were pre-labelled with [33P]-orthophosphate in phosphate-free medium 
for 4  h at 37 °C before being treated for 5 min in the absence (-) or presence (+) of 
muscimol (50 pM), with (+) or without (-) KN93 (4 pM; added 20 min prior to 
treatment). Following lysis o f neurons, receptor subunits were immunoprecipitated 
with polyclonal anti-(33 or anti-y 2 subunit antibodies, or non-specific rabbit IgG 
(rlgG) as a control, and protein-A beads. Proteins were then resolved by SDS-PAGE 
and [33P]-labelled GABAa  receptor subunits were visualised by autoradiography. 'IP', 
immunoprecipitation.
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treated with muscimol was of greater intensity than that detected under basal 
conditions, and this enhancement was prevented by co-application of KN93 (Fig. 
4.10). I did not detect any [33P]-protein bands from immunoprecipitations performed 
with the anti-y2 subunit antibody or non-specific control IgG. These results 
demonstrated that the GABAa receptor |33 subunit was phosphorylated under basal 
conditions, and that muscimol induced a KN93-sensitive increase in |33 subunit 
phosphorylation. They also demonstrated that the GABAa receptor y2 subunit was 
not phosphorylated under basal conditions or following treatment with muscimol. 
These data therefore suggested that stimulation of GABAa receptors induces 
CaMKII-dependent phosphorylation of the receptor (33 subunit, but not the y l  
subunit, in situ in cultured immature cortical neurons.
4.2.6 Production and Characterisation of Phosphorylation State-Specific 
Antibodies that recognise GABAa Receptor (33 Subunits Phosphorylated at S383, 
and at S409
Phosphorylation state-specific antibodies are powerful investigative tools for the 
detection and quantitation of changes in the phosphorylation state of specific sites of 
particular proteins. Previous studies using phosphorylation state-specific antibodies 
have begun to delineate neuronal signalling pathways that lead to changes in the 
phosphorylation state of specific residues of GABAa receptor subunits. For example, 
studies using a phosphorylation state-specific antibody that recognises the GABAa 
receptor (33 subunit phosphorylated at S408 and S409 (anti-|33-pS408/409) 
(Jovanovic et al., 2004) have shown that activation of muscarinic acetylcholine 
receptors (Brandon et al., 2002), or TrkB neurotrophin receptors (Jovanovic et al., 
2004), leads to PKC-dependent phosphorylation of the GABAa receptor (33 subunit at 
S408 and S409 in primary cultures of cortical neurons. Furthermore, activation of Dj 
dopamine receptors has been shown to induce PKA-dependent phosphorylation of the 
GABAa receptor (33 subunit at S408 and S409 in hippocampal slices (Terunuma et 
al., 2004). I therefore decided to raise phosphorylation state-specific antibodies that 
recognise the GABAa receptor (33 subunit phosphorylated at S383, or at S409, to 
determine whether CaMKII-dependent phosphorylation of the (13 subunit (Fig. 4.10)
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occurs at either or both of these residues (the in vitro phosphorylation sites) in 
cultured immature cortical neurons.
42.6.1 Design and Production of Peptide Immunogensy and Inoculation of Rabbits
I used short synthetic phospho-peptide immunogens ((33-S383-P or [33-S409-P 
peptides) for the production of phosphorylation state-specific antibodies that 
recognise the GABAa receptor (33 subunit phosphorylated at S383 (anti-(33-pS383 
antibody), or at S409 (anti-(33-pS409 antibody) (Section 2.4.3; Tables 2.4 and 2.6). 
Synthetic peptides were also used to characterise the antibodies (Table 2.4). The 
synthetic peptides corresponded to a short region (12 amino acids) surrounding either 
S383 or S409 of the GABAa receptor (33 subunit, and were modified with phospho- 
serine residues by chemical phosphorylation, where appropriate (Table 2.4; Section 
2.4.3). The peptides also contained an N-terminal cysteine residue for conjugation to 
the Limulus hemocyanin carrier-protein, via the cross-linker sulfo-MBS, where 
appropriate (Table 2.4; Section 2.4.3). All peptides were synthesised and HPLC 
purified at The Rockefeller University Protein/DNA Technology Centre in the USA 
(www.pdtc.rockefeller.edul . and were designed in accordance with the Centre’s 
guidelines (Section 2.4.3). The (33-S383-P and (33-S409-P peptides were each used to 
raise polyclonal antibodies in two rabbits. This part of the project was contracted out 
to Cocalico Biologicals Inc, in the USA (Section 2.4.3). Rabbits UCL-103 and UCL- 
104 were immunised with the (33-S383-P peptide, and rabbits UCL-105 and UCL-106 
were immunised with the (33-S409-P peptide. The rabbits were immunised using the 
standard company protocol, in Freund’s Complete Adjuvant.
4.2.6.2 Antibody Screen I
I monitored production of the desired antibodies in the rabbits by testing samples of 
serum, which had been taken from each rabbit at various stages of the project. A 
serum sample was obtained before the initial inoculation (pre-immune serum), after 
the initial inoculation and the second antigen boost (test-bleed 1), and following the 
third antigen boost (test-bleed 2). A timetable of the project is shown in Table 2.5. In 
the first antibody screen, I tested the affinity, site-specificity and phospho-specificity 
of the serum antibodies by using a dot-blot assay with the immunising and control
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synthetic peptides (Section 2.5.9; Figs. 4.11 and 4.12). In addition to detecting the 
desired antibodies, this screen was an important means of quality control, and was 
crucial for estimating the optimal time for exsanguination. I tested the immunising 
phospho-peptides, |33-S383-P and (33-S409-P, and a number of control peptides. 
These included the dephosphorylated forms of the immunising peptides, (33-S383 and 
|33-S408/S409, respectively, and a form of the |33-S408/S409 peptide that was 
phosphorylated at S408, |33-S408-P, or on both S408 and S409, (33-S408/S409-P 
(Table 2.4). To perform the dot-blot assay, I first prepared a peptide grid (one for 
each serum sample) by pipetting increasing amounts (0, 5, 25, 50 and 100 ng) of each 
synthetic peptide in a volume of 1 pi onto a piece of PVDF membrane. The peptides 
on each grid were then probed with one of the serum samples in a Western blot.
I first examined the serum samples obtained from UCL-103 and UCL-104, which had 
been immunised with the |33-S383-P peptide. As shown in Figure 4.11, the pre- 
immune serum from both UCL-103 (Fig. 4.11 A) and UCL-104 (Fig. 4.1 IB) did not 
display immunoreactivity to any of the peptides. However, both rabbits developed 
immunoreactivity towards the immunising peptides following the initial inoculation 
and the first two antigen boosts (Fig. 4.11C and D). UCL-103 (test-bleed 1) detected 
as little as 5 ng of the immunising (33-S383-P peptide (Fig. 4.11C). Immunoreactive 
spots were also detected with the control (33-S383 peptide, although they were much 
fainter than those for [33-S383-P (Fig. 4.11C). Immunoreactive spots were not 
detected in the absence of the peptides, or for any of the other control peptides (Fig. 
4.11C). Like UCL-103 (test-bleed 1), UCL-104 (test-bleed 1) detected as little as 5 
ng of the immunising [33-S383-P peptide and the control (33-S383 peptide (Fig.
4.1 ID). Once again, weaker spots were obtained for (33-S383 compared to (33-S383- 
P (Fig. 4.1 ID). Although immunoreactive spots were not detected in the absence of 
the peptides, or for the p3-S408/S409 or (33-S408-P peptides, faint spots were 
obtained with 25+ ng of the p3-S409-P and (33-S408/S409-P control peptides (Fig.
4.1 ID). After the third antigen boost, UCL-103 (test-bleed 2) still detected as little as 
5 ng of (33-S383-P, and faint bands were observed with only 50 and 100 ng of (33- 
S383 (Fig. 4 .11E). Very faint dots were also detected with 25+ ng of (33-S409-P, and 
50+ ng of (33-S408/S409-P (Fig. 4.11E). Immunoreactive spots were not detected in
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Figure 4.11. Immunoreactivity of UCL-103 and UCL-104 to the synthetic immunising 
and control peptides. Dot-blot assays were performed using crude serum samples 
obtained from two rabbits (UCL-103 and UCL-104) at different stages of antibody 
production, and the synthetic immunising ((33-S383-P) and control ((33-S383, (33- 
S408/S409, (33-S408-P, (33-S409-P and |33-S408/S409-P) peptides. T ’ indicates 
'phospho'. Increasing amounts (0, 5, 25, 50 and 100 ng) of each peptide were spotted 
onto PVDF membranes and Western blots were perfomed using a 1:100 dilution of the 
crude serum samples obtained from UCL-103 (A., C. and E.) and UCL-104 (B., D. 
and F.), before immunisation (A. and B.), after immunisation and two antigen boosts 
(C. and D.), and following a further antigen boost (E. and F.). A secondary anti-rabbit- 
AP antibody was used for detection. Key peptides involved in the charaterisation 
process are highlighted in red.
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Figure 4.12. Immunoreactivity of UCL-105 and UCL-106 to the synthetic immunising 
and control peptides. Dot-blot assays were performed using crude serum samples 
obtained from two rabbits (UCL-105 and UCL-106) at different stages of antibody 
production, and the synthetic immunising ((33-S409-P) and control (|33-S383, |33- 
S383-P, (33-S408/S409, |33-S408-P and |33-S408/S409-P) peptides. 'P1 indicates 
'phospho'. Increasing amounts (0, 5, 25, 50 and 100 ng) of each peptide were spotted 
onto PVDF membranes and Western blots were perfomed using a 1:100 dilution of the 
crude serum samples obtained from UCL-105 (A., C. and E.) and UCL-106 (B., D. 
and F.), before immunisation (A. and B.), after immunisation and two antigen boosts 
(C. and D.), and following a further antigen boost (E. and F.). A secondary anti- 
rabbit-AP antibody was used for detection. Key peptides involved in the 
charaterisation process are highlighted in red.
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the absence of peptides or with the control peptides, |33-S408/S409 and |33-S408-P 
(Fig. 4.11E). UCL-104 (test-bleed 2) displayed a similar immunoreactivity profile to 
UCL-104 (test-bleed 1), except that it showed stronger immunoreactivity towards (33- 
S383 (Fig. 4.1 ID and F).
At this stage of the antibody project, the serum from UCL-103 was displaying strong 
immunoreactivity towards the immunising peptide, (33-S383-P. The serum was also 
showing minimal immunoreactivity towards all of the control peptides. This implied 
that the serum contained antibodies with high affinity, site-specificity and phospho- 
specificity for (33-S383-P. However, as it appeared that cross-reactivity to the other 
phospho-peptides was beginning to increase with time, I progressed immediately to 
exsanguination, without the fourth antigen boost. The serum from UCL-104 was also 
displaying strong immunoreactivity towards the immunising peptide, (33-S383-P, but 
was also showing moderate immunoreactivity towards the dephosphorylated 
immunising peptide and slight cross-reactivity towards some of the other control 
phospho-peptides. This implied that the serum contained antibodies with high 
affinity and reasonable site- and phospho-specificity for (33-S383-P. As it appeared 
that cross-reactivity to the (33-S383 peptide was beginning to increase with time, I 
again progressed immediately to exsanguination, without the fourth antigen boost.
I next examined the serum samples obtained from rabbits UCL-105 and UCL-106, 
which had been immunised with the (33-S409-P peptide. As shown in Figure 4.12, 
the pre-immune serum from both UCL-105 (Fig. 4.12A) and UCL-106 (Fig. 4.12B) 
did not display immunoreactivity towards any of the peptides. However, both rabbits 
had developed immunoreactivity towards the immunising peptides following the 
initial inoculation and the first two antigen boosts (Fig. 4.12C and D). UCL-105 
(test-bleed 1) detected as little as 5 ng of the immunising (33-S409-P peptide and the 
P3-S408/S409-P peptide (Fig. 4.12C). Cross-reactivity was also detected with the 
(33-S408/S409 peptides, and weakly with 100 ng of (33-S408-P (Fig. 4.12C). UCL- 
105 (test-bleed 1) did not display any immunoreactivity in the absence of peptide or 
towards the remaining control peptides, |33-S383 and |33-S383-P (Fig. 4.12C). Like 
UCL-105 (test-bleed 1), UCL-106 (test-bleed 1) detected as little as 5 ng of the
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immunising (33-S409-P peptide and the (33-S408/S409-P peptide (Fig. 4.12D). 
Immunoreactive spots were not detected in the absence of peptide, or with any of the 
remaining control peptides, (33-S383, (33-S383-P, (33-S408/S409 and (33-S408-P (Fig. 
4.12D). After the third antigen boost, UCL-105 (test-bleed 2) had a similar 
immunoreactivity profile as UCL-105 (test-bleed 1), except for a stronger 
immunoreactivity towards 25+ ng of (33-S408-P (Fig. 4.12C and E). UCL-106 (test- 
bleed 2) also had a similar immunoreactivity profile to UCL-106 (test-bleed 1), 
except for weak immunoreactivity towards 25+ ng of (33-S408/S409, and stronger 
immunoreactivity towards (33-S409-P than (33-S408/S409-P (Fig. 4.12D and F).
At this stage of the antibody project, the serum from UCL-105 was displaying strong 
immunoreactivity towards the immunising peptide, (33-S409-P. The serum was also 
showing moderate immunoreactivity towards the dephosphorylated (33-S408/S409 
peptide and the di-phosphorylated (33-S408/S409-P peptide. This demonstrated that 
the UCL-105 serum contained antibodies with high affinity but only slight site- and 
phospho-specificity for (33-S409-P. As it appeared that cross-reactivity to (33-S408-P 
was increasing with time, I progressed immediately to exsanguination, without the 
fourth antigen boost. The serum from UCL-106 was also displaying strong 
immunoreactivity towards the immunising peptide, (33-S409-P, but was also showing 
weak immunoreactivity towards 25+ ng of the dephosphorylated |33-S408/S409 
peptide and modest cross-reactivity towards the (33-S408/S409-P peptide. This 
implied that the serum contained antibodies with high affinity and reasonable site- 
and phospho-specificity for (33-S409-P. Although the cross-reactivity towards (33- 
S408/S409-P had been reduced over time, it appeared that cross-reactivity to the 
dephosphorylated |33-S408/S409 peptide was beginning to increase with time. I 
therefore progressed immediately to exsanguination, without the fourth antigen boost.
42.6.3 Antibody Screen II
In the second antibody screen, I tested the affinity, site-specificity and phospho- 
specificity of the affinity-purified polyclonal anti-(33-pS383 and anti-(33-pS409 
antibodies for purified, bacterially expressed GST-(33 fusion proteins that had been 
phosphorylated, in vitro, by purified CaMKII. These included wild type GST-(33, and
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mutant GST-J33 fusion proteins in which various serine residues were replaced with 
alanine residues, namely GST-|33-S383A, GST-|33-S408A, GST-|33-S409A, GST-J33- 
S383A/S409A and GST-|33-S408A/S409A (Table 2.2). I chose the exsanguination 
sera from UCL-103 and UCL-106 as the preferred sera for affmity-purification, based 
on the findings of the first antibody screen (Section 4.2.6.2). Anti-(33-pS383 and anti- 
(33-pS409 antibodies were affinity-purified from the respective sera using protein-A 
columns, and (33-S383-P or (33-S409-P peptide columns (Section 2.5.2; Table 2.6).
I performed in vitro kinase assays essentially as described in Section 4.2.1, except 
that two sets of reactions (one ‘hot’ and one ‘cold’) were run in parallel (Section
2.5.13). The kinase reactions were set up in CaMKII Buffer, with 10 pg each of the 
wild type or mutant GST-(33 fusion proteins, purified CaMKII (a generous gift of 
Paul Greengard) and calmodulin. Before addition of the ATP, 10% (v/v) of each 
assay mix was transferred to a new tube to form a duplicate second set of assays. The 
first set of reactions commenced upon addition of ATP only (‘cold’ reactions), and 
the second set of assays upon addition of ATP and [y-32P]-ATP (‘hot’ reactions). 
Both sets of reactions were incubated in parallel at 30 °C for 15 min. Following 
SDS-PAGE, [32P]-labelled proteins from the second ‘hot’ set of reactions were 
detected by phosphorimaging. For the first ‘cold’ set, 1 pg of the respective GST- 
fusion protein from each of the assays was resolved by SDS-PAGE (one set of GST- 
fusion proteins per antibody) and analysed by Western blotting with the affinity- 
purified anti-(33-pS383 or anti-(33-pS409 antibodies.
As shown in Figure 4.13A, [32P]-labelled protein bands were detected at the predicted 
molecular weight of the wild type and mutant GST-(3 3-fusion proteins (~46 kDa) 
from kinase assays performed with GST-|33, GST-J33-S383A, GST-|33-S408A, GST- 
(33-S409A, and GST-(33-S408A/S409A. [32P]-protein bands were not obtained with 
GST-(33 in the absence of kinase (the mock reaction), with GST-p3-S383A/S409A (in 
which both phosphorylation sites were mutated) or with GST alone (Fig. 4.13A). 
This demonstrated, in addition to the previous findings in Section 4.2.1, that CaMKII 
phosphorylated the GST-(33 fusion proteins at S383 and S409. Furthermore, I was 
confident that the pattern of phosphorylation that was demonstrated in the ‘hot’
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Figure 4.13. The anti-p3-pS409 antibody specifically recognises GST-J33 
phosphorylated at S409. In vitro kinase assays were performed in the presence of 
purified CaMKII and 10 pg each of wild type (WT) GST-(33, GST-|33-S383A, GST- 
|33-S408A, GST-|33-S409A, GST-|33-S383A/S409A, GST-(33-S408A/S409A and GST, 
or in the absence of kinase (mock; with GST-(33) for 15 min at 30 °C. Before addition 
of the ATP mix, the reaction mixes were divided into two. A. The first set of assays 
were performed in the presence of ATP and [y-32P]-ATP. After resolving the proteins 
by SDS-PAGE, [32P]-GST-fusion proteins were detected by phosphorimaging. B. and 
C. The second set of assays were performed in parallel to those in A.' in the presence 
of ATP. After resolving a fraction of the assay (1 pg of each GST-fusion protein) by 
SDS-PAGE, the proteins were probed with the affinity-purified anti-|33-pS409 
antibody (B.) or anti-|33-pS383 antibody (C.), and an [125I]-anti-rabbit antibody.
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assays was representative of the phosphorylation that occurred in the ‘cold’ assays, 
because the ‘hot’ and ‘cold’ sets of reactions had been both prepared and performed 
in parallel. I therefore continued with analysis of the ‘cold’ GST-fusion proteins.
As shown in Figure 4.13B and C, I detected immunoreactive bands with the anti-(33- 
pS409 antibody (Fig. 4.13B), but not with the anti-(33-pS383 antibody (Fig. 4.13C). I 
obtained a single anti-|33-pS409 band at the predicted molecular weight of the GST- 
133 fusion proteins (~46 kDa) from assays performed with wild type GST-(33, GST- 
(33-S383A and GST-J33-S408A, all of which contained phosphorylated S409 residues 
(Fig. 4.13A and B). I did not obtain an immunoreactive band with GST-(33 in the 
absence of kinase, or with GST-|33-S409A, GST-(33-S383A/S409A, GST-(33- 
S408A/S409A or GST alone (Fig. 4.13B). The S409 phosphorylation site was not 
available for phosphorylation in any of these assays (Fig. 4.13A). These data 
demonstrated that the anti-(33-pS383 antibody did not detect GST-|33 fusion proteins 
that were phosphorylated on S383, or indeed any of the other GST-(33 fusion proteins 
that were tested. These results also showed that the anti-|33-pS409 antibody had 
affinity towards GST-(33 fusion proteins that were phosphorylated on S409, and that 
the antibody was site-specific and phospho-specific with respect to the S383, S408 
and S409 residues. This suggested that I had successfully raised a phosphorylation 
state-specific antibody that recognises phospho-S409 within the (denatured) major 
intracellular domain of the GABAa receptor (33 subunit in Western blots. The 
phosphorylation state-specific anti-(33-pS409 antibody was therefore suitable for 
further use.
4.2.7 Analysis of GABAa Receptor Phosphorylation in Cultured Immature 
Cortical Neurons using Phosphorylation State-Specific Antibodies
I have previously demonstrated agonist-induced KN93-sensitive phosphorylation of 
GABAa receptor (33 subunits in cultured immature cortical neurons (Fig. 4.10). To 
examine this further, I used phosphorylation state-specific antibodies to analyse the 
phosphorylation of specific sites within the (33 subunits following agonist treatment. 
Primary cultures of cortical neurons (E17; 6DIV) were incubated for 5 min at 37 °C 
in the absence or presence of muscimol (50 pM), with or without KN93 (4 pM; added
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20 min prior to treatment) (in HBS). Following the treatments, the neurons were 
lysed under denaturing conditions. Equal amounts of protein (250 pg) were then 
resolved by SDS-PAGE, and probed in a Western blot with an anti-(33 subunit 
antibody, or the affinity-purified anti-(3 3-pS409 or anti-(3 3-pS408/S409 
phosphorylation state-specific antibodies (Table 2.6).
As shown in Figure 4.14, an immunoreactive band was detected at the predicted 
molecular weight of the (33 subunit (58 kDa) from control and treated neurons with 
the anti-(33 subunit antibody and the anti-(33-pS408/S409 antibody. The band 
obtained with the anti-|33-pS408/S409 antibody was stronger in the muscimol-treated 
lane than in the untreated control lane, and this signal enhancement appeared to be at 
least partially blocked by KN93 (Fig. 4.14). However, I did not detect a 58-kDa 
immunoreactive band from control or treated neurons with the anti-(33-pS409 
antibody (Fig. 4.14). These results demonstrated that in cultured immature cortical 
neurons, the GABAa receptor (33 subunit was basally phosphorylated at both S408 
and S409, and that this phosphorylation was increased following muscimol treatment. 
As this enhancement appeared to be at least partially sensitive to KN93, it is possible 
that it was partly dependent on CaMKII. These data also demonstrated that the 
GABAa receptor (33 subunit was not phosphorylated to a detectable level at the single 
S409 site under basal conditions or following treatment with muscimol. These results 
suggested that muscimol-induced CaMKII-dependent phosphorylation of the GABAa 
receptor (33 subunit in cultured immature cortical neurons (Fig. 4.10) does not occur 
at S409 alone, and that it instead involves phosphorylation of other residues, such as 
both S408 and S409.
4.3 Discussion
Protein phosphorylation is a major mechanism for modulating GABAa receptor 
function and the efficacy of inhibitory synaptic transmission (Moss and Smart, 2001; 
Section 1.7). Although CaMKII has been shown to physically interact with GABAa 
receptors, and to phosphorylate the major intracellular domains of receptor subunits, 
in vitro, it remains to be determined whether GABAa receptors are substrates of 
CaMKII in neurons. In this study, I investigated various aspects of GABAa receptor
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Figure 4.14. Analysis of agonist-induced phosphorylation of the GABAa  receptor 
(33 subunit in immature cortical neurons. Primary cultures of cortical neurons (E17; 
6DIV) were incubated in the absence (-) or presence (+) of muscimol (50 pM) with 
(+) or without (-) KN93 (4 pM; 20 min pre-incubation) for 5 min at 37 °C. Neurons 
were lysed under denaturing conditions, and equal amounts of protein (250 pg) were 
resolved by SDS-PAGE. Proteins were then probed with a polyclonal anti-(33 subunit 
antibody, or a phosphorylation state-specific antibody that recognises the GABAa 
receptor (33 subunit phosphorylated at S409 (anti-(33-pS409), or S408 and S409 (anti- 
(33-pS408/S409), and an [125I]-anti-rabbit antibody.
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phosphorylation by CaMKII, with the aim of further understanding the cellular 
mechanisms that control the phosphorylation state of these receptors. This study has 
provided evidence to suggest that CaMKII selectively phosphorylates the GABAa 
receptor (3 and y subunits, in vitro, and that the yl and y3 subunits are novel in vitro 
substrates of CaMKII. Furthermore, that PP1, PP2A and PP2C, but not PP2B, 
dephosphorylate the (33 subunit at the CaMKII sites, in vitro. The results from this 
study have also demonstrated that depolarisation of cultured immature cortical 
neurons increases the level of enzymatically active CaMKII that associates with the 
major intracellular domain of the GABAa receptor (33 subunit, and triggers CaMKII- 
dependent phosphorylation of the (33 subunit, but not the y2 subunit, in situ. I 
propose that CaMKII-dependent phosphorylation of GABAa receptors is a major 
mechanism for modulating inhibitory neurotransmission and neuronal excitability.
The finding that CaMKII selectively phosphorylates the major intracellular domains 
of GABAa receptor (31-3 and yl-3 subunits, but not a l  or 6 subunits, in vitro, is 
consistent with previous studies showing that the major intracellular domains of the (3 
and y2 subunits are in vitro substrates of CaMKII (McDonald and Moss, 1994, 1997). 
However, the finding that CaMKII did not phosphorylate the major intracellular 
domain of the a l  subunit, in vitro, is in contrast to a previous study that demonstrates 
CaMKII-dependent phosphorylation of the a l  subunit in a synaptosomal membrane 
fraction (Chum et al., 2002). This difference may be explained by the presence of an 
unidentified GABAa receptor kinase downstream of CaMKII in the synaptosomal 
membrane fraction. Alternatively, it is possible that CaMKII is able to phosphorylate 
the a l  subunit when it is co-assembled with other subunits in a receptor complex in 
its full-length native state. Further studies are required to investigate whether the 
other a  subunits, a2-6, are substrates of CaMKII, and to identify the sites of 
phosphorylation in the novel subunit substrates, yl and y3. Nevertheless, these in 
vitro findings suggest that CaMKII holoenzymes may selectively phosphorylate the 
major intracellular domains of GABAa receptor (3 and y subunits in neurons. This 
selectivity could provide a potential mechanism for CaMKII to differentially regulate 
distinct GABAa receptor populations. Although, as the results of in vitro experiments 
do not always agree with the findings of experiments performed in situ, in neurons or
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heterologous cells, these results can only be used as a guide to cellular 
phosphorylation events (Moss et al., 1992a,b; McDonald and Moss, 1997; McDonald 
et al., 1998; Krishek et al., 1994; Brandon et al., 2000, 2003; Section 1.7.2; Table 
1.1). In Chapter 3, I found that native CaMKII bound to the major intracellular 
domains of GABAa receptor a l ,  pi-3, yl-3 and 6 subunits. This suggests that the 
selectivity of subunit phosphorylation observed in vitro is due to the recognition of 
particular consensus phosphorylation motifs, rather than the differential binding of 
CaMKII. However, in intact cells, binding may be a prerequisite of phosphorylation, 
and may control accessibility of the kinase to the phosphorylation sites.
My results confirmed previous studies showing that CaMKII phosphorylates the 
major intracellular domain of the |33 subunit at S383 (RKQSMPK) and S409 
(RRRSSQLK) (McDonald and Moss, 1997). The sequences preceding each of these 
sites conform with the consensus phosphorylation motif for CaMKII, Rxx(S/T) 
(where x is equivalent to any amino acid) (Kennelly and Krebs, 1991). However, 
consensus motifs can only predict the actual sites of protein phosphorylation. For 
example, I (this study), and others (McDonald and Moss, 1997), did not detect 
phosphorylation of the (33 subunit at S408, which forms part of a consensus CaMKII 
phosphorylation motif. Similarly, the identification of these in vitro phosphorylation 
sites can only serve as a guide to the sites that may be phosphorylated by CaMKII in 
neurons. S383 is conserved in the p i and |33 subunits, but not the (32 subunit. In 
contrast, S409 is conserved in all three (3 subunits. If both of these residues are 
CaMKII substrates in neurons, then the different patterns of subunit conservation may 
provide a mechanism for CaMKII to differentially phosphorylate (and regulate) 
distinct populations of GABAa receptors.
My analysis of the phosphorylation of GST-J33 by purified CaMKII revealed a 
maximum stoichiometry of phosphorylation of ~0.22 mol. phosphate mol. protein"1. 
This compared well with the value previously obtained (0.4 mol. phosphate mol. 
protein'1), which could not be enhanced by increasing enzyme concentration or assay 
duration (McDonald and Moss, 1997). The knowledge that these assay conditions 
supported a good stoichiometry of phosphorylation provided a control for the
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preparative phosphorylation of the GST-(33 fusion proteins for the phosphatase 
assays.
The finding that PP1, PP2A and PP2C, but not PP2B, each dephosphorylate the major 
intracellular domain of the GABAa receptor p3 subunit at S383 and S409, in vitro, 
has important implications for the dephosphorylation of GABAa receptors in vivo. 
However, as with the in vitro kinase assays, further studies are required to determine 
whether these findings are biologically significant in cells. Nevertheless, my findings 
are consistent with previous studies showing dephosphorylation of the major 
intracellular domain of the GABAa receptor (3 3 subunit, which has been 
phosphorylated by PKA at S409 (McDonald and Moss, 1997), by PP1 and PP2A, but 
not PP2B (Terunuma et ah, 2004). Previous studies have also demonstrated that PP1, 
PP2A and PP2B associate with neuronal GABAa receptor complexes (Terunuma et 
al., 2004; Jovanovic et al., 2004; Wang et al., 2003a; Section 1.7.2.2). It will 
therefore be of interest to confirm my findings in situ using phosphorylation state- 
specific antibodies or pre-labelling assays, and activators/inhibitors of the individual 
phosphatases. The investigation of PP2B will be of particular interest, because like 
CaMKII, this enzyme is activated by intracellular changes in the levels of calcium 
and CaM (Cohen, 1989).
The results of the ‘pull-down’-kinase experiments suggested that depolarisation of 
cultured immature cortical neurons by KC1 triggers an increase in the level of 
enzymatically active CaMKII that binds to GST-p3. Previous studies have shown 
that KC1 triggers depolarisation of cultured immature neurons, calcium influx and 
phosphorylation of CaMKII (Borodinsky et al., 2002, 2003). In Chapter 3 of this 
thesis, I found that only a constitutively active form of recombinant CaMKIIa, 
CaMKIIa-T286D, which mimics T286-autophosphorylation, bound to GST-p3 to a 
detectable level (Section 3.2.3). It is therefore possible that the endogenous T286- 
phosphorylated CaMKII also has a much greater binding affinity for GST-(33 than the 
non-T286-phosphorylated CaMKII. If so, then increasing the neuronal pool of the 
phosphorylated kinase (by KC1 treatment) could enhance the level of enzymatically 
active CaMKII (and the total level of CaMKII) that binds to GST-(33. However, I
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cannot exclude the possibility that the endogenous T286-phosphorylated and non- 
T286-phosphorylated forms of CaMKII have equivalent binding affinity for GST-(33, 
and that increasing the neuronal pool of phosphorylated CaMKIIa-T286 simply 
increases the probability of the phosphorylated, rather than the non-phosphorylated 
kinase from binding to GST-|33 (and that the total level of CaMKII that binds remains 
unchanged). Nevertheless, these results suggest that depolarisation of neurons and 
stimulation of CaMKIIa-T286 autophosphorylation could enhance GABAa receptor- 
associated CaMKII activity. However, further experiments are required to determine 
whether the targeting of CaMKII to GABAa receptors in neurons requires 
autophosphorylation.
It is important to note that a previous study has shown that CaMKII does not bind and 
phosphorylate GST-|31 (Brandon et al., 1999). Like GST-^3, GST-(31 is an in vitro 
substrate of purified CaMKII (McDonald and Moss, 1994), and a binding partner of 
CaMKII from brain (Section 3.2.1). It is perhaps surprising therefore, that CaMKII 
binds and phosphorylates GST-(33, but not GST-|31. A possible explanation for this 
apparent discrepancy is that CaMKII does bind and phosphorylate GST-(31 but that 
this effect was not detected in the previous study (Brandon et al., 1999). This is 
because the lack of associated CaMKII activity was inferred from the finding that the 
CaMKII inhibitor, W7, did not reduce GST-P1 -associated kinase activity (Brandon et 
al., 1999). Notably, W7 is a CaM antagonist (Roufogalis et al., 1983). As W7 was 
added to the in vitro kinase assay after binding had occurred, and as CaMKII gains 
autonomous activity following T286-phosphorylation and removal of calcium and 
CaM (Section 1.8), then any CaMKII that bound to GST-pl in the T286- 
phosphorylated state would be unlikely to be inhibited by W7. Given the finding that 
recombinant CaMKII only binds to receptor |3 subunits in the T286-phosphorylated 
state, this suggests that W7 may not cause a noticeable reduction in GST-(31- 
associated CaMKII activity. In my assays, I avoided this problem by pre-treating live 
cultured neurons with the CaMKII inhibitor, KN93 (which also competes with 
calmodulin), so that when the neurons were subsequently depolarised, any T286- 
autophosphorylation and hence CaMKII activation would be prevented or reduced. 
Although KN93 prevented a significant KC1-induced increase in GST-(33-associated
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kinase activity, it is important to note that this inhibitor did not completely block the 
effect of KC1 (the phosphorylation in assays using neurons co-treated with KC1 and 
KN93 was not significantly different to those treated with KC1 alone). It is possible 
that increasing the n numbers would reveal a significant difference. However, KC1- 
induced depolarisation may be enhancing the affinity of an additional kinase for GST- 
p3 (or decreasing the affinity of a phosphatase), which is insensitive to KN93. 
Hence, blocking CaMKII activation would only partially inhibit the KCl-induced 
increase in phosphorylation of GST-(33.
My studies demonstrated that in cultured immature cortical neurons, basal 
phosphorylation of CaMKII at T286 is reduced by BAPTA-AM and KN93, and 
therefore sensitive to changes in the concentration of calcium and CaM, and the 
ability of CaMKII to autophosphorylate. However, the results also showed that the 
total level of CaMKIIa protein is reduced following treatment with BAPTA-AM. 
This decrease may have caused, or contributed to the reduction in T286- 
phosphorylation of CaMKII that was detected following BAPTA-AM treatment. It is 
possible that with higher n numbers, the effect of BAPTA-AM on total levels of 
CaMKIIa will no longer be significant. However, it is also possible that calcium is 
required to maintain cellular levels of CaMKIIa protein. Indeed, it is tempting to 
speculate that this potential calcium-dependent process involves dendritic protein 
synthesis, as CaMKIIa mRNA has been localised to dendrites (Burgin et al., 1990; 
Paradies and Steward, 1997), and as local translation of CaMKIIa mRNA has been 
shown to be essential for maintaining the total level of CaMKIIa protein in neurons, 
and at PSDs (Miller et al., 2002).
Further investigations in cultured immature cortical neurons, revealed that stimulation 
of GABAa receptors leads to an increase in CaMKIIa phosphorylation at T286, 
which is blocked by KN93 and BAPTA-AM. As muscimol did not alter the total 
level of CaMKIIa protein, this suggested that activation of GABAa receptors triggers 
calcium/CaM-dependent autophosphorylation of CaMKIIa at T286. This is 
consistent with the finding that activation of GABAa receptors induces depolarisation 
and an increase in intracellular calcium concentration in cultured immature cortical
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neurons under similar experimental conditions (J.N. Jovanovic, unpublished data). It 
is also consistent with studies in cultured immature cerebellar granule cells showing 
that activation of GABAa receptors triggers an increase in intracellular calcium 
concentration via L-type voltage-gated calcium channels, and an enhancement in 
phosphorylation of CaMKII (Borodinsky et al., 2003). A GABAa receptor-mediated 
rise in intracellular calcium concentration has also been shown to occur in slices of 
developing neocortex (Yuste and Katz, 1991; Owens et al., 1996). I also found that 
the muscimol-induced increase in CaMKII phosphorylation lasted for only 15 
minutes (even when muscimol was applied for up to 30 and 60 minutes). The 
duration of this effect may be dependent upon the action of protein phosphatases on 
CaMKII and/or rapid sustained buffering of calcium. Alternatively, the effect of 
muscimol on T286-phosphorylation at later time points (30 and 60 minutes) may have 
been obscured by the phosphorylation of CaMKII at T286 that occurred under control 
conditions, or limited by GABAa receptor desensitisation.
I detected a small (10 to 15%) muscimol-induced increase in phosphorylation of PKC 
at S660 in immature cultured cortical neurons. This suggested that activation of 
GABAa receptors triggers a small increase in PKC activity. However, the increase in 
PKC activity induced by muscimol in this study was much lower than that observed 
following treatment of cultured cortical neurons with BDNF (Jovanovic et al., 2004). 
Further investigations will therefore be important in determining whether there is any 
functional relevance of this apparent increase in activity. It is possible that the level 
of PKC phosphorylation detected is underestimated. This is because the experiments 
were performed with a phosphorylation state-specific antibody that recognises 
multiple PKC isoforms (a, pi, (311, 6, e, r\ and 0), only some of which (a and |3) are 
calcium-dependent (Tanaka and Nishizuka, 1994; Song and Messing, 2005). It would 
therefore be desirable to conduct further experiments utilising antibodies that 
recognise specific PKC isoforms phosphorylated at S660. The accuracy of the results 
from these assays, as well as from those investigating basal and muscimol-induced 
phosphorylation of CaMKII at T286, could perhaps be improved by generating data 
that enables the calculation of a ratio of phosphorylated kinase to the total kinase for 
each treatment. However, the disadvantage of this alternative calculation is that
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changes in either phosphorylation or total protein levels would not be apparent. 
Further experiments could also be performed to increase the statistical confidence of 
the results, as only small changes in phosphorylation were detected, which may have 
been a result of investigating a heterogenous population of cells.
My studies demonstrated muscimol-induced CaMKII-dependent phosphorylation of 
GABAa receptor (33 subunits, but not y2 subunits, in situ in cultured immature 
cortical neurons. This is consistent with a number of findings in this thesis. Firstly, 
that CaMKII forms a native complex with GABAa receptor (33 subunits in brain. 
Secondly, that KCl-induced depolarisation of immature cortical neurons increases the 
level of enzymatically active CaMKII that binds to the major intracellular domain of 
the (33 subunit, and finally, that treatment of immature cortical neurons with 
muscimol triggers autophosphorylation of CaMKII at T286. My results are also 
consistent with a previous study showing that the GABAa receptor (33 subunit is 
phosphorylated in situ in cultured cortical neurons under basal conditions (Brandon et 
al., 2000; Jovanovic et al., 2004). The finding that CaMKII does not contribute to 
this basal phosphorylation (Brandon et al., 2000) further supports the hypothesis that 
CaMKII-dependent phosphorylation of GABAa receptors relies upon 
autophosphorylation-dependent targeting of the kinase to receptor complexes. 
Although I detected basal phosphorylation of CaMKII at T286 in these primary 
cultures, this measurement represented the total neuronal pool of CaMKII, and so the 
level of activated CaMKII at cell-surface GABAa receptors under basal conditions 
may still be undetectable or low. These data collectively support the view that in 
immature cortical neurons, where GABA is excitatory, CaMKII is a component of a 
GABAa receptor feedback loop, in which activation of GABAa receptors leads to 
depolarisation and autophosphorylation of CaMKII, binding of activated CaMKII to 
GABAa receptors and receptor subunit phosphorylation. Notably, these results do not 
provide conclusive evidence that CaMKII directly phosphorylates the (33 subunit in 
neurons. Indeed, CaMKII may be positioned upstream of another, possibly unknown 
kinase. It is also possible that CaMKII-dependent phosphorylation of GABAa 
receptors is not dependent upon activation of a calcium-dependent signalling 
pathway. Indeed, the binding of agonist may induce a conformational change of the
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receptor that modifies the relative binding and activity of various protein kinases and 
phosphatases, including enzymatically active CaMKII.
In this study, I did not detect either basal or muscimol-induced phosphorylation of the 
GABAa receptor y2 subunit in situ in cultured cortical neurons. This is consistent 
with a previous study showing that the GABAa receptor y2 subunit is not 
phosphorylated in situ in cultured cortical neurons under basal conditions or 
following treatment with BDNF (Jovanovic et al., 2004). As CaMKII has been 
shown to phosphorylate the y2 subunit at multiple sites in vitro (McDonald and Moss, 
1994), the findings in this study may further exemplify how kinase substrates can 
differ between experiments performed in vitro and in situ. However, it is possible 
that CaMKII-dependent phosphorylation of y2 subunits occurs under specific 
conditions that involve co-activation of other intracellular signalling pathways. 
Indeed, phosphorylation of the y2 subunit on tyrosine residues has only been detected 
in cultured cortical neurons following inhibition of tyrosine phosphatase activity 
(Brandon et al., 2001). Further studies investigating the phosphorylation of specific 
y2 subunit sites in response to activation of distinct intracellular signalling pathways 
will therefore be of interest.
In this study, I attempted to raise polyclonal phosphorylation state-specific antibodies 
that recognise GABAa receptor (33 subunits phosphorylated at S383, and at S409, to 
further investigate CaMKII-dependent phosphorylation of (33 subunits in situ in 
cultured immature cortical neurons. The anti-(33-pS383 and anti-(33-pS409 antibodies 
each recognised their respective peptide immunogen with high affinity, site- 
specificity and phospho-specificity. However, in the second antibody screen, only 
anti-(33-pS409 was able to recognise phosphorylated GST-(33 fusion proteins, which 
contain the full-length sequence of the major intracellular domain of the (33 subunit. 
Anti-(33-pS383 was therefore not suitable for further application. Further attempts to 
raise such an antibody may involve using a different length and/or sequence of 
immunising synthetic peptide (Czemik et al., 1997). However, this aspect of the 
design process is somewhat limited by the amino acid sequence surrounding the 
phosphorylation site of interest. For example, the immunising peptides for the anti-
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(33-pS409 and anti-|33-pS408/409 antibodies contain a greater number of basic amino 
acids (lysine, arginine and histidine) than the peptide for the anti-|33-pS383 antibody 
(Table 2.4), residues that are believed to increase the antigenicity of a synthetic 
peptide (Czemik et al., 1997). Further attempts could also involve coupling the 
peptide to the carrier protein by introducing the cysteine residue at the C-terminus 
rather than the N-terminus of the peptide. However, increasing the distance of the 
phosphorylated residue from the free end of the peptide can have an undesirable 
effect on antigenicity (Czemik et al., 1997). Although immunisation of a greater 
number of rabbits may increase the likelihood of raising a phosphorylation state- 
specific antibody, it is worth noting the general difficulty the Moss laboratory has 
encountered in raising phosphorylation state-specific antibodies that recognise 
GABAa receptor subunits that are phosphorylated at a single residue.
I found that the anti-(33-pS409 antibody recognised the full-length major intracellular 
domain of the GABAa receptor (33 subunit when it was phosphorylated at S409, and 
that the antibody exhibited good affinity, site-specificity and phospho-specificity. 
However, I did not detect a signal with the anti-(33-pS409 antibody when I probed 
native |33 subunits from cortical neuronal lysates that had been untreated or 
depolarised with muscimol. This suggested that S409 alone is not phosphorylated 
under basal conditions or following muscimol-induced depolarisation (within 5 min). 
This is consistent with the finding that GABAa receptor (33 subunits are 
phosphorylated at S408 and S409 in cultured cortical neurons under basal conditions 
(Brandon et al., 2000), and following muscimol-induced depolarisation (this study), 
and the results of the first antibody screen, which demonstrated that the anti-(33- 
pS409 antibody (UCL-106) had much greater affinity for the synthetic immunising 
peptide phosphorylated at S409, than that phosphorylated at both S408 and S409. 
Although further studies are required to show such phospho-specificity with the full- 
length protein, these findings suggest that the presence of a phosphate group at S408 
of the native (33 subunit may occlude detection of phosphorylation at S409 by anti- 
(33-pS409. Hence, a signal will only be detected with the anti-(33-pS409 antibody 
when S409 is phosphorylated and S408 is not. Another possible explanation for my 
findings is that other modifications of native (33 subunits prevent the anti-(33-pS409
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antibody from recognising a lone phosphorylated S409 residue. I therefore cannot 
completely exclude the possibility that S409 alone is phosphorylated in cortical 
neurons under basal conditions and/or following muscimol-induced depolarisation. It 
is also possible that the affinity of the anti-(33-pS409 antibody for the native (33- 
pS409 subunit is too low, and/or that there is an insufficient level of |33-pS409 
subunits in cortical neurons to be detected by this antibody.
In this study, I demonstrated that muscimol-induced depolarisation of cultured 
immature cortical neurons leads to enhanced phosphorylation of S408 and S409, but 
not S409 alone. This finding was based on the results of experiments using a 
phosphorylation state-specific antibody that recognises GABAa receptor (33 subunits 
phosphorylated at S408 and S409, anti-pS408/S409 (Jovanovic et al., 2004). As 
muscimol-induced depolarisation was also shown to trigger autophosphorylation and 
activation of CaMKII, it is possible that activation of CaMKII leads to 
phosphorylation of S408 (which is not an in vitro CaMKII site) and S409. As 
discussed previously, it is known that differences exist between in vitro and in situ 
systems. These differences may arise because of altered accessibility of a kinase to 
the consensus phosphorylation site in the full-length native protein. As shown with 
PKA (Section 1.7.2.1.2), this may be a result of interactions that occur between 
GABAa receptor subunits and a kinase or kinase-associated protein. It is also 
possible that CaMKII is upstream of another kinase that phosphorylates S408 and 
S409. However, as muscimol-induced phosphorylation of S408 and S409 does not 
appear to be abolished by KN93, then some level of phosphorylation may occur 
following direct activation of an alternative kinase (or inhibition of a phosphatase). 
Alternatively, an agonist-induced conformational change of the receptor may lead to 
altered phosphorylation of these sites (as discussed above). However, it is important 
to note that the anti-pS408/S409 antibody has never been screened against the wild 
type full-length GABAa receptor (33 subunit (|33 subunit that has not been subjected 
to site-directed mutagenesis) that has been phosphorylated solely on S383 or S409. 
This antibody may therefore be cross-reacting with native (33 subunits that are 
phosphorylated at either or both of these sites.
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The change in S408/S409 phosphorylation that occurs in cortical neurons following 
muscimol-induced depolarisation may only account for a fraction of the total (33 
subunit phosphorylation I observed in situ. It appears unlikely that the S409 residue 
is phosphorylated alone, but it is possible that the S383 residue (the other in vitro 
CaMKII site in the (33 subunit (McDonald and Moss, 1994, 1997)) is a site of 
CaMKII-dependent activity. Indeed, experiments involving pre-labelling of NG108- 
15 cells (that have been transfected with CaMKII) with [32P]-orthophosphate have 
shown that KCl-induced depolarisation leads to phosphorylation of the GABAa 
receptor (33 subunit predominantly at S383 (C.M. Houston, unpublished data). 
Further attempts to raise a phosphorylation state-specific antibody that recognises the 
(33 subunit phosphorylated at S383 may therefore provide a valuable tool for further 
investigation of CaMKII-dependent phosphorylation of GABAa receptors in neurons.
4.4 Conclusions
Overall, I conclude that CaMKII selectively phosphorylates the GABAa receptor 
(31-3 and v l-3  subunits, but not the a l  or 6 subunits, in vitro. Furthermore, I have 
found that the (33 subunit is dephosphorylated at the CaMKII sites by PP1, PP2A and 
PP2C, but not PP2B, in vitro. Depolarisation of cultured immature cortical neurons 
was found to enhance the level of enzymatically active CaMKII that binds to the 
major intracellular domain of the GABAa receptor (33 subunit, and to cause CaMKII- 
dependent phosphorylation of the (33 subunit, but not the y2 subunit, in situ. 
Experiments using phosphorylation state-specific antibodies further suggest that the 
(33 subunit is not phosphorylated at S409, and that some phosphorylation occurs at 
both S408 and S409. CaMKII-dependent phosphorylation of GABAa receptors may 
therefore play a major role in regulating the activity of GABAa receptors in brain, and 
therefore have significant consequences for the efficacy of inhibitory synaptic 
transmission and neuronal excitability.
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5.1 Background
The membrane stability and functional properties of synaptic GABAa receptors are 
critical determinants of the efficacy of central inhibitory synapses. Several studies 
have demonstrated that synaptic strength is directly related to the number of 
postsynaptic GABAa receptors, and that modulation of cellular processes that insert 
or remove GABAa receptors into or from the neuronal membrane can control 
synaptic efficacy. For example, variability in the amplitude of miniature inhibitory 
postsynaptic currents (mIPSCs) in cerebellar stellate cells has been attributed to 
differences in the number of postsynaptic GABAa receptors (Nusser et al., 1997). 
Following kindling-induced epilepsy, potentiation of postsynaptic responses in 
granule cells of the dentate gyrus is caused by an increase in the number of synaptic 
GABAa receptors (Otis et al., 1994; Nusser et al., 1998b). Similarly, treatment of 
cultured neurons with insulin leads to a rapid enhancement in the number of 
postsynaptic GABAa receptors and the amplitude of mIPSCs (Wan et al., 1997b; 
Wang et al., 2003b). Conversely, treatment of cultured hippocampal neurons with 
BDNF triggers a reduction in the amplitude of mIPSCs (Brunig et al., 2001; 
Jovanovic et al., 2004), and this is accompanied by a decrease in postsynaptic 
GABAa receptor immunoreactivity (Brunig et al., 2001). A number of mechanisms 
may contribute to such changes in the number of postsynaptic GABAa receptors. 
These include increased or decreased rates of GABAa receptor endocytosis, 
membrane insertion and/or degradation, and an alteration in the distribution of 
receptors on the cell surface. Understanding the molecular mechanisms that are 
involved in these processes is therefore fundamental to our understanding of 
GABAergic neurotransmission and plasticity at inhibitory synapses.
Clathrin-mediated endocytosis is a major mechanism by which many neuronal 
receptors are internalised from the neuronal surface to intracellular compartments 
(Chu et al., 1997; Carroll et al., 1999; Man et al., 2000; Pitcher et al., 1998). This 
process (reviewed in Mousavi et al., 2004) begins with the assembly of a clathrin coat 
on the cytoplasmic side of the membrane (reviewed in Brodsky et al., 2001). This 
comprises the coat protein clathrin, a member of the family of clathrin adaptor 
proteins (Hirst and Robinson, 1998), usually the adaptor-binding protein 2 (AP2), and
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several clathrin/endocytic accessory factors, such as amphiphysin and AP180 (Fig.
5.1 A; reviewed in Slepnev and De Camilli, 2000 and Traub, 2003). The adaptor 
proteins selectively bind membrane cargo proteins and lipids, and recruit clathrin and 
the other coat components to the neuronal surface. All binding is highly co-operative, 
and leads to formation of a clathrin polyhedral lattice, which induces deep 
invagination of the membrane and production of a clathrin-coated pit (Brodsky et a l, 
2001; Slepnev and De Camilli, 2000; Rappoport et al., 2004). The coated pit then 
undergoes dynamin-dependent scission to generate a free clathrin-coated vesicle 
(Brodsky et al., 2001). This transient structure is immediately uncoated to enable 
fusion with an early/sorting endosome (reviewed in Mellman, 1996, and Hirst and 
Robinson, 1998). At this juncture, the internalised receptors are directed to various 
cellular destinations: they may be sequestered in endosomes, targeted for degradation 
or recycled to the plasma membrane, in parallel with delivery of receptors from the de 
novo synthetic pathway (Mellman, 1996).
GABAa receptors undergo constitutive and agonist-dependent internalisation (Kittler 
et al., 2000a, 2005; Connolly et al., 1999a,b; Herring et al., 2003, 2005; Calkin and 
Barnes, 1994; Calkin et al., 1994; Tehrani and Barnes, 1991). Several lines of 
evidence suggest that GABAa receptors are removed from the neuron surface to 
intracellular compartments via a clathrin-mediated, dynamin-dependent endocytic 
pathway (Kittler et al., 2000a, 2005; see also Connolly et al., 1999b and Herring et 
al., 2003). For example, a number of studies have shown that GABAa receptors are 
co-purified with clathrin-coated vesicles from brain (Tehrani and Barnes, 1993; 
Tehrani et al., 1997; Kumar et al., 2003; Tehrani and Barnes, 1997). Furthermore, 
peptide blockade of the interaction between amphiphysin and dynamin leads to 
inhibition of GABAa receptor endocytosis in primary cultures of hippocampal 
neurons. This causes an increase in the amplitude of mIPSCs, which has been 
attributed to a corresponding increase in the number of postsynaptic GABAa 
receptors (Kittler et al., 2000a, 2005).
The AP2 adaptor plays a pivotal role in clathrin-mediated endocytosis. AP2 is a 
stable heterotetrameric complex that consists of two large (~100 kDa) adaptins, a  and
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Figure 5.1. Schematic representation of the domain structure of AP2 and the p2- 
adaptin. A. Schematic diagram of the heterotetrameric AP2 complex that comprises 2 
large (~100 kDa) adaptins, a  and |32, 1 medium (50 kDa) adaptin, p2, and a small (19 
kDa) adaptin, o2. The core region and the flexible linkers to the a  and |32 appendages 
are indicated. The core region mediates multiple interactions with membrane proteins 
and lipids to anchor AP2 to the membrane and for cargo recognition. Clathrin binds to 
the appendage and flexible linker of (32-adaptin. The a  and (32 appendages each bind 
several endocytic accessory proteins. Some examples o f these are shown in yellow. B. 
Schematic diagram of the p2-adaptin. Domains A (green) and B (blue) are comprised 
largely o f (3 structures. Residues 102-125 (grey line) are implicated in binding leucine- 
based motifs ([DE]xxxL[LI]). Residues 283-394 (blue line) of domain B contain a 
region for binding basic-rich motifs. Residues 408-435 (green line) of domain A 
contain a critical region for binding a classical tyrosine motif (Y xx0).
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|32, a medium-sized (50 kDa) adaptin, p2, and a small (19 kDa) adaptin, a 2 (Fig. 
5.1A; Hirst and Robinson, 1998; Collins et a l ,  2002). The globular carboxyl- 
terminal regions of the a -  and (32-adaptins form small appendages, which are each 
separated from the AP2 core by a proteolytically sensitive flexible linker (Fig. 5.1A; 
Collins et al., 2002; Owen et al., 2004; Kirchhausen et al., 1989; Zaremba and Keen, 
1985). The core region of AP2 forms multiple interactions with membrane proteins 
and lipids to recruit AP2 to the plasma membrane and for cargo recognition (Fig. 
5.1A; Gaidarov and Keen, 1999; Chang et al., 1993; Ohno et al., 1995; Owen and 
Evans, 1998; Rapoport et al., 1997; Rapoport et al., 1998; Rodionov and Bakke, 
1998). For example, the amino-terminus of the a-adaptin binds synaptotagmin 
(Haucke and De Camilli, 1999), PIP2 and PIP3 (Gaidarov et al., 1996; Gaidarov and 
Keen, 1999), and the p2-adaptin interacts with transmembrane cargo proteins (Ohno 
et al., 1995; Owen and Evans, 1998; Rodionov and Bakke, 1998; Owen et al., 2004) 
and PIP2 (Rohde et al., 2002). The a  and (32 appendages each bind several endocytic 
accessory factors, some of which are common to both of them (Fig. 5.1A). The a  and 
(32 appendages both bind AP180, EPS 15 and epsin 1 (Slepnev and De Camilli, 2000). 
The a  appendage also interacts with amphiphysin (Slepnev et al., 2000), and the (32 
appendage with clathrin (Owen et al, 2000; Slepnev and De Camilli, 2000). A 
clathrin-binding sequence is also present in the (32 flexible linker (Owen et al, 2000).
Interestingly, GABAa receptors have been shown to form native complexes with AP2 
and clathrin in brain (Kittler et al., 2000a; Kumar et al., 2003), and to co-localise with 
AP2 in primary cultures of hippocampal neurons (Kittler et al., 2000a). The 
interaction between GABAa receptors and AP2 is mediated by p2-adaptin, which 
binds directly to the major intracellular domain of the receptor (3, y2 and 6 subunits 
(Kittler et al., 2000a, 2005).
The p2-adaptin consists of an amino-terminal domain, which comprises the first third 
of the protein, and a carboxyl-terminal domain, which comprises the remaining two 
thirds of the protein (Aguilar et al., 1997; Owen and Evans, 1998; Collins et al., 
2002; Fig. 5 .IB). The carboxyl-terminal domain can be further organised into two 
sub-domains, A and B, which are comprised largely of (3-sheets (Fig. 5.IB; Owen and
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Evans, 1998).
The |^2-adaptin recruits cargo proteins into clathrin-coated pits by recognising 
specialised endocytosis signals in their cytoplasmic domains. There are currently 
three major p2-binding internalisation motifs: the tyrosine-based signals, the leucine- 
containing signals and the less well-characterised arginine/lysine-rich signals (or 
basic-rich motifs) (Fig. 5 .IB). The tyrosine-based signals include Yxx0 and NPxY 
(where x denotes a variable amino acid and 0  denotes a bulky hydrophobic residue 
(Leu, lie, Met or Phe)), although the latter signal may also conform to FxNPxY 
(reviewed in Bonifacino and Traub, 2003; Jadot et al., 1992; Boll et al., 2002; Chen 
et al., 1990). Yxx0 signals mediate rapid internalisation from the plasma membrane, 
and are involved in the targeting of proteins to lysosomes (Williams and Fukuda, 
1990; Harter and Mellman, 1992). These signals interact directly with the carboxyl- 
terminal domain of ^2-adaptin (Fig. 5 .IB; Ohno et al., 1995; Boll et al., 1996; Ohno 
et al., 1996; Owen and Evans, 1998), with residues D176 and W421 of p,2-adaptin 
being involved in the interaction (Nesterov et al., 1999; Owen and Evans, 1998). 
NPxY motifs bind the p2-adaptin at a site other than the Yxx0-binding region (Boll 
et al., 2002; Warren et al., 1998), and may interact with AP2 indirectly via other 
adaptor proteins (Mishra et al., 2002; Nagai et al., 2003).
The leucine-based signals take the form, [DE]xxxL[LI], where the residues four and 
five positions from the first leucine are typically, though not always, acidic, x denotes 
any amino acid, and the second leucine can be replaced by isoleucine or another 
hydrophobic residue (reviewed in Bonifacino and Traub, 2003). Leucine-based 
signals mediate rapid internalisation and endosomal/lysosomal targeting (Bonifacino 
and Traub, 2003). Evidence suggests that leucine-based motifs bind to the (32-adaptin 
of AP2 (Rapoport et al., 1998), as well as to the p2-adaptin at a site distinct from the 
Yxx0-binding region, between residues 102 and 125 of the amino-terminal domain 
(Fig. 5 .IB; Bonifacino and Traub, 2003; Bremnes et al., 1998; Rodionov and Bakke, 
1998; Hofmann et al., 1999; Marks et al., 1996; Ohno et al., 1995). However, direct 
interactions of this nature remain controversial (Bonifacino and Traub, 2003; Owen 
and Evans, 1998). The major intracellular domain of the GABAa receptor (32 subunit
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contains a dileucine motif, which has been implicated in mediating GABAa receptor 
endocytosis in cortical neuronal slices and HEK-293 cells (Herring et al., 2003, 
2005). This motif is also present in the major intracellular domains of the receptor pi 
and P3 subunits, but evidence suggests that it is not involved in the interaction of 
these subunits with the p2-adaptin (Kittler et al., 2005).
The non-canonical basic-rich motifs have only recently been identified in membrane 
proteins and receptors such as synaptotagmin 1 (Chapman et al., 1998; Haucke et al., 
2000), the a lb  subunit of the adrenergic receptor (Diviani et al., 2003), the GluR2 
subunit of the AMPA receptor (Lee et al., 2002) and the p subunits of the GABAa 
receptor (Kittler et al., 2005). These motifs have been shown to bind residues 283- 
394 of p2-adaptin (Fig. 5 .IB; Haucke et al., 2000; Chapman et al., 1998; Kittler et 
al., 2005). In the GABAa receptor P subunits, the basic-rich motif is the sole site of 
p2-adaptin binding, and encompasses the major sites of serine phosphorylation 
(Kittler et al., 2005). Interestingly, p2-adaptin binds to the basic-rich region in the p3 
subunit in a phosphorylation-dependent manner (Kittler et al., 2005). The p2-adaptin 
displays high affinity for the dephosphorylated binding region, and peptide blockade 
of this interaction results in an enhancement in the amplitude of mIPSCs and whole­
cell GABAa receptor currents, which has been attributed to a decreased rate of 
endocytosis and a corresponding increase in the number of cell-surface GABAa 
receptors (Kittler et al., 2005).
Although GABAa receptors are known to interact with the AP2 complex, the physical 
relationship between AP2 and the GABAa receptor y subunit family has not yet been 
fully described. In this chapter, I have taken a biochemical-based approach using 
affinity-purification assays, to investigate whether all members of the GABAa 
receptor y subunit family bind directly to AP2, and to identify the AP2 adaptins that 
mediate such binding. I also aimed to identify the molecular determinants governing 
the interaction between AP2 and the y2S subunit, and to investigate how this 
interaction is regulated. This approach has led to the discovery that GABAa receptor 
y subunits each bind directly and selectively to the p2-adaptin, and that the major 
intracellular domain of the y2S subunit contains two distinct binding sites for p2-
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adaptin. I show that sub-domain B of p,2-adaptin binds to a putative, basic-rich 
region in the N-terminal half of the y2S subunit, and that the Yxx0-interacting region 
of p2-adaptin (in sub-domain A) binds to the C-terminal half of the y2S subunit, 
which contains a classical tyrosine motif. I propose that these interactions facilitate 
the recruitment of synaptic GABAa receptors into clathrin-coated pits for 
internalisation, and that this is a key step in the regulation of postsynaptic GABAa 
receptor number and the efficacy of inhibitory synaptic transmission.
5.2 Results
An overview of the techniques used in this chapter is given in Figure 3.1.
5.2.1 The Major Intracellular Domain of Each GABAa Receptor y Subunit 
Interacts with the Native, Neuronal AP2 Adaptor Complex
To test whether native AP2 interacts with all members of the GABAa receptor y 
subunit family, I utilised affinity-purification assays and purified, bacterially 
expressed GST-fusion proteins of the major intracellular domain of GABAa receptor 
(33, y l, y2S, y2L and y3 subunits (GST-03, GST-yl, GST-y2S, GST-y2L and GST- 
y3), as well as recombinant GST (Sections 2.2.4 and 2.5.11; Kittler et al., 2005). The 
GST-fusion proteins were each exposed to a detergent-solubilised brain extract, and 
purified, together with any bound proteins, using glutathione-agarose beads. After 
resolving the protein complexes by SDS-PAGE, I probed for co-purified p2-adaptin 
by Western blotting with a monoclonal anti-p2 adaptin antibody (Sections 2.5.5 and 
2.5.7; Table 2.6). I obtained a single 50-kDa immunoreactive band corresponding to 
p.2 adaptin in the affinity-purification input lane, and from affinity-purifications using 
GST-03, GST-yl, GST-y2S, GST-y2L and GST-y3, but not GST alone (Fig. 5.2). 
These results demonstrated that the major intracellular domain of all members of the y 
subunit family, and of the 03 subunit, bound either directly or indirectly to the native, 
neuronal AP2 complex. This suggested that neuronal AP2 binds non-selectively to 
GABAa receptor y subunits, and that the major intracellular domain of each subunit is 
sufficient to mediate an interaction with AP2.
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Figure 5.2. The major intracellular domains of GABAa  receptor Y subunits bind 
to the u2-adaptin of AP2 in brain. Affinity-purification assays were performed using 
GST-fusion proteins (20 pg) of the major intracellular domains of GABAa  receptor 
Yl,  Y2S, Y2L and Y3 subunits, as well as GST alone. GST-fusion proteins were exposed 
to a detergent-solubilised brain extract, and purified using glutathione-agarose beads. 
The protein complexes were then resolved by SDS-PAGE and probed for the \i2- 
adaptin by immunoblotting with a monoclonal anti-p2 antibody, and an anti-mouse- 
HRP antibody for detection. 'Input' represents a proportion of the extract used in each 
binding assay.
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5.2.2 The Major Intracellular Domain of Each GABAa Receptor y Subunit Binds 
Directly and Selectively to the ji2-adaptin of the AP2 Adaptor Complex
I was next interested in determining whether the major intracellular domain of each 
GABAa receptor y subunit interacts directly with the individual adaptins of the AP2 
adaptor complex. To test for this, I utilised an in vitro protein expression system to 
transcribe and translate each of the two ~100 kDa AP2 adaptins, a  and (32, the 50 kDa 
adaptin, p,2, and the 19 kDa adaptin, o2  (Haucke et al., 2000; Kittler et al., 2005; 
Section 2.5.11.2; Table 2.2). This was done in the presence of [35S]-labelled 
methionine, and under the control of the T7 promoter (a  and \i2 adaptins) or the SP6 
promoter (|32 and o2  adaptins) (Kittler et al., 2005). I then performed affinity- 
purification assays using purified, bacterially expressed GST-fusion proteins of the 
major intracellular domain of each y subunit (GST-yl, GST-y2S, GST-y2L and GST- 
y3), as well as recombinant GST. The GST-fusion proteins were each exposed to the 
individual [35S]-adaptins ([35S]-a, [35S]-|32, [35S]-p2 or [35S]-a2), and purified using 
glutathione-agarose beads. After the protein complexes were resolved by SDS- 
PAGE, each [35S]-adaptin was visualised by phosphorimaging (Section 2.5.8). As 
shown in Figure 5 .3 ,1 detected a single band of 50 kDa corresponding to [35S]-p2 in 
the affinity-purification input lane, and from affinity-purification assays using GST- 
y l, GST-y2S, GST-y2L and GST-y3, but not GST alone. Interestingly, I also 
observed that the [35S]-p2 band was stronger from assays using GST-y2L compared to 
GST-yl, GST-y2S and GST-y3 (Fig. 5.3). Although I observed a single band at the 
expected molecular weight in the affinity-purification input lanes for [35S]-a, [35S]-|32, 
and [35S]-a2, I did not detect bands from the corresponding affinity-purification 
assays for any of the GST-y fusion proteins tested or GST (Fig. 5.3). These data 
demonstrated that [35S]-jx2, but not [35S]-a, [35S]-(32 or [35S]-a2, was co-purified with 
the major intracellular domain of each GABAa receptor y subunit, in vitro, and that 
[35S]-p2 co-purified with GST-y2L more than GST-yl, GST-y2S and GST-y3. This 
suggested that the major intracellular domain of each GABAa receptor y subunit 
binds directly and selectively to the [35S]-^i2-adaptin of the AP2 complex, in vitro, 
and that the strongest interaction occurs between [35S]-p2 and the major intracellular 
domain of the y2L subunit.
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Figure 5.3. The major intracellular domains of GABAa receptor y subunits bind 
selectively and directly to the p2-adaptin of AP2. Each adaptin subunit (a , |32, \\2 
and a2) was in vitro transcribed and translated under the T7 promoter in the presence 
of [35S]-labelled methionine. Affinity-purification assays were performed using GST- 
fusion proteins (20 pg) of the major intracellular domains of GABAa  receptor y l,  y2S, 
y2L and y3 subunits, as well as GST alone, and 5 pi of adaptin reaction mix. Proteins 
were resolved by SDS-PAGE, and [35S]-adaptins were visualised by 
phosphorimaging. 'Input' represents 50% (v/v) of the [35S]-adaptin reaction mix used 
in each assay.
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5.2.3 The Major Intracellular Domain of the GABAa Receptor y2S Subunit 
Contains Two Distinct Sites that each Bind Different Regions of the p2- Adaptin
Having shown that the major intracellular domain of each GABAa receptor y subunit 
interacts directly and selectively with the [35S]-p,2-adaptin, I was interested in 
identifying the amino acid region, or regions, in each protein that is involved in the 
interaction. I began by locating the binding region, or regions, in the major 
intracellular domain of the y2S subunit. To do this, I used affinity-purification assays 
and purified, bacterially expressed GST-fusion proteins of various fragments of the 
y2S subunit major intracellular domain (Fig. 5.4A; Table 2.2). I used GST-fusion 
proteins of the full-length loop (GST-y2S; residues 318-404), the N-terminal half of 
the loop (GST-N; residues 318-362) and the C-terminal half of the loop (GST-C; 
residues 363-404). I also used a GST-fusion protein of the epidermal growth factor 
receptor (EGFR) intracellular domain (GST-EGFR) (Table 2.2), which contains a 
classical tyrosine motif, as a positive control, and recombinant GST as a negative 
control. The GST-fusion proteins were each exposed to full-length [35S]-p,2 (Fig. 
5.4B; Section 5.2.2), and purified using glutathione-agarose beads. After the protein 
complexes were resolved by SDS-PAGE, [35S ]-p 2  was visualised by 
phosphorimaging. As shown in Figure 5.4C, I detected a single band of 50 kDa 
corresponding to [35S]-p2 in the affinity-purification input lane, and from affinity- 
purification assays using full-length GST-y2S, GST-N, GST-C and GST-EGFR, but 
not GST alone. Interestingly, I observed that the [35S]-p2 band was stronger from 
assays using GST-N compared to GST-C (Fig. 5.4C). These data demonstrated that 
[35S]-pi2 was co-purified with the major intracellular domain of the full-length 
GABAa receptor y2S subunit, as well as each individual half of the major intracellular 
domain, in vitro, and that [35S]-pi2 co-purified with GST-N more than GST-C. This 
suggested that the major intracellular domain of the GABAa receptor y2S subunit 
contains at least two distinct in vitro binding regions for [35S]-p2, and that the site, or 
sites, in the N-half of the major intracellular domain mediates the strongest 
interaction.
To determine the region, or regions, of p2 that binds to each of the y2S subunit sites, I 
next transcribed and translated different fragments of the p2 adaptin in vitro,
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Figure 5.4. The major intracellular domain of the GABAa receptor y2S subunit 
contains two distinct sites that each bind different domains of the p2-adaptin.
A. Schematic diagram of full-length (FL) GST-y2S (318-404) and GST-y2S deletion 
constructs (N: 318-362 and C: 363-404) used to map the binding site of p2-adaptin. B. 
Schematic diagram o f full-length p2-adaptin (1-435) and p2-adaptin deletion 
fragments (158-435, 158-407 and 283-394) used to map the binding site of the major 
intracellular domain (ICD) of the GABAa  receptor y2S subunit. Residues 407-435 
(green line) contain a domain for binding a classical tyrosine motif. Residues 283-394  
(blue line) contain a domain for binding basic-rich regions. C. Each adaptin construct 
(see 'B.') was in vitro transcribed and translated in the presence of [35S]-labelled 
methionine. Affinity-purification assays were performed using the GST-y2S fusion 
proteins (20 pg; see 'A.'), and GST alone, and 5 pi of adaptin reaction mix. Proteins 
were resolved by SDS-PAGE and [35S]-adaptins were visualised by phosphorimaging. 
'Input' represents 50% (v/v) of the [35S]-adaptin reaction mix used in each assay.
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including \i2 (158-435), p2 (158-407) and \x2 (283-394) (Fig. 5.4B; Table 2.2; 
Haucke et al., 2000; Kittler et al., 2005). This was done in the presence of r e ­
labelled methionine, and under the control of the T7 promoter (283-394) or the SP6 
promoter (158-435 and 158-407) (Kittler et al., 2005). I then tested binding of each 
adaptin fragment to each full-length and truncated GST-y2S fusion protein (GST-y2S, 
GST-N and GST-C), as well as GST-EGFR and GST alone. The GST-fusion 
proteins were each exposed to each of the [35S]-p2 adaptin fragments, and purified 
using glutathione-agarose beads. After the protein complexes were resolved by SDS- 
PAGE, each [35S]-p,2 adaptin fragment was visualised by phosphorimaging. As 
shown in Figure 5.4C, I detected a single band corresponding to [35S]-p2 (158-435) in 
the affinity-purification input lane, and from affinity-purification assays using full- 
length GST-y2S, GST-N, GST-C and GST-EGFR, but not GST alone. As shown for 
full-length [i2 (1-435), I observed that the [35S]-p2 band was stronger from assays 
using GST-N compared to GST-C (Fig. 5.4C). Interestingly, I detected a single, 
strong band corresponding to [35S]-p,2 (158-407) in the affinity-purification input 
lane, and from affinity-purification assays using full-length GST-y2S and GST-N, but 
not GST-C, GST-EGFR, or GST alone (Fig. 5.4C). Furthermore, this binding profile 
was identical to that of [35S]-p2 (283-394) (Fig. 5.4C). These data demonstrated that 
all [35S]-p2 fragments tested were co-purified with the full-length and N-half of the 
y2S subunit major intracellular domain. This suggested that the N-half of the loop 
binds strongly to [35S]-pi2 at a region located between residues 283 and 394. These 
data also demonstrated that full-length [35S]-p2 and [35S]-p2 (158-435), but not [35S]- 
\i2 (158-407) or [35S]-p,2 (283-394), co-purified with the C-half of the y2S major 
intracellular domain, and the EGFR. This suggested that binding of the C-half of the 
loop, and the EGFR, to [35S]-p,2 requires residues 408 to 435 of p2-adaptin (a region 
known to bind tyrosine-based motifs (Owen and Evans, 1998; Nesterov et al., 1999)), 
and that this interaction is weaker than that between the N-half of the loop and [35S]- 
p,2. These data collectively suggest that the major intracellular domain of the y2S 
subunit contains at least two distinct sites that each bind to different regions of [35S]- 
p2, in vitro.
Interestingly, residues 283-394 of p2 have been shown to contain a domain for
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binding basic-rich protein regions (Haucke et al., 2000; Chapman et al., 1998; Kittler 
et al., 2005). Furthermore, analysis of the sequence of the N-half of the major 
intracellular domain of the y2S subunit revealed that it contains such a putative region 
from residues 324 to 335 (Fig. 5.5A). Similarly, residues 408 to 435 of \i2 contain a 
domain for binding a tyrosine motif of the form Yxx0 (Owen and Evans, 1998; 
Nesterov et al., 1999), and analysis of the C-half of the major intracellular domain of 
the y2S subunit reveals such a motif in the form YECL (Fig. 5.5A). These data 
therefore support binding of residues 283-394 of \i2 to the basic-rich region in the 
proximal region of the y2S subunit major intracellular domain, and residues 408 to 
435 of p2 to the YECL motif in the more distal region of y2S loop.
5.2.4 p2-Adaptin Binds to a Putative Basic-Rich Region in the N-Terminus of the 
Major Intracellular Domain of the GABAa Receptor y2S Subunit
To identify the region in the N-half (residues 318-362) of the major intracellular 
domain of the y2S subunit that mediates binding to |i2-adaptin, I first generated a 
series of purified, bacterially expressed GST-y2S fusion proteins containing N- 
terminal deletions at intervals of ~10 amino acids. These included GST-y2S (327- 
404), GST-y2S (338-404) and GST-y2S (347-404) (Fig. 5.5A). The full-length (318- 
404) and truncated GST-y2S fusion proteins were each exposed to [35S]-p,2, and 
purified using glutathione-agarose beads. After the protein complexes were resolved 
by SDS-PAGE, [35S]-p2 was visualised by phosphorimaging. As shown in Figure 
5.5B, I detected a single, strong band of 50 kDa corresponding to [35S]-p2 in the 
affinity-purification input lane, and from affinity-purification assays using full-length 
GST-y2S. A weaker band was also seen from affinity-purification assays using GST- 
Y2S (327^404), GST-y2S (338-404) and GST-y2S (347-404) (Fig. 5.5B).
To determine whether each N-terminal truncation caused a significant loss of binding 
to [35S]-pi2,1 performed a quantitative analysis by measuring the intensity of each 
[35S]-p2 band using Bio-Rad Quantity One software (Sections 2.5.11.2 and 3.2.6.2). 
The band intensities obtained from the full-length and truncated GST-y2S fusion 
proteins were each normalised to the input value, and expressed as a percentage. This 
was repeated for a number of individual experiments in order to calculate the mean
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Figure 5.5. N-terminal deletions of the major intracellular domain of the y2S 
subunit disrupt binding to u2-adaptin. A. Schematic diagram of full-length and 
truncated GST-y2S fusion proteins used to map the u2-binding region in the N-half of 
the major intracellular domain of y2S. The predicted p2-binding regions in GST-y2S 
are indicated, including an N-half basic-rich region in blue and a C-half tyrosine motif 
in green. B. Affinity-purification assays were performed using in vitro transcribed and 
translated [35S]-p2-adaptin and the GST-y2S fusion proteins described in 'A.1 (20 pg). 
After proteins were resolved by SDS-PAGE, [35S]-p2-adaptins were visualised by 
phosphorimaging. 'Input' represents 50% (v/v) of the [35S]-adaptin reaction mix used 
in each assay. Brilliant-blue R stain showing equal-loading o f the GST-fusion proteins 
is shown below. C. The magnitude of [35S]-p2-binding to each GST-fusion protein 
was expressed as a percentage of the input value. The mean and sem were calculated 
using the results o f 3 independent experiments, and plotted in the chart shown. 
Differences between 318-404 and each truncation were analysed using the Student's 
paired t test. * denotes p<0.05.
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and standard error, and to perform a statistical analysis (Student’s paired t test). 
Quantitative analysis revealed that binding of [35S]-p,2 to full-length GST-y2S (318- 
404) (16.2%±1.0; n=3) was significantly greater than to GST-y2S (327-404) 
(4.6%±0.2; n=3; /?<0.05), in which the basic-rich region is disrupted, and GST-y2S 
(338-404) (4.9%±0.7; n=3; p<0.05) and GST-y2S (347-404) (6.7%±2.8; n=3; 
p<0.05), which do not contain the basic-rich region (Fig. 5.5C). I did not detect 
significant differences in [35S]-p,2-binding between any of the truncated forms of 
GST-y2S (p>0.05; n=3 for each comparison) (Fig. 5.5C). These data demonstrated 
that deletion of residues 318 to 326 significantly perturbs binding of [35S]-p2 to the 
major intracellular domain of y2S, and that deletion of residues 327 to 337 has no 
further effect. This suggests that some or all of residues 318-326 are required for 
binding of [35S]-p2 to the N-terminus of the major intracellular domain of y2S, and 
provides evidence to support binding of [35S]-jx2 to the putative basic-rich region 
between residues 323 and 336. The binding observed with GST-y2S (338-404) and 
GST-y2S (347-404) confirmed the presence of a second binding site in the major 
intracellular domain of the y2S subunit (Fig. 5.5), and supports a role for the tyrosine 
motif as a p2-binding site.
5.2.5 Investigating how the Interaction between the Major Intracellular Domain 
of the y2S Subunit and ji2-Adaptin is regulated
It has previously been shown that p2-adaptin binds to a basic-rich region in the major 
intracellular domain of GABAa receptor P subunits, and that this interaction is 
blocked by phosphorylation of conserved serine residues that lie within the binding 
region (Kittler et al., 2005). Interestingly, the putative basic-rich p2-binding domain 
identified in the y2S subunit contains a site of phosphorylation, at S327, for PKC 
(Moss et al., 1992a; Kellenberger et al., 1992; Krishek et al., 1994). This residue is 
the only site in the y2S subunit that is phosphorylated by PKC, and its 
phosphorylation state is involved in regulating the activity of recombinant and native 
GABAa receptors (Table 1.1; Moss et al., 1992a; Kellenberger et al., 1992; Krishek 
et al., 1994). In this study, I wanted to determine whether phosphorylation of S327 
regulates binding of p,2-adaptin to the y2S subunit. To test this, I used purified PKC 
to phosphorylate GST-y2S fusion proteins, in vitro. As shown in Figure 5.6A, I
198
L. B.
GST-y2S GST-y2S
+ PKC - PKC Input + PKC -PK C GST
m
M
< [32P]-GST-y2S
-  -  -
0.1
stoichiometry of phosphorylation 
(mol. phosphate mol. protein-1)
Figure 5.6. Investigating the role of phosphorylation in regulating binding of u2- 
adaptin to the GABAa receptor y2S subunit. A. Phosphorylation of GST-y2S fusion 
proteins by PKC. The stoichiometry of phosphorylation (mol. phosphate mol. protein- 
is given below each GST-fusion protein. B. Affinity-purification assays were 
performed using GST-y2S fusion proteins that were phosphorylated on S327 by PKC, 
or mock phosphorylated (20 pg), or GST alone. The GST-fusion proteins were 
exposed to [35S]-p2-adaptin, and precipitated using glutathione-agarose beads. The 
protein complexes were then resolved by SDS-PAGE, and [35S]-p2-adaptin was 
visualised by phosphorimaging. 'Input1 represents 10% (v/v) of the [35S]-p2 assay mix 
used in each binding assay.
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obtained a [32P]-labelled, ~36 kDa protein band corresponding to phosphorylated 
GST-y2S from the in vitro kinase assay performed in the presence of PKC, but not in 
its absence. I then performed affinity-purification assays using the 
phosphorylated/mock phosphorylated GST-y2S fusion proteins and [35S]-p2. As 
shown in Figure 5.6B, I obtained a 50-kDa band corresponding to [35S]-p,2 in the 
input lane and from affinity-purification assays using phosphorylated and mock 
phosphorylated GST-y2S fusion proteins, but not GST alone. However, the low 
stoichiometry of phosphorylation of GST-y2S (0.1 mol. phosphate mol. protein"1) 
meant that I could not reliably determine whether phosphorylation by PKC regulated 
the level of [35S]-|x2-binding to GST-y2S (Fig. 5.6; Section 2.5.14).
5.2.6 Analysis of the Putative |i2-Binding Domains identified in the Major 
Intracellular Domain of the y2S Subunit
5.2.6.1 Sequence Alignment o f  the Major Intracellular Domains o f GABAa 
Receptor y Subunits comparing the Similarity o f the Putative p2-Adaptin Binding 
Regions identified in the y2S Subunit
To determine whether the putative p2-adaptin binding sites identified in the major 
intracellular domain of the y2S subunit (Figs. 5.4 and 5.5) are conserved in all the y 
subunits, I constructed multiple sequence alignments of the y subunit family. This 
was done using ClustalW (Higgins, 1994), and The Jalview Java Alignment Editor 
for manual editing (Clamp et al., 2004). I observed conservation of a classical 
tyrosine motif in the C-terminal half of the major intracellular domain of all y 
subunits (Fig. 5.7A). This motif takes the form YQCL in yl, and YECL in y2 and y3 
(Fig. 5.7A). I also observed arginine- and lysine-rich clusters between 9 and 13 
amino acids in length at similar positions in the N-terminal half of the loops (Fig. 
5.7A). These data demonstrated that the putative basic-rich and tyrosine-based p2- 
adaptin-binding sites in the y2S subunit are common to all the y subunit isoforms. 
This suggested that p2-adaptin associates with the major intracellular domain of each 
y subunit by binding to a basic-rich region in the N-terminal half of the loop, and a 
tyrosine motif in the C-terminal half of the loop.
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Protein
Sequence o f Basic-Rich 
p2-Binding Region
GABAa  receptor y2 subunit (putative; 324-335) 
GABAa  receptor |31 subunit (401 -412)
GABAa  receptor |32 subunit (402-413)
GABAa  receptor (33 subunit (401-412) 
synaptotagmin 1 C2B domain (321-332) 
Adrenergic receptor a lb  subunit (371-378) 
AMPA receptor GluR2 subunit (844-853)
RKPSKDKDKKKK
KGRIRRRASQLK
KSRLRRRASQLK
KTHLRRRSSQLK
KRLKKKKTTIKK
RRRRRRRR
KRMKVAKNPQ
Figure 5.7. Sequence analysis of GABAa receptor y subunits showing the position 
of the putative AP2 binding sites. A. The sequences shown represent the major 
intracellular domains of murine GABAa receptor y l, y2 and y3 subunits. A black letter 
on a red box indicates a lysine or arginine residue that forms part of a basic-rich 
region. A black letter on a green box indicates a residues that forms part of a classical 
tyrosine motif (Y xx0). The light grey box indicates the sequence of the y2L insert, and 
the dark grey box indicates a region containing residues that are crucial for binding of 
\xl to the major intracellular domain of the y2S subunit. The GST-y2S truncations, T1 
(327-404), T2 (338-404) and T3 (347-404) are indicated with arrows. Numerals 
represent the position of amino acids in the given alignment, and begin with respect to 
the y2S subunit. B. Sequences of basic-rich p2-binding regions identified in neuronal 
membrane proteins and receptors.
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S.2.6.2 Comparison o f the Basic-Rich p2-Binding Region in the GABAa Receptor 
y2 Subunit with similar p2-Binding Regions in other Proteins 
I was next interested in comparing the putative basic-rich p,2-binding sequence I 
identified in the GABAa receptor y2 subunit with basic-rich p2-binding regions found 
in other proteins to determine whether there is any sequence homology. Figure 5.7B 
shows the amino acid sequences of the basic-rich p2-binding domains of GABAa 
receptor subunits and other proteins, including synaptotagmin-1, the a lb  subunit of 
the adrenergic receptor and the GluR2 subunit of the AMPA receptor. All these 
sequences contain a basic lysine/arginine-rich region that appears to be between 8 and 
12 residues in length (Fig. 5.7B). This further supports the finding of a basic-rich p2- 
adaptin binding site in the N-terminus of the major intracellular domain of the 
GABAa receptor y2 subunit.
5 3  D iscussion
Regulating the number of GABAa receptors at mammalian central synapses is a key 
mechanism for controlling the efficacy of inhibitory synaptic transmission and 
neuronal excitability (Nusser et al., 1997; Otis et al., 1994; Nusser et al., 1998b). 
GABAa receptors are constitutively internalised via a clathrin-mediated, dynamin- 
dependent pathway (Kittler et al., 2000a, 2005). The association between the 
GABAa receptor and the AP2 adaptor complex is believed to play an important role 
in this process (Kittler et al., 2000a, 2005). However, the physical interaction 
between these proteins has not yet been fully described. In this study, I investigated 
the interaction between GABAa receptor y subunits and AP2, with the aim of further 
understanding the molecular mechanisms by which GABAa receptors are internalised 
from the cell surface. This study has provided evidence to suggest that the major 
intracellular domains of GABAa receptor y subunits each bind selectively and directly 
to the p2-adaptin of AP2 in brain. Mapping studies further revealed that the major 
intracellular domain of the y2S subunit contains two distinct p2-adaptin binding sites. 
I demonstrated that one of these sites is located in the N-terminus of the major 
intracellular domain, and comprises a putative basic-rich p2-adaptin binding motif. 
This site was found to interact with sub-domain B of p2-adaptin. A second site was 
located in the carboxyl-terminal half of the major intracellular domain, and likely
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consists of a classical tyrosine-based p2-adaptin binding motif. This site was found 
to interact with the carboxyl-terminus of p2-adaptin, within sub-domain A. 
Interestingly, I found that both of the putative p2-binding motifs identified in the y2S 
subunit are common to all the y subunit isoforms. I propose that p2-adaptin forms 
multiple interactions with the receptor y subunits, and that these facilitate the 
recruitment of GABAa receptors into clathrin-coated pits for internalisation. This 
mechanism may play an important role in regulating postsynaptic GABAa receptor 
number and hence the efficacy of inhibitory synaptic transmission.
My studies demonstrated that the major intracellular domain of each GABAa receptor 
y subunit is able to form a complex with the native neuronal AP2 complex. They also 
revealed that the GABAa receptor y subunits each bind selectively to the p2-adaptin 
of the AP2 complex. This is consistent with previous studies demonstrating that the 
receptor 0 subunits also bind selectively to p2-adaptin (Kittler et al., 2005). Given 
the importance of p2-adaptin in cargo recognition (Ohno et al., 1995; Owen and 
Evans, 1998; Rodionov and Bakke, 1998), this suggests that binding of receptor y 
subunits (and 0 subunits) to p2-adaptin plays an important role in the selective 
translocation of GABAa receptors into clathrin-coated pits. It is perhaps not 
surprising that the a 2 subunit did not bind directly to the y subunits, as this adaptin 
appears to have a structural role within the AP2 complex (Collins et al., 2002). 
Interestingly, the membrane protein synaptotagmin is the only protein so far 
identified that interacts with both \i2- and a-adaptin (Haucke et al., 2000). Although 
synaptotagmin binds independently to each adaptin, it has been suggested that 
binding is co-operative (that binding to one adaptin enhances binding to the other and, 
hence, to the AP2 complex) (Haucke et al., 2000). It is therefore possible that 
GABAa receptors do not associate with multiple adaptins because co-operative 
binding is achieved through the multivalent interactions p2-adaptin forms with the 
different subunits (0, y and 5) that co-assemble to form a receptor complex. I shall 
return to this concept later in the discussion.
I also observed enhanced binding of p2-adaptin to the major intracellular domain of 
the y2L subunit compared to the other y subunit isoforms. This may be due to the
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presence of two consecutive leucine residues in the y2L insert sequence, 
LLRMFSFK. which may form part of a consensus leucine-based p2-binding motif, 
[DE]xxxL[LI] (see Section 5.1). However, evidence suggests that leucine-based 
motifs bind to the p2- and |3-adaptins (Rapoport et al., 1998; Rodionov and Bakke, 
1998), and I did not detect an interaction of y2L with (32-adaptin. Furthermore, the 
dileucine motif in the receptor p i and |33 subunits is not involved in the binding of 
either of these subunits to the p,2-adaptin (Kittler et al., 2005). The increased affinity 
of p2-adaptin for the y2L subunit may alternatively be explained by a conformational 
change that is a consequence of the eight amino acid insertion, and which results in 
enhanced access of p2-adaptin to the tyrosine-based and basic-rich binding sites.
The mapping experiments in this study revealed that the major intracellular domain of 
the y2S subunit contains two distinct p2-binding sites that each recognise different 
regions of the p2-adaptin. The evidence suggested that the p2-binding site in the 
amino-terminal half of the loop comprises a putative basic-rich motif consisting of up 
to eight arginine/lysine amino acids (residues 324-335), and that R324 and/or K325 
are critical residues of this motif. This was based on the finding that binding of p2- 
adaptin to the y2S subunit loop was significantly reduced by N-terminal loop 
deletions that disrupted or removed the basic-rich motif. Further support was 
obtained from the finding that this N-terminal loop region interacted with residues 
283 to 394 of p2-adaptin. This region of p2-adaptin has previously been shown to 
interact with a basic-rich motif in the (3 subunits of GABAa receptors (Kittler et al., 
2005), the synaptic vesicle protein synaptotagmin (Haucke et al., 2000; Chapman et 
al., 1998), and the a lb  subunit of the adrenergic receptor (Diviani et al., 2003). The 
amino acid similarity of the basic-rich motifs in these proteins and the receptor y 
subunits, and the ability of the y subunit major intracellular domains to each bind 
native neuronal AP2 complexes, suggests that the putative y2S basic-rich motif has a 
conserved role in binding the AP2 complex in neurons.
My studies also supported the idea that p2-adaptin binds to a second distinct site in 
the carboxyl-terminal half of the y2S subunit major intracellular domain, which 
comprises a classical tyrosine-based motif of the form, YECL (residues 367 to 370).
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This is based on the finding that binding of the C-terminal half of the y2S subunit, 
like the EGFR, to p,2-adaptin was significantly disrupted by deletion of the carboxyl- 
terminal region of p2-adaptin. Although co-crystallisation studies have shown that 
both D176 and W421 of sub-domain A of p2-adaptin are involved in binding 
tyrosine-based (Yxx0) internalisation signals (Owen and Evans, 1998), mutational 
analysis and affinity-purification experiments with the EGFR showed that while 
D176A partially inhibits p2-adaptin binding, W421A completely abrogates binding 
(Nesterov et al., 1999). Consistent with this, I found that the full-length and 
carboxyl-terminal half of the y2S subunit major intracellular domain, like the EGFR, 
only interacted with p2-adaptin deletion constructs that contained W421, suggesting 
that the YECL motif of the y2S subunit binds to a region of p2-adaptin containing 
W421. It is possible, that like the EGFR, this interaction is not essential for clathrin- 
dependent internalisation of GABAa receptors (Nesterov et al., 1999). Indeed, this 
study has identified two distinct p2-adaptin binding sites in the y2S subunit.
It has previously been shown that association of AP2 with synthetic peptides 
containing a YQRL endocytic motif induces a transition of AP2 from an inactive to 
an active state, which results in an increased binding capacity for the cargo protein 
synaptotagmin (Haucke and De Camilli, 1999; Owen and Evans, 1998). It is 
therefore possible that binding of p2-adaptin to the tyrosine motif in the y2S subunit 
increases the interaction of p2-adaptin with GABAa receptors. As p2-adaptin binds 
to the N-half binding site with greater affinity than to the C-half binding site, it is 
possible that the weak interaction with the tyrosine motif induces a conformational 
change that enables a stronger interaction to take place with the basic-rich motif. As 
previously mentioned in this discussion, co-operativity of binding of AP2 to GABAa 
receptors may also involve binding sites found on other receptor subunits. 
Furthermore, it is possible that binding of the AP2 complex to GABAa receptor 
subunits modifies the binding properties of clathrin/endocytic accessory proteins. 
The presence of multiple p2-adaptin binding sites in GABAa receptor subunits and 
the presence of binding co-operativity may enable neurons to regulate the rate of 
internalisation of distinct GABAa receptor populations.
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It would be interesting to investigate the role of individual p,2-adaptin binding sites in 
the internalisation of neuronal GABAa receptors in functional studies. 
Electrophysiological and biochemical experiments using synthetic peptides 
mimicking the putative p2-adaptin binding sites identified in y2S could help identify 
any co-operativity of binding, and to determine the importance of each site in the 
process of internalisation, and in the control of postsynaptic GABAa receptor number. 
As the putative basic-rich and tyrosine-based motifs identified in this study are 
common to all the y subunit isoforms, such peptides could also be used to investigate 
the role of these sites in mediating binding of p2-adaptin to the yl and y3 subunits, 
and the endocytosis of GABAa receptors that contain these subunits.
In this study, I attempted to investigate whether the interaction between the y2S 
subunit and p2-adaptin was regulated by phosphorylation. My approach was similar 
to that used by Kittler and colleagues (Kittler et al., 2005) to examine the phospho- 
dependence of p2-adaptin binding to the receptor (3 subunits. In this study, I utilised 
purified PKC to phosphorylate S327, which lies within the putative basic-rich region 
of the y2S subunit. Unfortunately, the low stoichiometry of phosphorylation 
prevented me from accurately assessing the level of p2-adaptin binding to the 
phosphorylated and mock-phosphorylated subunit forms. This is because the ratio of 
phosphorylated to mock-phosphorylated GST-fusion protein was very low, which 
meant that even if phosphorylation completely inhibited binding, it would only block 
a small proportion of the total p2-adaptin binding. Furthermore, as there are two 
distinct p2-adaptin binding sites in the major intracellular domain of the y2S subunit, 
then binding may not be completely abrogated by blockade of the interaction with the 
basic-rich region. However, given that phosphorylation of the basic-rich region in the 
receptor (33 subunit inhibited binding of p2-adaptin (Kittler et al., 2005), it is likely 
that phosphorylation of the putative basic-rich region in the y2S subunit would have a 
similar effect. Fortunately, this hypothesis can be tested by performing [35S]-p2- 
adaptin binding assays with synthetic peptides of the putative basic-rich binding 
motif, that are chemically phosphorylated or mock-phosphorylated at S327.
Phosphorylation of Y367 of the putative tyrosine-based motif in the y2S subunit may
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also regulate binding of p,2-adaptin. Phosphorylation of the tyrosine in Yxx0 binding 
motifs has previously been shown to interfere with binding of p2-adaptin (Ohno et 
al., 1996; Owen and Evans, 1998). Y367 of the y2S subunit has also been shown to 
be a site of phosphorylation for the tyrosine kinase Src in vitro and in heterologous 
cells (Moss et al., 1995; Valenzuela et al., 1995), and is constitutively phosphorylated 
in brain (Brandon et al., 2001). Phosphorylation of Y367 is known to result in 
enhanced receptor function due to an increase in the probability of channel opening 
(Moss et al., 1995). It would therefore be interesting to determine whether 
phosphorylation of this residue also perturbs binding of p,2-adaptin to regulate the 
number of receptors on the cell surface and, hence, GABAa receptor-mediated 
currents.
In addition to phosphorylation, the binding of AP2 to GABAa receptor y subunits 
may also be regulated by the interactions of these subunits with other cellular 
proteins. For example, binding of Src and PP2B to the y2 subunit is believed to 
involve amino acids 317 to 332 (Wang et al., 2003a; Sections 1.7.2.1.7 and 1.7.2.2.3), 
and may therefore involve residues of the putative basic-rich p2-adaptin binding site. 
Furthermore, the binding site for the palmitoyl acyl transferase, GODZ, in the y2 
subunit is believed to lie within amino acids 368 and 381 (Keller et al., 2004; Section 
1.6), and may therefore encompass some residues of the putative tyrosine-based p2- 
adaptin binding motif. It is also possible that the palmitoylation of cysteine residues 
within this GODZ-binding region (Keller et al., 2004; Rathenberg et al., 2004; 
Section 1.6) also regulates the interaction between the GABAa receptor y2 subunit 
and AP2.
5.4 Conclusions
Overall, I conclude that the GABAa receptor y subunits each bind directly and 
selectively to the p2-adaptin of AP2, and to the native AP2 complex in brain. The 
y2S subunit contains at least two distinct binding sites for p2-adaptin, which are 
located in the N- and C-terminal halves of the major intracellular domain. The N-half 
binding motif comprises a putative basic-rich region, and interacts with sub-domain B 
of p.2-adaptin. The C-terminal binding motif likely comprises a tyrosine-based
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interaction motif, and interacts with the C-terminus of p,2-adaptin, within sub-domain 
A. The putative basic-rich and tyrosine-based \i2-adaptin binding motifs are common 
to all the y subunit isoforms. The multivalent interactions between p2-adaptin and the 
receptor y subunits may underlie the ability of the AP2 complex to associate with 
GABAa receptors at the neuronal surface. This may facilitate the selective 
recruitment of GABAa receptors into clathrin-coated pits for internalisation, and be 
part of a molecular mechanism controlling the number of cell-surface GABAa 
receptors. The interaction between AP2 and GABAa receptor y subunits may 
therefore have significant consequences for the efficacy of inhibitory synaptic 
transmission.
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6.1 Biological and Clinical Implications of the Physical and Functional 
Interaction between CaMKII and the GABAa Receptor
The phosphorylation state of the GABAa receptor is believed to be an important 
determinant of channel activity and the efficacy of inhibitory neurotransmission 
(Moss and Smart, 2001; Poisbeau et a l,  1999; Section 1.7). A number of signalling 
pathways leading to changes in the phosphorylation state of GABAa receptors have 
now been described (Brandon et al., 2002; Jovanovic et al., 2004; Terunuma et al., 
2004; Wang et al., 2003b), and the precise means by which kinases are targeted to 
GABAa receptor scaffolds are beginning to emerge (Brandon et al., 1999, 2001, 
2002, 2003; Jovanovic et al., 2004). Although several lines of evidence suggest that 
CaMKII is involved in regulating GABAa receptor function in neurons (Aguayo et 
al., 1998; Wang et al., 1995; Kano et al., 1996; Section 3.1), the molecular 
mechanism of such regulation remains to be elucidated. In Chapters 3 and 4 of this 
thesis, I provided evidence for a model whereby activity-dependent recruitment of 
CaMKII to GABAa receptors is involved in regulating subunit phosphorylation (Fig. 
6. 1).
The data obtained in Chapter 3 revealed that CaMKIIa interacts physically with 
GABAa receptors in brain. Further investigations demonstrated that native CaMKIIa 
binds to the major intracellular domain of various receptor subunits without any 
apparent selectivity. The interaction between CaMKIIa and the intracellular domains 
of the receptor (3 subunits was found to be dependent upon phosphorylation of the 
kinase at T286, but appeared to be independent of GABAa receptor subunit 
phosphorylation. Indeed, a major binding site for CaMKII was located within the 
first 19 amino acids of the major intracellular domain of the receptor |3 subunit, at 
least 60 residues upstream of the CaMKII in vitro phosphorylation sites. These 
results suggested that neuronal stimuli that lead to an increase in intracellular calcium 
concentration and autophosphorylation of CaMKII at T286 could trigger binding of 
the kinase to GABAa receptors (Fig. 6.1). If this is the case, then this 
phosphorylation-dependent interaction may underlie the targeting of CaMKII to 
GABAa receptors in neurons. Furthermore, it may facilitate activity-dependent 
phospho-modulation of GABAa receptor activity and hence the efficacy of inhibitory
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Figure 6.1. Proposed model of CaMKII-dependent phosphorylation and 
functional modulation of GABAa receptors in immature cortical neurons.
Stimulation of GABAa  receptors triggers neuronal depolarisation and a rise in 
intracellular calcium concentration (J.N. Jovanovic, unpublished data), which may be 
mediated by voltage-dependent calcium channels. This is proposed to result in T286- 
autophosphorylation of CaMKII, and subsequent binding of the active kinase to 
GABAa  receptors. CaMKII then phosphorylates specific sites within the major 
intracellular domains of particular receptor subunits to modulate GABAa  receptor 
activity. This mechanism may provide positive feedback signalling to GABAa  
receptors during neuronal development as CaMKII is believed to enhance GABA- 
mediated currents in cortical neurons (Aguayo etal., 1998).
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synaptic transmission.
In Chapter 4 , 1 performed investigations using cultured immature cortical neurons, at 
a stage of development when GABAa receptors are depolarising (J.N. Jovanovic, 
unpublished data). In this system, I found that stimulation of GABAa receptors leads 
to calcium-dependent autophosphorylation of CaMKIIa at T286. It is tempting to 
speculate that this effect is mediated by activation of voltage-gated calcium channels 
and subsequent elevation of the intracellular calcium concentration (Fig. 6.1), since 
stimulation of GABAa receptors triggers an increase in intracellular calcium 
concentration in cultured immature cortical neurons under similar experimental 
conditions (J.N. Jovanovic, unpublished data). A GABAa receptor-mediated increase 
in intracellular calcium concentration has also been shown to occur in slices of 
developing neocortex (Yuste and Katz, 1991; Owens et al., 1996), developing 
hypothalamic neurons (Obrietan and van den Pol, 1996), and cultured cerebellar 
granule cells (Borodinsky et al., 2003; Connor et al. 1987) via voltage-gated calcium 
channels (Borodinsky et ah, 2003; Owens et al., 1996). Notably, it is unlikely that 
the activation of GABAa receptors increases intracellular calcium concentration due 
to the generation of osmotic tension by bicarbonate-induced chloride entry (Chavas et 
al., 2004), as the experiments in this study were performed in bicarbonate-free 
HEPES-buffered saline (see Chavas et al., 2004). Nevertheless, it is widely accepted 
that increasing intracellular calcium concentration induces autophosphorylation of 
CaMKII at T286 (Hudmon and Schulman, 2002). The ‘pull-down’-kinase assays 
performed in this chapter further demonstrated that depolarisation of cultured 
immature cortical neurons increases the functional interaction of CaMKII with the 
major intracellular domain of the GABAa receptor |33 subunit. These findings 
collectively reinforce the view that depolarisation of cultured immature cortical 
neurons could induce docking of T286-phosphorylated CaMKII to GABAa receptors 
(Fig. 6.1).
The data obtained in Chapter 4 revealed that purified CaMKII selectively 
phosphorylates the major intracellular domains of the GABAa receptor |3 and 
Y subunits, but not the a  or 6 subunits, in vitro, and identified the major intracellular
212
CHAPTER 6 General Discussion
domains of the yl and y3 subunits as novel substrates of CaMKII. The results also 
confirmed that S383 and S409 are the in vitro phosphorylation sites of CaMKII in the 
receptor (33 subunit (McDonald and Moss, 1997), and demonstrated that PP1, PP2A 
and PP2C, but not PP2B, dephosphorylate the (33 subunit, in vitro, at these CaMKII 
sites. These findings provided preliminary evidence that S383 and S409 of the (33 
subunit may be important sites of GABAa receptor phosphorylation-dependent 
modification in neurons.
A previous study has shown that CaMKII does not phosphorylate the GABAa 
receptor (33 subunit in cultured immature cortical neurons under basal conditions 
(Brandon et al., 2000). In this chapter, I revealed that muscimol-induced 
depolarisation of cultured immature cortical neurons triggers CaMKII-dependent 
phosphorylation of the receptor (33 subunit, but not the y2 subunit. Chapter 4 also 
documented attempts to raise phosphorylation state-specific antibodies to phospho- 
S383 and phospho-S409 of the receptor |33 subunit in order to examine the 
phosphorylation status of each residue following muscimol-induced depolarisation of 
cultured immature cortical neurons. This work exemplified the difficulty in raising 
such biological tools, and suggested that CaMKII-dependent phosphorylation of 
GABAa receptors does not occur solely at S409 in cultured immature cortical 
neurons. Moreover, the results suggested that CaMKII may be involved in 
phosphorylation of both S408 and S409, and did not exclude the possibility that S383 
is a major site of CaMKII phosphorylation in neurons.
It is tempting to speculate from the data obtained in Chapters 3 and 4 that muscimol- 
induced depolarisation of immature cortical neurons triggers CaMKII-dependent 
phosphorylation of GABAa receptors via differential targeting of the activated kinase 
to receptor complexes (Fig. 6.1). The translocation of CaMKII to GABAa receptors 
could enable a highly regulated response to local changes in calcium concentration 
driven by activation of GABAa receptors. This mechanism could mediate positive or 
negative feedback signalling to GABAa receptors during the early stages of neuron 
development, when GAB A is excitatory. Translocation of CaMKII to GABAa 
receptors could trigger a change in the activity and/or number of postsynaptic
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GABAa receptors, and therefore alter the strength and/or stability of GABAergic 
synapses, and inhibit or promote subsequent postsynaptic calcium entry.
Phosphorylation of GABAa receptors is believed to have important functional 
consequences for channel activity and neuronal excitability (Moss and Smart, 2001; 
Poisbeau et al., 1999; Section 1.7). Evidence suggests that the effect of 
phosphorylation on GABAa receptor functionality is dependent upon several factors, 
including cell type, subunit composition, and the identity of the kinase (Moss and 
Smart, 2001; Section 1.7). A number of studies now suggest that activation of 
CaMKII leads to an enhancement in GABAa receptor activity. In cortical neurons, an 
increase in intracellular calcium concentration leads to a CaMKII-dependent increase 
in the amplitude of GABA-mediated currents (Aguayo et al., 1998). Potentiation of 
GABA-mediated currents is also observed in cortical neurons following intracellular 
application of pre-activated CaMKII (catalytic and regulatory domains) (C.M. 
Houston, unpublished data). These results are consistent with findings from other 
cell-types. Addition of pre-activated CaMKII to cerebellar granule cells increases the 
amplitude of GABA-mediated currents (C.M. Houston, unpublished data), and 
increases the amplitude and decay time of IPSCs (C.M. Houston, unpublished data). 
Addition of CaMKII also potentiates GABA-induced currents in spinal dorsal horn 
neurons, and evoked IPSPs in hippocampal CA1 neurons (Wang et al., 1995). 
Moreover, intracellular application of purified, active CaMKII to cerebellar Purkinje 
neurons enhances the amplitude of both GABA-mediated currents and spontaneous 
IPSCs (Kano et al., 1996).
It is possible that CaMKII-dependent potentiation of GABAa receptor activity in 
neurons is a result of direct phosphorylation of receptor subunits. If so, then the data 
obtained in Chapters 3 and 4 suggest that the receptor |33 subunit could play an 
important role in such functional modulation. This is supported by recent 
investigations showing that intracellular application of pre-activated CaMKII 
increases the amplitude of GABA-mediated currents in NG108-15 cells expressing 
a l/|33  subunits and a l/p3 /y2  subunits, whereas the effect is abolished in cells 
expressing al/|33(S383A) subunits, and significantly reduced in cells expressing
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al/p3(S383A)/y2 subunits (C.M. Houston, unpublished data). Furthermore, addition 
of pre-activated CaMKII has no effect in cells expressing al/(32/v2, and only a small 
effect in cells expressing a l / p l / y2  (which is mediated via the y l  subunit) (C.M. 
Houston, unpublished data). These results therefore suggest that CaMKII-dependent 
functional modulation of GABAa receptors is mediated, at least in part, by S383 of 
the |33 subunit. This is consistent with the finding that KCl-induced depolarisation of 
NG108-15 cells induces phosphorylation of the GABAa receptor (33 subunit at S383 
(C.M. Houston, unpublished data). It is therefore tempting to speculate that in 
cultured immature cortical neurons, CaMKII-dependent phosphorylation of GABAa 
receptor (33 subunits occurs at S383 and enhances GABAa receptor activity, therefore 
contributing to a positive feedback-signalling pathway to GABAa receptors during 
neuronal development (Fig. 6.1). This could have a profound effect on the strength of 
GABAergic synapses, and hence the input-output relationship of neurons and the 
excitability of neural networks, as well as GABA-mediated calcium-dependent 
signalling events.
The physical and functional interaction of CaMKII with GABAa receptors may 
mediate long-term changes in the strength of inhibitory synapses (reviewed by 
Gaiarsa et al., 2002) during neuronal maturation and/or in adult neurons, which have 
important consequences for the excitability of neurons and neural circuits, network 
physiology and animal behaviour. Long-term potentiation (LTP) and long-term 
depression (LTD) of GABAergic synapses has been detected in various brain regions, 
including the cortex, hippocampus, cerebellum, lateral superior olive, deep cerebellar 
nucleus and brainstem (Gaiarsa et al., 2002). Indeed, in the developing hippocampus, 
stimulation of GABAa receptors has been shown to trigger membrane depolarisation, 
an increase in intracellular calcium concentration, via activation of voltage-gated 
calcium channels, and LTP of GABAa receptors (Caillard et al., 1999; Gubellini et 
al., 2001; Gaiarsa et al., 2002). Furthermore, in cerebellar Purkinje neurons, CaMKII 
has been implicated in the induction of a long-lasting rebound potentiation of 
GABAergic synapses in which activation of glutamatergic inputs leads to a calcium- 
dependent increase in GABAa receptor currents (Kano et al., 1992, 1996; Kawaguchi 
and Hirano, 2002).
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The results from Chapters 3 and 4 may have some clinical relevance as both CaMKII 
and the GABAa receptor (33 subunit have been implicated in the neurodevelopmental 
disorder, Angelman syndrome (AS). AS is characterised by severe mental 
retardation, epilepsy, motor impairment, sleep disturbances and craniofacial 
abnormalities (Williams et al., 1995; Buoni et al., 1999; Laan et al., 1999). AS 
results from various genetic abnormalities of chromosome region 15ql 1-13, such as 
maternal deletion, uniparental paternal disomy, imprinting defects and mutations 
within the UBE3A gene, which encodes an E6-P ubiquitin ligase (Jiang et al., 1999). 
Although in a small number of cases, no genetic abnormality has been identified 
(Jiang et al., 1999; Clayton-Smith and Laan, 2003). Investigations of a mouse model 
for AS, which was generated by a UbeSa maternal null mutation, have revealed 
deficits in hippocampal LTP and context-dependent learning that are thought to 
involve altered autophosphorylation and activity of CaMKII (Jiang et al., 1998; 
Weeber et al., 2003). However, in addition to Ube3a, chromosome region 15ql 1-13 
also contains a cluster of genes encoding the GABAa receptor (33, a5 and y3 subunits, 
namely GABRB3, GABRA5 and GABRG3 (Glatt et al., 1997). These genes are 
widely expressed in the developing mammalian brain (Laurie et al., 1992b), and 
mutant mice deficient in gabrb3 exhibit a number of phenotypic characteristics 
resembling AS (Homanics et al., 1997; DeLorey et al., 1998). Indeed, aberrant 
function of GABRB3 has been implicated in the severe epilepsy seen in AS patients 
with deletion of chromosome region 15ql 1-13 (Minassian et al., 1998). It is 
therefore possible that dysfunctional CaMKII-dependent phosphorylation of GABAa 
receptors is partially responsible for the AS phenotype.
6.2 Biological and Clinical Implications of the Interaction between the AP2 
Adaptor Complex and the GABAa Receptor
In addition to their functional properties, the total number of postsynaptic GABAa 
receptors also determines the efficacy of inhibitory synaptic transmission (Otis et al., 
1994; Nusser et al., 1998b; Wan et al., 1997b; Wang et al., 2003b; Brunig et al., 
2001; Jovanovic et al., 2004). Neuronal GABAa receptors are cycled constitutively 
between the plasma membrane and intracellular compartments (Connolly et al., 
1999a,b; Kittler et al., 2000a,b, 2004a, 2005). Internalisation of GABAa receptors
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occurs via a clathrin-mediated, dynamin-dependent pathway (Kittler et al., 2000a, 
2005; Tehrani and Barnes, 1993, 1997; Tehrani et al., 1997), and the interaction 
between the GABAa receptor and the AP2 adaptor complex is believed to play an 
important role in this process (Kittler et al., 2000a; Kumar et al., 2003). In Chapter 5 
of this thesis, I identified the molecular determinants of the interaction between the 
AP2 adaptor complex and the GABAa receptor y subunits.
The data from Chapter 5 revealed that the major intracellular domain of each GABAa 
receptor y subunit binds the native AP2 complex in brain. Further analysis using in 
vitro binding assays demonstrated that each GABAa receptor y subunit interacts 
directly and selectively with the p2-adaptin of AP2. The y2S subunit was shown to 
contain at least two distinct binding sites for p2-adaptin in the N- and C-terminal 
halves of the major intracellular domain. The N-half of y2S interacted with sub- 
domain B of p2-adaptin via a putative basic-rich binding motif. The C-half of y2S 
interacted with the C-terminus of p,2-adaptin, within sub-domain A, and this was 
proposed to occur via a tyrosine-based binding motif. The construction of multiple 
sequence alignments revealed that the putative basic-rich and tyrosine-based p.2- 
adaptin binding motifs are common to all the y subunit isoforms.
It is possible that the multivalent interactions between each GABAa receptor y 
subunit and p2-adaptin underlie the ability of AP2 to associate with GABAa receptors 
at the neuronal surface. This may facilitate the selective recruitment of GABAa 
receptors into clathrin-coated pits for internalisation, and therefore be part of a 
molecular mechanism involved in maintaining the number of cell-surface GABAa 
receptors and hence the strength of GABAergic synapses, neuronal excitability and 
the dynamics of neural networks. The interactions between AP2 and the GABAa 
receptor y subunits may also be the target of intracellular signalling pathways that 
modify constitutive rates of GABAa receptor endocytosis and therefore the stability 
of GABAa receptors at the neuronal surface. Furthermore, as GABAa receptors 
undergo constitutive and agonist-dependent endocytosis (Kittler et al., 2000a, 2005; 
Connolly et al., 1999a,b; Calkin and Barnes, 1994; Calkin et al., 1994; Tehrani and 
Barnes, 1991), it is important to consider the role of agonists and allosteric
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modulators in the internalisation process. For example, the GABAa receptor y 
subunit (predominantly y2) appears to be involved in the physical and functional 
interaction between GABAa receptors and benzodiazepines (Pritchett et al., 1989; 
Smith and Olsen, 1995). It is therefore possible that the multivalent interactions 
between the AP2 complex and the GABAa receptor y subunits are involved in the 
development of tolerance and dependence to benzodiazepines, a phenomenon that is 
known to limit the therapeutic use of these clinically active compounds.
6.3 Future Directions
Future research will inevitably extend our current knowledge of mechanisms that 
maintain or change the phosphorylation state and cell-surface stability of GABAa 
receptors. Throughout this thesis, I have commented on a number of steps that may 
be taken to further delineate the putative mechanisms described in this body of work. 
In the medium-term, it may be of interest to investigate additional effects of GABAa 
receptor activation during neuronal maturation. This could involve identifying other 
downstream effectors of CaMKII, as there is some evidence that this kinase is 
involved in the trophic effects of GABA during neuronal development (Borodinsky et 
al., 2003). Future research may also involve investigating whether upstream 
regulators of CaMKII, such as calmodulin, bind to and regulate GABAa receptors. It 
may also be of interest to further examine the potential role of CaMKII-dependent 
binding and phosphorylation in long-term plasticity at GABAergic synapses, such as 
in rebound potentiation, and in controlling the cell-surface stability of GABAa 
receptors. New insights into GABAa receptor trafficking may be obtained from work 
examining the functional role of the multiple AP2 binding sites in GABAa receptor 
subunits and complexes. Additional research may also determine whether GABAa 
receptor endocytosis occurs via a non-clathrin route, and identify further proteins and 
subunit modifications that are involved in mediating or regulating the internalisation 
of GABAa receptors.
In the longer term, the generation of knockin mice may also provide key insight into 
the phospho-modulation and cell-surface stability of GABAa receptors. The 
introduction of point mutations into the mouse genome that mimic or prevent
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phosphorylation at particular subunit sites combined with biochemical and 
electrophysiological experiments could not only confirm the sites of kinase activity in 
vivo, but the effects of phosphorylation on channel activity and cell-surface stability, 
and the signalling pathways that regulate this post-translational modification. This 
approach may also indicate whether developing and mature neurons use similar 
mechanisms to regulate the phosphorylation state of GABAa receptors. Knockin 
mice could also be used to characterise and confirm sequences involved in the 
binding of protein kinases and phosphatases to GABAa receptors, and to determine 
whether binding is a pre-requisite of subunit phosphorylation or other functional 
effects. Mutant mice could also be used to identify and confirm sequences involved 
in the trafficking of GABAa receptors to and from the neuronal surface.
It will also be interesting to investigate the interplay of protein kinases and 
phosphatases at GABAa receptor scaffolds. This will involve examining the binding 
dynamics of the various enzymes and their anchoring proteins, and other signalling 
components that may have similar or overlapping binding regions. In addition, it will 
involve extending our knowledge of where phosphorylation modifies binding of 
signalling molecules, and determining whether synergistic phosphorylation of 
different subunit sites occurs. The numerous phosphorylation sites and binding 
partners of a given GABAa receptor complex, together with the potential interplay 
between them, provides great potential for there being a large number of distinct 
functional states of the receptor. Combined with the heterogeneity of GABAa 
receptors, this could generate a wide range of responses. It will therefore be of 
interest to determine the cellular processes that limit such potential complexity, such 
as the spatio-temporal control of the expression, alternative splicing, sub-cellular 
targeting and stability of GABAa receptor-associated proteins. The complexity 
generated from the potential interplay of signalling molecules at GABAa receptors 
could contribute to the remarkable specificity of signalling responses to various 
extracellular stimuli. Furthermore, this complexity will continue to shape the 
intellectual and experimental challenge of elucidating the cellular, physiological and 
behavioural significance of neuronal signalling events that lead to changes in the
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phosphorylation state and cell-surface stability of GABAa receptors in health and 
disease.
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